_id	drug_pubchem_cid	disease_umls	drug_name	disease_name	status	date
AAFJXZWCNVJTMK-GUCUJZIJSA-N	PUBCHEM.COMPOUND:15942827	UMLS:C4721610	1,2:5,6-dianhydrogalactitol	Ovarian Cancer	Designated	2016-04-19
AAFJXZWCNVJTMK-GUCUJZIJSA-N	PUBCHEM.COMPOUND:15942827	UMLS:C0025149	1,2:5,6-dianhydrogalactitol	Medulloblastoma	Designated	2016-03-10
AAOVKJBEBIDNHE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3016	UMLS:C0751122	diazepam	Dravet Syndrome	Designated	2018-05-23
AARXZCZYLAFQQU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:12047567	UMLS:C0280100	motexafin gadolinium	solid tumors	Designated	2003-01-27
AARXZCZYLAFQQU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:12047567	UMLS:C0220650	motexafin gadolinium	brain metastases	Designated	2003-01-27
AARXZCZYLAFQQU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:12047567	UMLS:C0280100	motexafin gadolinium	solid tumors	Designated	2003-01-27
AARXZCZYLAFQQU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:12047567	UMLS:C0220650	motexafin gadolinium	brain metastases	Designated	2003-01-27
ABASMUXUCSQFKC-PKEKLUKKSA-N	PUBCHEM.COMPOUND:121490254	UMLS:C2931133	mongersen	Pediatric Crohn's disease	Designated/Withdrawn	2015-07-20
ACGDKVXYNVEAGU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3518	UMLS:C0007462	Guanethidine monosulfate	Causalgia	Designated/Withdrawn	1986-01-06
ACGDKVXYNVEAGU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3518	UMLS:C0034931	Guanethidine monosulfate	Reflex Sympathetic Dystrophy	Designated/Withdrawn	1986-01-06
ACPCMBPQKQTAQY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:67027333	UMLS:C0023467	N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea	Acute myelogenous leukemia	Designated/Withdrawn	2007-10-23
ACRHBAYQBXXRTO-OAQYLSRUSA-N	PUBCHEM.COMPOUND:132999	UMLS:C0340515	ivabradine	heart dysfunction	Designated/Withdrawn	2018-07-09
ACRHBAYQBXXRTO-OAQYLSRUSA-N	PUBCHEM.COMPOUND:132999	UMLS:C0007193	ivabradine	Dilated cardiomyopathy	Designated/Approved	2016-03-23
ACSROKXFXFNERX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51711	UMLS:C0338656	Pramiracetam Sulfate	Cognitive Dysfunction	Designated/Withdrawn	1991-11-04
ACTIUHUUMQJHFO-AMJCLVIFSA-N	PUBCHEM.COMPOUND:5354031	UMLS:C0162670	Ubiquinone	mitochondrial cytopathies	Designated	1999-12-14
ACTIUHUUMQJHFO-UPTCCGCDSA-N	PUBCHEM.COMPOUND:5281915	UMLS:C0235974	ubidecarenone	PANCREATIC CANCER	Designated	2017-11-08
ACTIUHUUMQJHFO-UPTCCGCDSA-N	PUBCHEM.COMPOUND:5281915	UMLS:C0020179	Coenzyme Q10	Huntington's Disease	Designated	2001-03-05
ACTIUHUUMQJHFO-UPTCCGCDSA-N	PUBCHEM.COMPOUND:5281915	UMLS:C0162670	Ubiquinone	mitochondrial cytopathies	Designated	1999-12-14
ACTIUHUUMQJHFO-UPTCCGCDSA-N	PUBCHEM.COMPOUND:5281915	UMLS:C0014527	ubidecarenone	Epidermolysis Bullosa	Designated	2018-04-16
ACTOXUHEUCPTEW-BOISPSKTSA-N	PUBCHEM.COMPOUND:5702243	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-BOISPSKTSA-N	PUBCHEM.COMPOUND:5702243	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-BOISPSKTSA-N	PUBCHEM.COMPOUND:5702243	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-BWHGAVFKSA-N	PUBCHEM.COMPOUND:5284619	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-BWHGAVFKSA-N	PUBCHEM.COMPOUND:5284619	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-BWHGAVFKSA-N	PUBCHEM.COMPOUND:5284619	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-CEUOBAOPSA-N	PUBCHEM.COMPOUND:5289394	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-CEUOBAOPSA-N	PUBCHEM.COMPOUND:5289394	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-CEUOBAOPSA-N	PUBCHEM.COMPOUND:5289394	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-FCCRBRQASA-N	PUBCHEM.COMPOUND:134687906	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-FCCRBRQASA-N	PUBCHEM.COMPOUND:134687906	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-FCCRBRQASA-N	PUBCHEM.COMPOUND:134687906	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-GRWVDKKHSA-N	PUBCHEM.COMPOUND:5353959	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-GRWVDKKHSA-N	PUBCHEM.COMPOUND:5353959	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-GRWVDKKHSA-N	PUBCHEM.COMPOUND:5353959	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-HRAVRIHDSA-N	PUBCHEM.COMPOUND:44629935	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-HRAVRIHDSA-N	PUBCHEM.COMPOUND:44629935	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-HRAVRIHDSA-N	PUBCHEM.COMPOUND:44629935	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IMDCDJEBSA-N	PUBCHEM.COMPOUND:76324338	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IMDCDJEBSA-N	PUBCHEM.COMPOUND:76324338	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IMDCDJEBSA-N	PUBCHEM.COMPOUND:76324338	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IWJSIHOMSA-N	PUBCHEM.COMPOUND:153274329	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IWJSIHOMSA-N	PUBCHEM.COMPOUND:153274329	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-IWJSIHOMSA-N	PUBCHEM.COMPOUND:153274329	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JMRHEKERSA-N	PUBCHEM.COMPOUND:6419898	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JMRHEKERSA-N	PUBCHEM.COMPOUND:6419898	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JMRHEKERSA-N	PUBCHEM.COMPOUND:6419898	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JNQYENBPSA-N	PUBCHEM.COMPOUND:71729958	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JNQYENBPSA-N	PUBCHEM.COMPOUND:71729958	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-JNQYENBPSA-N	PUBCHEM.COMPOUND:71729958	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-KWBWCIJSSA-N	PUBCHEM.COMPOUND:6440717	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-KWBWCIJSSA-N	PUBCHEM.COMPOUND:6440717	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-KWBWCIJSSA-N	PUBCHEM.COMPOUND:6440717	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-LFIIGWMYSA-N	PUBCHEM.COMPOUND:134715567	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-LFIIGWMYSA-N	PUBCHEM.COMPOUND:134715567	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-LFIIGWMYSA-N	PUBCHEM.COMPOUND:134715567	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-NHYPZVJXSA-N	PUBCHEM.COMPOUND:134717663	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-NHYPZVJXSA-N	PUBCHEM.COMPOUND:134717663	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-NHYPZVJXSA-N	PUBCHEM.COMPOUND:134717663	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OBURPCBNSA-N	PUBCHEM.COMPOUND:5356392	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OBURPCBNSA-N	PUBCHEM.COMPOUND:5356392	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OBURPCBNSA-N	PUBCHEM.COMPOUND:5356392	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OSLILNPBSA-N	PUBCHEM.COMPOUND:137704528	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OSLILNPBSA-N	PUBCHEM.COMPOUND:137704528	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-OSLILNPBSA-N	PUBCHEM.COMPOUND:137704528	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-QTKFNTAMSA-N	PUBCHEM.COMPOUND:135391165	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-QTKFNTAMSA-N	PUBCHEM.COMPOUND:135391165	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-QTKFNTAMSA-N	PUBCHEM.COMPOUND:135391165	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-SENNIVHBSA-N	PUBCHEM.COMPOUND:129627802	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-SENNIVHBSA-N	PUBCHEM.COMPOUND:129627802	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-SENNIVHBSA-N	PUBCHEM.COMPOUND:129627802	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5266	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5266	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5266	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-VRCNPYAISA-N	PUBCHEM.COMPOUND:131674879	UMLS:C0030498	Spiramycin	parasitic	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-VRCNPYAISA-N	PUBCHEM.COMPOUND:131674879	UMLS:C0239055	Spiramycin	CHRONIC CRYPTOSPORIDIOSIS	Designated/Withdrawn	1984-10-17
ACTOXUHEUCPTEW-VRCNPYAISA-N	PUBCHEM.COMPOUND:131674879	UMLS:C0021051	Spiramycin	Immunodeficiency	Designated/Withdrawn	1984-10-17
ACTRVOBWPAIOHC-XIXRPRMCSA-N	PUBCHEM.COMPOUND:2724354	UMLS:C0010691	Succimer	Cystinuria	Designated	1990-11-05
ACTRVOBWPAIOHC-XIXRPRMCSA-N	PUBCHEM.COMPOUND:2724354	UMLS:C0149921	Succimer	lead poisoning in children	Designated/Approved	1984-05-09
ACTRVOBWPAIOHC-XIXRPRMCSA-N	PUBCHEM.COMPOUND:2724354	UMLS:C0728899	Succimer	Intoxication	Designated	1991-03-22
ACTRVOBWPAIOHC-XIXRPRMCSA-N	PUBCHEM.COMPOUND:2724354	UMLS:C0022650	Succimer	KIDNEY STONE	Designated	1990-11-05
ACWZRVQXLIRSDF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10288191	UMLS:C0025202	binimetinib	melanoma	Designated	2013-11-19
ACWZRVQXLIRSDF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10288191	UMLS:C4721610	binimetinib	Ovarian Cancer	Designated	2014-07-31
AEQFSUDEHCCHBT-UHFFFAOYSA-M	PUBCHEM.COMPOUND:16760703	UMLS:C0043207	sodium valproate	Wolfram Syndrome	Designated	2015-08-05
AEQFSUDEHCCHBT-UHFFFAOYSA-M	PUBCHEM.COMPOUND:16760703	UMLS:C3203102	sodium valproate	PULMONARY ARTERIAL HYPERTENSION	Designated	2020-03-09
AEQFSUDEHCCHBT-UHFFFAOYSA-M	PUBCHEM.COMPOUND:16760703	UMLS:C0016667	Valproate	Fragile X Syndrome	Designated	2008-05-05
AFCGFAGUEYAMAO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71158	UMLS:C0016667	acamprosate	Fragile X Syndrome	Designated	2013-03-25
AFLFKFHDSCQHOL-IZZDOVSWSA-N	PUBCHEM.COMPOUND:9864881	UMLS:C0008312	elafibranor	Primary Biliary Cholangitis	Designated	2019-07-25
AHMIRVCNZZUANP-LPBAWZRYSA-N	PUBCHEM.COMPOUND:91668177	UMLS:C0520799	rusalatide acetate	Acute Radiation Syndrome	Designated	2017-09-07
AHYMHWXQRWRBKT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25171648	UMLS:C3539721	tepotinib	Non-Small Cell Lung Cancer	Designated/Approved	2020-10-26
AHYMHWXQRWRBKT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25171648	UMLS:C0027651	tepotinib	Tumor	Designated/Approved	2020-10-26
AILRADAXUVEEIR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68165256	UMLS:C3539721	brigatinib	Non-Small Cell Lung Cancer	Designated/Approved	2016-04-28
AILRADAXUVEEIR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68165256	UMLS:C3539721	brigatinib	Non-Small Cell Lung Cancer	Designated/Approved	2016-04-28
AINQERPKMNDVQT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565128	UMLS:C0206698	fimaporfin	Cholangiocarcinoma	Designated	2017-09-27
AJFWITSBVLLDCC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91820639	UMLS:C1325653	2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione	mitochondrial respiratory chain	Designated	2018-04-16
AJFWITSBVLLDCC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91820639	UMLS:C0012634	2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione	Disease	Designated	2018-04-16
AJIPIJNNOJSSQC-NYLIRDPKSA-N	PUBCHEM.COMPOUND:27125	UMLS:C3898147	estetrol	Neonatal Hypoxic Ischemic Encephalopathy	Designated	2019-03-28
AJKIRUJIDFJUKJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:29566	UMLS:C0235974	taurolidine	PANCREATIC CANCER	Designated	2016-05-16
AJKIRUJIDFJUKJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:29566	UMLS:C0027819	taurolidine	Neuroblastoma	Designated	2018-02-22
AKFJWRDCWYYTIG-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:9884642	UMLS:C0013264	naproxcinod	DUCHENNE MUSCULAR DYSTROPHY	Designated	2015-03-16
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0235280	sodium thiosulfate	Ototoxicity	Designated	2011-10-13
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0015376	sodium thiosulfate	Extravasation	Designated	2010-12-02
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0011633	sodium thiosulfate	Dermatomyositis	Designated	2014-10-28
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0235280	Sodium thiosulfate	Ototoxicity	Designated	2004-03-17
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0006666	sodium thiosulfate	Calciphylaxis	Designated	2011-11-09
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0006666	sodium thiosulfate	Calciphylaxis	Designated	2012-11-19
AKHNMLFCWUSKQB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24477	UMLS:C0006666	Sodium Thiosulfate	Calciphylaxis	Designated	2012-02-16
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C3714514	Fenretinide	Infections	Designated	2010-04-07
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0033809	Fenretinide	Pseudomonas aeruginosa	Designated	2010-04-07
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0010674	Fenretinide	Cystic Fibrosis	Designated	2010-04-07
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0079773	fenretinide	cutaneous T-cell lymphoma	Designated	2017-12-19
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0079774	fenretinide	Peripheral T-Cell Lymphoma	Designated	2013-09-04
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0027819	Fenretinide	Neuroblastoma	Designated	2005-10-05
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C2700204	fenretinide	Follicular T-cell lymphoma	Designated	2017-12-22
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0027651	fenretinide	Tumors	Designated/Withdrawn	2007-02-01
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0079774	fenretinide	Peripheral T-Cell Lymphoma	Designated	2017-12-22
AKJHMTWEGVYYSE-FXILSDISSA-N	PUBCHEM.COMPOUND:5288209	UMLS:C0079773	fenretinide	cutaneous T-cell lymphoma	Designated	2013-09-04
AKNNEGZIBPJZJG-MSOLQXFVSA-N	PUBCHEM.COMPOUND:275196	UMLS:C0002736	noscapine	Amyotrophic Lateral Sclerosis	Designated	2015-12-29
AKYHKWQPZHDOBW-DSXUQNDKSA-N	PUBCHEM.COMPOUND:11949689	UMLS:C0024530	quinine Sulfate	Malaria	Designated/Approved	2004-06-03
AKYHKWQPZHDOBW-DSXUQNDKSA-N	PUBCHEM.COMPOUND:11949689	UMLS:C0024530	quinine sulfate	Malaria	Designated	2008-12-02
ALEXXDVDDISNDU-JZYPGELDSA-N	PUBCHEM.COMPOUND:5744	UMLS:C2931173	hydrocortisone acetate	Pediatric ulcerative colitis	Designated	2017-06-27
ALHBJBCQLJZYON-PFSRBDOWSA-N	PUBCHEM.COMPOUND:71543365	UMLS:C0023467	iadademstat	Acute myeloid leukemia	Designated	2021-02-10
ALWKGYPQUAPLQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4456	UMLS:C0009377	neostigmine	Colonic Pseudo-Obstruction	Designated	2013-03-18
AMHZIUVRYRVYBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2896	UMLS:C1845862	cyclocreatine	Creatine transporter deficiency	Designated	2012-06-18
AMLYAMJWYAIXIA-VWNVYAMZSA-N	PUBCHEM.COMPOUND:176873	UMLS:C0555198	cilengitide	Malignant Glioma	Designated/Withdrawn	2005-05-27
AMNXBQPRODZJQR-DITALETJSA-N	PUBCHEM.COMPOUND:5745206	UMLS:C0020445	Implitapide	FAMILIAL HYPERCHOLESTEROLEMIA	Designated/Withdrawn	2004-08-13
AMNXBQPRODZJQR-DITALETJSA-N	PUBCHEM.COMPOUND:5745206	UMLS:C0023817	Implitapide	Fredrickson type I or V hyperlipoproteinemia	Designated/Withdrawn	2004-08-19
ANIAZGVDEUQPRI-ZJQCGQFWSA-N	PUBCHEM.COMPOUND:71511839	UMLS:C0020502	etelcalcetide	Hyperparathyroidism	Designated	2017-05-31
AOJJSUZBOXZQNB-TZSSRYMLSA-N	PUBCHEM.COMPOUND:31703	UMLS:C2239176	doxorubicin	HEPATOCELLULAR CARCINOMA	Designated	2009-08-25
AOJJSUZBOXZQNB-TZSSRYMLSA-N	PUBCHEM.COMPOUND:31703	UMLS:C0079773	doxorubicin	cutaneous T-cell lymphoma	Designated	2015-04-06
AOJJSUZBOXZQNB-VTZDEGQISA-N	PUBCHEM.COMPOUND:41867	UMLS:C0678222	Epirubicin	Breast cancer	Designated/Approved	1999-09-14
APFMVAHRFWBCDG-JUOYHRLASA-N	PUBCHEM.COMPOUND:170317	UMLS:C0040517	ecopipam hydrochloride	Tourette's Syndrome	Designated	2010-09-29
APFMVAHRFWBCDG-JUOYHRLASA-N	PUBCHEM.COMPOUND:170317	UMLS:C0023374	ecopipam hydrochloride	Lesch-Nyhan Disease	Designated	2009-07-21
APKFDSVGJQXUKY-INPOYWNPSA-N	PUBCHEM.COMPOUND:5280965	UMLS:C0019655	Liposomal amphotericin B	Histoplasmosis	Designated	1996-12-10
APKFDSVGJQXUKY-INPOYWNPSA-N	PUBCHEM.COMPOUND:5280965	UMLS:C0023290	Liposomal amphotericin B	Visceral leishmaniasis	Designated/Approved	1996-12-06
APKFDSVGJQXUKY-INPOYWNPSA-N	PUBCHEM.COMPOUND:5280965	UMLS:C0085436	Liposomal amphotericin B	Cryptococcal meningitis	Designated/Approved	1996-12-10
APKFDSVGJQXUKY-INPOYWNPSA-N	PUBCHEM.COMPOUND:5280965	UMLS:C0023290	amphotericin B	Visceral leishmaniasis	Designated	2010-09-15
APKFDSVGJQXUKY-INPOYWNPSA-N	PUBCHEM.COMPOUND:5280965	UMLS:C0023290	amphotericin B	Visceral leishmaniasis	Designated	2010-09-15
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C0043541	Amphotericin B lipid complex	Zygomycosis	Designated/Withdrawn	1996-05-06
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C0033735	Amphotericin B lipid complex	Protothecosis	Designated/Withdrawn	1996-08-21
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C0038034	Amphotericin B lipid complex	Sporotrichosis	Designated/Withdrawn	1996-09-23
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C0009186	Amphotericin B lipid complex	Coccidioidomycosis	Designated/Withdrawn	1996-05-06
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C1262313	Amphotericin B lipid complex	Invasive Fungal Infections	Designated/Approved	1991-12-05
APKFDSVGJQXUKY-VTPNKFOWSA-N	PUBCHEM.COMPOUND:118705500	UMLS:C1609535	Amphotericin B lipid complex	Invasive Candidiasis	Designated/Withdrawn	1996-06-27
AQHHHDLHHXJYJD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4946	UMLS:C0018916	propranolol	Hemangiomas	Designated/Approved	2008-09-05
AQHHHDLHHXJYJD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4946	UMLS:C0035344	Propranolol	Retinopathy of Prematurity	Designated	2019-08-23
ARFHIAQFJWUCFH-IZZDOVSWSA-N	PUBCHEM.COMPOUND:6842999	UMLS:C0041234	nifurtimox	Chagas Disease	Designated	2013-12-31
ARFHIAQFJWUCFH-IZZDOVSWSA-N	PUBCHEM.COMPOUND:6842999	UMLS:C0041234	nifurtimox	Chagas Disease	Designated/Approved	2010-08-05
ARIWANIATODDMH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14871	UMLS:C0020757	Monolaurin	Ichthyosis	Designated	1993-04-29
ARQUTWAXTHJROR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:18435899	UMLS:C0555198	crenolanib besylate	Malignant Glioma	Designated	2010-12-20
ARUVKPQLZAKDPS-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24462	UMLS:C0022578	copper sulfate	Keratoconus	Designated	2017-10-26
ASKZRYGFUPSJPN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:118513932	UMLS:C0026847	risdiplam	Spinal Muscular Atrophy	Designated/Approved	2017-01-04
AUBOIOCYVHATDV-QYLLOTSKSA-N	PUBCHEM.COMPOUND:134693628	UMLS:C3714796	pralmorelin hydrochloride	Growth hormone deficiency	Designated	2012-10-18
AUFUWRKPQLGTGF-FMKGYKFTSA-N	PUBCHEM.COMPOUND:20058	UMLS:C0268130	uridine triacetate	OROTIC ACIDURIA	Designated/Approved	2013-08-09
AUFUWRKPQLGTGF-FMKGYKFTSA-N	PUBCHEM.COMPOUND:20058	UMLS:C0032343	uridine triacetate	Poisoning	Designated/Approved	2009-05-01
AUFUWRKPQLGTGF-FMKGYKFTSA-N	PUBCHEM.COMPOUND:20058	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUFUWRKPQLGTGF-QRMSVCKNSA-N	PUBCHEM.COMPOUND:60004399	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUFUWRKPQLGTGF-RWDKGTSBSA-N	PUBCHEM.COMPOUND:44629990	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUFUWRKPQLGTGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:254731	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUFUWRKPQLGTGF-ZRJCITRHSA-N	PUBCHEM.COMPOUND:6547277	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUFUWRKPQLGTGF-ZZVYKPCYSA-N	PUBCHEM.COMPOUND:990800	UMLS:C0751651	2',3',5'-tri-o-acetyluridine	Mitochondrial disease	Designated/Withdrawn	2003-01-13
AUGCSOFQTDKPSO-RGVLZGJSSA-N	PUBCHEM.COMPOUND:16117309	UMLS:C2239176	Ivaltinostat	HEPATOCELLULAR CARCINOMA	Designated	2020-08-21
AUGCSOFQTDKPSO-RGVLZGJSSA-N	PUBCHEM.COMPOUND:16117309	UMLS:C0023467	Ivaltinostat	Acute myeloid leukemia	Designated	2021-01-08
AUJRCFUBUPVWSZ-BQWBZISASA-N	PUBCHEM.COMPOUND:57417071	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJRCFUBUPVWSZ-JMYRMHIVSA-M	PUBCHEM.COMPOUND:124081048	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJRCFUBUPVWSZ-UHFFFAOYSA-M	PUBCHEM.COMPOUND:24199313	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJRCFUBUPVWSZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6333901	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJRCFUBUPVWSZ-XTZHGVARSA-M	PUBCHEM.COMPOUND:6918453	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJRCFUBUPVWSZ-XTZHGVARSA-M	PUBCHEM.COMPOUND:6918453	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
AUJXLBOHYWTPFV-BLWRDSOESA-N	PUBCHEM.COMPOUND:138402870	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-BLWRDSOESA-N	PUBCHEM.COMPOUND:138402870	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-CVLRASHMSA-N	PUBCHEM.COMPOUND:458034	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-CVLRASHMSA-N	PUBCHEM.COMPOUND:458034	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-LDUXBRJQSA-N	PUBCHEM.COMPOUND:91826096	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-LDUXBRJQSA-N	PUBCHEM.COMPOUND:91826096	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-MADNPERPSA-N	PUBCHEM.COMPOUND:6917949	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-MADNPERPSA-N	PUBCHEM.COMPOUND:6917949	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-MXGHYKICSA-N	PUBCHEM.COMPOUND:23724556	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-MXGHYKICSA-N	PUBCHEM.COMPOUND:23724556	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-RQLJINDISA-N	PUBCHEM.COMPOUND:44448250	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-RQLJINDISA-N	PUBCHEM.COMPOUND:44448250	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3197	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3197	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-UJILECMYSA-N	PUBCHEM.COMPOUND:134692670	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUJXLBOHYWTPFV-UJILECMYSA-N	PUBCHEM.COMPOUND:134692670	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-VITLIGDRSA-N	PUBCHEM.COMPOUND:6857732	UMLS:C0018133	echinomycin	Graft-Versus-Host Disease	Designated	2017-01-05
AUJXLBOHYWTPFV-VITLIGDRSA-N	PUBCHEM.COMPOUND:6857732	UMLS:C0023467	echinomycin	Acute myeloid leukemia	Designated	2015-05-21
AUODDLQVRAJAJM-CTEDBMRYSA-N	PUBCHEM.COMPOUND:16219133	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-DOPPNGDLSA-N	PUBCHEM.COMPOUND:137705122	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-FWTPQNFYSA-N	PUBCHEM.COMPOUND:46738091	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-GQYOKNPUSA-N	PUBCHEM.COMPOUND:441204	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-KBTFJHITSA-N	PUBCHEM.COMPOUND:46781040	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-OKBXBIFFSA-N	PUBCHEM.COMPOUND:134693959	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-PIPVPTKYSA-N	PUBCHEM.COMPOUND:134129519	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-PTTDBYGSSA-N	PUBCHEM.COMPOUND:6419884	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-SVLAMSDMSA-N	PUBCHEM.COMPOUND:5702025	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21872021	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-VSPYWEHYSA-N	PUBCHEM.COMPOUND:75534857	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-XJQDNNTCSA-N	PUBCHEM.COMPOUND:16051951	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-XNQAQEGKSA-N	PUBCHEM.COMPOUND:44629924	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AUODDLQVRAJAJM-ZSHBVFQLSA-N	PUBCHEM.COMPOUND:86222708	UMLS:C0036202	Clindamycin hydrochloride	Sarcoidosis	Designated	2006-08-09
AURFZBICLPNKBZ-FFWOKMQNSA-N	PUBCHEM.COMPOUND:134688930	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-FFWOKMQNSA-N	PUBCHEM.COMPOUND:134688930	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-FZCSVUEKSA-N	PUBCHEM.COMPOUND:92787	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-FZCSVUEKSA-N	PUBCHEM.COMPOUND:92787	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-JITSNLRCSA-N	PUBCHEM.COMPOUND:21139953	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-JITSNLRCSA-N	PUBCHEM.COMPOUND:21139953	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-JMTGGFPBSA-N	PUBCHEM.COMPOUND:22833567	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-JMTGGFPBSA-N	PUBCHEM.COMPOUND:22833567	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-LOPWJTSLSA-N	PUBCHEM.COMPOUND:9883500	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-LOPWJTSLSA-N	PUBCHEM.COMPOUND:9883500	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-MHPDUSGUSA-N	PUBCHEM.COMPOUND:6708605	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-MHPDUSGUSA-N	PUBCHEM.COMPOUND:6708605	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-SRJHXTLLSA-N	PUBCHEM.COMPOUND:104881	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-SRJHXTLLSA-N	PUBCHEM.COMPOUND:104881	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-SUZPBREPSA-N	PUBCHEM.COMPOUND:16760287	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-SUZPBREPSA-N	PUBCHEM.COMPOUND:16760287	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-SYBPFIFISA-N	PUBCHEM.COMPOUND:92786	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-SYBPFIFISA-N	PUBCHEM.COMPOUND:92786	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:262961	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AURFZBICLPNKBZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:262961	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-YZRLXODZSA-N	PUBCHEM.COMPOUND:31402	UMLS:C0028064	allopregnanolone	neimann-pick disease	Designated/Withdrawn	2013-07-12
AURFZBICLPNKBZ-YZRLXODZSA-N	PUBCHEM.COMPOUND:31402	UMLS:C0038220	allopregnanolone	Status Epilepticus	Designated	2014-04-20
AVAACINZEOAHHE-VFZPANTDSA-N	PUBCHEM.COMPOUND:73303	UMLS:C0010674	Doripenem	Cystic Fibrosis	Designated	2004-07-16
AVAACINZEOAHHE-VFZPANTDSA-N	PUBCHEM.COMPOUND:73303	UMLS:C0009450	Doripenem	Infection	Designated	2004-07-16
AXRCEOKUDYDWLF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:176167	UMLS:C1332201	enzastaurin	Diffuse Large B-Cell Lymphoma	Designated	2009-03-04
AXRCEOKUDYDWLF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:176167	UMLS:C0017636	Enzastaurin	Glioblastoma multiforme	Designated	2005-09-19
AXSPHUWXYSZPBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:55361	UMLS:C3495801	gusperimus trihydrochloride	Wegener's Granulomatosis	Designated	2011-06-29
AYFVYJQAPQTCCC-GBXIJSLDSA-N	PUBCHEM.COMPOUND:6288	UMLS:C0037771	L-threonine	spastic paraparesis	Designated/Withdrawn	1992-07-24
AYFVYJQAPQTCCC-GBXIJSLDSA-N	PUBCHEM.COMPOUND:6288	UMLS:C0002736	L-threonine	Amyotrophic Lateral Sclerosis	Designated/Withdrawn	1989-02-06
AYFVYJQAPQTCCC-GBXIJSLDSA-N	PUBCHEM.COMPOUND:6288	UMLS:C0026838	L-threonine	Spasticity	Designated/Withdrawn	1992-07-24
AYUNIORJHRXIBJ-TXHRRWQRSA-N	PUBCHEM.COMPOUND:6505803	UMLS:C0026764	Tanespimycin	Multiple Myeloma	Designated	2004-09-09
AZSRSNUQCUDCGG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:118607832	UMLS:C3539721	mobocertinib	Non-Small Cell Lung Cancer	Designated	2019-12-17
BCFGMOOMADDAQU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:208908	UMLS:C0024623	lapatinib	Gastric Cancer	Designated/Withdrawn	2009-05-29
BDZCLIOURDFSFQ-HAZZGOGXSA-N	PUBCHEM.COMPOUND:16219293	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
BDZCLIOURDFSFQ-HAZZGOGXSA-N	PUBCHEM.COMPOUND:16219293	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
BDZCLIOURDFSFQ-HAZZGOGXSA-N	PUBCHEM.COMPOUND:16219293	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
BENFXAYNYRLAIU-QSVFAHTRSA-N	PUBCHEM.COMPOUND:72081	UMLS:C0019212	terlipressin	Hepatorenal Syndrome	Designated	2004-10-29
BENFXAYNYRLAIU-QSVFAHTRSA-N	PUBCHEM.COMPOUND:72081	UMLS:C0003962	terlipressin	Ascites	Designated	2016-09-08
BENFXAYNYRLAIU-QSVFAHTRSA-N	PUBCHEM.COMPOUND:72081	UMLS:C0014867	Terlipressin	Esophageal Varices	Designated	1986-03-06
BENFXAYNYRLAIU-QSVFAHTRSA-N	PUBCHEM.COMPOUND:72081	UMLS:C0019212	terlipressin	Hepatorenal Syndrome	Designated	2018-11-21
BEZZFPOZAYTVHN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40854	UMLS:C0010678	oxfendazole	Cysticercosis	Designated	2017-08-07
BEZZFPOZAYTVHN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40854	UMLS:C0338437	oxfendazole	Neurocysticercosis	Designated	2014-07-14
BEZZFPOZAYTVHN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40854	UMLS:C0010678	oxfendazole	Cysticercosis	Designated	2014-07-14
BFENHEAPFWQJFL-BTJKTKAUSA-N	PUBCHEM.COMPOUND:131801100	UMLS:C0009324	filgotinib maleate	Ulcerative Colitis	Designated	2017-10-05
BFENHEAPFWQJFL-BTJKTKAUSA-N	PUBCHEM.COMPOUND:131801100	UMLS:C2931173	filgotinib maleate	Pediatric ulcerative colitis	Designated	2017-10-05
BFENHEAPFWQJFL-BTJKTKAUSA-N	PUBCHEM.COMPOUND:131801100	UMLS:C2931133	filgotinib maleate	Pediatric Crohn's disease	Designated	2017-07-18
BFSMGDJOXZAERB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44462760	UMLS:C3539721	dabrafenib	Non-Small Cell Lung Cancer	Designated	2014-10-20
BFSMGDJOXZAERB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44462760	UMLS:C0555198	dabrafenib	Malignant Glioma	Designated	2016-02-08
BFSMGDJOXZAERB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44462760	UMLS:C0025202	dabrafenib	melanoma	Designated/Approved	2011-01-12
BFYIZQONLCFLEV-DAELLWKTSA-N	PUBCHEM.COMPOUND:60198	UMLS:C0012634	Exemestane	Disease	Designated/Approved	1991-09-19
BFYIZQONLCFLEV-DAELLWKTSA-N	PUBCHEM.COMPOUND:60198	UMLS:C0678222	Exemestane	Breast cancer	Designated/Approved	1991-09-19
BGLPECHZZQDNCD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44595079	UMLS:C0079774	cerdulatinib	Peripheral T-Cell Lymphoma	Designated	2018-09-21
BHLXTPHDSZUFHR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:155815	UMLS:C0037379	Varespladib	Snakebite	Designated	2019-03-25
BIFMNMPSIYHKDN-FJXQXJEOSA-N	PUBCHEM.COMPOUND:6918223	UMLS:C0878544	dexrazoxane hydrochloride	Cardiomyopathy	Designated	2014-08-19
BIIVYFLTOXDAOV-YVEFUNNKSA-N	PUBCHEM.COMPOUND:5287969	UMLS:C0023486	Alvocidib	Prolymphocytic Leukemia	Designated	2007-04-13
BIIVYFLTOXDAOV-YVEFUNNKSA-N	PUBCHEM.COMPOUND:5287969	UMLS:C0023434	Alvocidib	B-cell chronic lymphocytic leukemia	Designated	2007-04-13
BIIVYFLTOXDAOV-YVEFUNNKSA-N	PUBCHEM.COMPOUND:5287969	UMLS:C0023467	alvocidib	Acute myeloid leukemia	Designated	2014-04-21
BIXBBIPTYBJTRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68791	UMLS:C0860594	Imexon	Metastatic malignant melanoma	Designated/Withdrawn	2001-08-03
BIXBBIPTYBJTRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68791	UMLS:C4721610	imexon	Ovarian Cancer	Designated	2005-08-12
BIXBBIPTYBJTRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68791	UMLS:C0026764	Imexon	Multiple Myeloma	Designated	1996-11-08
BIXBBIPTYBJTRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68791	UMLS:C0281361	Imexon	Pancreatic adenocarcinoma	Designated/Withdrawn	2003-11-01
BJNLLBUOHPVGFT-CAYRISATSA-N	PUBCHEM.COMPOUND:133065662	UMLS:C0038172	teicoplanin	Staphylococcus aureus	Designated	2018-05-24
BJNLLBUOHPVGFT-CAYRISATSA-N	PUBCHEM.COMPOUND:133065662	UMLS:C3714514	teicoplanin	Infections	Designated	2018-05-24
BJNLLBUOHPVGFT-CAYRISATSA-N	PUBCHEM.COMPOUND:133065662	UMLS:C0010674	teicoplanin	Cystic Fibrosis	Designated	2018-05-24
BKBBTCORRZMASO-ZOWNYOTGSA-M	PUBCHEM.COMPOUND:24906323	UMLS:C0029463	Methotrexate sodium	Osteogenic sarcoma	Designated/Approved	1985-10-21
BKBBTCORRZMASO-ZOWNYOTGSA-M	PUBCHEM.COMPOUND:24906323	UMLS:C0029463	Methotrexate sodium	Osteogenic sarcoma	Designated/Approved	1985-10-21
BKCJZNIZRWYHBN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:100427	UMLS:C1261473	Palifosfamide	Soft Tissue Sarcomas	Designated/Withdrawn	2008-05-05
BKEMVGVBBDMHKL-VYFXDUNUSA-N	PUBCHEM.COMPOUND:56927879	UMLS:C0342543	Histrelin acetate	Central Precocious Puberty	Designated/Approved	1988-08-10
BKJIXTWSNXCKJH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:300471	UMLS:C0278883	Elesclomol	Metastatic melanoma	Designated	2007-12-18
BKRGVLQUQGGVSM-KBXCAEBGSA-N	PUBCHEM.COMPOUND:28864	UMLS:C3203102	lisuride	PULMONARY ARTERIAL HYPERTENSION	Designated	2013-01-17
BKXVVCILCIUCLG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54900	UMLS:C0039445	raloxifene hydrochloride	hereditary hemorrhagic telangiectasia	Designated	2010-08-20
BLMPQMFVWMYDKT-NZTKNTHTSA-N	PUBCHEM.COMPOUND:11556711	UMLS:C0026764	carfilzomib	Multiple Myeloma	Designated/Approved	2008-01-18
BLMPQMFVWMYDKT-NZTKNTHTSA-N	PUBCHEM.COMPOUND:11556711	UMLS:C0026764	carfilzomib	Multiple Myeloma	Designated/Approved	2008-01-18
BLMPQMFVWMYDKT-NZTKNTHTSA-N	PUBCHEM.COMPOUND:11556711	UMLS:C0023449	carfilzomib	Acute lymphoblastic leukemia	Designated	2021-01-21
BLPUOQGPBJPXRL-FNORWQNLSA-N	PUBCHEM.COMPOUND:641115	UMLS:C0014549	Antiepilepsirine	Tonic-Clonic Epilepsy	Designated	1989-03-23
BLPUOQGPBJPXRL-FNORWQNLSA-N	PUBCHEM.COMPOUND:641115	UMLS:C3826394	Antiepilepsirine	Epilepsy in children	Designated	1989-03-23
BLXXJMDCKKHMKV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4409	UMLS:C3495559	nabumetone	Juvenile rheumatoid arthritis	Designated	2008-05-05
BMGQWWVMWDBQGC-IIFHNQTCSA-N	PUBCHEM.COMPOUND:9829523	UMLS:C0023467	midostaurin	Acute myeloid leukemia	Designated/Approved	2009-07-07
BMGQWWVMWDBQGC-IIFHNQTCSA-N	PUBCHEM.COMPOUND:9829523	UMLS:C0024899	midostaurin	Mastocytosis	Designated/Approved	2010-04-30
BMKDZUISNHGIBY-ZETCQYMHSA-N	PUBCHEM.COMPOUND:71384	UMLS:C0015376	dexrazoxane	Extravasation	Designated/Approved	2004-03-25
BMKDZUISNHGIBY-ZETCQYMHSA-N	PUBCHEM.COMPOUND:71384	UMLS:C0878544	Dexrazoxane	Cardiomyopathy	Designated/Approved	1991-12-17
BMLMGCPTLHPWPY-REOHCLBHSA-N	PUBCHEM.COMPOUND:72390	UMLS:C0035222	L-2-oxothiazolidine-4-carboxylic acid	ADULT RESPIRATORY DISTRESS SYNDROME	Designated	1994-06-14
BMLMGCPTLHPWPY-REOHCLBHSA-N	PUBCHEM.COMPOUND:72390	UMLS:C0002736	L-2-oxothiazolidine-4-carboxylic acid	Amyotrophic Lateral Sclerosis	Designated	1996-07-30
BMLMGCPTLHPWPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65272	UMLS:C0002736	L-2-oxothiazolidine-4-carboxylic acid	Amyotrophic Lateral Sclerosis	Designated	1996-07-30
BMLMGCPTLHPWPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65272	UMLS:C0035222	L-2-oxothiazolidine-4-carboxylic acid	ADULT RESPIRATORY DISTRESS SYNDROME	Designated	1994-06-14
BNFRJXLZYUTIII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:122335	UMLS:C0678222	efaproxiral	Breast cancer	Designated	2004-07-28
BNFRJXLZYUTIII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:122335	UMLS:C0220650	efaproxiral	brain metastases	Designated	2004-07-28
BNJNAEJASPUJTO-DUOHOMBCSA-N	PUBCHEM.COMPOUND:122706909	UMLS:C0023467	vadastuximab talirine	Acute myeloid leukemia	Designated/Withdrawn	2015-11-10
BNRNXUUZRGQAQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398744	UMLS:C3203102	sildenafil	PULMONARY ARTERIAL HYPERTENSION	Designated	2011-07-28
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0282193	deferasirox	Iron Overload	Designated/Approved	2015-02-24
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0002312	deferasirox	alpha-Thalassemia	Designated/Approved	2015-02-24
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0282193	Deferasirox	Iron Overload	Designated/Approved	2002-11-21
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0002871	Deferasirox	Anemias	Designated/Approved	2002-11-21
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0282193	Deferasirox	Iron Overload	Designated/Approved	2002-11-21
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0002871	Deferasirox	Anemias	Designated/Approved	2002-11-21
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0282193	deferasirox	Iron Overload	Designated/Approved	2015-02-24
BOFQWVMAQOTZIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:214348	UMLS:C0002312	deferasirox	alpha-Thalassemia	Designated/Approved	2015-02-24
BOIAUNVCOPGNOT-STOTURBNSA-N	PUBCHEM.COMPOUND:71461381	UMLS:C0035372	6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate	Rett Syndrome	Designated	2016-11-03
BOWVQLFMWHZBEF-KTKRTIGZSA-N	PUBCHEM.COMPOUND:5283454	UMLS:C0032897	Oleoylethanolamide	Prader-Willi Syndrome	Designated	2017-06-08
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C0017636	temozolomide	Glioblastoma multiforme	Designated	2015-11-25
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C0555198	Temozolomide	High Grade Glioma	Designated/Withdrawn	2004-10-18
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C4684861	temozolomide	Recurrent Malignant Glioma	Designated/Approved	1998-10-05
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C0278883	Temozolomide	Metastatic melanoma	Designated/Withdrawn	1998-10-14
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C4684861	temozolomide	Recurrent Malignant Glioma	Designated/Approved	1998-10-05
BPEGJWRSRHCHSN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5394	UMLS:C0027819	Temozolomide	Neuroblastoma	Designated	2019-08-01
BPKAHTKRCLCHEA-UBFJEZKGSA-N	PUBCHEM.COMPOUND:5281104	UMLS:C0020502	paricalcitol	Hyperparathyroidism	Designated/Approved	2015-10-27
BPRHUIZQVSMCRT-VEUZHWNKSA-N	PUBCHEM.COMPOUND:446157	UMLS:C0020445	rosuvastatin	FAMILIAL HYPERCHOLESTEROLEMIA	Designated/Approved	2014-02-14
BRZYSWJRSDMWLG-CAXSIQPQSA-N	PUBCHEM.COMPOUND:2733531	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-DJWUNRQOSA-N	PUBCHEM.COMPOUND:123865	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-JRRILZOYSA-N	PUBCHEM.COMPOUND:134688573	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-KVXRWBJUSA-N	PUBCHEM.COMPOUND:447379	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-NQRKCNNJSA-N	PUBCHEM.COMPOUND:71308205	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-OBOPTQIOSA-N	PUBCHEM.COMPOUND:71684684	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-VVNRJQPTSA-N	PUBCHEM.COMPOUND:137967135	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BRZYSWJRSDMWLG-WFDQBLTDSA-N	PUBCHEM.COMPOUND:6710770	UMLS:C0013370	Geneticin	amoebiasis	Designated	2005-06-06
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C0001175	Atovaquone	AIDS	Designated/Approved	1990-09-10
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C1535939	Atovaquone	Pneumocystis carinii Pneumonia	Designated/Approved	1990-09-10
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C0019682	Atovaquone	HIV	Designated/Approved	1991-08-14
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C1535939	Atovaquone	Pneumocystis carinii Pneumonia	Designated/Approved	1991-08-14
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C0085315	Atovaquone	toxoplasma gondii encephalitis	Designated/Withdrawn	1993-03-16
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C0019682	Atovaquone	HIV	Designated/Withdrawn	1993-03-16
BSJMWHQBCZFXBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:74989	UMLS:C0085315	Atovaquone	toxoplasma gondii encephalitis	Designated/Withdrawn	1993-03-16
BSMCAPRUBJMWDF-KRWDZBQOSA-N	PUBCHEM.COMPOUND:16222096	UMLS:C4553416	cobimetinib	IIC	Designated/Approved	2014-01-31
BSMCAPRUBJMWDF-KRWDZBQOSA-N	PUBCHEM.COMPOUND:16222096	UMLS:C0025202	cobimetinib	melanoma	Designated/Approved	2014-01-31
BSVYJQAWONIOOU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:33958	UMLS:C0282687	tilorone dihydrochloride	Ebola Infection	Designated	2018-02-07
BSYNRYMUTXBXSQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2244	UMLS:C0026691	aspirin	Kawasaki Disease	Designated	2020-09-18
BTGNGJJLZOIYID-UHFFFAOYSA-N	PUBCHEM.COMPOUND:107706	UMLS:C0520799	Sivelestat	Acute Radiation Syndrome	Designated	2021-01-27
BTGNGJJLZOIYID-UHFFFAOYSA-N	PUBCHEM.COMPOUND:107706	UMLS:C0024623	sivelestat	Gastric Cancer	Designated	2020-06-05
BUROJSBIWGDYCN-AFTOUBNRSA-N	PUBCHEM.COMPOUND:87423409	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-BPIPWEEESA-N	PUBCHEM.COMPOUND:137303705	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-GAFNQWMWSA-N	PUBCHEM.COMPOUND:133268486	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-GAUTUEMISA-N	PUBCHEM.COMPOUND:11520894	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-MWBWAFHZSA-N	PUBCHEM.COMPOUND:137704508	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-OZFXDLPUSA-N	PUBCHEM.COMPOUND:74787553	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-QHPXJTPRSA-N	PUBCHEM.COMPOUND:25199957	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-QSRQGROMSA-N	PUBCHEM.COMPOUND:86289926	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-QVXCGEACSA-N	PUBCHEM.COMPOUND:71308311	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUROJSBIWGDYCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71433797	UMLS:C1261473	ridaforolimus	Soft tissue sarcoma	Designated/Withdrawn	2005-08-12
BUSXWGRAOZQTEY-SDBXPKJASA-N	PUBCHEM.COMPOUND:11318905	UMLS:C0035372	Trofinetide	Rett Syndrome	Designated	2015-02-11
BUSXWGRAOZQTEY-SDBXPKJASA-N	PUBCHEM.COMPOUND:11318905	UMLS:C0016667	Trofinetide	Fragile X Syndrome	Designated	2013-10-23
BVJRNKXVSYLNFD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60199173	UMLS:C2239176	3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride	HEPATOCELLULAR CARCINOMA	Designated	2017-07-03
BVJRNKXVSYLNFD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60199173	UMLS:C1332201	3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride	Diffuse Large B-Cell Lymphoma	Designated	2016-09-19
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C0429468	Sermorelin acetate	Anovulatory	Designated/Withdrawn	1990-02-13
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C0015544	Sermorelin acetate	growth failure	Designated/Approved	1988-09-14
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C3898072	Sermorelin acetate	Organic Growth Hormone Deficiency	Designated/Approved	1988-09-14
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C4084774	Sermorelin acetate	Weight loss	Designated/Withdrawn	1991-12-05
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C0001175	Sermorelin acetate	AIDS	Designated/Withdrawn	1991-12-05
BVLCEKWPOSAKSZ-YQMCHIOTSA-N	PUBCHEM.COMPOUND:16132412	UMLS:C0021359	Sermorelin acetate	Infertility	Designated/Withdrawn	1990-02-13
BVOZFCOTOYGLGD-VPQOAABJSA-N	PUBCHEM.COMPOUND:24847767	UMLS:C0221757	hyaluronic acid	ALPHA-1 ANTITRYPSIN DEFICIENCY	Designated	2002-03-19
BVOZFCOTOYGLGD-VPQOAABJSA-N	PUBCHEM.COMPOUND:24847767	UMLS:C0034067	hyaluronic acid	Emphysema	Designated	2002-03-19
BVOZFCOTOYGLGD-VPQOAABJSA-N	PUBCHEM.COMPOUND:24847767	UMLS:C0034067	hyaluronic acid	Emphysema	Designated	2017-01-18
BWCJZAGTBVMMTO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:139032792	UMLS:C0016667	Fenobam hydrochloride	Fragile X Syndrome	Designated	2006-11-20
BXNMTOQRYBFHNZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:159603	UMLS:C0079773	resiquimod	cutaneous T-cell lymphoma	Designated	2017-05-24
BXZVVICBKDXVGW-NKWVEPMBSA-N	PUBCHEM.COMPOUND:135398739	UMLS:C0021051	Dideoxyinosine	Immunodeficiency Syndrome	Designated/Withdrawn	1988-06-22
BYBLEWFAAKGYCD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4189	UMLS:C0029895	miconazole	Fungal otitis externa	Designated	2014-05-22
BYPFEZZEUUWMEJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4740	UMLS:C0004943	pentoxifylline	Behcet Syndrome	Designated	2012-06-14
CAKRAHQRJGUPIG-UHFFFAOYSA-L	PUBCHEM.COMPOUND:91997073	UMLS:C0017205	Alendronate disodium	Gaucher Disease	Designated	2001-02-13
CBPNZQVSJQDFBE-AQHKCTBXSA-N	PUBCHEM.COMPOUND:71433778	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-DYFDTRMFSA-N	PUBCHEM.COMPOUND:5938194	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-DZCFMHCPSA-N	PUBCHEM.COMPOUND:71296107	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-FAYWIXGWSA-N	PUBCHEM.COMPOUND:53486199	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-FUXHJELOSA-N	PUBCHEM.COMPOUND:6918289	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-GOFCWFHQSA-N	PUBCHEM.COMPOUND:145712265	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-HELDCPHESA-N	PUBCHEM.COMPOUND:137295275	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-HGVVHKDOSA-N	PUBCHEM.COMPOUND:23724530	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-KFZNZFKNSA-N	PUBCHEM.COMPOUND:71312019	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-LGVPMJLXSA-N	PUBCHEM.COMPOUND:152772378	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-MDHHOXSCSA-N	PUBCHEM.COMPOUND:9876533	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-NUTFMQKQSA-N	PUBCHEM.COMPOUND:154575198	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-PXVOFZQNSA-N	PUBCHEM.COMPOUND:18293306	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-QWRHTZMXSA-N	PUBCHEM.COMPOUND:86287409	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-RODMVNQKSA-N	PUBCHEM.COMPOUND:154827473	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:148191	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-UITOJQKMSA-N	PUBCHEM.COMPOUND:129317846	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-VBSVFFBFSA-N	PUBCHEM.COMPOUND:54608508	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-VYCIWTNRSA-N	PUBCHEM.COMPOUND:132274070	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBPNZQVSJQDFBE-ZJEVVSOISA-N	PUBCHEM.COMPOUND:24847874	UMLS:C0007134	Temsirolimus	Renal Cell Carcinoma	Designated/Approved	2004-12-16
CBQGYUDMJHNJBX-MOPGFXCFSA-N	PUBCHEM.COMPOUND:5311403	UMLS:C0027404	reboxetine	Narcolepsy	Designated	2018-10-15
CBQGYUDMJHNJBX-OALUTQOASA-N	PUBCHEM.COMPOUND:65856	UMLS:C0027404	reboxetine	Narcolepsy	Designated	2018-10-15
CBQGYUDMJHNJBX-RTBURBONSA-N	PUBCHEM.COMPOUND:127151	UMLS:C0027404	reboxetine	Narcolepsy	Designated	2018-10-15
CBQGYUDMJHNJBX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3022645	UMLS:C0027404	reboxetine	Narcolepsy	Designated	2018-10-15
CDAISMWEOUEBRE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:892	UMLS:C0035344	myo-inositol	Retinopathy of Prematurity	Designated	2005-04-07
CEFJVGZHQAGLHS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71584930	UMLS:C0238198	Ripretinib	Gastrointestinal Stromal Tumors	Designated/Approved	2014-10-02
CEUORZQYGODEFX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60795	UMLS:C0040517	aripiprazole	Tourette's Syndrome	Designated/Approved	2006-01-25
CEUORZQYGODEFX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60795	UMLS:C1425023	Aripiprazole	N-GLYCANASE 1	Designated	2019-07-22
CFMRIVODIXTERW-BDTNDASRSA-N	PUBCHEM.COMPOUND:11553430	UMLS:C0242852	[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol	Proliferative vitreoretinopathy	Designated	2020-04-13
CHNUOJQWGUIOLD-NFZZJPOKSA-N	PUBCHEM.COMPOUND:1549120	UMLS:C0282577	epalrestat	Congenital disorder of glycosylation	Designated	2020-03-26
CIBHDGPIOICRGX-ZQCHCGQNSA-N	PUBCHEM.COMPOUND:5311219	UMLS:C0595916	enisoprost	nephrotoxicity	Designated/Withdrawn	1989-10-20
CILIXQOJUNDIDU-ASQIGDHWSA-N	PUBCHEM.COMPOUND:16139605	UMLS:C0856825	Teduglutide	Acute Graft Versus Host Disease	Designated	2020-12-08
CIWBSHSKHKDKBQ-JLAZNSOCSA-N	PUBCHEM.COMPOUND:54670067	UMLS:C0036474	ascorbic acid	Scurvy	Designated/Approved	2007-08-31
CIWBSHSKHKDKBQ-JLAZNSOCSA-N	PUBCHEM.COMPOUND:54670067	UMLS:C0010674	ascorbic acid	Cystic Fibrosis	Designated	2018-07-30
CIWBSHSKHKDKBQ-JLAZNSOCSA-N	PUBCHEM.COMPOUND:54670067	UMLS:C0270911	ascorbic acid	Charcot-Marie-Tooth Disease Type 1A	Designated	2009-05-11
CJCSPKMFHVPWAR-JTQLQIEISA-N	PUBCHEM.COMPOUND:38853	UMLS:C0011854	methyldopa	Type 1 Diabetes	Designated	2017-01-12
CJXAEXPPLWQRFR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2782	UMLS:C0751122	clemizole	Dravet Syndrome	Designated	2017-04-19
CKLPLPZSUQEDRT-WPCRTTGESA-N	PUBCHEM.COMPOUND:44469321	UMLS:C0024530	cipargamin	Malaria	Designated	2020-05-01
CKLPLPZSUQEDRT-WPCRTTGESA-N	PUBCHEM.COMPOUND:44469321	UMLS:C0024530	Cipargamin	Malaria	Designated	2017-07-27
CKMOQBVBEGCJGW-UHFFFAOYSA-L	PUBCHEM.COMPOUND:135413496	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
CKRVBMUJCFKRND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86287614	UMLS:C0206698	Redaporfin	Cholangiocarcinoma	Designated	2017-04-12
CKTSBUTUHBMZGZ-SHYZEUOFSA-N	PUBCHEM.COMPOUND:13711	UMLS:C0023467	2'-deoxycytidine	Acute myelogenous leukemia	Designated	1996-09-09
CLEFVPILGAPOTG-NSHDSACASA-N	PUBCHEM.COMPOUND:146591762	UMLS:C0002895	6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one	Sickle Cell Disease	Designated	2020-09-18
CLQRMSBSMHXMMC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:153980	UMLS:C0010346	Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate	Crohn's Disease	Designated/Withdrawn	1998-05-13
CMJCXYNUCSMDBY-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:50922675	UMLS:C0025202	encorafenib	melanoma	Designated	2013-11-19
CMSMOCZEIVJLDB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2907	UMLS:C0018133	cyclophosphamide	GRAFT VERSUS HOST DISEASE	Designated	2011-06-17
CMSMOCZEIVJLDB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2907	UMLS:C0036421	cyclophosphamide	Systemic sclerosis	Designated	2011-06-07
CNSJWSLXKSJQFE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:46944243	UMLS:C1800706	3-pentylbenzenacetic acid sodium salt	Idiopathic Pulmonary Fibrosis	Designated	2015-02-11
COVZYZSDYWQREU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2478	UMLS:C0220654	Busulfan	neoplastic meningitis	Designated/Withdrawn	2001-03-05
COVZYZSDYWQREU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2478	UMLS:C0006826	Busulfan	MALIGNANCIES	Designated	1997-07-07
COVZYZSDYWQREU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2478	UMLS:C0006826	Busulfan	MALIGNANCIES	Designated	1994-04-21
COVZYZSDYWQREU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2478	UMLS:C0006826	Busulfan	MALIGNANCIES	Designated/Approved	1994-07-28
CPEUVMUXAHMANV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:35802	UMLS:C0029001	flubendazole	Onchocerciasis	Designated/Withdrawn	2013-10-25
CPEUVMUXAHMANV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:35802	UMLS:C0013884	flubendazole	Lymphatic Filariasis	Designated/Withdrawn	2014-01-23
CPKVUHPKYQGHMW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:410087	UMLS:C0014236	povidone iodine	Endophthalmitis	Designated	2018-11-30
CPKVUHPKYQGHMW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:410087	UMLS:C0014236	povidone iodine	Endophthalmitis	Designated	2017-11-27
CPMDPSXJELVGJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135423438	UMLS:C0036421	nintedanib	Systemic sclerosis	Designated/Approved	2016-07-06
CPMDPSXJELVGJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135423438	UMLS:C0206062	nintedanib	Interstitial lung disease	Designated/Approved	2016-07-06
CPMDPSXJELVGJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135423438	UMLS:C1800706	nintedanib	Idiopathic Pulmonary Fibrosis	Designated/Approved	2011-06-29
CPMDPSXJELVGJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135423438	UMLS:C0025500	Nintedanib	Mesothelioma	Designated	2016-12-12
CQOQDQWUFQDJMK-SSTWWWIQSA-N	PUBCHEM.COMPOUND:66414	UMLS:C0017636	2-methoxyestradiol	Glioblastoma	Designated/Withdrawn	2006-06-16
CQOQDQWUFQDJMK-SSTWWWIQSA-N	PUBCHEM.COMPOUND:66414	UMLS:C3203102	2-methoxyestradiol	PULMONARY ARTERIAL HYPERTENSION	Designated	2005-04-11
CQOQDQWUFQDJMK-SSTWWWIQSA-N	PUBCHEM.COMPOUND:66414	UMLS:C4721610	2-methoxyestradiol	Ovarian Cancer	Designated/Withdrawn	2005-04-04
CQOQDQWUFQDJMK-SSTWWWIQSA-N	PUBCHEM.COMPOUND:66414	UMLS:C0026764	2-methoxyestradiol	Multiple Myeloma	Designated/Withdrawn	2001-07-10
CRXRROKIRDSTAH-ZUDQWMAJSA-L	PUBCHEM.COMPOUND:134687480	UMLS:C0032580	magnesium lysinate bis eicosapentaenoate	Familial Adenomatous Polyposis	Designated	2015-12-23
CSKDFZIMJXRJGH-VWLPUNTISA-N	PUBCHEM.COMPOUND:16124688	UMLS:C3714514	tecovirimat	Infections	Designated	2010-09-29
CSKDFZIMJXRJGH-VWLPUNTISA-N	PUBCHEM.COMPOUND:16124688	UMLS:C0037356	tecovirimat	smallpox	Designated	2006-12-18
CSKDFZIMJXRJGH-VWLPUNTISA-N	PUBCHEM.COMPOUND:16124688	UMLS:C0206580	tecovirimat	Orthopoxvirus	Designated	2010-09-29
CSKDFZIMJXRJGH-VWLPUNTISA-N	PUBCHEM.COMPOUND:16124688	UMLS:C0037356	tecovirimat	smallpox	Designated/Approved	2006-12-27
CTENFNNZBMHDDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65340	UMLS:C0240059	dopamine hydrochloride	Intraventricular hemorrhage	Designated	2017-10-24
CTENFNNZBMHDDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65340	UMLS:C0857353	dopamine hydrochloride	Hypotensive	Designated	2017-10-24
CTENFNNZBMHDDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65340	UMLS:C0151526	dopamine hydrochloride	Premature	Designated	2017-10-24
CTPOHARTNNSRSR-APJZLKAGSA-N	PUBCHEM.COMPOUND:6917951	UMLS:C3203102	Beraprost	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	1999-04-29
CTPOHARTNNSRSR-NOQAJONNSA-N	PUBCHEM.COMPOUND:10501053	UMLS:C3203102	beraprost sodium 314d	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	2011-12-22
CTPOHARTNNSRSR-OUKQBFOZSA-N	PUBCHEM.COMPOUND:5282428	UMLS:C3203102	Beraprost	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	1999-04-29
CTPOHARTNNSRSR-SEYXRHQNSA-N	PUBCHEM.COMPOUND:45358438	UMLS:C3203102	Beraprost	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	1999-04-29
CTPOHARTNNSRSR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2352	UMLS:C3203102	Beraprost	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	1999-04-29
CUEDNFKBTFCOSV-UZVLBLASSA-L	PUBCHEM.COMPOUND:16683012	UMLS:C0023467	Sodium Stibogluconate	Acute myeloid leukemia	Designated	2017-06-05
CUEDNFKBTFCOSV-UZVLBLASSA-L	PUBCHEM.COMPOUND:16683012	UMLS:C0023283	Sodium stibogluconate	Cutaneous leishmaniasis	Designated	2006-06-16
CUEDNFKBTFCOSV-UZVLBLASSA-L	PUBCHEM.COMPOUND:16683012	UMLS:C0023283	sodium stibogluconate	Cutaneous leishmaniasis	Designated	2009-10-28
CUIHSIWYWATEQL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10113978	UMLS:C4721610	pazopanib	Ovarian Cancer	Designated/Withdrawn	2013-05-06
CUIHSIWYWATEQL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10113978	UMLS:C1261473	pazopanib	Soft Tissue Sarcomas	Designated/Approved	2009-10-20
CUIHSIWYWATEQL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10113978	UMLS:C0039445	pazopanib	hereditary hemorrhagic telangiectasia	Designated	2019-10-09
CULUWZNBISUWAS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:31593	UMLS:C0041234	benznidazole	Chagas Disease	Designated	2017-07-05
CULUWZNBISUWAS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:31593	UMLS:C0041234	benznidazole	Chagas Disease	Designated/Approved	2014-04-14
CURLTUGMZLYLDI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:280	UMLS:C0040997	carbon dioxide	Trigeminal Neuralgia	Designated	2015-12-17
CVSVTCORWBXHQV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:586	UMLS:C0020179	Creatine	Huntington's Disease	Designated/Withdrawn	2005-10-11
CVSVTCORWBXHQV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:586	UMLS:C0002736	creatine	Amyotrophic Lateral Sclerosis	Designated	2002-02-12
CVWXJKQAOSCOAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24889392	UMLS:C0023467	quizartinib	Acute myeloid leukemia	Designated	2009-03-18
CWRVKFFCRWGWCS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5917	UMLS:C0027404	pentetrazol	Narcolepsy	Designated	2017-03-16
CWRVKFFCRWGWCS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5917	UMLS:C0751757	pentetrazol	Idiopathic Hypersomnia	Designated	2015-09-09
CXKWCBBOMKCUKX-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6099	UMLS:C0025637	methylene blue	Methemoglobinemia	Designated	2012-07-24
CXOXHMZGEKVPMT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2789	UMLS:C0238111	clobazam	Lennox-Gastaut syndrome	Designated/Approved	2007-12-18
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
CXWQXGNFZLHLHQ-DPFCLETOSA-N	PUBCHEM.COMPOUND:25058166	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
CXWRXYDTWCBSJF-DPTNTHPESA-N	PUBCHEM.COMPOUND:59443782	UMLS:C0027819	firtecan pegol	Neuroblastoma	Designated	2011-04-18
CYOHGALHFOKKQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10127622	UMLS:C1337013	selumetinib	Differentiated Thyroid Cancer	Designated/Withdrawn	2016-05-10
CYOHGALHFOKKQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10127622	UMLS:C0027831	selumetinib	Neurofibromatosis type 1	Designated/Approved	2018-02-14
CYOHGALHFOKKQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10127622	UMLS:C0220633	selumetinib	Uveal melanoma	Designated/Withdrawn	2015-04-15
CYQFCXCEBYINGO-IAGOWNOFSA-N	PUBCHEM.COMPOUND:16078	UMLS:C2239176	delta-9-tetrahydrocannabinol	HEPATOCELLULAR CARCINOMA	Designated	2019-11-27
CYQFCXCEBYINGO-IAGOWNOFSA-N	PUBCHEM.COMPOUND:16078	UMLS:C4084774	Dronabinol	Weight loss	Designated/Approved	1991-01-15
CYQFCXCEBYINGO-IAGOWNOFSA-N	PUBCHEM.COMPOUND:16078	UMLS:C0001175	Dronabinol	AIDS	Designated/Approved	1991-01-15
CZAKJJUNKNPTTO-AJFJRRQVSA-N	PUBCHEM.COMPOUND:135463437	UMLS:C0268119	fosdenopterin	Molybdenum cofactor deficiency	Designated/Approved	2009-11-05
CZAKJJUNKNPTTO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135894389	UMLS:C0268119	fosdenopterin	Molybdenum cofactor deficiency	Designated/Approved	2009-11-05
CZGVOBIGEBDYTP-VSGBNLITSA-N	PUBCHEM.COMPOUND:53492727	UMLS:C0008312	linerixibat	Primary Biliary Cholangitis	Designated	2019-09-18
CZPDCEDNNVRQEX-INZIHYEWSA-L	PUBCHEM.COMPOUND:154723996	UMLS:C0162565	Heme arginate	Acute Porphyria	Designated	1988-03-10
CZPDCEDNNVRQEX-INZIHYEWSA-L	PUBCHEM.COMPOUND:154723996	UMLS:C3463824	Heme arginate	Myelodysplastic Syndromes	Designated	1994-03-01
DAEPDZWVDSPTHF-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23662274	UMLS:C0010674	Sodium pyruvate	Cystic Fibrosis	Designated	2003-03-31
DASQOOZCTWOQPA-GXKRWWSZSA-L	PUBCHEM.COMPOUND:11329481	UMLS:C0029463	Methotrexate sodium	Osteogenic sarcoma	Designated/Approved	1985-10-21
DBGIVFWFUFKIQN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3337	UMLS:C0238111	fenfluramine	Lennox-Gastaut syndrome	Designated	2017-06-19
DDBREPKUVSBGFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4763	UMLS:C0159020	phenobarbital	Neonatal seizures	Designated/Withdrawn	2017-10-25
DDBREPKUVSBGFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4763	UMLS:C0159020	Phenobarbital	Neonatal seizures	Designated	2020-02-26
DDBREPKUVSBGFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4763	UMLS:C0159020	phenobarbital	Neonatal seizures	Designated	2019-10-02
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0014544	midazolam	Epilepsy	Designated	2006-05-08
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C1148454	midazolam	seizure activity	Designated	2006-05-08
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0038220	midazolam	Status Epilepticus	Designated	2018-01-30
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0036572	midazolam	Seizures	Designated/Approved	2009-10-20
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C1148454	midazolam	seizure activity	Designated/Approved	2009-10-20
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C1959629	midazolam	Seizure	Designated/Approved	2009-10-20
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0036572	midazolam	Seizures	Designated	2016-02-08
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0038220	midazolam	Status Epilepticus	Designated/Approved	2016-02-04
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0036572	midazolam	Seizures	Designated	2012-07-24
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0038220	midazolam	Status Epilepticus	Designated	2016-02-18
DDLIGBOFAVUZHB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4192	UMLS:C0413048	midazolam	Insecticide poisoning	Designated	2016-02-08
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-FLDZURHUSA-N	PUBCHEM.COMPOUND:86289069	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-JPZSUCLZSA-N	PUBCHEM.COMPOUND:138107728	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-LIXSYSMXSA-N	PUBCHEM.COMPOUND:44311916	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-MEUDYGGUSA-N	PUBCHEM.COMPOUND:44420813	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-OULOTJBUSA-N	PUBCHEM.COMPOUND:448601	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-RRCPSWKPSA-N	PUBCHEM.COMPOUND:6400441	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:383414	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0001206	Octreotide	Acromegaly	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0206754	octreotide	Neuroendocrine Tumors	Designated	2010-08-05
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0027651	Octreotide	Tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0011993	Octreotide	Vipoma	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0016382	Octreotide	Flushing	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0391970	Octreotide	Malignant carcinoid tumors	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C0011991	Octreotide	Diarrhea	Designated/Approved	1998-08-24
DEQANNDTNATYII-XOEBDJBESA-N	PUBCHEM.COMPOUND:90488715	UMLS:C1443924	Octreotide	Severe diarrhea	Designated/Approved	1998-08-24
DERJYEZSLHIUKF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9703	UMLS:C0555198	Procarbazine HCl	Malignant Glioma	Designated	2006-08-08
DEVSOMFAQLZNKR-RJRFIUFISA-N	PUBCHEM.COMPOUND:71481097	UMLS:C0026764	selinexor	Multiple Myeloma	Designated/Approved	2015-01-05
DEVSOMFAQLZNKR-RJRFIUFISA-N	PUBCHEM.COMPOUND:71481097	UMLS:C0023467	selinexor	Acute myeloid leukemia	Designated	2014-05-14
DEVSOMFAQLZNKR-RJRFIUFISA-N	PUBCHEM.COMPOUND:71481097	UMLS:C1332201	selinexor	Diffuse Large B-Cell Lymphoma	Designated/Approved	2014-05-14
DEVSOMFAQLZNKR-RJRFIUFISA-N	PUBCHEM.COMPOUND:71481097	UMLS:C0026764	selinexor	Multiple Myeloma	Designated/Approved	2015-01-05
DEVSOMFAQLZNKR-RJRFIUFISA-N	PUBCHEM.COMPOUND:71481097	UMLS:C1261473	selinexor	Soft tissue sarcoma	Designated	2016-07-07
DGBIGWXXNGSACT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2802	UMLS:C0234166	Clonazepam	Hyperekplexia	Designated	1994-08-04
DGMKFQYCZXERLX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4922	UMLS:C0235974	Proglumide	PANCREATIC CANCER	Designated	2020-06-16
DGMKFQYCZXERLX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4922	UMLS:C0024623	Proglumide	Gastric Cancer	Designated	2020-07-23
DGMKFQYCZXERLX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4922	UMLS:C0149521	Proglumide	Chronic pancreatitis	Designated	2020-09-09
DGTVQJOTEDTFMR-VYFXDUNUSA-N	PUBCHEM.COMPOUND:126970648	UMLS:C0342543	Histrelin acetate	Central Precocious Puberty	Designated/Approved	1988-08-10
DGVCEXQFNYYRQI-BTJKTKAUSA-N	PUBCHEM.COMPOUND:46937352	UMLS:C1368683	milciclib maleate	epithelial tumors	Designated/Withdrawn	2012-09-20
DHMTURDWPRKSOA-RUZDIDTESA-N	PUBCHEM.COMPOUND:148195	UMLS:C0009450	lonafarnib	Infection	Designated	2013-11-19
DHMTURDWPRKSOA-RUZDIDTESA-N	PUBCHEM.COMPOUND:148195	UMLS:C0011220	lonafarnib	Hepatitis Delta Virus	Designated	2013-11-19
DHMTURDWPRKSOA-RUZDIDTESA-N	PUBCHEM.COMPOUND:148195	UMLS:C0033300	lonafarnib	Hutchinson-Gilford Progeria Syndrome	Designated/Approved	2011-04-18
DHZBEENLJMYSHQ-XCVPVQRUSA-N	PUBCHEM.COMPOUND:5944	UMLS:C0016436	cantharidin	Folliculitis	Designated	2012-07-24
DHZBEENLJMYSHQ-XCVPVQRUSA-N	PUBCHEM.COMPOUND:5944	UMLS:C0221271	cantharidin	Elastosis perforans serpiginosa	Designated	2012-07-24
DHZBEENLJMYSHQ-XCVPVQRUSA-N	PUBCHEM.COMPOUND:5944	UMLS:C0263382	cantharidin	Kyrle's disease	Designated	2012-07-24
DHZIAGCFFSRULK-UHFFFAOYSA-H	PUBCHEM.COMPOUND:91667962	UMLS:C0006666	hexasodium phytate	Calciphylaxis	Designated	2012-12-02
DIKSYHCCYVYKRO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54684617	UMLS:C0036421	paquinimod	Systemic sclerosis	Designated	2014-01-17
DJUFPMUQJKWIJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:107771	UMLS:C0041234	Pyronaridine	Chagas Disease	Designated	2019-10-21
DJWUNCQRNNEAKC-UHFFFAOYSA-L	PUBCHEM.COMPOUND:11192	UMLS:C0019202	Zinc acetate	Wilson's Disease	Designated/Approved	1985-11-06
DKHGMERMDICWDU-GHDNBGIDSA-N	PUBCHEM.COMPOUND:5282367	UMLS:C2239176	menatetrenone	HEPATOCELLULAR CARCINOMA	Designated	2010-11-02
DKHGMERMDICWDU-GHDNBGIDSA-N	PUBCHEM.COMPOUND:5282367	UMLS:C0023487	menatetrenone	Acute Promyelocytic Leukemia	Designated	2010-11-02
DKHGMERMDICWDU-GHDNBGIDSA-N	PUBCHEM.COMPOUND:5282367	UMLS:C0023467	menatetrenone	Acute myeloid leukemia	Designated	2011-03-17
DKHGMERMDICWDU-GHDNBGIDSA-N	PUBCHEM.COMPOUND:5282367	UMLS:C3463824	menatetrenone	MYELODYSPLASTIC SYNDROME	Designated	2011-02-04
DLGOEMSEDOSKAD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2578	UMLS:C0006826	Carmustine	MALIGNANCIES	Designated	2000-07-03
DMAHZCZCPVOYGS-ZLSDMPCXSA-L	PUBCHEM.COMPOUND:135565472	UMLS:C0027962	tin ethyl etiopurpurin	Nevus	Designated	2018-01-16
DMAHZCZCPVOYGS-ZLSDMPCXSA-L	PUBCHEM.COMPOUND:135565472	UMLS:C0007117	tin ethyl etiopurpurin	Basal cell carcinoma	Designated	2018-01-16
DMJNNHOOLUXYBV-PQTSNVLCSA-N	PUBCHEM.COMPOUND:441130	UMLS:C0035243	Meropenem	Respiratory Tract Infection	Designated/Withdrawn	2000-04-27
DMJNNHOOLUXYBV-PQTSNVLCSA-N	PUBCHEM.COMPOUND:441130	UMLS:C0010674	Meropenem	Cystic Fibrosis	Designated/Withdrawn	2000-04-27
DNUXJWBKTMJNEP-JVSLBXKQSA-N	PUBCHEM.COMPOUND:131842305	UMLS:C0494165	Disaccharide tripeptide glycerol dipalmitoyl	hepatic metastases	Designated	1990-03-01
DNUXJWBKTMJNEP-JVSLBXKQSA-N	PUBCHEM.COMPOUND:131842305	UMLS:C1319315	Disaccharide tripeptide glycerol dipalmitoyl	Colorectal Adenocarcinoma	Designated	1990-03-01
DOAUQKRTILFGHV-PDCMDPCFSA-N	PUBCHEM.COMPOUND:146170995	UMLS:C0036992	glepaglutide	Short Bowel Syndrome	Designated	2017-10-20
DOHVAKFYAHLCJP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135413525	UMLS:C0079773	Peldesine	cutaneous T-cell lymphoma	Designated	1993-10-05
DOMWKUIIPQCAJU-LJHIYBGHSA-N	PUBCHEM.COMPOUND:169870	UMLS:C0151526	hydroxyprogesterone caproate	Preterm Birth	Designated/Approved	2007-01-25
DOMWKUIIPQCAJU-LJHIYBGHSA-N	PUBCHEM.COMPOUND:169870	UMLS:C0151526	hydroxyprogesterone caproate	Preterm Birth	Designated/Approved	2007-01-25
DOUYETYNHWVLEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57469	UMLS:C0007099	Imiquimod	Carcinoma in Situ	Designated	2014-12-03
DPFYBZWSVVKNPZ-AQWIXGDGSA-N	PUBCHEM.COMPOUND:71315856	UMLS:C0155119	Dextran 70	Recurrent corneal erosion	Designated	1990-03-05
DPFYBZWSVVKNPZ-SYWJPMBBSA-N	PUBCHEM.COMPOUND:92043573	UMLS:C0010674	dextran 1	Cystic Fibrosis	Designated	2003-03-21
DPHUWDIXHNQOSY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10331844	UMLS:C0235974	napabucasin	PANCREATIC CANCER	Designated	2016-10-25
DPHUWDIXHNQOSY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10331844	UMLS:C0024623	napabucasin	Gastric Cancer	Designated/Withdrawn	2016-06-20
DQCKKXVULJGBQN-XFWGSAIBSA-N	PUBCHEM.COMPOUND:5360515	UMLS:C0241910	naltrexone	Autoimmune hepatitis	Designated	2015-01-13
DQCKKXVULJGBQN-XFWGSAIBSA-N	PUBCHEM.COMPOUND:5360515	UMLS:C0032768	naltrexone	Postherpetic neuralgia	Designated	2015-02-23
DQCKKXVULJGBQN-XFWGSAIBSA-N	PUBCHEM.COMPOUND:5360515	UMLS:C0010346	naltrexone	Crohn's Disease	Designated	2010-01-19
DQHNAVOVODVIMG-RGECMCKFSA-M	PUBCHEM.COMPOUND:5487426	UMLS:C0010674	Tiotropium bromide	Cystic Fibrosis	Designated/Withdrawn	2008-01-08
DQHNAVOVODVIMG-RGECMCKFSA-M	PUBCHEM.COMPOUND:5487426	UMLS:C1547996	Tiotropium bromide	Pulmonary Function	Designated/Withdrawn	2008-01-08
DQJDBUPLRMRBAB-WZTVWXICSA-N	PUBCHEM.COMPOUND:24970412	UMLS:C0268407	tafamidis meglumine	Amyloid cardiomyopathy	Designated/Approved	2012-02-17
DQOCFCZRZOAIBN-AZCDKEHOSA-L	PUBCHEM.COMPOUND:146156970	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-AZCDKEHOSA-L	PUBCHEM.COMPOUND:146156970	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-BYFNXCQMSA-M	PUBCHEM.COMPOUND:152743320	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-BYFNXCQMSA-M	PUBCHEM.COMPOUND:152743320	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-IQFXPAJWSA-L	PUBCHEM.COMPOUND:45357193	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-IQFXPAJWSA-L	PUBCHEM.COMPOUND:45357193	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-JLKASCPDSA-L	PUBCHEM.COMPOUND:6474319	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-JLKASCPDSA-L	PUBCHEM.COMPOUND:6474319	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-PMEYKKDOSA-L	PUBCHEM.COMPOUND:50935334	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-PMEYKKDOSA-L	PUBCHEM.COMPOUND:50935334	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-UVKKECPRSA-L	PUBCHEM.COMPOUND:24892771	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-UVKKECPRSA-L	PUBCHEM.COMPOUND:24892771	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
DQOCFCZRZOAIBN-WZHZPDAFSA-L	PUBCHEM.COMPOUND:16056828	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
DQQCJDBYNZMPOA-FFXKMJQXSA-N	PUBCHEM.COMPOUND:6852399	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
DQQCJDBYNZMPOA-FFXKMJQXSA-N	PUBCHEM.COMPOUND:6852399	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
DQQCJDBYNZMPOA-FFXKMJQXSA-N	PUBCHEM.COMPOUND:6852399	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
DRFDPXKCEWYIAW-UHFFFAOYSA-M	PUBCHEM.COMPOUND:4194514	UMLS:C0029434	risedronate sodium	Osteogenesis Imperfecta	Designated/Withdrawn	2006-12-18
DRHXTSWSUAJOJZ-FMDGEEDCSA-N	PUBCHEM.COMPOUND:5289024	UMLS:C0039373	N-acetyl-glucosamine thiazoline	Tay-Sachs Disease	Designated	2006-02-06
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C2239176	melatonin	HEPATOCELLULAR CARCINOMA	Designated	2019-02-28
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0038819	Melatonin	Heat Stroke	Designated	2019-04-22
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0035344	Melatonin	Retinopathy of Prematurity	Designated	2020-04-20
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0559477	melatonin	Perinatal asphyxia	Designated	2018-03-08
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0038525	melatonin	Subarachnoid Hemorrhage	Designated	2018-03-28
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0035344	Melatonin	Retinopathy of Prematurity	Designated	2020-04-20
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C2937358	Melatonin	Intracerebral Hemorrhage	Designated	2020-01-22
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0036992	melatonin	Short Bowel Syndrome	Designated	2017-02-14
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0520799	melatonin	Acute Radiation Syndrome	Designated	2018-10-22
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0039082	melatonin	Syndrome	Designated	2016-11-03
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0877792	Melatonin	Circadian rhythm sleep disorders	Designated	1993-11-15
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0014356	melatonin	Enterocolitis	Designated	2017-01-25
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C3898147	melatonin	Neonatal Hypoxic Ischemic Encephalopathy	Designated	2013-04-12
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0456909	Melatonin	Blind	Designated	1993-11-15
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0851578	Melatonin	Sleep-wake disorder	Designated	2004-07-09
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0456909	Melatonin	Blind	Designated	2004-07-09
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0572025	melatonin	Acetaminophen overdose	Designated	2017-03-02
DRLFMBDRBRZALE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:896	UMLS:C0235974	melatonin	PANCREATIC CANCER	Designated	2019-10-09
DRMCATBEKSVAPL-BNTLRKBRSA-N	PUBCHEM.COMPOUND:9887053	UMLS:C4721610	Oxaliplatin	Ovarian Cancer	Designated	1992-10-06
DSBPAFWXMCKFIM-BSOLPCOYSA-N	PUBCHEM.COMPOUND:9844677	UMLS:C0027796	L-threonyl-L-prolyl-L-prolyl-L-threonine	Neuropathic Pain	Designated	2005-04-26
DSBPAFWXMCKFIM-BSOLPCOYSA-N	PUBCHEM.COMPOUND:9844677	UMLS:C0037929	L-threonyl-L-prolyl-L-prolyl-L-threonine	Spinal Cord Injury	Designated	2005-04-26
DSDNAKHZNJAGHN-GGIHZKEUSA-N	PUBCHEM.COMPOUND:44564218	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-IHCAYWNCSA-N	PUBCHEM.COMPOUND:104826	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-MXTYGGKSSA-N	PUBCHEM.COMPOUND:5702546	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5148108	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-VQBCBPMFSA-N	PUBCHEM.COMPOUND:6324660	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-WLJYXNHNSA-N	PUBCHEM.COMPOUND:134688669	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DSDNAKHZNJAGHN-YOHYOAFPSA-N	PUBCHEM.COMPOUND:2733497	UMLS:C0030200	resiniferatoxin	intractable pain	Designated	2003-05-13
DUGMCDWNXXFHDE-VZYDHVRKSA-N	PUBCHEM.COMPOUND:6450830	UMLS:C3714796	ibutamoren mesylate	Growth hormone deficiency	Designated	2017-06-15
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C3539721	osimertinib	Non-Small Cell Lung Cancer	Designated/Approved	2014-09-04
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C1414313	osimertinib	EPIDERMAL GROWTH FACTOR RECEPTOR	Designated/Approved	2014-09-04
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C3539721	osimertinib	Non-Small Cell Lung Cancer	Designated/Approved	2014-09-04
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C3539721	osimertinib	Non-Small Cell Lung Cancer	Designated/Approved	2014-09-04
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C1414313	osimertinib	EPIDERMAL GROWTH FACTOR RECEPTOR	Designated/Approved	2014-09-04
DUYJMQONPNNFPI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71496458	UMLS:C1414313	osimertinib	EPIDERMAL GROWTH FACTOR RECEPTOR	Designated/Approved	2014-09-04
DVASNQYQOZHAJN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:41870	UMLS:C0020433	Flumecinol	Hyperbilirubinemia	Designated/Withdrawn	1985-01-15
DVZQUMSQEGOYMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:122540907	UMLS:C0017636	(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid	Glioblastoma	Designated	2018-08-09
DWGQFQRWFYIINU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134687437	UMLS:C2363142	tinostamustine hydrochloride	T-Cell Prolymphocytic Leukemia	Designated	2019-03-15
DWGQFQRWFYIINU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134687437	UMLS:C0026764	tinostamustine hydrochloride	Multiple Myeloma	Designated	2018-04-02
DWLTUUXCVGVRAV-XWRHUKJGSA-N	PUBCHEM.COMPOUND:9832404	UMLS:C0039082	davunetide	Syndrome	Designated	2018-02-22
DWLTUUXCVGVRAV-XWRHUKJGSA-N	PUBCHEM.COMPOUND:9832404	UMLS:C0038868	davunetide	Progressive supranuclear palsy	Designated	2009-12-07
DWLTUUXCVGVRAV-XWRHUKJGSA-N	PUBCHEM.COMPOUND:9832404	UMLS:C1423715	davunetide	ADNP	Designated	2018-02-22
DWYRIWUZIJHQKQ-SANMLTNESA-N	PUBCHEM.COMPOUND:118023034	UMLS:C0024899	avapritinib	Mastocytosis	Designated	2016-01-21
DWYRIWUZIJHQKQ-SANMLTNESA-N	PUBCHEM.COMPOUND:118023034	UMLS:C0238198	avapritinib	Gastrointestinal Stromal Tumors	Designated/Approved	2016-01-06
DYDCUQKUCUHJBH-REOHCLBHSA-N	PUBCHEM.COMPOUND:449215	UMLS:C0017205	L-cycloserine	Gaucher's Disease	Designated	1989-08-01
DYLUUSLLRIQKOE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:89683805	UMLS:C0023467	enasidenib	Acute myelogenous leukemia	Designated/Approved	2014-06-12
DYNHJHQFHQTFTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10366136	UMLS:C0024623	crenolanib	Gastric Cancer	Designated	2019-10-21
DYNHJHQFHQTFTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10366136	UMLS:C0006826	crenolanib	Cancer	Designated	2019-10-21
DYNHJHQFHQTFTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10366136	UMLS:C1261473	crenolanib	Soft tissue sarcoma	Designated	2011-03-18
DYNHJHQFHQTFTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10366136	UMLS:C0023467	crenolanib	Acute myelogenous leukemia	Designated	2012-10-31
DZNHRKNLTYYMQA-ZIGBGYJWSA-N	PUBCHEM.COMPOUND:135738681	UMLS:C4721579	Leucovorin calcium	Metastatic colorectal cancer	Designated/Withdrawn	1988-06-23
FASDKYOPVNHBLU-SSDOTTSWSA-N	PUBCHEM.COMPOUND:59868	UMLS:C1540912	Dexpramipexole	Hypereosinophilic syndrome	Designated	2019-04-22
FASDKYOPVNHBLU-SSDOTTSWSA-N	PUBCHEM.COMPOUND:59868	UMLS:C0002736	dexpramipexole	Amyotrophic Lateral Sclerosis	Designated	2007-10-11
FASDKYOPVNHBLU-ZETCQYMHSA-N	PUBCHEM.COMPOUND:119570	UMLS:C0040517	pramipexole	Tourette's Syndrome	Designated	2008-01-31
FBHSPRKOSMHSIF-GRMWVWQJSA-N	PUBCHEM.COMPOUND:189821	UMLS:C3495559	deflazacort	JIA	Designated/Withdrawn	2015-10-22
FBHSPRKOSMHSIF-GRMWVWQJSA-N	PUBCHEM.COMPOUND:189821	UMLS:C0003864	deflazacort	Arthritis	Designated/Withdrawn	2015-10-22
FBHSPRKOSMHSIF-GRMWVWQJSA-N	PUBCHEM.COMPOUND:189821	UMLS:C0013264	deflazacort	DUCHENNE MUSCULAR DYSTROPHY	Designated/Approved	2013-08-16
FBHSPRKOSMHSIF-GRMWVWQJSA-N	PUBCHEM.COMPOUND:189821	UMLS:C0013264	deflazacort	DUCHENNE MUSCULAR DYSTROPHY	Designated	2010-09-16
FBHSPRKOSMHSIF-GRMWVWQJSA-N	PUBCHEM.COMPOUND:189821	UMLS:C0013264	deflazacort	DUCHENNE MUSCULAR DYSTROPHY	Designated/Approved	2013-08-16
FBKMWOJEPMPVTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135564890	UMLS:C0025202	epacadostat	melanoma	Designated	2016-02-11
FBOZXECLQNJBKD-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:126941	UMLS:C3495559	methotrexate	Juvenile rheumatoid arthritis	Designated/Withdrawn	1993-08-23
FBOZXECLQNJBKD-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:126941	UMLS:C0026896	Methotrexate	Myasthenia Gravis	Designated	2014-08-28
FBOZXECLQNJBKD-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:126941	UMLS:C0242852	methotrexate	Proliferative vitreoretinopathy	Designated	2018-04-11
FBOZXECLQNJBKD-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:126941	UMLS:C0023449	methotrexate	Acute lymphoblastic leukemia	Designated	2009-08-20
FBOZXECLQNJBKD-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:126941	UMLS:C0032987	methotrexate	Ectopic Pregnancy	Designated	2019-03-25
FBPFZTCFMRRESA-KVTDHHQDSA-N	PUBCHEM.COMPOUND:6251	UMLS:C0006267	MANNITOL	Bronchiectasis	Designated/Approved	2005-02-11
FBPFZTCFMRRESA-KVTDHHQDSA-N	PUBCHEM.COMPOUND:6251	UMLS:C0010674	MANNITOL	Cystic Fibrosis	Designated/Approved	2005-02-11
FCCNSUIJIOOXEZ-SJYYZXOBSA-N	PUBCHEM.COMPOUND:37720	UMLS:C0026703	pentosan polysulfate	Mucopolysaccharidosis	Designated	2020-04-28
FCKJYANJHNLEEP-SRLFHJKTSA-N	PUBCHEM.COMPOUND:6434253	UMLS:C0543799	24,25 dihydroxycholecalciferol	uremic osteodystrophy	Designated	1987-02-27
FCKJYANJHNLEEP-XRWYNYHCSA-N	PUBCHEM.COMPOUND:5283748	UMLS:C3536983	Secalciferol	Familial Hypophosphatemic Rickets	Designated	1993-07-26
FCWSQAKOPTZCOD-SQYSSJHTSA-N	PUBCHEM.COMPOUND:101163123	UMLS:C0750952	etoposide toniribate	Biliary Tract Cancer	Designated	2019-02-11
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C4721610	olaparib	Ovarian Cancer	Designated/Approved	2013-10-16
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C1514428	olaparib	Primary Peritoneal Cancer	Designated/Approved	2018-05-15
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C4721610	olaparib	Ovarian Cancer	Designated/Approved	2013-10-16
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C1514428	olaparib	Primary Peritoneal Cancer	Designated/Approved	2018-05-15
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C1514428	olaparib	Primary Peritoneal Cancer	Designated/Approved	2018-05-15
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C0238122	olaparib	Fallopian Tube Cancer	Designated/Approved	2018-05-15
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C4721610	olaparib	Ovarian Cancer	Designated/Approved	2013-10-16
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C0238122	olaparib	Fallopian Tube Cancer	Designated/Approved	2018-05-15
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C4721610	olaparib	Ovarian Cancer	Designated/Approved	2013-10-16
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C0235974	olaparib	PANCREATIC CANCER	Designated/Approved	2018-10-11
FDLYAMZZIXQODN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23725625	UMLS:C0238122	olaparib	Fallopian Tube Cancer	Designated/Approved	2018-05-15
FDMUNKXWYMSZIR-NQWKWHCYSA-N	PUBCHEM.COMPOUND:11531457	UMLS:C0024530	artemisone	Malaria	Designated	2017-07-19
FDRNWTJTHBSPMW-BBJOQENWSA-L	PUBCHEM.COMPOUND:9570985	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FDRNWTJTHBSPMW-GNXCPKRQSA-L	PUBCHEM.COMPOUND:5362369	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FDRNWTJTHBSPMW-JQVQFYFGSA-L	PUBCHEM.COMPOUND:59844	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FDRNWTJTHBSPMW-PHCXSBOASA-L	PUBCHEM.COMPOUND:11957491	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FDRNWTJTHBSPMW-UYIJMJIKSA-L	PUBCHEM.COMPOUND:12971800	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FDRNWTJTHBSPMW-ZJTMPOFJSA-L	PUBCHEM.COMPOUND:9601224	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
FECGNJPYVFEKOD-VMPITWQZSA-N	PUBCHEM.COMPOUND:11609955	UMLS:C0019829	resminostat	hodgkin's lymphoma	Designated	2011-09-16
FECGNJPYVFEKOD-VMPITWQZSA-N	PUBCHEM.COMPOUND:11609955	UMLS:C2239176	resminostat	HEPATOCELLULAR CARCINOMA	Designated	2011-06-29
FEQOLYDPQKHFTD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46932299	UMLS:C3887898	tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride	Infantile spasms	Designated	2016-06-20
FFBDFADSZUINTG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1329	UMLS:C0010674	8 Cyclopentyl 1,3-dipropylxanthine	Cystic Fibrosis	Designated/Withdrawn	1997-03-24
FGXWKSZFVQUSTL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3151	UMLS:C0271586	domperidone	Hypoprolactinemia	Designated	2011-09-02
FHEAIOHRHQGZPC-KIWGSFCNSA-N	PUBCHEM.COMPOUND:3081884	UMLS:C0026769	glatiramer acetate	Multiple Sclerosis	Designated/Approved	1987-11-09
FHEAIOHRHQGZPC-KIWGSFCNSA-N	PUBCHEM.COMPOUND:3081884	UMLS:C0002736	glatiramer acetate	Amyotrophic Lateral Sclerosis	Designated	2007-11-14
FIAFUQMPZJWCLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5361	UMLS:C0376358	Suramin	Prostate Cancer	Designated	1997-05-06
FIAFUQMPZJWCLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5361	UMLS:C0041228	suramin	African Trypanosomiasis	Designated	2021-01-25
FIBJDTSHOUXTKV-BRHMIFOHSA-N	PUBCHEM.COMPOUND:118856773	UMLS:C0040034	Lepirudin	Thrombocytopenia	Designated/Approved	1997-02-13
FIBJDTSHOUXTKV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:139600825	UMLS:C0040034	Lepirudin	Thrombocytopenia	Designated/Approved	1997-02-13
FIDMEHCRMLKKPZ-YSMBQZINSA-N	PUBCHEM.COMPOUND:10186184	UMLS:C0206754	fosbretabulin tromethamine	Neuroendocrine Tumors	Designated	2015-12-29
FIDMEHCRMLKKPZ-YSMBQZINSA-N	PUBCHEM.COMPOUND:10186184	UMLS:C0017638	fosbretabulin tromethamine	Glioma	Designated	2016-06-08
FIGNGSHKNAHTSH-JJMFXPFOSA-N	PUBCHEM.COMPOUND:9874592	UMLS:C0555198	Berubicin	Malignant Glioma	Designated	2020-06-09
FIHJKUPKCHIPAT-AHIGJZGOSA-N	PUBCHEM.COMPOUND:6917864	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-AHIGJZGOSA-N	PUBCHEM.COMPOUND:6917864	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-AHIGJZGOSA-N	PUBCHEM.COMPOUND:6917864	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-AHIGJZGOSA-N	PUBCHEM.COMPOUND:6917864	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-AXFKQHSWSA-N	PUBCHEM.COMPOUND:9821433	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-AXFKQHSWSA-N	PUBCHEM.COMPOUND:9821433	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-AXFKQHSWSA-N	PUBCHEM.COMPOUND:9821433	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-AXFKQHSWSA-N	PUBCHEM.COMPOUND:9821433	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-DRVUCALVSA-N	PUBCHEM.COMPOUND:126963478	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-DRVUCALVSA-N	PUBCHEM.COMPOUND:126963478	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-DRVUCALVSA-N	PUBCHEM.COMPOUND:126963478	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-DRVUCALVSA-N	PUBCHEM.COMPOUND:126963478	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-HXMLZIBGSA-N	PUBCHEM.COMPOUND:156252	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-HXMLZIBGSA-N	PUBCHEM.COMPOUND:156252	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-HXMLZIBGSA-N	PUBCHEM.COMPOUND:156252	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-HXMLZIBGSA-N	PUBCHEM.COMPOUND:156252	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-JQXDXKTESA-N	PUBCHEM.COMPOUND:5464098	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-JQXDXKTESA-N	PUBCHEM.COMPOUND:5464098	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-JQXDXKTESA-N	PUBCHEM.COMPOUND:5464098	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-JQXDXKTESA-N	PUBCHEM.COMPOUND:5464098	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-MFMTXCBGSA-N	PUBCHEM.COMPOUND:146160078	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-MFMTXCBGSA-N	PUBCHEM.COMPOUND:146160078	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-MFMTXCBGSA-N	PUBCHEM.COMPOUND:146160078	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-MFMTXCBGSA-N	PUBCHEM.COMPOUND:146160078	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-NKHDUEHSSA-N	PUBCHEM.COMPOUND:65664	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-NKHDUEHSSA-N	PUBCHEM.COMPOUND:65664	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-NKHDUEHSSA-N	PUBCHEM.COMPOUND:65664	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-NKHDUEHSSA-N	PUBCHEM.COMPOUND:65664	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-OQYNCAMDSA-N	PUBCHEM.COMPOUND:53486426	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-OQYNCAMDSA-N	PUBCHEM.COMPOUND:53486426	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-OQYNCAMDSA-N	PUBCHEM.COMPOUND:53486426	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-OQYNCAMDSA-N	PUBCHEM.COMPOUND:53486426	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-PNDUOAGUSA-N	PUBCHEM.COMPOUND:129009911	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-PNDUOAGUSA-N	PUBCHEM.COMPOUND:129009911	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-PNDUOAGUSA-N	PUBCHEM.COMPOUND:129009911	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-PNDUOAGUSA-N	PUBCHEM.COMPOUND:129009911	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-RLQWWVEOSA-N	PUBCHEM.COMPOUND:16394563	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-RLQWWVEOSA-N	PUBCHEM.COMPOUND:16394563	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-RLQWWVEOSA-N	PUBCHEM.COMPOUND:16394563	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-RLQWWVEOSA-N	PUBCHEM.COMPOUND:16394563	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-RUYKMDFCSA-N	PUBCHEM.COMPOUND:49769200	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-RUYKMDFCSA-N	PUBCHEM.COMPOUND:49769200	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-RUYKMDFCSA-N	PUBCHEM.COMPOUND:49769200	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-RUYKMDFCSA-N	PUBCHEM.COMPOUND:49769200	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-RVBFJZMGSA-N	PUBCHEM.COMPOUND:129317578	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-RVBFJZMGSA-N	PUBCHEM.COMPOUND:129317578	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-RVBFJZMGSA-N	PUBCHEM.COMPOUND:129317578	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-RVBFJZMGSA-N	PUBCHEM.COMPOUND:129317578	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:105031	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:105031	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:105031	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:105031	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-WNZKYHKJSA-N	PUBCHEM.COMPOUND:60196289	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIHJKUPKCHIPAT-WNZKYHKJSA-N	PUBCHEM.COMPOUND:60196289	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-WNZKYHKJSA-N	PUBCHEM.COMPOUND:60196289	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-WNZKYHKJSA-N	PUBCHEM.COMPOUND:60196289	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-XIIQFBLFSA-N	PUBCHEM.COMPOUND:91746179	UMLS:C0024530	artesunate	Malaria	Designated/Approved	2006-03-28
FIHJKUPKCHIPAT-XIIQFBLFSA-N	PUBCHEM.COMPOUND:91746179	UMLS:C0024530	artesunate	Malaria	Designated	2019-07-22
FIHJKUPKCHIPAT-XIIQFBLFSA-N	PUBCHEM.COMPOUND:91746179	UMLS:C0024530	Artesunate	Malaria	Designated	1999-07-19
FIHJKUPKCHIPAT-XIIQFBLFSA-N	PUBCHEM.COMPOUND:91746179	UMLS:C0024530	Artesunate	Malaria	Designated	2017-09-05
FIITXXIVUIXYMI-RQJHMYQMSA-N	PUBCHEM.COMPOUND:164486	UMLS:C0235974	doranidazole	PANCREATIC CANCER	Designated	2018-11-30
FJCDSQATIJKQKA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54766013	UMLS:C0024623	Vactosertib	Gastric Cancer	Designated	2020-09-28
FJCDSQATIJKQKA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54766013	UMLS:C2239176	N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline	HEPATOCELLULAR CARCINOMA	Designated	2017-06-14
FJLBFSROUSIWMA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4174	UMLS:C0039082	metyrapone	Syndrome	Designated	2012-09-25
FJLUJBDSFBGOPL-YOKUEUOXSA-N	PUBCHEM.COMPOUND:44566638	UMLS:C2239176	uttroside B	HEPATOCELLULAR CARCINOMA	Designated	2021-01-19
FJZZPCZKBUKGGU-AUSIDOKSSA-N	PUBCHEM.COMPOUND:23652731	UMLS:C0017205	eliglustat	Gaucher Disease	Designated/Approved	2008-09-17
FKCMADOPPWWGNZ-YUMQZZPRSA-N	PUBCHEM.COMPOUND:6918572	UMLS:C0025202	Talabostat	melanoma	Designated	2017-03-20
FKCMADOPPWWGNZ-YUMQZZPRSA-N	PUBCHEM.COMPOUND:6918572	UMLS:C0235974	Talabostat	PANCREATIC CANCER	Designated	2017-03-16
FKCMADOPPWWGNZ-YUMQZZPRSA-N	PUBCHEM.COMPOUND:6918572	UMLS:C1261473	Talabostat	Soft tissue sarcoma	Designated	2021-01-26
FKCMADOPPWWGNZ-YUMQZZPRSA-N	PUBCHEM.COMPOUND:6918572	UMLS:C0023467	Talabostat	Acute myelogenous leukemia	Designated	2019-08-21
FLFGNMFWNBOBGE-FNNZEKJRSA-N	PUBCHEM.COMPOUND:6438895	UMLS:C0023467	elacytarabine	Acute myeloid leukemia	Designated	2008-06-18
FMGSKLZLMKYGDP-USOAJAOKSA-N	PUBCHEM.COMPOUND:5881	UMLS:C0001623	Dehydroepiandrosterone (DHEA)	Adrenal Insufficiency	Designated	2003-08-19
FMGSKLZLMKYGDP-USOAJAOKSA-N	PUBCHEM.COMPOUND:5881	UMLS:C0014060	Dehydroepiandrosterone	SLE	Designated/Withdrawn	1994-07-13
FMGSKLZLMKYGDP-USOAJAOKSA-N	PUBCHEM.COMPOUND:5881	UMLS:C0024141	Dehydroepiandrosterone	SYSTEMIC LUPUS ERYTHEMATOSUS	Designated/Withdrawn	1994-07-13
FMMOOAYVCKXGMF-XMCVDNGOSA-N	PUBCHEM.COMPOUND:124037379	UMLS:C0016719	9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester	Friedreich's Ataxia	Designated	2016-05-23
FNHKPVJBJVTLMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11167602	UMLS:C2239176	regorafenib	HEPATOCELLULAR CARCINOMA	Designated/Approved	2015-06-04
FNHKPVJBJVTLMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11167602	UMLS:C0238198	regorafenib	Gastrointestinal Stromal Tumors	Designated/Approved	2011-01-12
FNHKPVJBJVTLMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11167602	UMLS:C0017636	Regorafenib	Glioblastoma multiforme	Designated	2019-07-01
FNKQXYHWGSIFBK-RPDRRWSUSA-N	PUBCHEM.COMPOUND:135398654	UMLS:C0751435	sapropterin	Hyperphenylalaninemia	Designated/Approved	2004-01-29
FNVKWTCPMNNIND-WDTSGDEMSA-N	PUBCHEM.COMPOUND:71587496	UMLS:C2239176	L-tyrosine-L-serine-L-leucine	HEPATOCELLULAR CARCINOMA	Designated	2004-09-10
FOHHNHSLJDZUGQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:37393	UMLS:C2930826	Halofantrine	Acute malaria	Designated/Approved	1991-11-04
FPOHNWQLNRZRFC-ZHACJKMWSA-N	PUBCHEM.COMPOUND:6918837	UMLS:C0019829	panobinostat	hodgkin's lymphoma	Designated/Withdrawn	2009-09-18
FPOHNWQLNRZRFC-ZHACJKMWSA-N	PUBCHEM.COMPOUND:6918837	UMLS:C0079773	Panobinostat	cutaneous T-cell lymphoma	Designated/Withdrawn	2007-09-26
FPOHNWQLNRZRFC-ZHACJKMWSA-N	PUBCHEM.COMPOUND:6918837	UMLS:C0026764	panobinostat	Multiple Myeloma	Designated/Approved	2012-08-20
FPVKHBSQESCIEP-JQCXWYLXSA-N	PUBCHEM.COMPOUND:439693	UMLS:C0079774	Pentostatin	Peripheral T-Cell Lymphomas	Designated	1999-11-24
FPVKHBSQESCIEP-JQCXWYLXSA-N	PUBCHEM.COMPOUND:439693	UMLS:C0079773	Pentostatin	cutaneous T-cell lymphoma	Designated	1998-03-27
FPVKHBSQESCIEP-JQCXWYLXSA-N	PUBCHEM.COMPOUND:439693	UMLS:C0023434	Pentostatin	Chronic Lymphocytic Leukemia	Designated	1991-01-29
FSBTYDWUUWLHBD-UDXTWCDOSA-N	PUBCHEM.COMPOUND:25079425	UMLS:C0342543	Nafarelin acetate	Central Precocious Puberty	Designated/Approved	1988-07-20
FSBTYDWUUWLHBD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25084011	UMLS:C0342543	Nafarelin acetate	Central Precocious Puberty	Designated/Approved	1988-07-20
FSVJFNAIGNNGKK-KRWDZBQOSA-N	PUBCHEM.COMPOUND:445900	UMLS:C0036323	(R)-praziquantel	Schistosomiasis	Designated	2017-06-27
FSVJFNAIGNNGKK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4891	UMLS:C0338437	Praziquantel	Neurocysticercosis	Designated/Withdrawn	1988-04-18
FSWNJZRQQVVVJT-UHFFFAOYSA-L	PUBCHEM.COMPOUND:18442052	UMLS:C0002736	bis-choline tetrathiomolybdate	Amyotrophic Lateral Sclerosis	Designated	2017-06-05
FSWNJZRQQVVVJT-UHFFFAOYSA-L	PUBCHEM.COMPOUND:18442052	UMLS:C0008312	bis-choline tetrathiomolybdate	Primary Biliary Cholangitis	Designated	2020-04-06
FSYKKLYZXJSNPZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1088	UMLS:C0028768	sarcosine	Obsessive compulsive disorder	Designated	2011-10-12
FTALBRSUTCGOEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5070	UMLS:C0020179	Riluzole	Huntington's Disease	Designated	1996-10-15
FTALBRSUTCGOEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5070	UMLS:C0002736	Riluzole	Amyotrophic Lateral Sclerosis	Designated/Approved	1993-03-16
FUZYTVDVLBBXDL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5113032	UMLS:C0020179	selisistat	Huntington's Disease	Designated	2009-12-07
FVJCUZCRPIMVLB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11528958	UMLS:C0393571	verdiperstat	Multiple System Atrophy	Designated	2019-02-15
FVVDKUPCWXUVNP-UHFFFAOYSA-M	PUBCHEM.COMPOUND:2724368	UMLS:C0010346	Aminosalicylate sodium	Crohn's Disease	Designated/Withdrawn	1993-04-06
FVVDKUPCWXUVNP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16051922	UMLS:C0010346	Aminosalicylate sodium	Crohn's Disease	Designated/Withdrawn	1993-04-06
FVWAMONNJGNNHY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44472513	UMLS:C0038868	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	Progressive supranuclear palsy	Designated	2011-04-18
FWCVZAQENIZVMY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71602803	UMLS:C0002895	Voxelotor	Sickle Cell Disease	Designated/Approved	2015-12-29
FWCVZAQENIZVMY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71602803	UMLS:C0085298	Voxelotor	SCD	Designated/Approved	2015-12-29
FWFGIHPGRQZWIW-SQNIBIBYSA-N	PUBCHEM.COMPOUND:15547703	UMLS:C0023467	Tosedostat	Acute myeloid leukemia	Designated/Withdrawn	2008-12-10
FWLMVFUGMHIOAA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25117126	UMLS:C4721610	defactinib	Ovarian Cancer	Designated	2015-02-12
FWYSMLBETOMXAG-QHCPKHFHSA-N	PUBCHEM.COMPOUND:45138674	UMLS:C0877635	letermovir	Cytomegalovirus viremia	Designated/Approved	2011-12-12
FWYSMLBETOMXAG-QHCPKHFHSA-N	PUBCHEM.COMPOUND:45138674	UMLS:C0205725	letermovir	Human cytomegalovirus	Designated/Approved	2011-12-12
FXKSEJFHKVNEFI-GCZBSULCSA-N	PUBCHEM.COMPOUND:38351	UMLS:C0010674	amikacin sulfate	Cystic Fibrosis	Designated	2015-01-05
FXKSEJFHKVNEFI-GCZBSULCSA-N	PUBCHEM.COMPOUND:38351	UMLS:C0033809	amikacin sulfate	Pseudomonas aeruginosa	Designated	2015-01-05
FXKSEJFHKVNEFI-GCZBSULCSA-N	PUBCHEM.COMPOUND:38351	UMLS:C3714514	amikacin sulfate	Infections	Designated	2015-01-05
FYJROXRIVQPKRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:45139106	UMLS:C0024623	apatinib mesylate	Gastric Cancer	Designated	2017-06-15
FZVMMANVVHMVBM-OIXLVLAFSA-N	PUBCHEM.COMPOUND:70693548	UMLS:C0520799	rusalatide acetate	Acute Radiation Syndrome	Designated	2017-09-07
GAJWNIKZLYZYSY-OKUPSQOASA-N	PUBCHEM.COMPOUND:11527330	UMLS:C0024301	apilimod dimesylate	follicular lymphoma	Designated	2019-07-01
GAKUNXBDVGLOFS-DUZKARGPSA-N	PUBCHEM.COMPOUND:9960925	UMLS:C0520799	mosedipimod	Acute Radiation Syndrome	Designated	2017-12-19
GAKUNXBDVGLOFS-INJBRAEYSA-N	PUBCHEM.COMPOUND:87183232	UMLS:C0520799	mosedipimod	Acute Radiation Syndrome	Designated	2017-12-19
GAKUNXBDVGLOFS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53827958	UMLS:C0520799	mosedipimod	Acute Radiation Syndrome	Designated	2017-12-19
GAKUNXBDVGLOFS-WCCXBCNRSA-N	PUBCHEM.COMPOUND:87183063	UMLS:C0520799	mosedipimod	Acute Radiation Syndrome	Designated	2017-12-19
GAMYYCRTACQSBR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:67504	UMLS:C0002736	Imidazopyridine	Amyotrophic Lateral Sclerosis	Designated	2019-07-22
GAQMWPRWVIGRRV-IVDGIBIRSA-N	PUBCHEM.COMPOUND:70683024	UMLS:C0854467	Pegfilgrastim	Myelosuppression	Designated/Approved	2013-11-20
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C0238462	pralsetinib	Thyroid cancer	Designated/Approved	2020-05-26
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C0238463	pralsetinib	medullary	Designated/Approved	2020-05-26
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C0694890	pralsetinib	rearranged during transfection	Designated/Approved	2018-04-11
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C1337013	pralsetinib	papillary thyroid cancer	Designated/Approved	2020-05-26
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C3539721	pralsetinib	Non-Small Cell Lung Cancer	Designated/Approved	2018-04-11
GBLBJPZSROAGMF-SIYOEGHHSA-N	PUBCHEM.COMPOUND:129073603	UMLS:C0238461	pralsetinib	anaplastic thyroid cancer	Designated/Approved	2020-05-26
GCQYYIHYQMVWLT-HQNLTJAPSA-N	PUBCHEM.COMPOUND:5282192	UMLS:C0019360	Sorivudine	Zoster	Designated/Withdrawn	1995-11-09
GCQYYIHYQMVWLT-HQNLTJAPSA-N	PUBCHEM.COMPOUND:5282192	UMLS:C4553551	Sorivudine	Shingles	Designated/Withdrawn	1995-11-09
GDLBFKVLRPITMI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3019	UMLS:C0032897	diazoxide	Prader Willi syndrome	Designated	2012-12-03
GDLPAGOVHZLZEK-JBUFHSOLSA-L	PUBCHEM.COMPOUND:158780	UMLS:C4721610	oglufanide disodium	Ovarian Cancer	Designated	2001-09-24
GECHUMIMRBOMGK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5336	UMLS:C0011608	Sulfapyridine	Dermatitis Herpetiformis	Designated	1990-09-10
GEJDGVNQKABXKG-CFKGEZKQSA-N	PUBCHEM.COMPOUND:24795069	UMLS:C0040517	valbenazine	Tourette Syndrome	Designated	2017-10-19
GFFXZLZWLOBBLO-ASKVSEFXSA-N	PUBCHEM.COMPOUND:6435808	UMLS:C0279628	Tezacitabine	adenocarcinoma of the esophagus	Designated	2003-01-27
GFJCILQBXUTOGN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:15942270	UMLS:C0162309	((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid	X-Linked Adrenoleukodystrophy	Designated	2016-12-05
GFJWACFSUSFUOG-ZJTJBYBXSA-M	PUBCHEM.COMPOUND:23668320	UMLS:C0006434	Dehydroepiandrosterone sulfate sodium	Burns	Designated	1997-01-29
GFVBDLIBPSGFDL-ZOWNYOTGSA-N	PUBCHEM.COMPOUND:131801108	UMLS:C0235280	(R)-Azasetron besylate	Ototoxicity	Designated	2017-08-16
GHASVSINZRGABV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3385	UMLS:C0152018	Fluorouracil	Esophageal carcinoma	Designated	1989-10-27
GHASVSINZRGABV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3385	UMLS:C0334277	Fluorouracil	Metastatic adenocarcinoma	Designated/Withdrawn	1989-02-06
GHASVSINZRGABV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3385	UMLS:C0338106	Fluorouracil	adenocarcinoma of the colon	Designated/Withdrawn	1989-02-06
GHASVSINZRGABV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3385	UMLS:C5206582	Fluorouracil	Advanced Colorectal Carcinoma	Designated	1990-04-18
GHASVSINZRGABV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3385	UMLS:C0017636	Fluorouracil	Glioblastoma multiforme	Designated	2000-06-29
GHBFNMLVSPCDGN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3033877	UMLS:C0856727	Monooctanoin	Cholesterol gallstones	Designated/Approved	1984-05-30
GHILNKWBALQPDP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134168328	UMLS:C0001206	Paltusotine	Acromegaly	Designated	2020-07-07
GIUYCYHIANZCFB-FJFJXFQQSA-N	PUBCHEM.COMPOUND:30751	UMLS:C0023434	Fludarabine phosphate	Chronic Lymphocytic Leukemia	Designated/Approved	1989-04-18
GIUYCYHIANZCFB-FJFJXFQQSA-N	PUBCHEM.COMPOUND:30751	UMLS:C0024305	Fludarabine phosphate	Non-Hodgkins Lymphoma	Designated	1989-04-18
GIUYCYHIANZCFB-FJFJXFQQSA-N	PUBCHEM.COMPOUND:30751	UMLS:C0278791	Fludarabine phosphate	Refractory CLL	Designated/Approved	1989-04-18
GJKXGJCSJWBJEZ-XRSSZCMZSA-N	PUBCHEM.COMPOUND:25077495	UMLS:C0342543	Deslorelin	Central Precocious Puberty	Designated	1987-11-05
GJOHLWZHWQUKAU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6135	UMLS:C1535939	Primaquine phosphate	Pneumocystis carinii Pneumonia	Designated	1993-07-23
GJOHLWZHWQUKAU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6135	UMLS:C0276527	Primaquine phosphate	Pneumonia associated with AIDS	Designated	1993-07-23
GJPICJJJRGTNOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104865	UMLS:C3203102	bosentan	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2000-10-06
GJPICJJJRGTNOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104865	UMLS:C1800706	bosentan	Idiopathic Pulmonary Fibrosis	Designated/Withdrawn	2008-09-30
GJPICJJJRGTNOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104865	UMLS:C0036421	bosentan	Systemic sclerosis	Designated/Withdrawn	2010-06-07
GJPICJJJRGTNOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104865	UMLS:C0041582	bosentan	Ulcers	Designated/Withdrawn	2010-06-07
GJPICJJJRGTNOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104865	UMLS:C3203102	bosentan	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2000-10-06
GJQPMPFPNINLKP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3038	UMLS:C0522224	dichlorphenamide	Paralyses	Designated/Approved	2010-09-02
GJSURZIOUXUGAL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2803	UMLS:C0006826	Clonidine	Cancer	Designated/Approved	1989-01-24
GJSURZIOUXUGAL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2803	UMLS:C0030193	Clonidine	Pain	Designated/Approved	1989-01-24
GKDRMWXFWHEQQT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11671467	UMLS:C0002880	fostamatinib	Autoimmune hemolytic anemia	Designated	2018-01-31
GKHIVNAUVKXIIY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11950170	UMLS:C0036421	Belumosudil	Systemic sclerosis	Designated	2020-09-04
GKMPTIBZVGZJDN-RJLNLWLESA-N	PUBCHEM.COMPOUND:123133491	UMLS:C0025500	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt	Mesothelioma	Designated	2011-12-22
GLXYOFXNKBTMQL-YKCHQESGSA-N	PUBCHEM.COMPOUND:134687212	UMLS:C0018133	synthetic preImplantation factor	GRAFT VERSUS HOST DISEASE	Designated	2018-05-08
GLXYOFXNKBTMQL-YKCHQESGSA-N	PUBCHEM.COMPOUND:134687212	UMLS:C0520799	Synthetic PreImplantation Factor	Acute Radiation Syndrome	Designated	2018-12-19
GMBQZIIUCVWOCD-UQHLGXRBSA-N	PUBCHEM.COMPOUND:91439	UMLS:C0002736	smilagenin	Amyotrophic Lateral Sclerosis	Designated	2011-07-21
GMBQZIIUCVWOCD-WWASVFFGSA-N	PUBCHEM.COMPOUND:92095	UMLS:C0002736	sarsasapogenin	Amyotrophic Lateral Sclerosis	Designated/Withdrawn	2004-06-18
GMUQJDAYXZXBOT-UHFFFAOYSA-M	PUBCHEM.COMPOUND:16211148	UMLS:C0010346	Aminosalicylate sodium	Crohn's Disease	Designated/Withdrawn	1993-04-06
GMVPRGQOIOIIMI-DWKJAMRDSA-N	PUBCHEM.COMPOUND:5280723	UMLS:C1142264	Alprostadil	critical limb ischemia	Designated/Withdrawn	1993-10-20
GMVPRGQOIOIIMI-DWKJAMRDSA-N	PUBCHEM.COMPOUND:5280723	UMLS:C1306889	Alprostadil	Peripheral arterial occlusive disease	Designated/Withdrawn	1993-10-20
GMZVRMREEHBGGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4843	UMLS:C0027066	Piracetam	Myoclonus	Designated/Withdrawn	1987-10-02
GNNDEPIMDAZHRQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54576299	UMLS:C0017636	altiratinib	Glioblastoma multiforme	Designated	2014-08-19
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0023434	lenalidomide	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2007-01-17
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0242647	lenalidomide	Nodal marginal zone lymphoma	Designated/Approved	2017-01-04
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C2200312	lenalidomide	marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated/Approved	2015-04-29
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C3463824	lenalidomide	Myelodysplastic Syndromes	Designated/Approved	2004-01-29
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C4721414	lenalidomide	Mantle cell lymphoma	Designated/Approved	2009-04-27
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0349632	lenalidomide	Splenic marginal zone lymphoma	Designated/Approved	2017-01-04
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0026764	lenalidomide	Multiple Myeloma	Designated/Approved	2001-09-20
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0026764	lenalidomide	Multiple Myeloma	Designated/Approved	2001-09-20
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0024301	lenalidomide	follicular lymphoma	Designated/Approved	2013-09-17
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C0026764	lenalidomide	Multiple Myeloma	Designated/Approved	2001-09-20
GOTYRUGSSMKFNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216326	UMLS:C1332201	lenalidomide	Diffuse Large B-Cell Lymphoma	Designated	2011-03-28
GOWDQYRMBCOOJR-JHMJKTBASA-M	PUBCHEM.COMPOUND:145711124	UMLS:C0235974	2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate	PANCREATIC CANCER	Designated	2019-09-11
GPEYTRIZYSZRRK-MHZLTWQESA-N	PUBCHEM.COMPOUND:100951591	UMLS:C0206754	Ceclazepide	Neuroendocrine Tumors	Designated	2016-05-12
GPKJTRJOBQGKQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:237	UMLS:C0032326	Quinacrine hydrochloride	Pneumothorax	Designated/Withdrawn	1984-10-17
GPKJTRJOBQGKQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:237	UMLS:C0282687	quinacrine	Ebola Infection	Designated	2019-09-10
GPKJTRJOBQGKQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:237	UMLS:C2239176	quinacrine	HEPATOCELLULAR CARCINOMA	Designated	2012-09-28
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0027651	vemurafenib	Tumors	Designated/Withdrawn	2013-11-26
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0238463	vemurafenib	papillary thyroid cancer	Designated/Withdrawn	2013-11-26
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0023443	vemurafenib	Hairy Cell Leukemia	Designated/Withdrawn	2014-08-26
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0878675	vemurafenib	Erdheim-Chester Disease	Designated/Approved	2016-08-02
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0238461	vemurafenib	Anaplastic thyroid carcinoma	Designated/Withdrawn	2013-11-26
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C0025202	vemurafenib	melanoma	Designated/Approved	2010-12-20
GPXBXXGIAQBQNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42611257	UMLS:C3539721	vemurafenib	Non-Small Cell Lung Cancer	Designated/Withdrawn	2014-09-08
GRHLMSBCOPRFNA-UHFFFAOYSA-M	PUBCHEM.COMPOUND:131842090	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
GRHLMSBCOPRFNA-UHFFFAOYSA-M	PUBCHEM.COMPOUND:131842090	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
GROMEQPXDKRRIE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9799487	UMLS:C0013264	rimeporide	DUCHENNE MUSCULAR DYSTROPHY	Designated	2017-09-19
GRZXWCHAXNAUHY-NSISKUIASA-N	PUBCHEM.COMPOUND:24788740	UMLS:C0024623	Ipatasertib	Gastric Cancer	Designated/Withdrawn	2014-04-30
GSDSWSVVBLHKDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:149096	UMLS:C0876973	Levofloxacin	Pulmonary infections	Designated	2008-02-27
GSDSWSVVBLHKDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:149096	UMLS:C0010674	Levofloxacin	Cystic Fibrosis	Designated	2008-02-27
GSDSWSVVBLHKDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:149096	UMLS:C0004611	Levofloxacin	Bacteria	Designated	2008-02-27
GSDSWSVVBLHKDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:149096	UMLS:C0033809	Levofloxacin	Pseudomonas aeruginosa	Designated	2008-02-27
GSDSWSVVBLHKDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4583	UMLS:C0010043	Ofloxacin	corneal ulcers	Designated/Approved	1991-04-18
GTTBEUCJPZQMDZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:176871	UMLS:C0555198	Erlotinib Hydrochloride	malignant gliomas	Designated	2003-07-18
GUJYDLHACHDKAJ-CFWZQLQRSA-N	PUBCHEM.COMPOUND:25079036	UMLS:C0342543	Nafarelin acetate	Central Precocious Puberty	Designated/Approved	1988-07-20
GUJYDLHACHDKAJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25077648	UMLS:C0342543	Nafarelin acetate	Central Precocious Puberty	Designated/Approved	1988-07-20
GUWXKKAWLCENJA-WGWHJZDNSA-N	PUBCHEM.COMPOUND:135564655	UMLS:C0023467	guadecitabine	Acute myeloid leukemia	Designated/Withdrawn	2015-09-29
GVUGOAYIVIDWIO-UFWWTJHBSA-N	PUBCHEM.COMPOUND:16143379	UMLS:C0564444	Epidermal growth factor (human)	Cutaneous wound	Designated/Withdrawn	1985-03-06
GWBBVOVXJZATQQ-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23894	UMLS:C0005944	Etidronate disodium	Metabolic Bone Disease	Designated/Withdrawn	1991-05-02
GWBBVOVXJZATQQ-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23894	UMLS:C0149911	Etidronate disodium	Hypercalcemia of malignancy	Designated/Approved	1986-03-21
GWBBVOVXJZATQQ-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23894	UMLS:C0005944	Etidronate disodium	Metabolic Bone Disease	Designated/Withdrawn	1991-05-02
GWJOFBXSBDVUMH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16219992	UMLS:C0010674	Tyloxapol	Cystic Fibrosis	Designated	1995-03-08
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0027832	bortezomib	Neurofibromatosis Type 2	Designated	2016-07-05
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C4721414	bortezomib	Mantle cell lymphoma	Designated/Approved	2012-05-30
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C4721414	bortezomib	Mantle cell lymphoma	Designated/Approved	2012-05-30
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0026764	bortezomib	Multiple Myeloma	Designated/Approved	2003-01-15
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0023449	bortezomib	Acute lymphoblastic leukemia	Designated/Withdrawn	2015-02-03
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0024301	bortezomib	follicular non-Hodgkin lymphoma	Designated/Withdrawn	2011-01-04
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0026764	bortezomib	Multiple Myeloma	Designated/Approved	2003-01-15
GXJABQQUPOEUTA-RDJZCZTQSA-N	PUBCHEM.COMPOUND:387447	UMLS:C0026764	bortezomib	Multiple Myeloma	Designated/Approved	2003-01-15
GYAVMUDJCHAASE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:9796440	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
GYAVMUDJCHAASE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:9796440	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
GYDJEQRTZSCIOI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5526	UMLS:C0005779	tranexamic acid	coagulopathies	Designated/Approved/Withdrawn	1985-12-03
GYHCTFXIZSNGJT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216237	UMLS:C0085413	tolvaptan	Autosomal dominant polycystic kidney disease	Designated/Approved	2012-04-06
GYQYAJJFPNQOOW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49803313	UMLS:C0023467	gilteritinib	Acute myeloid leukemia	Designated/Approved	2017-07-13
GZSOSUNBTXMUFQ-YFAPSIMESA-N	PUBCHEM.COMPOUND:5281613	UMLS:C0036421	diosmin	Systemic sclerosis	Designated	2018-05-15
GZUITABIAKMVPG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5035	UMLS:C0678222	raloxifene	Breast cancer	Designated/Approved	2005-07-14
HAYYBYPASCDWEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25141092	UMLS:C3539721	entrectinib	Non-Small Cell Lung Cancer	Designated/Approved	2015-02-03
HAYYBYPASCDWEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25141092	UMLS:C0027819	entrectinib	Neuroblastoma	Designated/Withdrawn	2014-12-22
HAYYBYPASCDWEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25141092	UMLS:C0280100	entrectinib	solid tumors	Designated/Approved	2017-07-05
HBNPJJILLOYFJU-VMPREFPWSA-N	PUBCHEM.COMPOUND:60663	UMLS:C4721610	mibefradil	Ovarian Cancer	Designated	2007-06-15
HBNPJJILLOYFJU-VMPREFPWSA-N	PUBCHEM.COMPOUND:60663	UMLS:C0017636	mibefradil	Glioblastoma multiforme	Designated	2009-08-25
HBNPJJILLOYFJU-VMPREFPWSA-N	PUBCHEM.COMPOUND:60663	UMLS:C0235974	mibefradil	PANCREATIC CANCER	Designated	2008-10-16
HBOMLICNUCNMMY-XLPZGREQSA-N	PUBCHEM.COMPOUND:35370	UMLS:C0001175	zidovudine	AIDS	Designated/Approved	1985-07-17
HCDMJFOHIXMBOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86705695	UMLS:C0206698	Pemigatinib	Cholangiocarcinoma	Designated/Approved	2018-03-12
HCDMJFOHIXMBOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86705695	UMLS:C0014457	Pemigatinib	Eosinophilia	Designated	2019-08-21
HCDMJFOHIXMBOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86705695	UMLS:C0027651	Pemigatinib	Neoplasms	Designated	2019-08-21
HCZQIIVHWYFIPW-UKKRHICBSA-N	PUBCHEM.COMPOUND:9859470	UMLS:C0268274	(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol	GM2 Gangliosidosis	Designated	2019-08-01
HDHDTKMUACZDAA-PHNIDTBTSA-N	PUBCHEM.COMPOUND:11993702	UMLS:C1337111	setmelanotide	POMC	Designated/Approved	2016-04-04
HDHDTKMUACZDAA-PHNIDTBTSA-N	PUBCHEM.COMPOUND:11993702	UMLS:C0032897	setmelanotide	Prader-Willi Syndrome	Designated	2015-09-21
HDHDTKMUACZDAA-PHNIDTBTSA-N	PUBCHEM.COMPOUND:11993702	UMLS:C3554225	setmelanotide	LEPTIN RECEPTOR DEFICIENCY	Designated/Approved	2017-11-27
HDHDTKMUACZDAA-PHNIDTBTSA-N	PUBCHEM.COMPOUND:11993702	UMLS:C0752166	setmelanotide	Bardet-Biedl Syndrome	Designated	2019-09-19
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0751383	Trehalose	Batten Disease	Designated	2020-10-21
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0026850	trehalose	Muscular Dystrophy	Designated	2013-10-25
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0086647	Trehalose	mps iii	Designated	2020-04-29
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0026706	Trehalose	Mucopolysaccharidosis type III	Designated	2020-04-29
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0024408	trehalose	SCA3	Designated	2014-11-17
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0002736	trehalose	Amyotrophic Lateral Sclerosis	Designated	2020-11-18
HDTRYLNUVZCQOY-LIZSDCNHSA-N	PUBCHEM.COMPOUND:7427	UMLS:C0007758	trehalose	Cerebellar Ataxia	Designated	2014-11-17
HDXDQPRPFRKGKZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:86291103	UMLS:C0079773	tenalisib	cutaneous T-cell lymphoma	Designated	2018-04-04
HEBKCHPVOIAQTA-NGQZWQHPSA-N	PUBCHEM.COMPOUND:6912	UMLS:C0686353	ribitol	Limb-girdle muscular dystrophy	Designated	2019-01-16
HEMJJKBWTPKOJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3463	UMLS:C0027877	gemfibrozil	neuronal ceroid lipofuscinoses	Designated	2017-08-02
HFNKQEVNSGCOJV-OAHLLOKOSA-N	PUBCHEM.COMPOUND:25126798	UMLS:C0023449	Ruxolitinib	Acute lymphoblastic leukemia	Designated	2016-07-18
HFNKQEVNSGCOJV-OAHLLOKOSA-N	PUBCHEM.COMPOUND:25126798	UMLS:C0235974	ruxolitinib	PANCREATIC CANCER	Designated	2013-08-16
HFNKQEVNSGCOJV-OAHLLOKOSA-N	PUBCHEM.COMPOUND:25126798	UMLS:C0018133	ruxolitinib	GRAFT VERSUS HOST DISEASE	Designated/Approved	2016-11-03
HFNKQEVNSGCOJV-OAHLLOKOSA-N	PUBCHEM.COMPOUND:25126798	UMLS:C0032463	ruxolitinib	Polycythemia Vera	Designated/Approved	2010-03-26
HFVNWDWLWUCIHC-GUPDPFMOSA-N	PUBCHEM.COMPOUND:34457	UMLS:C0019829	Prednimustine	hodgkin's lymphomas	Designated/Withdrawn	1985-06-17
HGHOBRRUMWJWCU-FXQIFTODSA-N	PUBCHEM.COMPOUND:219042	UMLS:C0035334	Epitalon	Retinitis Pigmentosa	Designated/Withdrawn	2010-09-02
HHGRMHMXKPQNGF-AAMRAYDJSA-N	PUBCHEM.COMPOUND:146157506	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHGRMHMXKPQNGF-AAMRAYDJSA-N	PUBCHEM.COMPOUND:146157506	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-SAOVQBGCSA-N	PUBCHEM.COMPOUND:134692690	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHGRMHMXKPQNGF-SAOVQBGCSA-N	PUBCHEM.COMPOUND:134692690	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-VTQYNGMESA-N	PUBCHEM.COMPOUND:131954606	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-VTQYNGMESA-N	PUBCHEM.COMPOUND:131954606	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHGRMHMXKPQNGF-WEZTXPJVSA-N	PUBCHEM.COMPOUND:9952841	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHGRMHMXKPQNGF-WEZTXPJVSA-N	PUBCHEM.COMPOUND:9952841	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-WNSNRMDMSA-N	PUBCHEM.COMPOUND:6915835	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-WNSNRMDMSA-N	PUBCHEM.COMPOUND:6915835	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHGRMHMXKPQNGF-ZKNOEPHOSA-N	PUBCHEM.COMPOUND:53877232	UMLS:C0023434	Inecalcitol	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2014-05-14
HHGRMHMXKPQNGF-ZKNOEPHOSA-N	PUBCHEM.COMPOUND:53877232	UMLS:C0023467	inecalcitol	Acute myeloid leukemia	Designated/Withdrawn	2015-08-03
HHXHVIJIIXKSOE-QILQGKCVSA-N	PUBCHEM.COMPOUND:25077993	UMLS:C0162565	Histrelin	Acute intermittent porphyria	Designated	1991-05-03
HHXHVIJIIXKSOE-QILQGKCVSA-N	PUBCHEM.COMPOUND:25077993	UMLS:C0162532	Histrelin	Variegate Porphyria	Designated	1991-05-03
HHXHVIJIIXKSOE-QILQGKCVSA-N	PUBCHEM.COMPOUND:25077993	UMLS:C0342543	Histrelin	Central Precocious Puberty	Designated/Approved	2005-11-18
HHXHVIJIIXKSOE-QILQGKCVSA-N	PUBCHEM.COMPOUND:25077993	UMLS:C0342543	Histrelin acetate	Central Precocious Puberty	Designated/Approved	1988-08-10
HHXHVIJIIXKSOE-QILQGKCVSA-N	PUBCHEM.COMPOUND:25077993	UMLS:C0342856	Histrelin	Coproporphyria	Designated	1991-05-03
HHZIURLSWUIHRB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:644241	UMLS:C0023473	nilotinib	Chronic myelogenous leukemia	Designated/Approved	2006-04-27
HHZIURLSWUIHRB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:644241	UMLS:C0238198	nilotinib	Gastrointestinal Stromal Tumors	Designated/Withdrawn	2007-03-20
HHZIURLSWUIHRB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:644241	UMLS:C0023473	nilotinib	Chronic myelogenous leukemia	Designated/Approved	2006-04-27
HIBICIOPDUTNRR-XTHCGPPUSA-L	PUBCHEM.COMPOUND:86619108	UMLS:C3714514	amikacin sulfate	Infections	Designated	2015-01-05
HIBICIOPDUTNRR-XTHCGPPUSA-L	PUBCHEM.COMPOUND:86619108	UMLS:C0010674	amikacin sulfate	Cystic Fibrosis	Designated	2015-01-05
HIBICIOPDUTNRR-XTHCGPPUSA-L	PUBCHEM.COMPOUND:86619108	UMLS:C0033809	amikacin sulfate	Pseudomonas aeruginosa	Designated	2015-01-05
HIBICIOPDUTNRR-XTHCGPPUSA-N	PUBCHEM.COMPOUND:5458175	UMLS:C0010674	amikacin sulfate	Cystic Fibrosis	Designated	2015-01-05
HIBICIOPDUTNRR-XTHCGPPUSA-N	PUBCHEM.COMPOUND:5458175	UMLS:C0033809	amikacin sulfate	Pseudomonas aeruginosa	Designated	2015-01-05
HIBICIOPDUTNRR-XTHCGPPUSA-N	PUBCHEM.COMPOUND:5458175	UMLS:C3714514	amikacin sulfate	Infections	Designated	2015-01-05
HIFJCPQKFCZDDL-ACWOEMLNSA-N	PUBCHEM.COMPOUND:5311181	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-ACWOEMLNSA-N	PUBCHEM.COMPOUND:5311181	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-CSAIKYROSA-N	PUBCHEM.COMPOUND:53486260	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-CSAIKYROSA-N	PUBCHEM.COMPOUND:53486260	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-GBSCXWAGSA-N	PUBCHEM.COMPOUND:51397006	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-GBSCXWAGSA-N	PUBCHEM.COMPOUND:51397006	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-JYTNZNGZSA-N	PUBCHEM.COMPOUND:91746214	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-JYTNZNGZSA-N	PUBCHEM.COMPOUND:91746214	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-NYBPDPFASA-N	PUBCHEM.COMPOUND:54313	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-NYBPDPFASA-N	PUBCHEM.COMPOUND:54313	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-PNQLYJIOSA-N	PUBCHEM.COMPOUND:134694981	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-PNQLYJIOSA-N	PUBCHEM.COMPOUND:134694981	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-QSGBCQANSA-N	PUBCHEM.COMPOUND:20838499	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-QSGBCQANSA-N	PUBCHEM.COMPOUND:20838499	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-QYUAYYPJSA-N	PUBCHEM.COMPOUND:89077401	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-QYUAYYPJSA-N	PUBCHEM.COMPOUND:89077401	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-SGSAMSKHSA-N	PUBCHEM.COMPOUND:6435378	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIFJCPQKFCZDDL-SGSAMSKHSA-N	PUBCHEM.COMPOUND:6435378	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53394043	UMLS:C3203102	iloprost	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-04-06
HIFJCPQKFCZDDL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53394043	UMLS:C0036421	iloprost	Systemic sclerosis	Designated	2019-05-09
HIZCTWCPHWUPFU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:61156	UMLS:C0751748	glyceryl tribenzoate	Nonketotic Hyperglycinemia	Designated	2019-10-15
HIZCTWCPHWUPFU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:61156	UMLS:C0020179	glycerol tribenzoate	huntingtons disease	Designated	2019-09-10
HJHVQCXHVMGZNC-DHUMWTJCSA-M	PUBCHEM.COMPOUND:23690471	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJHVQCXHVMGZNC-JCJNLNMISA-M	PUBCHEM.COMPOUND:23672955	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJHVQCXHVMGZNC-LOPNDLIXSA-M	PUBCHEM.COMPOUND:23706209	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJHVQCXHVMGZNC-UHFFFAOYSA-M	PUBCHEM.COMPOUND:44134727	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJHVQCXHVMGZNC-XDELSAJESA-M	PUBCHEM.COMPOUND:91873261	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJHVQCXHVMGZNC-XOSDQFCBSA-M	PUBCHEM.COMPOUND:134694338	UMLS:C0010674	sodium fusidate	Cystic Fibrosis	Designated	2020-02-13
HJKBJIYDJLVSAO-UHFFFAOYSA-L	PUBCHEM.COMPOUND:31195	UMLS:C0149911	Disodium clodronate	Hypercalcemia of malignancy	Designated	1993-06-16
HJLSLZFTEKNLFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5479	UMLS:C0013370	Tinidazole	amebiasis	Designated/Approved	2003-08-20
HJLSLZFTEKNLFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5479	UMLS:C0017536	tinidazole	Giardiasis	Designated/Approved	2002-04-18
HJOCKFVCMLCPTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71424	UMLS:C0751362	viloxazine HCL	Cataplexy and narcolepsy	Designated/Withdrawn	1984-06-11
HKEDBKXRDHFCFB-LUAQNYIXSA-N	PUBCHEM.COMPOUND:44566777	UMLS:C0026764	avicin d	Multiple Myeloma	Designated	2015-03-24
HKEDBKXRDHFCFB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3216	UMLS:C0026764	avicin d	Multiple Myeloma	Designated	2015-03-24
HKFMQJUJWSFOLY-OAQYLSRUSA-N	PUBCHEM.COMPOUND:6918388	UMLS:C0035372	sarizotan	Rett Syndrome	Designated	2015-07-07
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C1832033	everolimus	Subependymal Giant Cell Astrocytoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C2247022	everolimus	tuberous sclerosis complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0024419	everolimus	Waldenstrom Macroglobulinemia	Designated/Withdrawn	2010-09-16
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C1832033	everolimus	Subependymal Giant Cell Astrocytoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0041341	everolimus	Tuberous Sclerosis Complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0206754	everolimus	Neuroendocrine Tumors	Designated/Approved	2008-02-14
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0206633	everolimus	Angiomyolipoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0751674	everolimus	Lymphangioleiomyomatosis	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C2247022	everolimus	tuberous sclerosis complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0206633	everolimus	Angiomyolipoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0334633	everolimus	Lymphoplasmacytic Lymphoma	Designated/Withdrawn	2010-09-16
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C1332201	everolimus	Diffuse Large B-Cell Lymphoma	Designated/Withdrawn	2014-06-02
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0751674	everolimus	Lymphangioleiomyomatosis	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C2247022	everolimus	tuberous sclerosis complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0041341	everolimus	Tuberous Sclerosis Complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C1832033	everolimus	Subependymal Giant Cell Astrocytoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0751674	everolimus	Lymphangioleiomyomatosis	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0041341	everolimus	Tuberous Sclerosis Complex	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0206754	everolimus	Neuroendocrine Tumors	Designated/Approved	2008-02-14
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0024623	everolimus	Gastric Cancer	Designated/Withdrawn	2011-05-24
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C0206633	everolimus	Angiomyolipoma	Designated/Approved	2009-06-08
HKVAMNSJSFKALM-GKUWKFKPSA-N	PUBCHEM.COMPOUND:6442177	UMLS:C2239176	everolimus	HEPATOCELLULAR CARCINOMA	Designated/Withdrawn	2012-07-23
HLNZYALGGXMQQC-TVASSOHNSA-N	PUBCHEM.COMPOUND:136015147	UMLS:C0023449	granaticin B	Acute lymphoblastic leukemia	Designated	2018-03-07
HLNZYALGGXMQQC-TVASSOHNSA-N	PUBCHEM.COMPOUND:136015147	UMLS:C3542401	granaticin B	Acute Lymphoblastic Leukemia	Designated	2018-03-07
HLNZYALGGXMQQC-VHAJSWNUSA-N	PUBCHEM.COMPOUND:136018428	UMLS:C0023449	granaticin B	Acute lymphoblastic leukemia	Designated	2018-03-07
HLNZYALGGXMQQC-VHAJSWNUSA-N	PUBCHEM.COMPOUND:136018428	UMLS:C3542401	granaticin B	Acute Lymphoblastic Leukemia	Designated	2018-03-07
HLNZYALGGXMQQC-WFDKWETCSA-N	PUBCHEM.COMPOUND:138319140	UMLS:C3542401	granaticin B	Acute Lymphoblastic Leukemia	Designated	2018-03-07
HLNZYALGGXMQQC-WFDKWETCSA-N	PUBCHEM.COMPOUND:138319140	UMLS:C0023449	granaticin B	Acute lymphoblastic leukemia	Designated	2018-03-07
HMABYWSNWIZPAG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9931954	UMLS:C4721610	rucaparib	Ovarian Cancer	Designated/Approved	2012-07-31
HMABYWSNWIZPAG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9931954	UMLS:C4721610	rucaparib	Ovarian Cancer	Designated/Approved	2012-07-31
HMHVCUVYZFYAJI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5356	UMLS:C2363129	sulthiame	Benign Epilepsy Of Childhood With Centrotemporal Spikes	Designated/Withdrawn	2013-07-25
HMHVCUVYZFYAJI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5356	UMLS:C0376532	sulthiame	rolandic epilepsy	Designated/Withdrawn	2013-07-25
HMLGSIZOMSVISS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:139595263	UMLS:C0039082	anakinra	Syndromes	Designated/Approved	2010-08-19
HNJWVTLAOZFLEK-OOWZQQDUSA-N	PUBCHEM.COMPOUND:49848291	UMLS:C0238461	ribavirin elaidate	Anaplastic thyroid carcinoma	Designated	2011-09-02
HNJWVTLAOZFLEK-OOWZQQDUSA-N	PUBCHEM.COMPOUND:49848291	UMLS:C0238463	ribavirin elaidate	papillary thyroid cancer	Designated	2011-09-02
HNNIWKQLJSNAEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65464	UMLS:C1568868	Benzydamine hydrochloride	Oral Mucositis	Designated	1998-05-18
HNNIWKQLJSNAEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65464	UMLS:C3887461	Benzydamine hydrochloride	Head and Neck Cancer	Designated	1998-05-18
HOGVTUZUJGHKPL-HTVVRFAVSA-N	PUBCHEM.COMPOUND:65399	UMLS:C0026764	triciribine	Multiple Myeloma	Designated	2008-02-01
HOMGKSMUEGBAAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3690	UMLS:C0029463	ifosfamide	bone sarcomas	Designated	1985-08-07
HOMGKSMUEGBAAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3690	UMLS:C0855197	Ifosfamide	Testicular Cancer	Designated/Approved	1987-01-20
HPHUVLMMVZITSG-LURJTMIESA-N	PUBCHEM.COMPOUND:5284583	UMLS:C0159020	levetiracetam	Neonatal seizures	Designated	2010-04-30
HQBGGOLLNATNQC-INZIHYEWSA-N	PUBCHEM.COMPOUND:135564839	UMLS:C3463824	Heme arginate	Myelodysplastic Syndromes	Designated	1994-03-01
HQBGGOLLNATNQC-INZIHYEWSA-N	PUBCHEM.COMPOUND:135564839	UMLS:C0162565	Heme arginate	Acute Porphyria	Designated	1988-03-10
HRHKSTOGXBBQCB-VFWICMBZSA-N	PUBCHEM.COMPOUND:13116	UMLS:C4048328	Porfiromycin	cervical cancer	Designated	1997-03-13
HRHKSTOGXBBQCB-VFWICMBZSA-N	PUBCHEM.COMPOUND:13116	UMLS:C3887461	Porfiromycin	Head and Neck Cancer	Designated	1995-09-19
HRNLUBSXIHFDHP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9865515	UMLS:C3463824	Mocetinostat	MYELODYSPLASTIC SYNDROME	Designated	2014-06-12
HRNLUBSXIHFDHP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9865515	UMLS:C1332201	mocetinostat	Diffuse Large B-Cell Lymphoma	Designated	2014-08-07
HSHNITRMYYLLCV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5280567	UMLS:C2239176	4-Methylumbelliferone	HEPATOCELLULAR CARCINOMA	Designated	2020-03-30
HSHNITRMYYLLCV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5280567	UMLS:C0152018	4-Methylumbelliferone	Esophageal carcinoma	Designated	2020-04-20
HSHNITRMYYLLCV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5280567	UMLS:C0235974	4-Methylumbelliferone	PANCREATIC CANCER	Designated	2020-03-13
HSUDWURBWSUCOB-IBEPEKEJSA-N	PUBCHEM.COMPOUND:44147881	UMLS:C4721610	Protaxel	Ovarian Cancer	Designated	2003-05-21
HSWLVDBGZCETRH-UHFFFAOYSA-O	PUBCHEM.COMPOUND:132472120	UMLS:C0025202	trabedersen	Malignant Melanoma	Designated	2011-08-22
HSWLVDBGZCETRH-UHFFFAOYSA-O	PUBCHEM.COMPOUND:132472120	UMLS:C0235974	trabedersen	PANCREATIC CANCER	Designated	2009-07-21
HSWLVDBGZCETRH-UHFFFAOYSA-O	PUBCHEM.COMPOUND:132472120	UMLS:C0555198	trabedersen	Malignant Glioma	Designated	2002-06-05
HTQBXNHDCUEHJF-JHBIHAKISA-N	PUBCHEM.COMPOUND:138394057	UMLS:C0033845	exenatide	Idiopathic Intracranial Hypertension	Designated	2017-05-16
HTQBXNHDCUEHJF-URRANESESA-N	PUBCHEM.COMPOUND:56927919	UMLS:C0033845	exenatide	Idiopathic Intracranial Hypertension	Designated	2017-05-16
HTQBXNHDCUEHJF-XWLPCZSASA-N	PUBCHEM.COMPOUND:45588096	UMLS:C0033845	exenatide	Idiopathic Intracranial Hypertension	Designated	2017-05-16
HTTJABKRGRZYRN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:772	UMLS:C0010674	Heparin	Cystic Fibrosis	Designated/Withdrawn	2005-11-03
HUASEDVYRABWCV-NDEPHWFRSA-N	PUBCHEM.COMPOUND:90937527	UMLS:C0235974	upamostat	PANCREATIC CANCER	Designated	2017-10-16
HUASEDVYRABWCV-NDEPHWFRSA-N	PUBCHEM.COMPOUND:90937527	UMLS:C0235974	upamostat	PANCREATIC CANCER	Designated	2017-10-16
HUASEDVYRABWCV-NDEPHWFRSA-N	PUBCHEM.COMPOUND:90937527	UMLS:C0235974	upamostat	PANCREATIC CANCER	Designated	2017-10-16
HUASEDVYRABWCV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:72754524	UMLS:C0235974	upamostat	PANCREATIC CANCER	Designated	2017-10-16
HUCXKZBETONXFO-NJFMWZAGSA-N	PUBCHEM.COMPOUND:5282199	UMLS:C1839259	geranylgeranylacetone	Spinal and Bulbar Muscular Atrophy	Designated	2020-06-26
HUCXKZBETONXFO-NJFMWZAGSA-N	PUBCHEM.COMPOUND:5282199	UMLS:C0520799	geranylgeranylacetone	Acute Radiation Syndrome	Designated	2020-06-10
HUCXKZBETONXFO-NJFMWZAGSA-N	PUBCHEM.COMPOUND:5282199	UMLS:C0085605	Geranylgeranylacetone	Liver Failure	Designated	2020-06-16
HUFOZJXAKZVRNJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57335384	UMLS:C3539721	rociletinib	Non-Small Cell Lung Cancer	Designated	2013-05-14
HUFOZJXAKZVRNJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57335384	UMLS:C1414313	rociletinib	EPIDERMAL GROWTH FACTOR RECEPTOR	Designated	2013-05-14
HVFWCHDZDIRYBZ-MQZJHDQISA-N	PUBCHEM.COMPOUND:72710874	UMLS:C1325653	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	mitochondrial respiratory chain	Designated	2014-11-17
HVXKQKFEHMGHSL-GOOCMWNKSA-N	PUBCHEM.COMPOUND:10458325	UMLS:C1418605	Tesevatinib	ARPKD	Designated	2016-03-01
HVXKQKFEHMGHSL-GOOCMWNKSA-N	PUBCHEM.COMPOUND:10458325	UMLS:C0085548	Tesevatinib	Autosomal Recessive Polycystic Kidney Disease	Designated	2016-03-01
HVXKQKFEHMGHSL-GOOCMWNKSA-N	PUBCHEM.COMPOUND:10458325	UMLS:C3539721	tesevatinib	Non-Small Cell Lung Cancer	Designated	2017-08-03
HWJPWWYTGBZDEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:213043	UMLS:C0010674	iclaprim	Cystic Fibrosis	Designated	2017-09-14
HWSLMIXAPNOWGU-AWEZNQCLSA-N	PUBCHEM.COMPOUND:22869857	UMLS:C0016667	(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	Fragile X Syndrome	Designated	2015-12-09
HWXIGFIVGWUZAO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:50942	UMLS:C0006267	doxofylline	Bronchiectasis	Designated	2014-02-14
HWXVIOGONBBTBY-ONEGZZNKSA-N	PUBCHEM.COMPOUND:46216796	UMLS:C0032463	pacritinib	Polycythemia Vera	Designated	2008-03-13
HWXVIOGONBBTBY-ONEGZZNKSA-N	PUBCHEM.COMPOUND:46216796	UMLS:C0040028	pacritinib	ESSENTIAL THROMBOCYTHEMIA	Designated	2008-03-13
HWXVIOGONBBTBY-ONEGZZNKSA-N	PUBCHEM.COMPOUND:46216796	UMLS:C0001815	pacritinib	Primary Myelofibrosis	Designated	2008-03-13
HWXVIOGONBBTBY-ONEGZZNKSA-N	PUBCHEM.COMPOUND:46216796	UMLS:C0026987	pacritinib	Myelofibrosis	Designated	2008-03-13
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C4553297	Albendazole	Hydatid Disease	Designated/Approved	1996-01-17
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C0152069	Albendazole	Alveolar echinococcosis	Designated/Approved	1996-01-17
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C0010709	Albendazole	Cysts	Designated/Approved	1996-01-18
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C0013502	Albendazole	Hydatid disease	Designated/Approved	1996-01-17
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C0014544	Albendazole	Epilepsy	Designated/Approved	1996-01-18
HXHWSAZORRCQMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2082	UMLS:C0338437	Albendazole	Neurocysticercosis	Designated/Approved	1996-01-18
HXNFUBHNUDHIGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398752	UMLS:C0740394	Oxypurinol	Hyperuricemia	Designated	1998-11-09
HYAFETHFCAUJAY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4829	UMLS:C4275242	pioglitazone	Sudden sensorineural hearing loss	Designated	2019-12-12
HYFHYPWGAURHIV-BRXDYEKISA-N	PUBCHEM.COMPOUND:5458297	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-JCNWCSDUSA-N	PUBCHEM.COMPOUND:45356872	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-JFIAXGOJSA-N	PUBCHEM.COMPOUND:285033	UMLS:C0023473	omacetaxine mepesuccinate	Chronic myelogenous leukemia	Designated/Approved	2006-03-10
HYFHYPWGAURHIV-JFIAXGOJSA-N	PUBCHEM.COMPOUND:285033	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-PWNJXPRTSA-N	PUBCHEM.COMPOUND:71296925	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-RZCBTRPQSA-N	PUBCHEM.COMPOUND:56841046	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3628	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYFHYPWGAURHIV-ZEDNPHJLSA-N	PUBCHEM.COMPOUND:72332	UMLS:C0023473	homoharringtonine	Chronic myelogenous leukemia	Designated	2002-02-08
HYHJFNXFVPGMBI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:100773	UMLS:C0555198	2-chloroethyl-3-sarcosinamide-1-nitrosourea	malignant gliomas	Designated	2001-08-03
HYHJFNXFVPGMBI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:100773	UMLS:C0555198	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Malignant Glioma	Designated	2001-11-15
HYHMLYSLQUKXKP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10472693	UMLS:C0020445	bempedoic acid	FAMILIAL HYPERCHOLESTEROLEMIA	Designated	2021-04-05
HYHSBSXUHZOYLX-WDSKDSINSA-M	PUBCHEM.COMPOUND:7059524	UMLS:C1547996	S-nitrosoglutathione	Pulmonary Function	Designated	2009-05-12
HYHSBSXUHZOYLX-WDSKDSINSA-M	PUBCHEM.COMPOUND:7059524	UMLS:C0010674	S-nitrosoglutathione	Cystic Fibrosis	Designated	2009-05-12
HYHSBSXUHZOYLX-WDSKDSINSA-M	PUBCHEM.COMPOUND:7059524	UMLS:C0341950	S-nitrosoglutathione	Severe Preeclampsia	Designated	2012-12-28
HYHSBSXUHZOYLX-WDSKDSINSA-N	PUBCHEM.COMPOUND:104858	UMLS:C0341950	S-nitrosoglutathione	Severe Preeclampsia	Designated	2012-12-28
HYHSBSXUHZOYLX-WDSKDSINSA-N	PUBCHEM.COMPOUND:104858	UMLS:C0010674	S-nitrosoglutathione	Cystic Fibrosis	Designated	2009-05-12
HYHSBSXUHZOYLX-WDSKDSINSA-N	PUBCHEM.COMPOUND:104858	UMLS:C1547996	S-nitrosoglutathione	Pulmonary Function	Designated	2009-05-12
HYIMSNHJOBLJNT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4485	UMLS:C0282488	Nifedipine	Interstitial Cystitis	Designated	1991-06-13
HZAXFHJVJLSVMW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:700	UMLS:C0014867	ethanolamine	Esophageal Varices	Designated	2014-01-17
HZAXFHJVJLSVMW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:700	UMLS:C0042345	ethanolamine	Varices	Designated	2014-01-17
HZLFFNCLTRVYJG-WWGOJCOQSA-N	PUBCHEM.COMPOUND:25027363	UMLS:C0004779	patidegib	Nevoid Basal Cell Carcinoma Syndrome	Designated	2017-07-19
HZQDCMWJEBCWBR-UUOKFMHZSA-N	PUBCHEM.COMPOUND:104762	UMLS:C0017665	Mizoribine	membranous nephropathy	Designated	2020-11-09
IAKHMKGGTNLKSZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:6167	UMLS:C0393665	Colchicine	Chronic progressive multiple sclerosis	Designated/Withdrawn	1985-12-09
IAKHMKGGTNLKSZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:6167	UMLS:C0242656	Colchicine	Progression	Designated/Withdrawn	1985-12-09
IAKHMKGGTNLKSZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:6167	UMLS:C0004943	Colchicine	Behcet Syndrome	Designated	2007-09-25
IAKHMKGGTNLKSZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:6167	UMLS:C0231170	Colchicine	Disability	Designated/Withdrawn	1985-12-09
IAKHMKGGTNLKSZ-INIZCTEOSA-N	PUBCHEM.COMPOUND:6167	UMLS:C0031069	colchicine	Familial Mediterranean Fever	Designated/Approved	2007-09-25
IAZDPXIOMUYVGZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:679	UMLS:C0037578	Dimethylsulfoxide	SOFT TISSUE INJURY	Designated	1997-04-15
IBLNKMRFIPWSOY-FNORWQNLSA-N	PUBCHEM.COMPOUND:5311454	UMLS:C0020501	Stiripentol	Primary Hyperoxaluria	Designated	2021-02-22
IBLNKMRFIPWSOY-FNORWQNLSA-N	PUBCHEM.COMPOUND:5311454	UMLS:C0751122	stiripentol	Dravet Syndrome	Designated/Approved	2008-10-30
IBRSMMVMVMCYCS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135430840	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
IBXPAFBDJCXCDW-MHFPCNPESA-A	PUBCHEM.COMPOUND:118984457	UMLS:C0023467	oblimersen	Acute myelocytic leukemia	Designated	2001-08-28
IBXPAFBDJCXCDW-MHFPCNPESA-A	PUBCHEM.COMPOUND:118984457	UMLS:C0025202	oblimersen	Malignant Melanoma	Designated	2000-07-31
IBXPAFBDJCXCDW-MHFPCNPESA-A	PUBCHEM.COMPOUND:118984457	UMLS:C0023434	oblimersen	Chronic Lymphocytic Leukemia	Designated	2001-08-28
IBXPAFBDJCXCDW-MHFPCNPESA-A	PUBCHEM.COMPOUND:118984457	UMLS:C0026764	oblimersen	Multiple Myeloma	Designated	2001-08-28
ICKFFNBDFNZJSX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25295	UMLS:C0235974	chloropyramine	PANCREATIC CANCER	Designated	2010-10-22
IDBPHNDTYPBSNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51263	UMLS:C0032768	Alfentanil	Postherpetic neuralgia	Designated	2005-07-08
IDBPHNDTYPBSNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51263	UMLS:C0019682	Alfentanil	HIV	Designated	2005-08-09
IDBPHNDTYPBSNI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51263	UMLS:C0442874	Alfentanil	Neuropathy	Designated	2005-08-09
IDIIJJHBXUESQI-DFIJPDEKSA-N	PUBCHEM.COMPOUND:101526	UMLS:C0041296	moxifloxacin hydrochloride	Tuberculosis	Designated/Withdrawn	2014-04-30
IDRGFNPZDVBSSE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:117909640	UMLS:C3539721	N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide	Non-Small Cell Lung Cancer	Designated	2017-09-05
IDRGFNPZDVBSSE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:117909640	UMLS:C1414313	N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide	EPIDERMAL GROWTH FACTOR RECEPTOR	Designated	2017-09-05
IEJSCSAMMLUINT-NRFANRHFSA-N	PUBCHEM.COMPOUND:135430970	UMLS:C4721610	Plevitrexed	Ovarian Cancer	Designated/Withdrawn	2007-05-14
IEJSCSAMMLUINT-NRFANRHFSA-N	PUBCHEM.COMPOUND:135430970	UMLS:C0024623	Plevitrexed	stomach cancer	Designated/Withdrawn	2007-05-29
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0023434	idelalisib	Chronic Lymphocytic Leukemia	Designated/Approved	2013-10-15
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0349632	idelalisib	Splenic marginal zone lymphoma	Designated	2013-10-15
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0023434	idelalisib	Chronic Lymphocytic Leukemia	Designated	2011-08-25
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C1367654	idelalisib	Marginal zone lymphoma	Designated	2013-10-15
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0024301	idelalisib	follicular lymphoma	Designated/Approved	2013-09-26
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0855095	idelalisib	Small Lymphocytic Lymphoma	Designated/Approved	2013-10-15
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0024419	idelalisib	lymphoplasmacytic lymphoma	Designated	2013-09-26
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0334633	idelalisib	Lymphoplasmacytic Lymphoma	Designated	2013-09-26
IFSDAJWBUCMOAH-HNNXBMFYSA-N	PUBCHEM.COMPOUND:11625818	UMLS:C0242647	idelalisib	Nodal marginal zone lymphoma	Designated	2013-10-15
IHHXIUAEPKVVII-PTKYJSHISA-N	PUBCHEM.COMPOUND:9819903	UMLS:C0013274	Ibuprofen lysine	Patent ductus arteriosus	Designated/Approved	1996-10-29
IHHXIUAEPKVVII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9863332	UMLS:C0013274	Ibuprofen lysine	Patent ductus arteriosus	Designated/Approved	1996-10-29
IHHXIUAEPKVVII-ZSCHJXSPSA-N	PUBCHEM.COMPOUND:9841440	UMLS:C0013274	Ibuprofen lysine	Patent ductus arteriosus	Designated/Approved	1996-10-29
IHOVFYSQUDPMCN-XAKVHENESA-N	PUBCHEM.COMPOUND:3036703	UMLS:C0023467	Zosuquidar trihydrochloride	Acute myeloid leukemia	Designated	2005-12-15
IHRNYHWGJUMPFJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44562555	UMLS:C0235974	Caflanone	PANCREATIC CANCER	Designated	2019-09-25
IIBYAHWJQTYFKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:39042	UMLS:C0574083	bezafibrate	Barth Syndrome	Designated	2013-07-24
IIMIOEBMYPRQGU-UHFFFAOYSA-L	PUBCHEM.COMPOUND:177358	UMLS:C3540630	Picoplatin	Small Cell Lung Cancer	Designated	2005-11-02
IIXWYSCJSQVBQM-LLVKDONJSA-N	PUBCHEM.COMPOUND:71731823	UMLS:C3539721	Lorlatinib	Non-Small Cell Lung Cancer	Designated/Approved	2015-06-23
IKPNWIGTWUZCKM-JEDNCBNOSA-N	PUBCHEM.COMPOUND:135242	UMLS:C0036980	Tilarginine acetate	Cardiogenic shock	Designated	2005-04-11
IMOZEMNVLZVGJZ-QGZVFWFLSA-N	PUBCHEM.COMPOUND:11561674	UMLS:C0009324	apremilast	Ulcerative Colitis	Designated	2018-01-17
IMOZEMNVLZVGJZ-QGZVFWFLSA-N	PUBCHEM.COMPOUND:11561674	UMLS:C0004943	apremilast	Behcet Syndrome	Designated/Approved	2013-01-17
IMYZQPCYWPFTAG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4032	UMLS:C0040517	Mecamylamine	Tourette's Syndrome	Designated	1998-10-14
INJOMKTZOLKMBF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3519	UMLS:C0016667	guanfacine	Fragile X Syndrome	Designated	1999-08-05
INWLQCZOYSRPNW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4062	UMLS:C0019682	mepivacaine	HIV	Designated	2006-10-18
INWLQCZOYSRPNW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4062	UMLS:C0442874	mepivacaine	Neuropathy	Designated	2006-10-18
INWLQCZOYSRPNW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4062	UMLS:C0032768	mepivacaine	Postherpetic neuralgia	Designated	2007-01-08
IOEMETRLOWNXGW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54368	UMLS:C0026914	Piritrexim isethionate	Mycobacterium avium-intracellulare	Designated/Withdrawn	1988-06-13
IOEMETRLOWNXGW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54368	UMLS:C3714514	Piritrexim isethionate	Infections	Designated/Withdrawn	1988-06-13
IOEMETRLOWNXGW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54368	UMLS:C0040557	Piritrexim isethionate	Toxoplasma gondii	Designated/Withdrawn	1988-06-13
IPOKCKJONYRRHP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54585	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
IPVFGAYTKQKGBM-BYPJNBLXSA-N	PUBCHEM.COMPOUND:50313	UMLS:C0744831	fialuridine	Chronic active hepatitis B	Designated	1992-07-24
IQWHCHZFYPIVRV-UHFFFAOYSA-I	PUBCHEM.COMPOUND:216258	UMLS:C0010674	colistimethate sodium	Cystic Fibrosis	Designated	2020-03-19
IQWHCHZFYPIVRV-UHFFFAOYSA-I	PUBCHEM.COMPOUND:216258	UMLS:C0035243	colistimethate sodium	respiratory infection	Designated	2020-03-19
IRPYFWIZKIOHQN-XTZHGVARSA-N	PUBCHEM.COMPOUND:138402869	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
IRPYFWIZKIOHQN-XTZHGVARSA-N	PUBCHEM.COMPOUND:138402869	UMLS:C0013370	auranofin	amebiasis	Designated	2010-04-30
IRSCQMHQWWYFCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398740	UMLS:C0019357	ganciclovir	Herpetic keratitis	Designated/Approved	2007-03-22
IRSCQMHQWWYFCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398740	UMLS:C0041582	ganciclovir	Ulcers	Designated/Approved	2007-03-22
IRSCQMHQWWYFCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398740	UMLS:C0010823	Gancyclovir	Cytomegalovirus Infections	Designated/Withdrawn	1985-06-07
ISAVYTVYFVQUDY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:8814	UMLS:C0010674	Tyloxapol	Cystic Fibrosis	Designated	1995-03-08
ISWRGOKTTBVCFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40632	UMLS:C1800706	pirfenidone	Idiopathic Pulmonary Fibrosis	Designated	2014-07-31
ISWRGOKTTBVCFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40632	UMLS:C0036421	pirfenidone	Systemic sclerosis	Designated	2013-11-19
ISWRGOKTTBVCFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40632	UMLS:C0206062	pirfenidone	Interstitial lung disease	Designated	2013-11-19
ISWRGOKTTBVCFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40632	UMLS:C1800706	pirfenidone	Idiopathic Pulmonary Fibrosis	Designated/Approved	2004-03-05
ISWRGOKTTBVCFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:40632	UMLS:C0206062	pirfenidone	Interstitial lung disease	Designated	2020-03-11
ITFLMCXLENHUAD-PYFZXISVSA-L	PUBCHEM.COMPOUND:134820153	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
ITFLMCXLENHUAD-PYFZXISVSA-L	PUBCHEM.COMPOUND:134820153	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
ITFLMCXLENHUAD-WZHZPDAFSA-L	PUBCHEM.COMPOUND:70678542	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
ITFLMCXLENHUAD-WZHZPDAFSA-L	PUBCHEM.COMPOUND:70678542	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
ITFLMCXLENHUAD-WZHZPDAFSA-M	PUBCHEM.COMPOUND:129893562	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
ITFLMCXLENHUAD-WZHZPDAFSA-M	PUBCHEM.COMPOUND:129893562	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
ITPDYQOUSLNIHG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:441325	UMLS:C0042514	Amiodarone HCl	Ventricular tachycardia	Designated/Approved	1994-03-16
ITPDYQOUSLNIHG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:441325	UMLS:C0042510	Amiodarone HCl	Ventricular Fibrillation	Designated/Approved	1994-03-16
IUVCFHHAEHNCFT-INIZCTEOSA-N	PUBCHEM.COMPOUND:72950888	UMLS:C1367654	umbralisib	Marginal zone lymphoma	Designated/Approved	2019-04-11
IUVCFHHAEHNCFT-INIZCTEOSA-N	PUBCHEM.COMPOUND:72950888	UMLS:C0024301	umbralisib	follicular lymphoma	Designated/Approved	2020-03-04
IUVCFHHAEHNCFT-INIZCTEOSA-N	PUBCHEM.COMPOUND:72950888	UMLS:C0242647	umbralisib	Nodal marginal zone lymphoma	Designated/Approved	2019-04-11
IUVCFHHAEHNCFT-INIZCTEOSA-N	PUBCHEM.COMPOUND:72950888	UMLS:C0349632	umbralisib	Splenic marginal zone lymphoma	Designated/Approved	2019-04-11
IVTMXOXVAHXCHI-YXLMWLKOSA-N	PUBCHEM.COMPOUND:104778	UMLS:C0030567	levodopa and carbidopa	Parkinson's Disease	Designated/Approved	2000-01-18
IWMJORKECAFMRX-USANWJRDSA-N	PUBCHEM.COMPOUND:137254226	UMLS:C0017638	3-(1-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester	Glioma	Designated	2017-12-06
IWUCXVSUMQZMFG-AFCXAGJDSA-N	PUBCHEM.COMPOUND:37542	UMLS:C0524910	ribavirin	chronic hepatitis c	Designated/Approved	2003-04-04
IWUCXVSUMQZMFG-AFCXAGJDSA-N	PUBCHEM.COMPOUND:37542	UMLS:C0019101	ribavirin	Hemorrhagic Fever with Renal Syndrome	Designated	1991-04-12
IXOXBSCIXZEQEQ-UHTZMRCNSA-N	PUBCHEM.COMPOUND:3011155	UMLS:C0023449	nelarabine	Acute lymphoblastic leukemia	Designated/Approved	2004-08-10
IXOXBSCIXZEQEQ-UHTZMRCNSA-N	PUBCHEM.COMPOUND:3011155	UMLS:C0278721	nelarabine	Lymphoblastic Lymphoma	Designated/Approved	2004-08-10
IXOXBSCIXZEQEQ-UHTZMRCNSA-N	PUBCHEM.COMPOUND:3011155	UMLS:C1961102	nelarabine	Acute Lymphoblastic Leukemia	Designated/Approved	2004-08-10
IXOXBSCIXZEQEQ-UHTZMRCNSA-N	PUBCHEM.COMPOUND:3011155	UMLS:C0023434	nelarabine	Chronic Lymphocytic Leukemia	Designated	1999-09-02
IXSVOCGZBUJEPI-HTQYORAHSA-N	PUBCHEM.COMPOUND:135431094	UMLS:C0041327	Rifalazil	Pulmonary tuberculosis	Designated	1999-04-13
IXYNFLOLUBKHQU-FZCWJHTDSA-N	PUBCHEM.COMPOUND:121492440	UMLS:C0009324	cobitolimod	Ulcerative Colitis	Designated	2017-08-08
IXZOHGPZAQLIBH-NRFANRHFSA-N	PUBCHEM.COMPOUND:67335295	UMLS:C0026764	iberdomide	Multiple Myeloma	Designated	2018-12-19
IYETZZCWLLUHIJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:92913	UMLS:C0030568	Selegiline HCl	Postencephalitic Parkinsonism	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:92913	UMLS:C0030569	Selegiline HCl	Symptomatic parkinsonism	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:92913	UMLS:C0030567	Selegiline HCl	Idiopathic Parkinson's disease	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-UTONKHPSSA-N	PUBCHEM.COMPOUND:26758	UMLS:C0030567	Selegiline HCl	Idiopathic Parkinson's disease	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-UTONKHPSSA-N	PUBCHEM.COMPOUND:26758	UMLS:C0030568	Selegiline HCl	Postencephalitic Parkinsonism	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-UTONKHPSSA-N	PUBCHEM.COMPOUND:26758	UMLS:C0030569	Selegiline HCl	Symptomatic parkinsonism	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-YDALLXLXSA-N	PUBCHEM.COMPOUND:199604	UMLS:C0030568	Selegiline HCl	Postencephalitic Parkinsonism	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-YDALLXLXSA-N	PUBCHEM.COMPOUND:199604	UMLS:C0030567	Selegiline HCl	Idiopathic Parkinson's disease	Designated/Approved	1984-11-07
IYETZZCWLLUHIJ-YDALLXLXSA-N	PUBCHEM.COMPOUND:199604	UMLS:C0030569	Selegiline HCl	Symptomatic parkinsonism	Designated/Approved	1984-11-07
IYFNEFQTYQPVOC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135413547	UMLS:C0152021	udenafil	Congenital heart disease	Designated	2015-08-31
IYFNEFQTYQPVOC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135413547	UMLS:C0152424	udenafil	Single ventricle	Designated	2015-08-31
IYIKLHRQXLHMJQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2157	UMLS:C0042514	Amiodarone	Ventricular tachycardia	Designated	1993-08-17
JACAAXNEHGBPOQ-LLVKDONJSA-N	PUBCHEM.COMPOUND:164509	UMLS:C0017638	talampanel	Glioma	Designated/Withdrawn	2009-02-17
JACAAXNEHGBPOQ-LLVKDONJSA-N	PUBCHEM.COMPOUND:164509	UMLS:C0002736	talampanel	Amyotrophic Lateral Sclerosis	Designated/Withdrawn	2008-03-24
JALHGCPDPSNJNY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10158453	UMLS:C0002895	prasugrel hydrochloride	Sickle Cell Disease	Designated	2015-05-26
JAZBEHYOTPTENJ-JLNKQSITSA-N	PUBCHEM.COMPOUND:446284	UMLS:C0032580	eicosapentaenoic acid	Familial Adenomatous Polyposis	Designated	2011-03-08
JBDGDEWWOUBZPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2132	UMLS:C0017205	ambroxol	Gaucher Disease	Designated	2011-06-29
JCOHXVDKRMWUQP-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23718384	UMLS:C0280209	tasisulam sodium	melanoma stages	Designated/Withdrawn	2009-09-03
JDXCOXKBIGBZSK-PSNKNOTQSA-N	PUBCHEM.COMPOUND:133083018	UMLS:C0026896	Zilucoplan	Myasthenia Gravis	Designated	2019-08-26
JDZOTSLZMQDFLG-BTJKTKAUSA-N	PUBCHEM.COMPOUND:5284439	UMLS:C0007194	perhexiline maleate	Hypertrophic Cardiomyopathy	Designated	2012-06-14
JESCETIFNOFKEU-SJORKVTESA-N	PUBCHEM.COMPOUND:16046068	UMLS:C0040997	vixotrigine	Trigeminal Neuralgia	Designated	2013-07-24
JFMWPOCYMYGEDM-XFULWGLBSA-N	PUBCHEM.COMPOUND:25127112	UMLS:C0040028	ruxolitinib phosphate	ESSENTIAL THROMBOCYTHEMIA	Designated	2010-03-22
JFMWPOCYMYGEDM-XFULWGLBSA-N	PUBCHEM.COMPOUND:25127112	UMLS:C0026987	ruxolitinib phosphate	myelofibrosis	Designated/Approved	2008-09-05
JFSOSUNPIXJCIX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3025067	UMLS:C0013384	eltoprazine HCl	Dyskinesia	Designated	2016-02-08
JFSOSUNPIXJCIX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3025067	UMLS:C0030567	eltoprazine HCl	Parkinson's Disease	Designated	2016-02-08
JFVVPUGGRUGRBJ-AVRDEDQJSA-N	PUBCHEM.COMPOUND:129851403	UMLS:C4721610	cantrixil	Ovarian Cancer	Designated	2015-04-20
JFVZFKDSXNQEJW-CQSZACIVSA-N	PUBCHEM.COMPOUND:5481350	UMLS:C0282474	tenofovir disoproxil fumarate	Mother to Child Transmission	Designated/Withdrawn	2016-09-27
JFVZFKDSXNQEJW-CQSZACIVSA-N	PUBCHEM.COMPOUND:5481350	UMLS:C0019169	tenofovir disoproxil fumarate	hepatitis B virus	Designated/Withdrawn	2016-09-27
JGCMEBMXRHSZKX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16004692	UMLS:C1800706	macitentan	Idiopathic Pulmonary Fibrosis	Designated/Withdrawn	2009-04-14
JGCMEBMXRHSZKX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16004692	UMLS:C2363973	macitentan	Chronic thromboembolic pulmonary hypertension	Designated	2017-06-15
JGCMEBMXRHSZKX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16004692	UMLS:C3203102	macitentan	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2009-09-03
JGDXFQORBMPJGR-YUMQZZPRSA-N	PUBCHEM.COMPOUND:11683005	UMLS:C0079774	Darinaparsin	Peripheral T-Cell Lymphoma	Designated	2010-09-13
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0001125	idebenone	LACTIC ACIDOSIS	Designated/Withdrawn	2009-05-22
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0039082	idebenone	Syndrome	Designated/Withdrawn	2009-05-22
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0085584	idebenone	Encephalopathy	Designated/Withdrawn	2009-05-22
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C1857287	idebenone	Stroke-like episodes	Designated/Withdrawn	2009-05-22
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0162671	idebenone	MELAS	Designated/Withdrawn	2009-05-22
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0016719	idebenone	Friedreich's Ataxia	Designated	2004-03-25
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0013264	idebenone	DUCHENNE MUSCULAR DYSTROPHY	Designated	2007-02-16
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0917796	idebenone	Leber's Hereditary Optic Neuropathy	Designated	2006-10-31
JGPMMRGNQUBGND-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3686	UMLS:C0162670	idebenone	MITOCHONDRIAL MYOPATHY	Designated/Withdrawn	2009-05-22
JGSARLDLIJGVTE-MBNYWOFBSA-M	PUBCHEM.COMPOUND:640429	UMLS:C0398368	picibanil	lymphatic malformations	Designated	2011-03-17
JGSARLDLIJGVTE-MBNYWOFBSA-M	PUBCHEM.COMPOUND:640429	UMLS:C0398368	picibanil	lymphatic malformations	Designated	2009-05-15
JGWRKYUXBBNENE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25151352	UMLS:C0017525	pexidartinib	Giant Cell Tumor	Designated/Approved	2014-02-14
JGWRKYUXBBNENE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25151352	UMLS:C0039106	pexidartinib	Pigmented villonodular synovitis	Designated/Approved	2014-02-14
JICJBGPOMZQUBB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68870	UMLS:C0035372	tianeptine	Rett Syndrome	Designated	2018-03-08
JJICLMJFIKGAAU-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23700083	UMLS:C0001175	Ganciclovir sodium	AIDS	Designated/Approved/Withdrawn	1985-10-31
JJICLMJFIKGAAU-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23700083	UMLS:C0206178	Ganciclovir sodium	Cytomegalovirus Retinitis	Designated/Approved/Withdrawn	1985-10-31
JJOFNSLZHKIJEV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11192129	UMLS:C0022577	Lodoxamide tromethamine	Vernal keratoconjunctivitis	Designated/Approved	1991-10-16
JJVZSYKFCOBILL-MKMRYRNGSA-N	PUBCHEM.COMPOUND:91865076	UMLS:C0023467	motixafortide	Acute myeloid leukemia	Designated	2013-09-05
JJVZSYKFCOBILL-MKMRYRNGSA-N	PUBCHEM.COMPOUND:91865076	UMLS:C0235974	motixafortide	PANCREATIC CANCER	Designated	2019-02-01
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C4721610	Amifostine	Ovarian carcinoma	Designated	1990-05-30
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C4721610	Amifostine	Ovarian carcinoma	Designated/Approved	1990-05-30
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C0043352	Amifostine	Xerostomia	Designated/Approved	1998-05-12
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C0600688	Amifostine	toxicities	Designated	1998-11-24
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C0278883	Amifostine	Metastatic melanoma	Designated	1990-05-30
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C4721610	Ethiofos	Ovarian Cancer	Designated/Withdrawn	1989-08-01
JKOQGQFVAUAYPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2141	UMLS:C3463824	Amifostine	Myelodysplastic Syndromes	Designated	1999-10-04
JLEBZPBDRKPWTD-TURQNECASA-O	PUBCHEM.COMPOUND:439924	UMLS:C0001125	nicotinamide riboside	LACTIC ACIDOSIS	Designated	2017-01-25
JLEBZPBDRKPWTD-TURQNECASA-O	PUBCHEM.COMPOUND:439924	UMLS:C1857287	nicotinamide riboside	Stroke-like episodes	Designated	2017-01-25
JLEBZPBDRKPWTD-TURQNECASA-O	PUBCHEM.COMPOUND:439924	UMLS:C1852373	nicotinamide riboside	Mitochondrial encephalopathy	Designated	2017-01-25
JLEBZPBDRKPWTD-TURQNECASA-O	PUBCHEM.COMPOUND:439924	UMLS:C0162671	nicotinamide riboside	MELAS	Designated	2017-01-25
JLEBZPBDRKPWTD-TURQNECASA-O	PUBCHEM.COMPOUND:439924	UMLS:C0039082	nicotinamide riboside	Syndrome	Designated	2017-01-25
JLYAXFNOILIKPP-KXQOOQHDSA-N	PUBCHEM.COMPOUND:24978538	UMLS:C0026987	navitoclax	myelofibrosis	Designated	2019-11-18
JMNXSNUXDHHTKQ-QVMSTPCGSA-N	PUBCHEM.COMPOUND:3036507	UMLS:C4721610	squalamine lactate	Ovarian Cancer	Designated	2001-05-11
JMNXSNUXDHHTKQ-QVMSTPCGSA-N	PUBCHEM.COMPOUND:3036507	UMLS:C0677936	squalamine lactate	cancer refractory	Designated	2001-05-11
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:11960529	UMLS:C4721610	veliparib	Epithelial Ovarian Cancer	Designated	2009-09-03
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:11960529	UMLS:C2239176	veliparib	HEPATOCELLULAR CARCINOMA	Designated	2009-11-20
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:11960529	UMLS:C0220650	veliparib	brain metastases	Designated	2014-12-17
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:11960529	UMLS:C0017636	veliparib	Glioblastoma multiforme	Designated	2008-05-09
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:11960529	UMLS:C4509816	veliparib	Squamous non-small cell lung cancer	Designated	2016-11-03
JNODQFNWMXFMEV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:197033	UMLS:C0020179	dimebon	Huntington's Disease	Designated	2009-05-12
JNWFIPVDEINBAI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565962	UMLS:C0019156	defibrotide	Hepatic Veno-Occlusive Disease	Designated/Approved	2003-05-21
JNWFIPVDEINBAI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565962	UMLS:C0019156	defibrotide	Hepatic Veno-Occlusive Disease	Designated	2007-01-08
JNWFIPVDEINBAI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565962	UMLS:C0856825	defibrotide	Acute Graft Versus Host Disease	Designated	2020-05-14
JNWFIPVDEINBAI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565962	UMLS:C0857305	Defibrotide	Thrombocytopenic purpura	Designated	1985-07-05
JNZBHHQBPHSOMU-WNQIDUERSA-N	PUBCHEM.COMPOUND:10216431	UMLS:C0023467	Amonafide L-malate	Acute myeloid leukemia	Designated/Withdrawn	2006-12-20
JOAHPSVPXZTVEP-YXJHDRRASA-N	PUBCHEM.COMPOUND:443951	UMLS:C0036421	terguride	Systemic sclerosis	Designated/Withdrawn	2013-05-17
JOAHPSVPXZTVEP-YXJHDRRASA-N	PUBCHEM.COMPOUND:443951	UMLS:C3203102	terguride	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	2008-05-02
JOATXPAWOHTVSZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2663	UMLS:C0013720	celiprolol	Ehlers-Danlos Syndrome	Designated	2015-01-05
JOITUBWXBFATOR-HKBOAZHASA-N	PUBCHEM.COMPOUND:71587904	UMLS:C3542021	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	Duchenne and Becker Muscular Dystrophy	Designated	2006-01-18
JOOXLOJCABQBSG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16722836	UMLS:C0032463	Fedratinib	Polycythemia Vera	Designated	2013-03-21
JOOXLOJCABQBSG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16722836	UMLS:C0001815	Fedratinib	Primary Myelofibrosis	Designated/Approved	2009-05-18
JOZGNYDSEBIJDH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:43157	UMLS:C2239176	eniluracil	HEPATOCELLULAR CARCINOMA	Designated	2005-12-15
JPBOABGEVHVPNM-ANYVIMDKSA-N	PUBCHEM.COMPOUND:11490752	UMLS:C0010674	Brevenal	Cystic Fibrosis	Designated	2018-04-02
JPBOABGEVHVPNM-GFIBHCGLSA-N	PUBCHEM.COMPOUND:46886836	UMLS:C0010674	Brevenal	Cystic Fibrosis	Designated	2018-04-02
JPBOABGEVHVPNM-KGIMXCGWSA-N	PUBCHEM.COMPOUND:11227586	UMLS:C0010674	Brevenal	Cystic Fibrosis	Designated	2018-04-02
JPBOABGEVHVPNM-LPEULFRDSA-N	PUBCHEM.COMPOUND:15965874	UMLS:C0010674	Brevenal	Cystic Fibrosis	Designated	2018-04-02
JQLBBYLGWHUHRW-KUBAVDMBSA-N	PUBCHEM.COMPOUND:44626120	UMLS:C0013264	Edasalonexent	DUCHENNE MUSCULAR DYSTROPHY	Designated	2014-11-17
JQUBXCDDRXAMLF-IXPVHAAZSA-N	PUBCHEM.COMPOUND:16735504	UMLS:C0008312	(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol	Primary Biliary Cholangitis	Designated	2021-02-01
JRHNIQQUVJOPQC-AQNFWKISSA-N	PUBCHEM.COMPOUND:216385	UMLS:C0026709	odiparcil	Mucopolysaccharidosis Type VI	Designated	2017-08-03
JRTRSJGZMRQDHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:92044406	UMLS:C0010674	heparin sodium	Cystic Fibrosis	Designated	2019-07-29
JRTRSJGZMRQDHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:92044406	UMLS:C0010674	Heparin sodium	Cystic Fibrosis	Designated	2006-06-29
JTQBMTFVGGUDPN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25400580	UMLS:C0265962	6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one	Netherton Syndrome	Designated	2015-06-18
JTVPZMFULRWINT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5467	UMLS:C0040517	Tiapride	Tourette's Syndrome	Designated/Withdrawn	1998-04-21
JUQLTPCYUFPYKE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5074	UMLS:C0017636	Ritanserin	Glioblastoma	Designated	2017-05-11
JUTBAVRYDAKVGQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21133161	UMLS:C0600688	emeramide	Toxicity	Designated	2012-04-06
JVLBPIPGETUEET-GAAHOAFPSA-O	PUBCHEM.COMPOUND:5361918	UMLS:C3160897	Methylnaltrexone	Opioid-Induced Constipation	Designated/Withdrawn	1996-06-17
JVTAAEKCZFNVCJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:612	UMLS:C0038363	Lactic acid	Aphthous Stomatitis	Designated	1999-06-29
JWBPVFVNISJVEM-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23669229	UMLS:C0036572	caffeine and sodium benzoate	Seizure	Designated	2012-08-22
JWHPPWBIIQMBQC-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23697158	UMLS:C0020179	laquinimod sodium	Huntington's Disease	Designated	2017-01-31
JWHYSEDOYMYMNM-QGZVFWFLSA-N	PUBCHEM.COMPOUND:11236126	UMLS:C0008312	seladelpar	Primary Biliary Cholangitis	Designated	2016-11-07
JWNPDZNEKVCWMY-VQHVLOKHSA-N	PUBCHEM.COMPOUND:9915743	UMLS:C0678222	neratinib	Breast cancer	Designated	2019-08-26
JWNPDZNEKVCWMY-VQHVLOKHSA-N	PUBCHEM.COMPOUND:9915743	UMLS:C0220650	neratinib	brain metastases	Designated	2019-08-26
JYGXADMDTFJGBT-VWUMJDOOSA-N	PUBCHEM.COMPOUND:5754	UMLS:C0006287	hydrocortisone	Bronchopulmonary Dysplasia	Designated	2020-05-13
JYGXADMDTFJGBT-VWUMJDOOSA-N	PUBCHEM.COMPOUND:5754	UMLS:C0001623	Hydrocortisone	Adrenal Insufficiency	Designated/Approved	2015-05-13
JYHHQTRVJFMEGR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57411069	UMLS:C0016667	5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione	Fragile X Syndrome	Designated	2017-06-12
JYSJVJJVLNYRKL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53395169	UMLS:C0030200	Elcatonin	intractable pain	Designated	1995-09-25
JZCILZBQRWUKME-SPOOISQMSA-N	PUBCHEM.COMPOUND:154731995	UMLS:C0022568	valine-valine-ganciclovir	Keratitis	Designated	2007-05-21
JZCILZBQRWUKME-SPOOISQMSA-N	PUBCHEM.COMPOUND:154731995	UMLS:C0022573	valine-valine-ganciclovir	Keratoconjunctivitis	Designated	2007-05-21
KAICRBBQCRKMPO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9920716	UMLS:C0751882	amifampridine phosphate	congenital myasthenic syndromes	Designated	2015-03-03
KAICRBBQCRKMPO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9920716	UMLS:C0026896	amifampridine phosphate	Myasthenia Gravis	Designated	2016-08-31
KAICRBBQCRKMPO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9920716	UMLS:C0022972	amifampridine phosphate	Lambert-Eaton Myasthenic Syndrome	Designated/Approved	2009-11-12
KAQKFAOMNZTLHT-OZUDYXHBSA-N	PUBCHEM.COMPOUND:5282411	UMLS:C0042373	epoprostenol	Vascular Disease	Designated/Approved	1999-03-22
KAQKFAOMNZTLHT-OZUDYXHBSA-N	PUBCHEM.COMPOUND:5282411	UMLS:C0016736	epoprostenol	Frostbite	Designated	2020-04-20
KAQKFAOMNZTLHT-OZUDYXHBSA-N	PUBCHEM.COMPOUND:5282411	UMLS:C3203102	Epoprostenol	Primary Pulmonary Hypertension	Designated/Approved	1985-09-25
KAQKFAOMNZTLHT-OZUDYXHBSA-N	PUBCHEM.COMPOUND:5282411	UMLS:C0264936	epoprostenol	Secondary pulmonary hypertension	Designated/Approved	1999-03-22
KBGAYAKRZNYFFG-BOHATCBPSA-N	PUBCHEM.COMPOUND:14017587	UMLS:C1853926	aceneuramic acid	Hereditary inclusion body myopathy	Designated/Withdrawn	2011-09-23
KBOPZPXVLCULAV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4075	UMLS:C2931173	mesalamine	Pediatric ulcerative colitis	Designated	2010-01-19
KDGFLJKFZUIJMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49806720	UMLS:C3539721	alectinib	Non-Small Cell Lung Cancer	Designated/Approved	2015-01-27
KDGFLJKFZUIJMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49806720	UMLS:C3539721	alectinib	Non-Small Cell Lung Cancer	Designated/Approved	2015-01-27
KDLRVYVGXIQJDK-AWPVFWJPSA-N	PUBCHEM.COMPOUND:446598	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-AWPVFWJPSA-N	PUBCHEM.COMPOUND:446598	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-AWPVFWJPSA-N	PUBCHEM.COMPOUND:446598	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-BVGIQVCNSA-N	PUBCHEM.COMPOUND:129627692	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-BVGIQVCNSA-N	PUBCHEM.COMPOUND:129627692	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-BVGIQVCNSA-N	PUBCHEM.COMPOUND:129627692	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NKPHASNASA-N	PUBCHEM.COMPOUND:46783762	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NKPHASNASA-N	PUBCHEM.COMPOUND:46783762	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NKPHASNASA-N	PUBCHEM.COMPOUND:46783762	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-NOWPCOIGSA-N	PUBCHEM.COMPOUND:29029	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NOWPCOIGSA-N	PUBCHEM.COMPOUND:29029	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-NOWPCOIGSA-N	PUBCHEM.COMPOUND:29029	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NQQGAZBYSA-N	PUBCHEM.COMPOUND:129009913	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-NQQGAZBYSA-N	PUBCHEM.COMPOUND:129009913	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-NQQGAZBYSA-N	PUBCHEM.COMPOUND:129009913	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-PSUNAQLJSA-N	PUBCHEM.COMPOUND:53245639	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-PSUNAQLJSA-N	PUBCHEM.COMPOUND:53245639	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-PSUNAQLJSA-N	PUBCHEM.COMPOUND:53245639	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2786	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2786	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2786	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-ZNZDIMKLSA-N	PUBCHEM.COMPOUND:27281318	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KDLRVYVGXIQJDK-ZNZDIMKLSA-N	PUBCHEM.COMPOUND:27281318	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-ZNZDIMKLSA-N	PUBCHEM.COMPOUND:27281318	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-ZUWRKQLMSA-N	PUBCHEM.COMPOUND:45357041	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-ZUWRKQLMSA-N	PUBCHEM.COMPOUND:45357041	UMLS:C1535939	Clindamycin	Pneumocystis carinii Pneumonia	Designated	1988-10-28
KDLRVYVGXIQJDK-ZUWRKQLMSA-N	PUBCHEM.COMPOUND:45357041	UMLS:C0276527	Clindamycin	Pneumonia associated with AIDS	Designated	1988-10-28
KFQUAMTWOJHPEJ-DAGMQNCNSA-N	PUBCHEM.COMPOUND:135407110	UMLS:C0023290	Allopurinol riboside	Visceral leishmaniasis	Designated/Withdrawn	1985-12-04
KFQUAMTWOJHPEJ-DAGMQNCNSA-N	PUBCHEM.COMPOUND:135407110	UMLS:C0041234	Allopurinol riboside	Chagas' disease	Designated/Withdrawn	1985-12-04
KGPGQDLTDHGEGT-CUIWZYKSSA-N	PUBCHEM.COMPOUND:133268464	UMLS:C0158371	dalbavancin	Acute osteomyelitis	Designated	2015-03-30
KGPGQDLTDHGEGT-FOPUKGCJSA-N	PUBCHEM.COMPOUND:135659030	UMLS:C0158371	dalbavancin	Acute osteomyelitis	Designated	2015-03-30
KGPGQDLTDHGEGT-JCIKCJKQSA-N	PUBCHEM.COMPOUND:16134410	UMLS:C0158371	dalbavancin	Acute osteomyelitis	Designated	2015-03-30
KGPGQDLTDHGEGT-SZUNQUCBSA-N	PUBCHEM.COMPOUND:16134627	UMLS:C0158371	dalbavancin	Acute osteomyelitis	Designated	2015-03-30
KGPGQDLTDHGEGT-VBZOGQDBSA-N	PUBCHEM.COMPOUND:23724878	UMLS:C0158371	dalbavancin	Acute osteomyelitis	Designated	2015-03-30
KGWDUNBJIMUFAP-KVVVOXFISA-N	PUBCHEM.COMPOUND:5282489	UMLS:C0014867	Ethanolamine oleate	Esophageal Varices	Designated/Approved	1984-03-22
KHDBHVDCUGRVLA-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23724967	UMLS:C0280100	motexafin gadolinium	solid tumors	Designated	2003-01-27
KHDBHVDCUGRVLA-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23724967	UMLS:C0220650	motexafin gadolinium	brain metastases	Designated	2003-01-27
KHPXUQMNIQBQEV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:970	UMLS:C2239176	anhydrous enol-oxaloacetate	HEPATOCELLULAR CARCINOMA	Designated	2018-03-07
KHPXUQMNIQBQEV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:970	UMLS:C0017638	oxaloacetate	gliomas	Designated	2012-07-24
KHPXUQMNIQBQEV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:970	UMLS:C0002736	oxaloacetic acid	Amyotrophic Lateral Sclerosis	Designated	2015-11-18
KIHYPELVXPAIDH-HNSNBQBZSA-N	PUBCHEM.COMPOUND:44599207	UMLS:C0085655	Siponimod	Polymyositis	Designated/Withdrawn	2013-11-26
KIHYPELVXPAIDH-HNSNBQBZSA-N	PUBCHEM.COMPOUND:44599207	UMLS:C0011633	siponimod	Dermatomyositis	Designated/Withdrawn	2014-07-10
KINULKKPVJYRON-PVNXHVEDSA-N	PUBCHEM.COMPOUND:6917792	UMLS:C0023467	bisantrene HCl	Acute myeloid leukemia	Designated	2014-02-14
KJADKKWYZYXHBB-XBWDGYHZSA-N	PUBCHEM.COMPOUND:5284627	UMLS:C0238111	Topiramate	Lennox-Gastaut syndrome	Designated/Approved	1992-11-25
KJFBVJALEQWJBS-XUXIUFHCSA-N	PUBCHEM.COMPOUND:471161	UMLS:C0877635	maribavir	Cytomegalovirus viremia	Designated	2011-06-07
KJFBVJALEQWJBS-XUXIUFHCSA-N	PUBCHEM.COMPOUND:471161	UMLS:C0877635	maribavir	Cytomegalovirus viremia	Designated	2007-02-01
KJFBVJALEQWJBS-XUXIUFHCSA-N	PUBCHEM.COMPOUND:471161	UMLS:C0012634	maribavir	Disease	Designated	2007-02-01
KJFBVJALEQWJBS-XUXIUFHCSA-N	PUBCHEM.COMPOUND:471161	UMLS:C0012634	maribavir	Disease	Designated	2011-06-07
KJQFBVYMGADDTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21157	UMLS:C0750979	Buthionine sulfoxamine	Primary Malignant Brain Tumors	Designated	2005-10-05
KJQFBVYMGADDTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21157	UMLS:C0027819	Buthionine sulfoxamine	Neuroblastoma	Designated	2005-10-05
KKGQTZUTZRNORY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:107970	UMLS:C0393819	fingolimod	Chronic inflammatory demyelinating polyneuropathy	Designated/Withdrawn	2010-04-30
KKYABQBFGDZVNQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11552706	UMLS:C0238288	losmapimod	Facioscapulohumeral muscular dystrophy	Designated	2020-01-27
KKZJGLLVHKMTCM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4212	UMLS:C1328504	Mitoxantrone	Hormone refractory prostate cancer	Designated/Approved	1996-08-21
KKZJGLLVHKMTCM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4212	UMLS:C0026769	Mitoxantrone	Multiple Sclerosis	Designated/Approved	1999-08-13
KKZJGLLVHKMTCM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4212	UMLS:C0393665	Mitoxantrone	Progressive multiple sclerosis	Designated/Approved	1999-08-13
KLEGMTRDCCDFJK-XDQSQZFTSA-N	PUBCHEM.COMPOUND:121492004	UMLS:C0002726	Inotersen	Amyloidosis	Designated/Approved	2012-07-24
KLEGMTRDCCDFJK-XDQSQZFTSA-N	PUBCHEM.COMPOUND:121492004	UMLS:C2751492	Inotersen	Transthyretin Amyloidosis	Designated/Approved	2012-07-24
KLNFSAOEKUDMFA-UHFFFAOYSA-M	PUBCHEM.COMPOUND:154731013	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
KLNFSAOEKUDMFA-UHFFFAOYSA-M	PUBCHEM.COMPOUND:154731013	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
KLNFSAOEKUDMFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24200453	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
KLNFSAOEKUDMFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24200453	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
KLNFSAOEKUDMFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24200453	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
KLNFSAOEKUDMFA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24200453	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
KMSKQZKKOZQFFG-CBFOJMSHSA-N	PUBCHEM.COMPOUND:131750285	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-CBIZWKIZSA-N	PUBCHEM.COMPOUND:45358767	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-FQSDZSELSA-N	PUBCHEM.COMPOUND:122173004	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-HSUXVGOQSA-N	PUBCHEM.COMPOUND:636397	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-MJKUFRJISA-N	PUBCHEM.COMPOUND:137704806	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-MJTHYZEOSA-N	PUBCHEM.COMPOUND:6712062	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-NCXNULAVSA-N	PUBCHEM.COMPOUND:6917695	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4844	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-ULRATTRFSA-N	PUBCHEM.COMPOUND:134692159	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-YHKVCKOMSA-N	PUBCHEM.COMPOUND:3033521	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMSKQZKKOZQFFG-YXRRJAAWSA-N	PUBCHEM.COMPOUND:11296583	UMLS:C0029463	Pirarubicin	Osteosarcoma	Designated	2020-10-29
KMUNHOKTIVSFRA-KXFIGUGUSA-N	PUBCHEM.COMPOUND:135409256	UMLS:C0010823	filociclovir	Cytomegalovirus Infections	Designated	2010-11-29
KNUXHTWUIVMBBY-JRJYXWDASA-N	PUBCHEM.COMPOUND:135537060	UMLS:C0235974	Rintatolimod	PANCREATIC CANCER	Designated	2020-12-17
KPWYNAGOBXLMSE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9893228	UMLS:C1800706	tipelukast	Idiopathic Pulmonary Fibrosis	Designated	2014-10-20
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0026838	L-baclofen	Spasticity	Designated	1991-12-17
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0007789	L-baclofen	Cerebral Palsy	Designated	1992-01-30
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0026838	L-baclofen	Spasticity	Designated	1992-01-30
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0037929	L-baclofen	Spinal Cord Injury	Designated	1991-12-17
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0026769	L-baclofen	Multiple Sclerosis	Designated	1991-12-17
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0040997	L-baclofen	Trigeminal Neuralgia	Designated	1990-07-13
KPYSYYIEGFHWSV-MRVPVSSYSA-N	PUBCHEM.COMPOUND:44600	UMLS:C0040997	L-baclofen	Trigeminal Neuralgia	Designated	1998-01-06
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0026769	L-baclofen	Multiple Sclerosis	Designated	1991-12-17
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0040997	L-baclofen	Trigeminal Neuralgia	Designated	1998-01-06
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0037929	L-baclofen	Spinal Cord Injury	Designated	1991-12-17
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0026838	L-baclofen	Spasticity	Designated	1992-01-30
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0007789	L-baclofen	Cerebral Palsy	Designated	1992-01-30
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0026838	L-baclofen	Spasticity	Designated	1991-12-17
KPYSYYIEGFHWSV-QMMMGPOBSA-N	PUBCHEM.COMPOUND:44602	UMLS:C0040997	L-baclofen	Trigeminal Neuralgia	Designated	1990-07-13
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0270780	baclofen	Degenerative myelopathy	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0022116	baclofen	Ischemia	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026769	baclofen	Multiple Sclerosis	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026838	baclofen	Spasticity	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026976	baclofen	Transverse myelitis	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0037930	baclofen	Spinal tumor	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0037933	baclofen	Spinal Diseases	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0037929	baclofen	Spinal Cord Injury	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0038587	baclofen	Withdrawal Syndrome	Designated	2020-12-31
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026838	baclofen	Spasticity	Designated/Approved	1991-12-16
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0037929	baclofen	Spinal Cord Injury	Designated/Approved	1991-12-16
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026838	Baclofen	Spasticity	Designated	1994-09-26
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0458219	baclofen	Complex regional pain syndrome	Designated	2015-10-28
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0007789	Baclofen	Cerebral Palsy	Designated	1994-09-26
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0026769	baclofen	Multiple Sclerosis	Designated/Approved	1991-12-16
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C1384641	baclofen	Cervical spondylosis	Designated/Approved	1987-11-10
KPYSYYIEGFHWSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2284	UMLS:C0013421	baclofen	Dystonia	Designated	2003-12-02
KQDRVXQXKZXMHP-LLVKDONJSA-N	PUBCHEM.COMPOUND:9838712	UMLS:C0877042	reparixin	graft loss	Designated	2012-09-25
KQOXLKOJHVFTRN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1684	UMLS:C0014378	pleconaril	Enteroviral infection	Designated	2014-12-22
KQOXLKOJHVFTRN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1684	UMLS:C0854706	pleconaril	infection in the neonate	Designated	2014-12-22
KQXDHUJYNAXLNZ-XQSDOZFQSA-N	PUBCHEM.COMPOUND:3085092	UMLS:C3540630	Salinomycin	Small Cell Lung Cancer	Designated	2019-12-12
KRMDCWKBEZIMAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2160	UMLS:C0014804	Amitriptyline	Erythromelalgia	Designated	2020-05-27
KSERXGMCDHOLSS-LJQANCHMSA-N	PUBCHEM.COMPOUND:11719003	UMLS:C0025202	Ulixertinib	melanoma	Designated	2013-06-24
KSMZEXLVHXZPEF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25017411	UMLS:C1261473	Anlotinib	Soft tissue sarcoma	Designated	2017-06-19
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-DFPPEFKWSA-M	PUBCHEM.COMPOUND:71563341	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-DFPPEFKWSA-N	PUBCHEM.COMPOUND:136675526	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-HAZZGOGXSA-M	PUBCHEM.COMPOUND:13271066	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-HAZZGOGXSA-N	PUBCHEM.COMPOUND:23707296	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-HAZZGOGXSA-N	PUBCHEM.COMPOUND:23707296	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-HAZZGOGXSA-N	PUBCHEM.COMPOUND:23707296	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KSRLIXGNPXAZHD-UHFFFAOYSA-M	PUBCHEM.COMPOUND:32731	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
KSRLIXGNPXAZHD-UHFFFAOYSA-M	PUBCHEM.COMPOUND:32731	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
KSRLIXGNPXAZHD-UHFFFAOYSA-M	PUBCHEM.COMPOUND:32731	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
KTAVBOYXMBQFGR-MAODNAKNSA-J	PUBCHEM.COMPOUND:11953897	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
KTBSXLIQKWEBRB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53380437	UMLS:C0018133	itacitinib	GRAFT VERSUS HOST DISEASE	Designated	2017-04-17
KTEIFNKAUNYNJU-GFCCVEGCSA-N	PUBCHEM.COMPOUND:11626560	UMLS:C3539721	crizotinib	Non-Small Cell Lung Cancer	Designated/Approved	2010-09-13
KTEIFNKAUNYNJU-GFCCVEGCSA-N	PUBCHEM.COMPOUND:11626560	UMLS:C0024302	crizotinib	large cell lymphoma	Designated/Approved	2012-09-28
KTEIFNKAUNYNJU-GFCCVEGCSA-N	PUBCHEM.COMPOUND:11626560	UMLS:C0027819	crizotinib	Neuroblastoma	Designated	2012-10-31
KTEIFNKAUNYNJU-GFCCVEGCSA-N	PUBCHEM.COMPOUND:11626560	UMLS:C3539721	crizotinib	Non-Small Cell Lung Cancer	Designated/Approved	2010-09-13
KTUFNOKKBVMGRW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5291	UMLS:C1709527	imatinib	Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	2005-10-11
KTUFNOKKBVMGRW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5291	UMLS:C1709527	imatinib	Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	2005-10-11
KTUFNOKKBVMGRW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5291	UMLS:C3203102	Imatinib	PULMONARY ARTERIAL HYPERTENSION	Designated	2020-12-21
KTUFNOKKBVMGRW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5291	UMLS:C0023473	Imatinib	Chronic myelogenous leukemia	Designated/Approved	2001-01-31
KTUFNOKKBVMGRW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5291	UMLS:C3203102	imatinib	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	2010-04-07
KUVIULQEHSCUHY-XYWKZLDCSA-N	PUBCHEM.COMPOUND:21700	UMLS:C0018133	beclomethasone dipropionate	Graft-Versus-Host Disease	Designated	1998-03-27
KUZYSQSABONDME-QRLOMCMNSA-N	PUBCHEM.COMPOUND:25014653	UMLS:C4721610	vintafolide	Ovarian Cancer	Designated	2013-12-16
KVHRYLNQDWXAGI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46848915	UMLS:C0012634	Balipodect	Disorder	Designated	2019-06-19
KVHRYLNQDWXAGI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46848915	UMLS:C0016667	Balipodect	Fragile X Syndrome	Designated	2019-06-13
KVUAALJSMIVURS-ZEDZUCNESA-L	PUBCHEM.COMPOUND:135883785	UMLS:C4721579	Leucovorin calcium	Metastatic colorectal cancer	Designated/Withdrawn	1988-06-23
KVUAALJSMIVURS-ZEDZUCNESA-L	PUBCHEM.COMPOUND:135883785	UMLS:C4721579	Leucovorin calcium	Metastatic colorectal cancer	Designated/Withdrawn	1988-06-23
KVUAALJSMIVURS-ZEDZUCNESA-N	PUBCHEM.COMPOUND:135436482	UMLS:C4721579	Leucovorin calcium	Metastatic colorectal cancer	Designated/Withdrawn	1988-06-23
KWIUHFFTVRNATP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:247	UMLS:C0019880	Betaine	Homocystinuria	Designated/Approved	1994-05-16
KXMZDGSRSGHMMK-VWLOTQADSA-N	PUBCHEM.COMPOUND:46215462	UMLS:C0023467	(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine	Acute myeloid leukemia	Designated	2014-11-05
KZIMLUFVKJLCCH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9942657	UMLS:C0520799	imidazolyl ethanamide pentandioic acid	Acute Radiation Syndrome	Designated	2018-09-17
LAMIXXKAWNLXOC-INIZCTEOSA-N	PUBCHEM.COMPOUND:6918848	UMLS:C0025286	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	Meningioma	Designated	2012-01-13
LAMIXXKAWNLXOC-INIZCTEOSA-N	PUBCHEM.COMPOUND:6918848	UMLS:C0027809	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	Schwannoma	Designated	2012-01-13
LBHLFPGPEGDCJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:115358	UMLS:C0024530	tafenoquine	Malaria	Designated/Approved	2013-01-15
LCFFREMLXLZNHE-GBOLQPHISA-N	PUBCHEM.COMPOUND:73388818	UMLS:C0398650	rilzabrutinib	Immune thrombocytopenic purpura	Designated	2018-10-15
LCQLHJZYVOQKHU-VKHMYHEASA-N	PUBCHEM.COMPOUND:121396	UMLS:C1829844	carglumic acid	Organic acidemias	Designated/Approved	2014-06-17
LCQLHJZYVOQKHU-VKHMYHEASA-N	PUBCHEM.COMPOUND:121396	UMLS:C0268543	carglumic acid	N-acetylglutamate synthetase deficiency	Designated/Approved	1998-01-20
LCTONWCANYUPML-UHFFFAOYSA-M	PUBCHEM.COMPOUND:107735	UMLS:C0206062	Pyruvate	Interstitial lung disease	Designated	2001-02-21
LDCRTTXIJACKKU-ONEGZZNKSA-N	PUBCHEM.COMPOUND:637568	UMLS:C0016719	dimethyl fumarate	Friedreich's Ataxia	Designated	2013-09-11
LDCYZAJDBXYCGN-VIFPVBQESA-N	PUBCHEM.COMPOUND:439280	UMLS:C0751436	L-5-hydroxytryptophan	Tetrahydrobiopterin Deficiency	Designated	1999-01-20
LEBVLXFERQHONN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2474	UMLS:C0032768	bupivacaine	Postherpetic neuralgia	Designated	2008-06-18
LEBVLXFERQHONN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2474	UMLS:C0030193	bupivacaine	Pain	Designated	2008-06-18
LEEIJTHMHDMWLJ-CQSZACIVSA-N	PUBCHEM.COMPOUND:11703255	UMLS:C3850141	resatorvid	Acute-On-Chronic Liver Failure	Designated	2018-01-02
LFQSCWFLJHTTHZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:702	UMLS:C0392621	Dehydrated alcohol	methanol poisoning	Designated	2020-07-10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:702	UMLS:C4551472	dehydrated alcohol	Hypertrophic obstructive cardiomyopathy	Designated/Approved	2013-09-11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:702	UMLS:C0040997	dehydrated alcohol	Trigeminal Neuralgia	Designated	2012-03-16
LFVPBERIVUNMGV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:163751	UMLS:C0020179	fasudil HCL	huntingtons disease	Designated	2020-08-25
LFVPBERIVUNMGV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:163751	UMLS:C0039082	Fasudil hydrochloride	Syndrome	Designated	2021-01-07
LFWCJABOXHSRGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6433095	UMLS:C0038525	clazosentan	Subarachnoid Hemorrhage	Designated	2006-02-16
LFWCJABOXHSRGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6433095	UMLS:C0265110	clazosentan	Cerebral Vasospasm	Designated	2006-02-16
LGWACEZVCMBSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57384863	UMLS:C0555198	Paxalisib	Malignant Glioma	Designated	2020-08-21
LIOLIMKSCNQPLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25145656	UMLS:C0027651	capmatinib	Tumor	Designated/Approved	2019-03-15
LIOLIMKSCNQPLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25145656	UMLS:C3539721	capmatinib	Non-Small Cell Lung Cancer	Designated/Approved	2019-03-15
LIRYPHYGHXZJBZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11707110	UMLS:C0278883	trametinib	stage iv melanoma	Designated/Approved	2010-12-20
LJIRBXZDQGQUOO-KVTDHHQDSA-N	PUBCHEM.COMPOUND:99681	UMLS:C0345967	5,6-dihydro-5-azacytidine	Malignant mesothelioma	Designated	1992-05-11
LJTSIMVOOOLKOL-FNRDIUJOSA-N	PUBCHEM.COMPOUND:24875259	UMLS:C0023467	antroquinonol	Acute myeloid leukemia	Designated	2015-04-30
LJTSIMVOOOLKOL-FNRDIUJOSA-N	PUBCHEM.COMPOUND:24875259	UMLS:C0235974	antroquinonol	PANCREATIC CANCER	Designated	2015-01-21
LJTSIMVOOOLKOL-FNRDIUJOSA-N	PUBCHEM.COMPOUND:24875259	UMLS:C2239176	antroquinonol	HEPATOCELLULAR CARCINOMA	Designated	2015-07-23
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C0010674	liposomal amikacin	Cystic Fibrosis	Designated	2006-03-09
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C0033809	liposomal amikacin	Pseudomonas aeruginosa	Designated	2009-08-25
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C3714514	liposomal amikacin	Infections	Designated/Approved	2013-03-25
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C0854135	liposomal amikacin	Pseudomonas aeruginosa Infections	Designated	2006-03-09
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C0006267	liposomal amikacin	Bronchiectasis	Designated	2009-08-25
LKCWBDHBTVXHDL-CAIQVSFASA-N	PUBCHEM.COMPOUND:456591	UMLS:C1265234	liposomal amikacin	Non-Tuberculous Mycobacteria	Designated/Approved	2013-03-25
LKCWBDHBTVXHDL-RMDFUYIESA-N	PUBCHEM.COMPOUND:37768	UMLS:C3714514	amikacin sulfate	Infections	Designated	2015-01-05
LKCWBDHBTVXHDL-RMDFUYIESA-N	PUBCHEM.COMPOUND:37768	UMLS:C0033809	amikacin sulfate	Pseudomonas aeruginosa	Designated	2015-01-05
LKCWBDHBTVXHDL-RMDFUYIESA-N	PUBCHEM.COMPOUND:37768	UMLS:C0010674	amikacin sulfate	Cystic Fibrosis	Designated	2015-01-05
LKDRXBCSQODPBY-OEXCPVAWSA-N	PUBCHEM.COMPOUND:439312	UMLS:C0032897	D-tagatose	Prader-Willi Syndrome	Designated	2017-01-19
LKVFMOMQYXIFRK-KSVAIKAXSA-N	PUBCHEM.COMPOUND:91864495	UMLS:C0948031	solnatide	Primary Graft Dysfunction	Designated	2016-02-04
LKVFMOMQYXIFRK-KSVAIKAXSA-N	PUBCHEM.COMPOUND:91864495	UMLS:C0268436	solnatide	Pseudohypoaldosteronism Type 1	Designated	2016-02-08
LLEUXCDZPQOJMY-AAEUAGOBSA-N	PUBCHEM.COMPOUND:100094	UMLS:C0276535	L-glutamyl-L-tryptophan	AIDS-related Kaposi's sarcoma	Designated	1999-10-20
LLXISKGBWFTGEI-FQEVSTJZSA-N	PUBCHEM.COMPOUND:44224257	UMLS:C0026764	filanesib	Multiple Myeloma	Designated	2014-05-06
LMBWSYZSUOEYSN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:28343	UMLS:C0001175	Diethyldithiocarbamate	AIDS	Designated	1986-04-03
LMEKQMALGUDUQG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2265	UMLS:C0018133	Azathioprine	Graft-Versus-Host Disease	Designated	1999-09-14
LMHIPJMTZHDKEW-XQYLJSSYSA-M	PUBCHEM.COMPOUND:6364626	UMLS:C0016736	epoprostenol	Frostbite	Designated	2020-04-20
LMHIPJMTZHDKEW-XQYLJSSYSA-M	PUBCHEM.COMPOUND:6364626	UMLS:C3203102	Epoprostenol	Primary Pulmonary Hypertension	Designated/Approved	1985-09-25
LMHIPJMTZHDKEW-XQYLJSSYSA-M	PUBCHEM.COMPOUND:6364626	UMLS:C0042373	epoprostenol	Vascular Disease	Designated/Approved	1999-03-22
LMHIPJMTZHDKEW-XQYLJSSYSA-M	PUBCHEM.COMPOUND:6364626	UMLS:C0264936	epoprostenol	Secondary pulmonary hypertension	Designated/Approved	1999-03-22
LMHIPJMTZHDKEW-XQYLJSSYSA-N	PUBCHEM.COMPOUND:21158562	UMLS:C0264936	epoprostenol	Secondary pulmonary hypertension	Designated/Approved	1999-03-22
LMHIPJMTZHDKEW-XQYLJSSYSA-N	PUBCHEM.COMPOUND:21158562	UMLS:C3203102	Epoprostenol	Primary Pulmonary Hypertension	Designated/Approved	1985-09-25
LMHIPJMTZHDKEW-XQYLJSSYSA-N	PUBCHEM.COMPOUND:21158562	UMLS:C0042373	epoprostenol	Vascular Disease	Designated/Approved	1999-03-22
LMHIPJMTZHDKEW-XQYLJSSYSA-N	PUBCHEM.COMPOUND:21158562	UMLS:C0016736	epoprostenol	Frostbite	Designated	2020-04-20
LMWOPQOPFYJQLI-UHFFFAOYSA-L	PUBCHEM.COMPOUND:14157383	UMLS:C0017205	Alendronate disodium	Gaucher Disease	Designated	2001-02-13
LMYRWZFENFIFIT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6269	UMLS:C0010606	Para-toluenesulfonamide	Adenoid Cystic Carcinoma	Designated	2017-01-30
LNFCWEXGZIEGJW-TXSVMFMRSA-O	PUBCHEM.COMPOUND:78318119	UMLS:C1609535	Rezafungin	Invasive Candidiasis	Designated	2016-02-08
LNFCWEXGZIEGJW-TXSVMFMRSA-O	PUBCHEM.COMPOUND:78318119	UMLS:C0877445	Rezafungin	Candidemia	Designated	2016-02-08
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C1325653	alpha-tocotrienol quinone	mitochondrial respiratory chain	Designated/Withdrawn	2010-10-21
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C0016719	vatiquinone	Friedreich's Ataxia	Designated	2014-01-31
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C0035372	vatiquinone	Rett Syndrome	Designated	2014-11-17
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C0751651	vatiquinone	Mitochondrial disease	Designated	2020-08-10
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C0266468	vatiquinone	Pontocerebellar Hypoplasia	Designated	2017-10-18
LNOVHERIIMJMDG-XZXLULOTSA-N	PUBCHEM.COMPOUND:46184405	UMLS:C0023264	vatiquinone	Leigh Syndrome	Designated	2014-06-04
LOLPPWBBNUVNQZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398495	UMLS:C0023467	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea	Acute myeloid leukemia	Designated	2009-11-12
LOMMPXLFBTZENJ-ZACQAIPSSA-N	PUBCHEM.COMPOUND:117947097	UMLS:C0019562	3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile	von Hippel-Lindau Disease	Designated	2020-06-24
LOUPRKONTZGTKE-WZBLMQSHSA-N	PUBCHEM.COMPOUND:3034034	UMLS:C0024530	quinine sulfate	Malaria	Designated	2008-12-02
LOUPRKONTZGTKE-WZBLMQSHSA-N	PUBCHEM.COMPOUND:3034034	UMLS:C0024530	quinine Sulfate	Malaria	Designated/Approved	2004-06-03
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0038525	sodium nitrite	Subarachnoid Hemorrhage	Designated	2007-01-17
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C3203102	sodium nitrite	PULMONARY ARTERIAL HYPERTENSION	Designated	2008-07-08
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0238080	sodium nitrite	Cyanide poisoning	Designated	2007-04-18
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0035126	sodium nitrite	ischemia reperfusion injury	Designated	2009-09-03
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0002895	sodium nitrite	Sickle Cell Disease	Designated	2007-04-02
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0750151	sodium nitrite	Vaso-Occlusive Crisis	Designated	2007-04-02
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0017107	sodium nitrite	Gas Poisoning	Designated	2012-01-09
LPXPTNMVRIOKMN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668193	UMLS:C0002895	Sodium Nitrite	Sickle Cell Disease	Designated	2020-03-25
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C3463824	Venetoclax	Myelodysplastic Syndromes	Designated	2019-06-12
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C1332201	4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	Diffuse Large B-Cell Lymphoma	Designated	2014-03-27
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0023434	venetoclax	Chronic Lymphocytic Leukemia	Designated/Approved	2012-09-20
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0026764	venetoclax	Multiple Myeloma	Designated	2016-08-29
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0023434	venetoclax	Chronic Lymphocytic Leukemia	Designated/Approved	2012-09-20
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0023434	venetoclax	Chronic Lymphocytic Leukemia	Designated/Approved	2012-09-20
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0023449	Venetoclax	Acute lymphoblastic leukemia	Designated	2020-10-26
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C3540630	Venetoclax	Small Cell Lung Cancer	Designated	2020-11-05
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C0023467	venetoclax	Acute myeloid leukemia	Designated/Approved	2016-02-04
LQBVNQSMGBZMKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:49846579	UMLS:C4721414	venetoclax	Mantle cell lymphoma	Designated	2017-08-31
LQCLVBQBTUVCEQ-BFKGUNNCSA-N	PUBCHEM.COMPOUND:6713914	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-CLPGKMRCSA-N	PUBCHEM.COMPOUND:5289436	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-DURLPPERSA-N	PUBCHEM.COMPOUND:133562799	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-GSELTXNRSA-N	PUBCHEM.COMPOUND:17675	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-ISONCDLBSA-N	PUBCHEM.COMPOUND:146158448	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-MCQAQMIOSA-N	PUBCHEM.COMPOUND:5284630	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-QTFUVMRISA-N	PUBCHEM.COMPOUND:202225	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-RFHKDOLOSA-N	PUBCHEM.COMPOUND:6708521	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LQCLVBQBTUVCEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:418931	UMLS:C0004096	Troleandomycin	Asthma	Designated/Withdrawn	1989-09-21
LRCZQSDQZJBHAF-PUBGEWHCSA-N	PUBCHEM.COMPOUND:6918473	UMLS:C0235974	DHA-paclitaxel	PANCREATIC CANCER	Designated/Withdrawn	2001-09-25
LRCZQSDQZJBHAF-PUBGEWHCSA-N	PUBCHEM.COMPOUND:6918473	UMLS:C0278701	DHA-paclitaxel	adenocarcinoma of the stomach	Designated/Withdrawn	2003-05-01
LRCZQSDQZJBHAF-PUBGEWHCSA-N	PUBCHEM.COMPOUND:6918473	UMLS:C0860594	DHA-paclitaxel	Metastatic malignant melanoma	Designated/Withdrawn	2002-10-10
LRNSXWGEKABTMP-XWLNNSFXSA-N	PUBCHEM.COMPOUND:10307231	UMLS:C4721610	Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val	Ovarian Cancer	Designated	2016-06-08
LRSYFEZBIMVWRY-VWMHFEHESA-N	PUBCHEM.COMPOUND:44247677	UMLS:C0220994	L-ornithine phenylacetate	Hyperammonemia	Designated	2010-04-07
LRSYFEZBIMVWRY-VWMHFEHESA-N	PUBCHEM.COMPOUND:44247677	UMLS:C0019151	L-ornithine phenylacetate	Hepatic Encephalopathy	Designated	2010-04-07
LRSYFEZBIMVWRY-VWMHFEHESA-N	PUBCHEM.COMPOUND:44247677	UMLS:C0162557	L-ornithine phenylacetate	Acute liver failure	Designated	2010-04-07
LTEJRLHKIYCEOX-OCCSQVGLSA-N	PUBCHEM.COMPOUND:11154925	UMLS:C2239176	brivanib alaninate	HEPATOCELLULAR CARCINOMA	Designated/Withdrawn	2011-03-18
LTVDFSLWFKLJDQ-IEOSBIPESA-N	PUBCHEM.COMPOUND:2734086	UMLS:C1325653	Alpha-tocopherol quinone	mitochondrial respiratory chain	Designated	2006-03-28
LTWQNYPDAUSXBC-CDJGKPBYSA-L	PUBCHEM.COMPOUND:9568637	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
LTWQNYPDAUSXBC-CDJGKPBYSA-L	PUBCHEM.COMPOUND:9568637	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
LTWQNYPDAUSXBC-CDJGKPBYSA-L	PUBCHEM.COMPOUND:9568637	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
LUCXVPAZUDVVBT-UNTBIKODSA-N	PUBCHEM.COMPOUND:54840	UMLS:C0040517	Atomoxetine hydrochloride	Tourette's Syndrome	Designated/Withdrawn	2003-08-26
LUKBXSAWLPMMSZ-OWOJBTEDSA-N	PUBCHEM.COMPOUND:445154	UMLS:C0016719	trans-resveratrol	FRIEDREICHS ATAXIA	Designated	2017-08-16
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C0020445	Sodium dichloroacetate	FAMILIAL HYPERCHOLESTEROLEMIA	Designated	1990-06-11
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C3203102	sodium dichloroacetate	PULMONARY ARTERIAL HYPERTENSION	Designated	2010-11-29
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C4025276	Sodium dichloroacetate	Congenital lactic acidosis	Designated	1990-06-11
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C2747816	Sodium dichloroacetate	Severe Malaria	Designated	1994-11-10
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C4025276	Sodium dichloroacetate	Congenital lactic acidosis	Designated/Withdrawn	1997-12-31
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C4707283	sodium dichloroacetate	Systemic monochloroacetic acid poisoning	Designated	2003-07-03
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C0018674	Sodium dichloroacetate	HEAD INJURY	Designated/Withdrawn	1999-06-14
LUPNKHXLFSSUGS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:517326	UMLS:C0001125	Sodium dichloroacetate	LACTIC ACIDOSIS	Designated	1994-11-10
LVASCWIMLIKXLA-CABCVRRESA-N	PUBCHEM.COMPOUND:456390	UMLS:C0036421	Halofuginone	Systemic sclerosis	Designated	2000-02-07
LVASCWIMLIKXLA-LSDHHAIUSA-N	PUBCHEM.COMPOUND:400772	UMLS:C0036421	Halofuginone	Systemic sclerosis	Designated	2000-02-07
LVASCWIMLIKXLA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62894	UMLS:C0036421	Halofuginone	Systemic sclerosis	Designated	2000-02-07
LVXJQMNHJWSHET-AATRIKPKSA-N	PUBCHEM.COMPOUND:11511120	UMLS:C3539721	dacomitinib	Non-Small Cell Lung Cancer	Designated/Approved	2015-03-03
LVZYXEALRXBLJZ-ISQYCPACSA-N	PUBCHEM.COMPOUND:71587831	UMLS:C0026987	imetelstat	myelofibrosis	Designated	2015-06-11
LVZYXEALRXBLJZ-ISQYCPACSA-N	PUBCHEM.COMPOUND:71587831	UMLS:C3463824	imetelstat	MYELODYSPLASTIC SYNDROME	Designated	2015-12-23
LWXUIUUOMSMZKJ-KLFWAVJMSA-M	PUBCHEM.COMPOUND:72196309	UMLS:C0238013	isavuconazonium sulfate	Invasive aspergillosis	Designated/Approved	2013-05-06
LWXUIUUOMSMZKJ-KLFWAVJMSA-M	PUBCHEM.COMPOUND:72196309	UMLS:C1609535	isavuconazonium sulfate	Invasive Candidiasis	Designated	2014-10-20
LWXUIUUOMSMZKJ-KLFWAVJMSA-M	PUBCHEM.COMPOUND:72196309	UMLS:C0043541	isavuconazonium sulfate	Zygomycosis	Designated/Approved	2013-10-25
LWXUIUUOMSMZKJ-KLFWAVJMSA-M	PUBCHEM.COMPOUND:72196309	UMLS:C0877445	isavuconazonium sulfate	Candidemia	Designated	2014-10-20
LXMSZDCAJNLERA-ZHYRCANASA-N	PUBCHEM.COMPOUND:5833	UMLS:C1384514	spironolactone	Primary Hyperaldosteronism	Designated	2014-05-22
LXZZYRPGZAFOLE-UHFFFAOYSA-L	PUBCHEM.COMPOUND:5702198	UMLS:C0279637	Cisplatin	Anal Cancer	Designated	2016-09-06
LYPFDBRUNKHDGX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60751	UMLS:C0007137	Temoporfin	Squamous Cell Carcinomas	Designated	1999-10-28
LZQXMCNBQHANEY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21195079	UMLS:C0568062	glucarpidase	Methotrexate Toxicity	Designated/Approved	2003-08-19
LZXMUJCJAWVHPZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44557636	UMLS:C1970038	dipraglurant	Levodopa-induced dyskinesias	Designated	2015-12-29
MAFITCMHQZUUQZ-VZUYHUTRSA-N	PUBCHEM.COMPOUND:135390845	UMLS:C0023467	apomorphine palmitate	Acute myeloid leukemia	Designated	2018-06-04
MASNOZXLGMXCHN-ZLPAWPGGSA-N	PUBCHEM.COMPOUND:16132283	UMLS:C0020615	glucagon	Hypoglycemia	Designated	2012-12-05
MASNOZXLGMXCHN-ZLPAWPGGSA-N	PUBCHEM.COMPOUND:16132283	UMLS:C3888018	glucagon	Congenital Hyperinsulinism	Designated	2012-12-05
MBBCVAKAJPKAKM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9853053	UMLS:C0020445	lomitapide	FAMILIAL HYPERCHOLESTEROLEMIA	Designated/Approved	2007-10-23
MBBCVAKAJPKAKM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9853053	UMLS:C0023817	lomitapide	Familial Chylomicronemia	Designated	2011-03-03
MBMBGCFOFBJSGT-KUBAVDMBSA-N	PUBCHEM.COMPOUND:445580	UMLS:C0035334	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retinitis Pigmentosa	Designated	2014-05-21
MBMBGCFOFBJSGT-KUBAVDMBSA-N	PUBCHEM.COMPOUND:445580	UMLS:C0002895	docosahexaenoic acid	Sickle Cell Disease	Designated	2015-04-27
MBMBGCFOFBJSGT-KUBAVDMBSA-N	PUBCHEM.COMPOUND:445580	UMLS:C0036992	docosahexaenoic acid	Short Bowel Syndrome	Designated	2015-06-01
MBOMYENWWXQSNW-AWEZNQCLSA-N	PUBCHEM.COMPOUND:56844015	UMLS:C0026764	ixazomib citrate	Multiple Myeloma	Designated/Approved	2011-02-18
MDCUNMLZLNGCQA-HWOAGHQOSA-N	PUBCHEM.COMPOUND:44201346	UMLS:C3203102	tiprelestat	PULMONARY ARTERIAL HYPERTENSION	Designated	2012-12-28
MDFXJBQEWLCGHP-MFOYZWKCSA-N	PUBCHEM.COMPOUND:5391612	UMLS:C0041296	Aconiazide	Tuberculosis	Designated/Withdrawn	1988-06-20
MDQMFOHHSFMREL-YIYMUJAPSA-N	PUBCHEM.COMPOUND:134819826	UMLS:C0235974	acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide	PANCREATIC CANCER	Designated/Withdrawn	2011-02-18
MDTNUYUCUYPIHE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11477084	UMLS:C3203102	Sitaxsentan Sodium	PULMONARY ARTERIAL HYPERTENSION	Designated	2004-11-02
MDTNUYUCUYPIHE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11477084	UMLS:C0024117	Sitaxsentan Sodium	CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Designated	2004-11-02
MDTNUYUCUYPIHE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11477084	UMLS:C0018802	Sitaxsentan Sodium	Congestive heart failure	Designated	2004-11-02
MDYZKJNTKZIUSK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71388	UMLS:C0010674	Tyloxapol	Cystic Fibrosis	Designated	1995-03-08
MEFKEPWMEQBLKI-AIRLBKTGSA-N	PUBCHEM.COMPOUND:34755	UMLS:C0005956	S-adenosylmethionine	myelopathy	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-N	PUBCHEM.COMPOUND:34755	UMLS:C0001175	S-adenosylmethionine	AIDS	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-O	PUBCHEM.COMPOUND:24762165	UMLS:C0005956	S-adenosylmethionine	myelopathy	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-O	PUBCHEM.COMPOUND:24762165	UMLS:C0001175	S-adenosylmethionine	AIDS	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-O	PUBCHEM.COMPOUND:24762165	UMLS:C0005956	S-adenosylmethionine	myelopathy	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-O	PUBCHEM.COMPOUND:24762165	UMLS:C0001175	S-adenosylmethionine	AIDS	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-P	PUBCHEM.COMPOUND:56593143	UMLS:C0005956	S-adenosylmethionine	myelopathy	Designated	1998-04-30
MEFKEPWMEQBLKI-AIRLBKTGSA-P	PUBCHEM.COMPOUND:56593143	UMLS:C0001175	S-adenosylmethionine	AIDS	Designated	1998-04-30
MFBCDACCJCDGBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11518241	UMLS:C0079154	trifarotene	congenital ichthyosis	Designated	2014-06-06
MGCQZNBCJBRZDT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:18340	UMLS:C0020651	Midodrine HCl	ORTHOSTATIC HYPOTENSION	Designated/Approved	1985-06-21
MGNVWUDMMXZUDI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:428573	UMLS:C3536715	eprodisate	Secondary amyloidosis	Designated	1999-04-06
MGQITOFVXOEWNL-INZIHYEWSA-N	PUBCHEM.COMPOUND:3086464	UMLS:C3463824	Heme arginate	Myelodysplastic Syndromes	Designated	1994-03-01
MGQITOFVXOEWNL-INZIHYEWSA-N	PUBCHEM.COMPOUND:3086464	UMLS:C0162565	Heme arginate	Acute Porphyria	Designated	1988-03-10
MGTLGARADRIKNV-GFCCVEGCSA-N	PUBCHEM.COMPOUND:56846912	UMLS:C2931822	(s)-perillyl alcohol temozolomide carbamate	Nasopharyngeal carcinoma	Designated	2017-07-27
MGTLGARADRIKNV-GFCCVEGCSA-N	PUBCHEM.COMPOUND:56846912	UMLS:C0027627	(s)-perillyl alcohol temozolomide carbamate	Metastases	Designated	2017-02-28
MGTLGARADRIKNV-GFCCVEGCSA-N	PUBCHEM.COMPOUND:56846912	UMLS:C0678222	(s)-perillyl alcohol temozolomide carbamate	Breast cancer	Designated	2017-02-28
MIMNFCVQODTQDP-NDLVEFNKSA-N	PUBCHEM.COMPOUND:118984458	UMLS:C0023434	oblimersen	Chronic Lymphocytic Leukemia	Designated	2001-08-28
MIMNFCVQODTQDP-NDLVEFNKSA-N	PUBCHEM.COMPOUND:118984458	UMLS:C0026764	oblimersen	Multiple Myeloma	Designated	2001-08-28
MIMNFCVQODTQDP-NDLVEFNKSA-N	PUBCHEM.COMPOUND:118984458	UMLS:C0025202	oblimersen	Malignant Melanoma	Designated	2000-07-31
MIMNFCVQODTQDP-NDLVEFNKSA-N	PUBCHEM.COMPOUND:118984458	UMLS:C0023467	oblimersen	Acute myelocytic leukemia	Designated	2001-08-28
MIQPIUSUKVNLNT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4659569	UMLS:C2751492	Tolcapone	Transthyretin Amyloidosis	Designated	2013-12-24
MISPBGHDNZYFNM-BTJKTKAUSA-N	PUBCHEM.COMPOUND:9918581	UMLS:C0398650	avatrombopag maleate	IDIOPATHIC THROMBOCYTOPENIC PURPURA	Designated/Approved	2011-09-01
MISPBGHDNZYFNM-BTJKTKAUSA-N	PUBCHEM.COMPOUND:9918581	UMLS:C0040034	avatrombopag maleate	Thrombocytopenia	Designated	2019-12-19
MIWWSGDADVMLTG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68792	UMLS:C0041228	fexinidazole	African Trypanosomiasis	Designated	2016-04-04
MJQUEDHRCUIRLF-BXOMOELISA-N	PUBCHEM.COMPOUND:6435419	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-DDYLLZMUSA-N	PUBCHEM.COMPOUND:134817197	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-DECOFNLXSA-N	PUBCHEM.COMPOUND:5884629	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-IBMAKELESA-N	PUBCHEM.COMPOUND:133635911	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-JGGKDZLHSA-N	PUBCHEM.COMPOUND:124918436	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-JYXSRQLPSA-N	PUBCHEM.COMPOUND:146159872	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-KOWVOJLTSA-N	PUBCHEM.COMPOUND:5477635	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-MDGOTRLRSA-N	PUBCHEM.COMPOUND:16760328	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-MEBWOBETSA-N	PUBCHEM.COMPOUND:22524140	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-PXXLITNBSA-N	PUBCHEM.COMPOUND:122173102	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-SGXMQRQHSA-N	PUBCHEM.COMPOUND:6473739	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-SGXMQRQHSA-N	PUBCHEM.COMPOUND:6473739	UMLS:C0014859	bryostatin-1	esophageal cancer	Designated	2001-12-03
MJQUEDHRCUIRLF-TVIXENOKSA-N	PUBCHEM.COMPOUND:5280757	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-TVIXENOKSA-N	PUBCHEM.COMPOUND:5280757	UMLS:C0014859	bryostatin-1	esophageal cancer	Designated	2001-12-03
MJQUEDHRCUIRLF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:433902	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-VUHCRTQMSA-N	PUBCHEM.COMPOUND:5458769	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-YCVQJEHTSA-N	PUBCHEM.COMPOUND:44277532	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-ZVHDYJKJSA-N	PUBCHEM.COMPOUND:14078847	UMLS:C0016667	bryostatin 1	Fragile X Syndrome	Designated	2015-03-31
MJQUEDHRCUIRLF-ZVHDYJKJSA-N	PUBCHEM.COMPOUND:14078847	UMLS:C0014859	bryostatin-1	esophageal cancer	Designated	2001-12-03
MJUVRTYWUMPBTR-MRXNPFEDSA-N	PUBCHEM.COMPOUND:46199646	UMLS:C0010674	Tezacaftor	Cystic Fibrosis	Designated	2014-04-24
MKDNDKMECWBLOF-WDSKDSINSA-N	PUBCHEM.COMPOUND:44473414	UMLS:C0017638	florilglutamic acid	Glioma	Designated	2016-05-11
MKJIEFSOBYUXJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6018	UMLS:C0040517	tetrabenazine	Tourette's Syndrome	Designated	2009-07-01
MKJIEFSOBYUXJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6018	UMLS:C0020179	Tetrabenazine	Huntington's Disease	Designated/Approved	1997-12-11
MKJIEFSOBYUXJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6018	UMLS:C0686347	Tetrabenazine	Tardive Dyskinesia	Designated	1998-05-12
MKJIEFSOBYUXJB-VFJJUKLQSA-N	PUBCHEM.COMPOUND:73437646	UMLS:C0040517	deutetrabenazine	Tourette Syndrome	Designated	2015-01-13
MKUXAQIIEYXACX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398513	UMLS:C0019357	acyclovir	Herpetic keratitis	Designated/Withdrawn	2010-09-16
MKUXAQIIEYXACX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398513	UMLS:C0019357	acyclovir	Herpetic keratitis	Designated/Approved	2010-12-13
MKUXAQIIEYXACX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398513	UMLS:C0022568	acyclovir	Keratitis	Designated	2016-05-03
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0079218	sorafenib	desmoid tumors	Designated	2019-02-28
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0238462	sorafenib	Anaplastic Thyroid	Designated/Approved	2011-12-12
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0238461	sorafenib	Cancer	Designated/Approved	2011-12-12
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C2239176	Sorafenib	HEPATOCELLULAR CARCINOMA	Designated/Approved	2006-04-20
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0238463	sorafenib	medullary thyroid cancer	Designated/Approved	2011-12-12
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0007134	Sorafenib	Renal Cell Carcinoma	Designated/Approved	2004-10-08
MLDQJTXFUGDVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216239	UMLS:C0278883	Sorafenib	stage iv melanoma	Designated/Withdrawn	2006-09-29
MLKXDPUZXIRXEP-MFOYZWKCSA-N	PUBCHEM.COMPOUND:1548887	UMLS:C0035334	sulindac	Retinitis Pigmentosa	Designated	2020-08-04
MLSVJHOYXJGGTR-COZVRORISA-N	PUBCHEM.COMPOUND:124080868	UMLS:C0042974	Desmopressin acetate	von Willebrand's Disease	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-COZVRORISA-N	PUBCHEM.COMPOUND:124080868	UMLS:C0272324	Desmopressin acetate	Mild hemophilia A	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-GHZYFSNVSA-N	PUBCHEM.COMPOUND:146160431	UMLS:C0272324	Desmopressin acetate	Mild hemophilia A	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-GHZYFSNVSA-N	PUBCHEM.COMPOUND:146160431	UMLS:C0042974	Desmopressin acetate	von Willebrand's Disease	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-IFHOVBQLSA-N	PUBCHEM.COMPOUND:9833407	UMLS:C0272324	Desmopressin acetate	Mild hemophilia A	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-IFHOVBQLSA-N	PUBCHEM.COMPOUND:9833407	UMLS:C0042974	Desmopressin acetate	von Willebrand's Disease	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-MOMGZFCSSA-N	PUBCHEM.COMPOUND:16051969	UMLS:C0272324	Desmopressin acetate	Mild hemophilia A	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-MOMGZFCSSA-N	PUBCHEM.COMPOUND:16051969	UMLS:C0042974	Desmopressin acetate	von Willebrand's Disease	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64758	UMLS:C0272324	Desmopressin acetate	Mild hemophilia A	Designated/Approved	1991-01-22
MLSVJHOYXJGGTR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64758	UMLS:C0042974	Desmopressin acetate	von Willebrand's Disease	Designated/Approved	1991-01-22
MODVSQKJJIBWPZ-VLLPJHQWSA-N	PUBCHEM.COMPOUND:6918574	UMLS:C0278883	tesetaxel	stage iv melanoma	Designated	2008-11-21
MODVSQKJJIBWPZ-VLLPJHQWSA-N	PUBCHEM.COMPOUND:6918574	UMLS:C4521788	tesetaxel	IIB	Designated	2008-11-21
MODVSQKJJIBWPZ-VLLPJHQWSA-N	PUBCHEM.COMPOUND:6918574	UMLS:C0024623	tesetaxel	Gastric Cancer	Designated	2008-12-22
MODVSQKJJIBWPZ-VLLPJHQWSA-N	PUBCHEM.COMPOUND:6918574	UMLS:C4553416	tesetaxel	IIC	Designated	2008-11-21
MOTJMGVDPWRKOC-QPVYNBJUSA-N	PUBCHEM.COMPOUND:159594	UMLS:C0027726	Atrasentan	Nephrotic Syndrome	Designated/Withdrawn	2016-09-29
MQJKPEGWNLWLTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2955	UMLS:C0040558	Dapsone	Toxoplasmosis	Designated	1994-11-07
MQQNFDZXWVTQEH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4413	UMLS:C0235974	Nafamostat	PANCREATIC CANCER	Designated	2020-05-11
MQXWPWOCXGARRK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:67454400	UMLS:C0002736	Reldesemtiv	Amyotrophic Lateral Sclerosis	Designated	2019-12-11
MREOOEFUTWFQOC-UHFFFAOYSA-M	PUBCHEM.COMPOUND:54715158	UMLS:C0024623	Tegafur/gimeracil/oteracil	Gastric Cancer	Designated	2006-07-20
MRGCZDWBFFUEES-CWBCWDDISA-L	PUBCHEM.COMPOUND:11583399	UMLS:C0085469	temocillin sodium	Burkholderia cepacia	Designated	2004-04-21
MRGCZDWBFFUEES-CWBCWDDISA-L	PUBCHEM.COMPOUND:11583399	UMLS:C0876973	temocillin sodium	Pulmonary infections	Designated	2004-04-21
MRYYMYCQXMFJNE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:136033680	UMLS:C0750974	Poly-ICLC	primary brain tumors	Designated	1997-03-17
MSYKRHVOOPPJKU-BDAKNGLRSA-N	PUBCHEM.COMPOUND:9837243	UMLS:C0393619	brivaracetam	Symptomatic myoclonus	Designated	2005-10-05
MSYKRHVOOPPJKU-BDAKNGLRSA-N	PUBCHEM.COMPOUND:9837243	UMLS:C0014553	brivaracetam	childhood absence epilepsy	Designated	2019-12-03
MSYKRHVOOPPJKU-BDAKNGLRSA-N	PUBCHEM.COMPOUND:9837243	UMLS:C4317339	brivaracetam	Juvenile Absence Epilepsy	Designated	2019-12-03
MTHORRSSURHQPZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71354	UMLS:C0024143	Bindarit	Lupus Nephritis	Designated	1998-02-03
MTSXPVSZJVNPBE-OCOINPOZSA-M	PUBCHEM.COMPOUND:16218873	UMLS:C0023290	corifungin	Visceral leishmaniasis	Designated	2011-07-06
MTSXPVSZJVNPBE-OCOINPOZSA-M	PUBCHEM.COMPOUND:16218873	UMLS:C0487784	corifungin	Amebic Meningoencephalitis	Designated	2011-08-22
MUDCDMMNYVJLEB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9871944	UMLS:C0023473	4,5-dibromorhodamine 123	Chronic myelogenous leukemia	Designated/Withdrawn	2003-04-10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	PUBCHEM.COMPOUND:6013	UMLS:C0019682	Testosterone	HIV	Designated/Withdrawn	1996-02-05
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	PUBCHEM.COMPOUND:6013	UMLS:C0006625	Testosterone	Wasting	Designated/Withdrawn	1996-02-05
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	PUBCHEM.COMPOUND:6013	UMLS:C4084774	Testosterone	Weight loss	Designated	1997-09-22
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	PUBCHEM.COMPOUND:6013	UMLS:C0019682	Testosterone	HIV	Designated	1997-09-22
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	PUBCHEM.COMPOUND:6013	UMLS:C4084774	Testosterone	Weight loss	Designated/Withdrawn	1996-02-05
MUOKSQABCJCOPU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24748573	UMLS:C0206698	Silmitasertib	Cholangiocarcinoma	Designated	2016-12-22
MUSGYEMSJUFFHT-UWABRSFTSA-N	PUBCHEM.COMPOUND:131634231	UMLS:C0024790	S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	Paroxysmal nocturnal hemoglobinuria	Designated	2014-10-09
MUSGYEMSJUFFHT-UWABRSFTSA-N	PUBCHEM.COMPOUND:131634231	UMLS:C1418558	S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	paroxysmal nocturnal hemoglobinuria	Designated	2014-10-09
MUTNCGKQJGXKEM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:108143	UMLS:C1859592	Tamibarotene	APL	Designated	2007-10-11
MUTNCGKQJGXKEM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:108143	UMLS:C0023487	Tamibarotene	Acute Promyelocytic Leukemia	Designated	2007-10-11
MUTNCGKQJGXKEM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:108143	UMLS:C0023467	tamibarotene	Acute myeloid leukemia	Designated	2017-08-16
MVGSNCBCUWPVDA-MFOYZWKCSA-N	PUBCHEM.COMPOUND:5472495	UMLS:C0032580	Exisulind	Adenomatous Polyposis Coli	Designated	1994-02-14
MVGSNCBCUWPVDA-MFOYZWKCSA-N	PUBCHEM.COMPOUND:5472495	UMLS:C0206677	Exisulind	Adenomatous Polyps	Designated	1994-02-14
MWKYMZXCGYXLPL-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:57495353	UMLS:C0021051	leniolisib	Immunodeficiency	Designated	2018-01-30
MWKYMZXCGYXLPL-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:57495353	UMLS:C0497156	leniolisib	Lymphadenopathy	Designated	2018-01-30
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C1265234	Nitric oxide	NTM	Designated	2017-09-26
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C1800706	nitric oxide	Idiopathic Pulmonary Fibrosis	Designated	2017-01-31
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C1135361	nitric oxide	Persistent pulmonary hypertension	Designated/Approved	2012-06-18
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0036202	Nitric oxide	Sarcoidosis	Designated	2005-02-16
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0041296	nitric oxide	Tuberculous	Designated	2018-06-05
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0041296	Nitric oxide	Tuberculosis	Designated	2017-09-26
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0750151	nitric oxide	Vaso-Occlusive Crisis	Designated	2008-09-05
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C3714514	Nitric oxide	Infections	Designated	2017-09-26
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0010674	nitric oxide	Cystic Fibrosis	Designated	2014-09-23
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0030193	nitric oxide	Pain	Designated	2008-09-05
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C1135361	Nitric oxide	Persistent pulmonary hypertension	Designated/Approved	1993-06-22
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0231224	nitric oxide	crises	Designated	2008-09-05
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C3203102	nitric oxide	PULMONARY ARTERIAL HYPERTENSION	Designated	2011-12-28
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0010674	nitric oxide	Cystic Fibrosis	Designated	2013-09-11
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0035222	Nitric oxide	Acute respiratory distress syndrome	Designated	1995-07-10
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0031190	nitric oxide	Persistent pulmonary hypertension of the newborn	Designated	2017-01-25
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0024115	nitric oxide	Lung Disease	Designated	2018-06-05
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C0746102	Nitric oxide	Chronic lung disease	Designated	2004-09-27
MWUXSHHQAYIFBG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145068	UMLS:C3203102	nitric oxide	PULMONARY ARTERIAL HYPERTENSION	Designated	2017-01-25
MWWSFMDVAYGXBV-RUELKSSGSA-N	PUBCHEM.COMPOUND:443939	UMLS:C1261473	Liposomal doxorubicin hydrochloride	Soft Tissue Sarcomas	Designated	2006-12-27
MWYDSXOGIBMAET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565596	UMLS:C1367654	copanlisib	Marginal zone lymphoma	Designated	2017-02-07
MWYDSXOGIBMAET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565596	UMLS:C0349632	copanlisib	Splenic marginal zone lymphoma	Designated	2017-02-07
MWYDSXOGIBMAET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565596	UMLS:C0024301	copanlisib	follicular lymphoma	Designated/Approved	2015-02-05
MWYDSXOGIBMAET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565596	UMLS:C0242647	copanlisib	Nodal marginal zone lymphoma	Designated	2017-02-07
MXDPZUIOZWKRAA-PRDSJKGBSA-K	PUBCHEM.COMPOUND:132274234	UMLS:C0206754	lutetium Lu 177 dotatate	Neuroendocrine Tumors	Designated/Approved	2009-01-12
MXDPZUIOZWKRAA-PRDSJKGBSA-K	PUBCHEM.COMPOUND:132274234	UMLS:C0206754	lutetium Lu 177 dotatate	Neuroendocrine Tumors	Designated/Approved	2009-01-12
MXWHMTNPTTVWDM-NXOFHUPFSA-N	PUBCHEM.COMPOUND:5351154	UMLS:C0348394	Mitoguazone	Diffuse non-Hodgkin's lymphoma	Designated	1994-03-18
MXWHMTNPTTVWDM-NXOFHUPFSA-N	PUBCHEM.COMPOUND:5351154	UMLS:C0001175	Mitoguazone	AIDS	Designated	1994-03-18
MXWHMTNPTTVWDM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9991	UMLS:C0348394	Mitoguazone	Diffuse non-Hodgkin's lymphoma	Designated	1994-03-18
MXWHMTNPTTVWDM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9991	UMLS:C0001175	Mitoguazone	AIDS	Designated	1994-03-18
MXWHMTNPTTVWDM-VEPASKNESA-N	PUBCHEM.COMPOUND:76961227	UMLS:C0348394	Mitoguazone	Diffuse non-Hodgkin's lymphoma	Designated	1994-03-18
MXWHMTNPTTVWDM-VEPASKNESA-N	PUBCHEM.COMPOUND:76961227	UMLS:C0001175	Mitoguazone	AIDS	Designated	1994-03-18
MXWHMTNPTTVWDM-XVVXZDBVSA-N	PUBCHEM.COMPOUND:5363702	UMLS:C0348394	Mitoguazone	Diffuse non-Hodgkin's lymphoma	Designated	1994-03-18
MXWHMTNPTTVWDM-XVVXZDBVSA-N	PUBCHEM.COMPOUND:5363702	UMLS:C0001175	Mitoguazone	AIDS	Designated	1994-03-18
MYPYJXKWCTUITO-LYRMYLQWSA-N	PUBCHEM.COMPOUND:14969	UMLS:C0014236	vancomycin	Endophthalmitis	Designated	2012-12-27
MYSWGUAQZAJSOK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2764	UMLS:C0006267	ciprofloxacin	Bronchiectasis	Designated	2011-06-01
MZPVEMOYADUARK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91667513	UMLS:C4721414	Orelabrutinib	Mantle cell lymphoma	Designated	2020-12-30
NAVMQTYZDKMPEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:82146	UMLS:C0079773	Bexarotene	cutaneous T-cell lymphoma	Designated/Approved	1999-06-18
NBMKJKDGKREAPL-DVTGEIKXSA-N	PUBCHEM.COMPOUND:20469	UMLS:C0009324	beclomethasone	Ulcerative Colitis	Designated	2009-03-04
NCNRHFGMJRPRSK-MDZDMXLPSA-N	PUBCHEM.COMPOUND:6918638	UMLS:C0079774	Belinostat	Peripheral T-Cell Lymphoma	Designated/Approved	2009-09-03
NCWZOASIUQVOFA-FWZJPQCDSA-N	PUBCHEM.COMPOUND:11501341	UMLS:C4509023	florbetaben F18	Light chain (AL) amyloidosis	Designated	2020-04-07
NDAUXUAQIAJITI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2083	UMLS:C0522224	Albuterol	Paralysis	Designated	2002-03-12
NDAUXUAQIAJITI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2083	UMLS:C0037929	Albuterol	Spinal Cord Injury	Designated	2002-03-12
NDTYTMIUWGWIMO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10819	UMLS:C0017638	perillyl alcohol	Glioma	Designated	2011-04-18
NEBUOXBYNAHKFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51357549	UMLS:C0014804	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	Erythromelalgia	Designated	2012-11-19
NEYNJQRKHLUJRU-DZUOILHNSA-N	PUBCHEM.COMPOUND:9853654	UMLS:C0238462	pentagastrin	Medullary thyroid carcinoma	Designated	2009-05-29
NEYNJQRKHLUJRU-DZUOILHNSA-N	PUBCHEM.COMPOUND:9853654	UMLS:C0238462	pentagastrin	medullary thyroid cancer	Designated	2020-04-21
NGCGMRBZPXEPOZ-HBBGHHHDSA-N	PUBCHEM.COMPOUND:11980076	UMLS:C1689985	Gonadorelin acetate	Absence	Designated/Approved	1987-04-22
NGCGMRBZPXEPOZ-HBBGHHHDSA-N	PUBCHEM.COMPOUND:11980076	UMLS:C0341862	Gonadorelin acetate	Hypothalamic amenorrhea	Designated/Approved	1987-04-22
NGOGFTYYXHNFQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3547	UMLS:C0002736	Fasudil	Amyotrophic Lateral Sclerosis	Designated	2020-01-15
NGOGFTYYXHNFQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3547	UMLS:C0338451	Fasudil	Frontotemporal dementia	Designated	2020-09-09
NGOGFTYYXHNFQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3547	UMLS:C0038868	Fasudil	Progressive supranuclear palsy	Designated	2020-12-21
NGOGFTYYXHNFQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3547	UMLS:C0038525	fasudil	Subarachnoid Hemorrhage	Designated	2019-09-05
NGWSFRIPKNWYAO-SHTIJGAHSA-N	PUBCHEM.COMPOUND:11347535	UMLS:C0026764	marizomib	Multiple Myeloma	Designated	2013-12-13
NGWSFRIPKNWYAO-SHTIJGAHSA-N	PUBCHEM.COMPOUND:11347535	UMLS:C0555198	marizomib	Malignant Glioma	Designated	2015-09-21
NHTGHBARYWONDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:441350	UMLS:C0012236	metyrosine	Velocardiofacial Syndrome	Designated	2008-07-25
NHTGHBARYWONDQ-JTQLQIEISA-N	PUBCHEM.COMPOUND:441350	UMLS:C0033975	metyrosine	Psychosis	Designated	2008-07-25
NHTGHBARYWONDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3125	UMLS:C0235974	Racemetyrosine	PANCREATIC CANCER	Designated	2020-07-31
NHTKGYOMICWFQZ-BBOXMAMFSA-N	PUBCHEM.COMPOUND:134812042	UMLS:C0750952	fosgemcitabine palabenamide	Biliary Tract Cancer	Designated	2019-06-11
NHXLMOGPVYXJNR-ATOGVRKGSA-N	PUBCHEM.COMPOUND:16129706	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-ATOGVRKGSA-N	PUBCHEM.COMPOUND:16129706	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NHXLMOGPVYXJNR-FMGBKAQLSA-N	PUBCHEM.COMPOUND:44291156	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-FMGBKAQLSA-N	PUBCHEM.COMPOUND:44291156	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NHXLMOGPVYXJNR-FQSIDJEASA-N	PUBCHEM.COMPOUND:71308696	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NHXLMOGPVYXJNR-FQSIDJEASA-N	PUBCHEM.COMPOUND:71308696	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-HVEUVEBASA-N	PUBCHEM.COMPOUND:44377662	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NHXLMOGPVYXJNR-HVEUVEBASA-N	PUBCHEM.COMPOUND:44377662	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16129681	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NHXLMOGPVYXJNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16129681	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-UYURUMNQSA-N	PUBCHEM.COMPOUND:16161315	UMLS:C0014867	Somatostatin	Esophageal Varices	Designated	1994-12-22
NHXLMOGPVYXJNR-UYURUMNQSA-N	PUBCHEM.COMPOUND:16161315	UMLS:C0423772	Somatostatin	Cutaneous Fistulas	Designated	1988-06-20
NICJCIQSJJKZAH-AWEZNQCLSA-N	PUBCHEM.COMPOUND:148189	UMLS:C0007134	irofulven	Renal Cell Carcinoma	Designated/Withdrawn	1999-07-27
NICJCIQSJJKZAH-AWEZNQCLSA-N	PUBCHEM.COMPOUND:148189	UMLS:C4721610	irofulven	Ovarian Cancer	Designated/Withdrawn	1999-07-06
NICJCIQSJJKZAH-AWEZNQCLSA-N	PUBCHEM.COMPOUND:148189	UMLS:C0346976	6-hydroxymethylacylfulvene	metastatic pancreatic cancer	Designated/Withdrawn	1999-04-06
NIJJYAXOARWZEE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:3549980	UMLS:C0016667	Valproate	Fragile X Syndrome	Designated	2008-05-05
NIJJYAXOARWZEE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3121	UMLS:C1332201	Valproic acid	Diffuse Large B-Cell Lymphoma	Designated	2017-03-30
NIJJYAXOARWZEE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3121	UMLS:C0016667	Valproate	Fragile X Syndrome	Designated	2008-05-05
NIVZHWNOUVJHKV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2368	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1988-09-20
NIVZHWNOUVJHKV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2368	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1989-11-24
NJLRKAMQPVVOIU-IDLGWYNRSA-N	PUBCHEM.COMPOUND:11980904	UMLS:C0730328	verteporfin	Central Serous Chorioretinopathy	Designated	2012-03-09
NKDFYOWSKOHCCO-YPVLXUMRSA-N	PUBCHEM.COMPOUND:5459840	UMLS:C0013264	20-hydroxyecdysone	DUCHENNE MUSCULAR DYSTROPHY	Designated	2018-05-10
NLVFBUXFDBBNBW-PBSUHMDJSA-N	PUBCHEM.COMPOUND:36294	UMLS:C0006267	Tobramycin	Bronchiectasis	Designated	1999-06-18
NMHJRGCKGFRFAQ-ZKFIMABGSA-N	PUBCHEM.COMPOUND:450505	UMLS:C0031511	Iobenguane Sulfate I 131	Pheochromocytoma	Designated/Approved/Withdrawn	1984-11-14
NMUSYJAQQFHJEW-KVTDHHQDSA-N	PUBCHEM.COMPOUND:9444	UMLS:C0023467	Azacitidine	Acute myeloid leukemia	Designated/Approved	2008-06-18
NMUSYJAQQFHJEW-KVTDHHQDSA-N	PUBCHEM.COMPOUND:9444	UMLS:C3463824	azacitidine	Myelodysplastic Syndromes	Designated/Approved	2001-12-03
NNACHAUCXXVJSP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9948102	UMLS:C0027404	Pitolisant	Narcolepsy	Designated/Approved	2010-05-17
NNACHAUCXXVJSP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9948102	UMLS:C0027404	pitolisant	Narcolepsy	Designated/Approved	2010-05-17
NNUHKSNTEOVPHV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:145994613	UMLS:C0079772	cobomarsen	T-Cell Lymphoma	Designated	2020-07-21
NNUHKSNTEOVPHV-XHZCTNOISA-N	PUBCHEM.COMPOUND:126480232	UMLS:C0079772	cobomarsen	T-Cell Lymphoma	Designated	2020-07-21
NNYBQONXHNTVIJ-QGZVFWFLSA-N	PUBCHEM.COMPOUND:667528	UMLS:C0023434	R-etodolac	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2002-12-09
NOEGNKMFWQHSLB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:237332	UMLS:C0002895	5-hydroxymethyl-2-furfuraldehyde	Sickle Cell Disease	Designated	2006-05-26
NOFOAYPPHIUXJR-APNQCZIXSA-N	PUBCHEM.COMPOUND:457964	UMLS:C0282687	aphidicolin	Ebola Virus Infection	Designated	2016-04-20
NOJBHZIZNPMQRT-CBASKZFISA-N	PUBCHEM.COMPOUND:51049993	UMLS:C4048195	Encaleret sulfate	Autosomal dominant hypocalcemia	Designated	2020-11-24
NOSYGQGJJZNNMA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9548889	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
NOSYGQGJJZNNMA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9548889	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
NOWRLNPOENZFHP-ARHDFHRDSA-N	PUBCHEM.COMPOUND:445212	UMLS:C2931185	N-Methanocarbathymidine	Neonatal herpes	Designated	2014-10-15
NOYPYLRCIDNJJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5583	UMLS:C0278512	Trimetrexate	Metastatic Osteogenic Sarcoma	Designated/Withdrawn	2000-08-10
NPAGDVCDWIYMMC-IZPLOLCNSA-N	PUBCHEM.COMPOUND:9904	UMLS:C3542021	nandrolone	Duchenne and Becker Muscular Dystrophy	Designated	2017-06-13
NPAGDVCDWIYMMC-IZPLOLCNSA-N	PUBCHEM.COMPOUND:9904	UMLS:C0686353	nandrolone	Limb-girdle muscular dystrophy	Designated	2019-12-04
NPOCDVAOUKODSQ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:86278362	UMLS:C0751435	pegvaliase-pqpz	Hyperphenylalaninemia	Designated/Approved	1995-03-08
NQDJXKOVJZTUJA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4463	UMLS:C0019693	nevirapine	HIV infection	Designated	2009-11-25
NQPDXQQQCQDHHW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:50248	UMLS:C0015652	triclabendazole	Fascioliasis	Designated	2016-06-27
NQPDXQQQCQDHHW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:50248	UMLS:C0015652	triclabendazole	Fascioliasis	Designated/Approved	2017-04-17
NQUUPTGRJYIXSL-YPDXTJLXSA-N	PUBCHEM.COMPOUND:131954443	UMLS:C3540630	rovalpituzumab tesirine	Small Cell Lung Cancer	Designated/Withdrawn	2015-12-22
NRUKOCRGYNPUPR-ANTWWVKXSA-N	PUBCHEM.COMPOUND:54610154	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-CRZAWEBOSA-N	PUBCHEM.COMPOUND:275784	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-CTWARWOPSA-N	PUBCHEM.COMPOUND:137701349	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-DKQCQWADSA-N	PUBCHEM.COMPOUND:129009948	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-DYPKOKSYSA-N	PUBCHEM.COMPOUND:134694361	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-NFIYYIGVSA-N	PUBCHEM.COMPOUND:5284623	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-OMLXZSNTSA-N	PUBCHEM.COMPOUND:90659141	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-OQMCATNJSA-N	PUBCHEM.COMPOUND:6708778	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-PSZSYXFXSA-N	PUBCHEM.COMPOUND:34698	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-QBPJDGROSA-N	PUBCHEM.COMPOUND:452548	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5396	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-VEUOYOFCSA-N	PUBCHEM.COMPOUND:122172961	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NRUKOCRGYNPUPR-ZVYBSHBNSA-N	PUBCHEM.COMPOUND:23724511	UMLS:C0023452	Teniposide	Childhood Acute Lymphocytic Leukemia	Designated/Approved	1984-11-01
NSMXQKNUPPXBRG-SECBINFHSA-N	PUBCHEM.COMPOUND:501254	UMLS:C0023467	Lisofylline	Acute myeloid leukemia	Designated	1999-06-10
NSQSAUGJQHDYNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66558664	UMLS:C0024301	tazemetostat	follicular lymphoma	Designated/Approved	2017-11-14
NSQSAUGJQHDYNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66558664	UMLS:C1261473	tazemetostat	Soft tissue sarcoma	Designated/Approved	2017-06-15
NSQSAUGJQHDYNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66558664	UMLS:C0025500	tazemetostat	Mesothelioma	Designated	2017-09-28
NSQSAUGJQHDYNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66558664	UMLS:C0008487	tazemetostat	Chordoma	Designated	2018-05-23
NSQSAUGJQHDYNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66558664	UMLS:C0206743	tazemetostat	Rhabdoid Tumors	Designated	2016-02-04
NTYJJOPFIAHURM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:774	UMLS:C0025202	Histamine	Malignant Melanoma	Designated	2000-02-01
NTYJJOPFIAHURM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:774	UMLS:C0023467	Histamine	Acute myeloid leukemia	Designated	1999-12-15
NUKYPUAOHBNCPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1727	UMLS:C0026976	dalfampridine	Transverse myelitis	Designated	2019-11-25
NUKYPUAOHBNCPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1727	UMLS:C0018378	4-Aminopyridine	Guillain-Barre Syndrome	Designated	2005-12-14
NUKYPUAOHBNCPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1727	UMLS:C0026769	dalfampridine	Multiple Sclerosis	Designated/Approved	1987-06-02
NUKYPUAOHBNCPY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1727	UMLS:C4545488	Fampridine	Incomplete spinal cord injury	Designated	1997-06-02
NVKAWKQGWWIWPM-ABEVXSGRSA-N	PUBCHEM.COMPOUND:10635	UMLS:C0006625	Dihydrotestosterone	Wasting	Designated	1996-02-05
NVKAWKQGWWIWPM-ABEVXSGRSA-N	PUBCHEM.COMPOUND:10635	UMLS:C4084774	Dihydrotestosterone	Weight loss	Designated	1996-02-05
NVKAWKQGWWIWPM-ABEVXSGRSA-N	PUBCHEM.COMPOUND:10635	UMLS:C0019682	Dihydrotestosterone	HIV	Designated	1996-02-05
NWIBSHFKIJFRCO-WUDYKRTCSA-N	PUBCHEM.COMPOUND:5746	UMLS:C1370932	mitomycin	carcinoma of the renal pelvis and ureter	Designated/Approved	2014-09-08
NWIBSHFKIJFRCO-WUDYKRTCSA-N	PUBCHEM.COMPOUND:5746	UMLS:C4087468	mitomycin	Transitional Cell Carcinoma of the Renal Pelvis	Designated/Approved	2014-09-08
NWIBSHFKIJFRCO-WUDYKRTCSA-N	PUBCHEM.COMPOUND:5746	UMLS:C1867441	mitomycin	Pterygium	Designated	2011-01-13
NWIBSHFKIJFRCO-WUDYKRTCSA-N	PUBCHEM.COMPOUND:5746	UMLS:C0017601	Mitomycin-C	Glaucoma	Designated	1993-08-20
NWIBSHFKIJFRCO-WUDYKRTCSA-N	PUBCHEM.COMPOUND:5746	UMLS:C0017601	mitomycin-C	Glaucoma	Designated/Approved	2008-01-08
NXQKSXLFSAEQCZ-SFHVURJKSA-N	PUBCHEM.COMPOUND:137278711	UMLS:C3539721	sotorasib	Non-Small Cell Lung Cancer	Designated	2019-05-01
NYDXNILOWQXUOF-GXKRWWSZSA-L	PUBCHEM.COMPOUND:135413520	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
NYDXNILOWQXUOF-GXKRWWSZSA-M	PUBCHEM.COMPOUND:136253316	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
NYNZQNWKBKUAII-KBXCAEBGSA-N	PUBCHEM.COMPOUND:46188928	UMLS:C0280100	larotrectinib	solid tumors	Designated/Approved	2017-05-09
NYNZQNWKBKUAII-KBXCAEBGSA-N	PUBCHEM.COMPOUND:46188928	UMLS:C1261473	Larotrectinib	Soft tissue sarcoma	Designated	2015-08-31
NYQPLPNEESYGNO-IBGZPJMESA-N	PUBCHEM.COMPOUND:130731	UMLS:C0023449	Talotrexin	Acute lymphoblastic leukemia	Designated/Withdrawn	2006-05-08
NZCRJKRKKOLAOJ-CPJOEXDVSA-N	PUBCHEM.COMPOUND:57507834	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-CPJOEXDVSA-N	PUBCHEM.COMPOUND:57507834	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-HQDKJBBOSA-N	PUBCHEM.COMPOUND:16667733	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-HQDKJBBOSA-N	PUBCHEM.COMPOUND:16667733	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-IEOSPBRCSA-N	PUBCHEM.COMPOUND:66577007	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-IEOSPBRCSA-N	PUBCHEM.COMPOUND:66577007	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-IIBMFGDOSA-N	PUBCHEM.COMPOUND:72111	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-IIBMFGDOSA-N	PUBCHEM.COMPOUND:72111	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-KOPWYESNSA-N	PUBCHEM.COMPOUND:72698618	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-KOPWYESNSA-N	PUBCHEM.COMPOUND:72698618	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-KPKMWDGOSA-N	PUBCHEM.COMPOUND:101307877	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-KPKMWDGOSA-N	PUBCHEM.COMPOUND:101307877	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-LGPAXTBISA-N	PUBCHEM.COMPOUND:46783403	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-LGPAXTBISA-N	PUBCHEM.COMPOUND:46783403	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-LXVXMSHWSA-N	PUBCHEM.COMPOUND:71296876	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-LXVXMSHWSA-N	PUBCHEM.COMPOUND:71296876	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53395233	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53395233	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-UPMLHBPDSA-N	PUBCHEM.COMPOUND:134754219	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-UPMLHBPDSA-N	PUBCHEM.COMPOUND:134754219	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-VJYREXROSA-N	PUBCHEM.COMPOUND:134754217	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-VJYREXROSA-N	PUBCHEM.COMPOUND:134754217	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-VXTOCXBKSA-N	PUBCHEM.COMPOUND:42608884	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-VXTOCXBKSA-N	PUBCHEM.COMPOUND:42608884	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-WSTNJLQSSA-N	PUBCHEM.COMPOUND:135391139	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-WSTNJLQSSA-N	PUBCHEM.COMPOUND:135391139	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-XRCRFVBUSA-N	PUBCHEM.COMPOUND:6436173	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZCRJKRKKOLAOJ-XRCRFVBUSA-N	PUBCHEM.COMPOUND:6436173	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-XWSQLESMSA-N	PUBCHEM.COMPOUND:44384716	UMLS:C0002895	Rifaximin	Sickle Cell Disease	Designated	2020-10-28
NZCRJKRKKOLAOJ-XWSQLESMSA-N	PUBCHEM.COMPOUND:44384716	UMLS:C0019151	rifaximin	Hepatic Encephalopathy	Designated/Approved	1998-02-10
NZHGWWWHIYHZNX-CSKARUKUSA-N	PUBCHEM.COMPOUND:5282230	UMLS:C0017638	Tranilast	Glioma	Designated	2003-12-02
NZHGWWWHIYHZNX-CSKARUKUSA-N	PUBCHEM.COMPOUND:5282230	UMLS:C0017601	tranilast	Glaucoma	Designated	2010-12-23
NZVYCXVTEHPMHE-ZSUJOUNUSA-N	PUBCHEM.COMPOUND:16130571	UMLS:C0744831	thymalfasin	Chronic active hepatitis B	Designated	1991-05-03
NZVYCXVTEHPMHE-ZSUJOUNUSA-N	PUBCHEM.COMPOUND:16130571	UMLS:C0012236	Thymalfasin	DiGeorge Anomaly	Designated	1998-01-08
NZVYCXVTEHPMHE-ZSUJOUNUSA-N	PUBCHEM.COMPOUND:16130571	UMLS:C0025202	Thymalfasin	Malignant Melanoma	Designated	2006-03-13
NZVYCXVTEHPMHE-ZSUJOUNUSA-N	PUBCHEM.COMPOUND:16130571	UMLS:C2239176	Thymalfasin	HEPATOCELLULAR CARCINOMA	Designated	2000-03-06
OAKGNIRUXAZDQF-BGGMETADSA-N	PUBCHEM.COMPOUND:131861370	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OAKGNIRUXAZDQF-DFZJEWIASA-N	PUBCHEM.COMPOUND:134694917	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OAKGNIRUXAZDQF-HTLBVUBBSA-N	PUBCHEM.COMPOUND:66577020	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OAKGNIRUXAZDQF-NTEXKKDHSA-N	PUBCHEM.COMPOUND:131801266	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OAKGNIRUXAZDQF-RYORMVDLSA-N	PUBCHEM.COMPOUND:129894409	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OAKGNIRUXAZDQF-TXHRRWQRSA-N	PUBCHEM.COMPOUND:11534420	UMLS:C0238198	retaspimycin	gastrointestinal stromal tumor	Designated/Withdrawn	2007-08-31
OBKXEAXTFZPCHS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4775	UMLS:C0023487	Phenylbutyrate	Acute Promyelocytic Leukemia	Designated	2000-01-19
OBMJQRLIQQTJLR-USGQOSEYSA-N	PUBCHEM.COMPOUND:9810709	UMLS:C4721610	aldoxorubicin	Ovarian Cancer	Designated	2014-09-24
OBMJQRLIQQTJLR-USGQOSEYSA-N	PUBCHEM.COMPOUND:9810709	UMLS:C3540630	aldoxorubicin	Small Cell Lung Cancer	Designated	2014-09-24
OBMJQRLIQQTJLR-USGQOSEYSA-N	PUBCHEM.COMPOUND:9810709	UMLS:C0017636	aldoxorubicin	Glioblastoma multiforme	Designated	2014-09-24
OBMJQRLIQQTJLR-USGQOSEYSA-N	PUBCHEM.COMPOUND:9810709	UMLS:C1261473	Aldoxorubicin	Soft tissue sarcoma	Designated	2011-06-29
OBMJQRLIQQTJLR-USGQOSEYSA-N	PUBCHEM.COMPOUND:9810709	UMLS:C0281361	Aldoxorubicin	adenocarcinoma of the pancreas	Designated	2011-04-18
OBZHEBDUNPOCJG-HLWLYVGMSA-N	PUBCHEM.COMPOUND:134689748	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-IBEOWVBCSA-N	PUBCHEM.COMPOUND:134613184	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-ILYNEHRHSA-N	PUBCHEM.COMPOUND:5311038	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-KNJYOZPASA-N	PUBCHEM.COMPOUND:146036893	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-SMVPYXKTSA-N	PUBCHEM.COMPOUND:56965767	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-SZTGPWMUSA-N	PUBCHEM.COMPOUND:46936354	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-WBXJDKIVSA-N	PUBCHEM.COMPOUND:636403	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
OBZHEBDUNPOCJG-WZCASOPNSA-N	PUBCHEM.COMPOUND:21913	UMLS:C0020179	carbenoxolone	Huntington's Disease	Designated	2014-07-02
ODUOJXZPIYUATO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:107751	UMLS:C0341306	racecadotril	Microvillus inclusion disease	Designated	2020-04-13
ODVKSTFPQDVPJZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:105102	UMLS:C0026691	Ulinastatin	Kawasaki Disease	Designated	2020-06-12
ODZBBRURCPAEIQ-PIXDULNESA-N	PUBCHEM.COMPOUND:446727	UMLS:C0235974	Brivudin	PANCREATIC CANCER	Designated/Withdrawn	2007-11-15
OEBIHOVSAMBXIB-SJKOYZFVSA-N	PUBCHEM.COMPOUND:129103609	UMLS:C0280100	(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one	solid tumors	Designated	2018-09-24
OEUUFNIKLCFNLN-LLVKDONJSA-N	PUBCHEM.COMPOUND:135413558	UMLS:C0282193	Deferitrin	Iron Overload	Designated/Withdrawn	2004-04-14
OFEZSBMBBKLLBJ-BAJZRUMYSA-N	PUBCHEM.COMPOUND:6303	UMLS:C0023449	Cordycepin	Acute lymphocytic leukemia	Designated	2007-07-05
OGBMKVWORPGQRR-UMXFMPSGSA-N	PUBCHEM.COMPOUND:16133850	UMLS:C0158447	Teriparatide	Idiopathic osteoporosis	Designated	1999-10-28
OGBMKVWORPGQRR-UMXFMPSGSA-N	PUBCHEM.COMPOUND:16133850	UMLS:C0033835	Teriparatide	Pseudohypoparathyroidism	Designated/Approved	1987-01-09
OGBMKVWORPGQRR-UMXFMPSGSA-N	PUBCHEM.COMPOUND:16133850	UMLS:C0020626	Teriparatide	Hypoparathyroidism	Designated/Approved	1987-01-09
OGBMKVWORPGQRR-UMXFMPSGSA-N	PUBCHEM.COMPOUND:16133850	UMLS:C0020598	Teriparatide	Hypocalcemia	Designated/Approved	1987-01-09
OGBMKVWORPGQRR-UMXFMPSGSA-N	PUBCHEM.COMPOUND:16133850	UMLS:C0020626	teriparatide	Hypoparathyroidism	Designated	2014-04-18
OGMADIBCHLQMIP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9082	UMLS:C4316899	Cysteamine hydrochloride	Cystinosis	Designated/Approved	1997-08-19
OGSBUKJUDHAQEA-WMCAAGNKSA-N	PUBCHEM.COMPOUND:148121	UMLS:C0079772	pralatrexate	T-Cell Lymphoma	Designated/Approved	2006-07-20
OGSBUKJUDHAQEA-WMCAAGNKSA-N	PUBCHEM.COMPOUND:148121	UMLS:C0279680	pralatrexate	Transitional Cell Carcinoma of the Urinary Bladder	Designated	2010-05-03
OGSBUKJUDHAQEA-WMCAAGNKSA-N	PUBCHEM.COMPOUND:148121	UMLS:C1332201	pralatrexate	Diffuse Large B-Cell Lymphoma	Designated	2008-10-20
OGSBUKJUDHAQEA-WMCAAGNKSA-N	PUBCHEM.COMPOUND:148121	UMLS:C3160869	pralatrexate	Metastatic Transitional Cell Carcinoma	Designated	2010-05-03
OGSBUKJUDHAQEA-WMCAAGNKSA-N	PUBCHEM.COMPOUND:148121	UMLS:C0024301	pralatrexate	follicular lymphoma	Designated	2008-10-20
OGSPWJRAVKPPFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2088	UMLS:C0029434	alendronate	Osteogenesis Imperfecta	Designated/Withdrawn	2003-03-31
OHRURASPPZQGQM-GCCNXGTGSA-N	PUBCHEM.COMPOUND:5352062	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-GCCNXGTGSA-N	PUBCHEM.COMPOUND:5352062	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-MWQPNCDWSA-N	PUBCHEM.COMPOUND:91110640	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-MWQPNCDWSA-N	PUBCHEM.COMPOUND:91110640	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-OYTWCIJESA-N	PUBCHEM.COMPOUND:123135747	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-OYTWCIJESA-N	PUBCHEM.COMPOUND:123135747	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-QDBHDZETSA-N	PUBCHEM.COMPOUND:57515973	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-QDBHDZETSA-N	PUBCHEM.COMPOUND:57515973	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-QPJBHPOGSA-N	PUBCHEM.COMPOUND:154574495	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-QPJBHPOGSA-N	PUBCHEM.COMPOUND:154574495	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3425	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3425	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-WDCUYUQDSA-N	PUBCHEM.COMPOUND:56840936	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-WDCUYUQDSA-N	PUBCHEM.COMPOUND:56840936	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-WOADUJSRSA-N	PUBCHEM.COMPOUND:129905275	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OHRURASPPZQGQM-WOADUJSRSA-N	PUBCHEM.COMPOUND:129905275	UMLS:C0079772	romidepsin	T-Cell Lymphomas	Designated/Approved	2004-09-30
OIRCOABEOLEUMC-GEJPAHFPSA-N	PUBCHEM.COMPOUND:16129704	UMLS:C0040034	bivalirudin	Thrombocytopenia	Designated	2005-11-02
OIRCOABEOLEUMC-GEJPAHFPSA-N	PUBCHEM.COMPOUND:16129704	UMLS:C0272285	bivalirudin	Heparin-induced thrombocytopenia	Designated	2005-11-02
OIRCOABEOLEUMC-GEJPAHFPSA-N	PUBCHEM.COMPOUND:16129704	UMLS:C0302148	bivalirudin	Thrombosis	Designated	2005-11-02
OIRDTQYFTABQOQ-KQYNXXCUSA-N	PUBCHEM.COMPOUND:60961	UMLS:C0006118	Adenosine	Brain Tumors	Designated/Withdrawn	1989-08-01
OIRUWDYJGMHDHJ-AFXVCOSJSA-N	PUBCHEM.COMPOUND:11685945	UMLS:C0280209	retaspimycin hydrochloride	melanoma stages	Designated/Withdrawn	2008-06-24
OJGDCBLYJGHCIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2442	UMLS:C1527336	Bromhexine	Sjogren Syndrome	Designated/Withdrawn	1989-05-15
OJGDCBLYJGHCIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2442	UMLS:C0022575	Bromhexine	Keratoconjunctivitis Sicca	Designated/Withdrawn	1989-05-15
OJICYBSWSZGRFB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68234908	UMLS:C0041582	Telacebec	Ulcer	Designated	2021-01-13
OJLOPKGSLYJEMD-URPKTTJQSA-N	PUBCHEM.COMPOUND:5282381	UMLS:C0595939	misoprostol	Intrauterine Fetal Death	Designated	2005-01-10
OKHMDSCYUWAQPT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71434	UMLS:C0019202	trientine tetrahydrochloride	Wilsons Disease	Designated	2016-03-10
OLBWFRRUHYQABZ-MRVPVSSYSA-N	PUBCHEM.COMPOUND:6918474	UMLS:C3887898	carisbamate	Infantile spasms	Designated	2012-03-16
OLBWFRRUHYQABZ-MRVPVSSYSA-N	PUBCHEM.COMPOUND:6918474	UMLS:C0238111	carisbamate	Lennox-Gastaut syndrome	Designated	2017-08-02
OLDWOVJAXRWCGT-FBHGDYMESA-N	PUBCHEM.COMPOUND:124081779	UMLS:C0206698	(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride	Cholangiocarcinoma	Designated	2015-11-19
OMPATGZMNFWVOH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24986824	UMLS:C0023467	2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid	Acute myeloid leukemia	Designated	2018-08-16
OMWCXCBGEFHCTN-FGYAAKKASA-N	PUBCHEM.COMPOUND:46212391	UMLS:C0079218	tegavivint	desmoid tumors	Designated	2018-04-11
ONDYALNGTUAJDX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54682876	UMLS:C0026764	Tasquinimod	Multiple Myeloma	Designated	2017-04-10
ONIQOQHATWINJY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25102847	UMLS:C0238461	cabozantinib	Anaplastic thyroid carcinoma	Designated/Approved	2010-11-29
ONIQOQHATWINJY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25102847	UMLS:C2239176	cabozantinib	HEPATOCELLULAR CARCINOMA	Designated/Approved	2017-03-02
ONIQOQHATWINJY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25102847	UMLS:C0238463	cabozantinib	papillary thyroid cancer	Designated/Approved	2010-11-29
ONJQDTZCDSESIW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:656641	UMLS:C2937220	polidocanol	Venous malformations	Designated	2015-02-19
OOUGLTULBSNHNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11219835	UMLS:C0003076	ataluren	Aniridia	Designated	2015-09-01
OOUGLTULBSNHNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11219835	UMLS:C0026847	ataluren	Spinal Muscular Atrophy	Designated	2008-03-10
OOUGLTULBSNHNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11219835	UMLS:C0026850	ataluren	Muscular Dystrophy	Designated	2005-01-10
OOUGLTULBSNHNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11219835	UMLS:C0023786	ataluren	Mucopolysaccharidosis Type I	Designated/Withdrawn	2014-12-10
OOUGLTULBSNHNF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11219835	UMLS:C0010674	ataluren	Cystic Fibrosis	Designated/Withdrawn	2004-09-01
OPXLLQIJSORQAM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4030	UMLS:C0040954	mebendazole	whipworm	Designated/Approved	2014-09-03
OQDQIFQRNZIEEJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68677842	UMLS:C0036421	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	Systemic sclerosis	Designated	2015-03-31
ORMHJJCIJXWHFH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9925625	UMLS:C0036572	propofol hemisuccinate	Seizures	Designated	2016-08-19
ORQGHAJIWGGFJK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:132260161	UMLS:C0016952	2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid	Galactosemia	Designated	2019-05-23
ORQGHAJIWGGFJK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:132260161	UMLS:C0349653	2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid	Phosphomannomutase 2 deficiency	Designated	2020-09-21
ORYDPOVDJJZGHQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135413511	UMLS:C2239176	tirapazamine	HEPATOCELLULAR CARCINOMA	Designated	2015-11-30
ORYDPOVDJJZGHQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135413511	UMLS:C3887461	tirapazamine	Head and Neck Cancer	Designated	2002-10-23
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C0006287	Lucinactant	Bronchopulmonary Dysplasia	Designated	2005-10-21
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C0025048	Lucinactant	of meconium aspiration	Designated/Withdrawn	1996-07-30
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C1968593	Lucinactant	Respiratory Distress Syndrome In Premature Infants	Designated	1995-10-18
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C0006287	Lucinactant	Bronchopulmonary Dysplasia	Designated	2006-05-23
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C0010674	Lucinactant	Cystic Fibrosis	Designated	2010-10-21
OSPNFKYGOFXGBX-YWWKUQGPSA-N	PUBCHEM.COMPOUND:145722609	UMLS:C0035222	Lucinactant	Acute respiratory distress syndrome	Designated	1995-07-17
OSZNNLWOYWAHSS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5824	UMLS:C0026896	neostigmine methylsulfate	Myasthenia Gravis	Designated	2012-02-17
OTBXOEAOVRKTNQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135409400	UMLS:C0032463	Anagrelide	Polycythemia Vera	Designated	1985-06-11
OTBXOEAOVRKTNQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135409400	UMLS:C0040028	Anagrelide	ESSENTIAL THROMBOCYTHEMIA	Designated/Approved	1988-01-27
OTBXOEAOVRKTNQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135409400	UMLS:C0023473	Anagrelide	Chronic myelogenous leukemia	Designated	1986-07-14
OTBXOEAOVRKTNQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135409400	UMLS:C0836924	Anagrelide	Thrombocytosis	Designated	1986-07-14
OUBCNLGXQFSTLU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:115355	UMLS:C0268490	Nitisinone	Tyrosinemia Type 1	Designated/Approved	1995-05-16
OUBCNLGXQFSTLU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:115355	UMLS:C0268490	Nitisinone	Tyrosinemia Type 1	Designated/Approved	1995-05-16
OUBCNLGXQFSTLU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:115355	UMLS:C0002066	nitisinone	Alkaptonuria	Designated	2001-10-19
OUJTZYPIHDYQMC-LJQANCHMSA-N	PUBCHEM.COMPOUND:6918493	UMLS:C1800706	ambrisentan	Idiopathic Pulmonary Fibrosis	Designated/Withdrawn	2009-12-23
OUJTZYPIHDYQMC-LJQANCHMSA-N	PUBCHEM.COMPOUND:6918493	UMLS:C3203102	ambrisentan	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2004-07-16
OUKYUETWWIPKQR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10302451	UMLS:C1800706	saracatinib	Idiopathic Pulmonary Fibrosis	Designated	2019-03-11
OUUYBRCCFUEMLH-YDALLXLXSA-N	PUBCHEM.COMPOUND:9927978	UMLS:C0025202	melphalan hydrochloride	melanoma	Designated	2008-11-12
OUUYBRCCFUEMLH-YDALLXLXSA-N	PUBCHEM.COMPOUND:9927978	UMLS:C0025202	melphalan hydrochloride	cutaneous melanoma	Designated	2008-11-12
OUUYBRCCFUEMLH-YDALLXLXSA-N	PUBCHEM.COMPOUND:9927978	UMLS:C2239176	melphalan hydrochloride	HEPATOCELLULAR CARCINOMA	Designated	2013-09-26
OUUYBRCCFUEMLH-YDALLXLXSA-N	PUBCHEM.COMPOUND:9927978	UMLS:C0206754	melphalan hydrochloride	Neuroendocrine Tumors	Designated	2009-05-22
OVRNDRQMDRJTHS-FMDGEEDCSA-N	PUBCHEM.COMPOUND:24139	UMLS:C0013264	N-Acetylglucosamine	DUCHENNE MUSCULAR DYSTROPHY	Designated	2020-09-23
OVRNDRQMDRJTHS-RTRLPJTCSA-N	PUBCHEM.COMPOUND:439174	UMLS:C0013264	N-Acetylglucosamine	DUCHENNE MUSCULAR DYSTROPHY	Designated	2020-09-23
OVRNDRQMDRJTHS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:899	UMLS:C0013264	N-Acetylglucosamine	DUCHENNE MUSCULAR DYSTROPHY	Designated	2020-09-23
OVXQHPWHMXOFRD-UHFFFAOYSA-M	PUBCHEM.COMPOUND:10547	UMLS:C0271093	echothiophate iodide	Stargardt's disease	Designated	2014-06-02
OWAUGAMNPZHEOJ-YKZVIGSYSA-N	PUBCHEM.COMPOUND:25084151	UMLS:C0342543	Histrelin acetate	Central Precocious Puberty	Designated/Approved	1988-08-10
OWBFCJROIKNMGD-BQYQJAHWSA-N	PUBCHEM.COMPOUND:6918736	UMLS:C4721610	rigosertib	Ovarian Cancer	Designated/Withdrawn	2012-03-16
OWBFCJROIKNMGD-BQYQJAHWSA-N	PUBCHEM.COMPOUND:6918736	UMLS:C0235974	rigosertib	PANCREATIC CANCER	Designated/Withdrawn	2011-03-18
OWBFCJROIKNMGD-BQYQJAHWSA-N	PUBCHEM.COMPOUND:6918736	UMLS:C3463824	rigosertib	Myelodysplastic Syndromes	Designated	2009-09-03
OXVFDZYQLGRLCD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4147757	UMLS:C0016719	leriglitazone	FRIEDREICHS ATAXIA	Designated	2019-08-01
OXVFDZYQLGRLCD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4147757	UMLS:C0162309	hydroxypioglitazone	X-Linked Adrenoleukodystrophy	Designated	2017-01-30
OXVFDZYQLGRLCD-USSMZTJJSA-N	PUBCHEM.COMPOUND:45359068	UMLS:C0016719	leriglitazone	FRIEDREICHS ATAXIA	Designated	2019-08-01
OYTKINVCDFNREN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5918	UMLS:C0022972	amifampridine	Lambert-Eaton Myasthenic Syndrome	Designated/Approved	1990-12-18
OYTKINVCDFNREN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5918	UMLS:C0751882	3,4-diaminopyridine	congenital myasthenic syndrome	Designated	2017-03-30
OYVAGSVQBOHSSS-ITQDJCQPSA-O	PUBCHEM.COMPOUND:122172957	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
OYVAGSVQBOHSSS-NHOVFDEISA-O	PUBCHEM.COMPOUND:46930982	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
OYVAGSVQBOHSSS-QRQYLRPSSA-O	PUBCHEM.COMPOUND:456190	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	1999-02-09
OYVAGSVQBOHSSS-QRQYLRPSSA-O	PUBCHEM.COMPOUND:456190	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	2010-12-20
OYVAGSVQBOHSSS-UAPAGMARSA-O	PUBCHEM.COMPOUND:5460769	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	1999-02-09
OYVAGSVQBOHSSS-UAPAGMARSA-O	PUBCHEM.COMPOUND:5460769	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	2010-12-20
OYVAGSVQBOHSSS-UHFFFAOYSA-O	PUBCHEM.COMPOUND:84068	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
OYVAGSVQBOHSSS-UHFFFAOYSA-O	PUBCHEM.COMPOUND:84068	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	1999-02-09
OYVAGSVQBOHSSS-UHFFFAOYSA-O	PUBCHEM.COMPOUND:84068	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	2010-12-20
OYVAGSVQBOHSSS-WXFSZRTFSA-O	PUBCHEM.COMPOUND:5360373	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
OYVAGSVQBOHSSS-WXFSZRTFSA-O	PUBCHEM.COMPOUND:5360373	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	2010-12-20
OYVAGSVQBOHSSS-WXFSZRTFSA-O	PUBCHEM.COMPOUND:5360373	UMLS:C0235974	Bleomycin	PANCREATIC CANCER	Designated	1999-02-09
OZOMQRBLCMDCEG-CHHVJCJISA-M	PUBCHEM.COMPOUND:5353563	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
OZOMQRBLCMDCEG-CHHVJCJISA-M	PUBCHEM.COMPOUND:5353563	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
OZOMQRBLCMDCEG-CHHVJCJISA-M	PUBCHEM.COMPOUND:5353563	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
OZOMQRBLCMDCEG-VIZOYTHASA-M	PUBCHEM.COMPOUND:6604728	UMLS:C0043207	dantrolene sodium	Wolfram Syndrome	Designated	2016-02-17
OZOMQRBLCMDCEG-VIZOYTHASA-M	PUBCHEM.COMPOUND:6604728	UMLS:C0038819	dantrolene sodium	Heat Stroke	Designated	2012-09-25
OZOMQRBLCMDCEG-VIZOYTHASA-M	PUBCHEM.COMPOUND:6604728	UMLS:C0027849	Dantrolene sodium	Neuroleptic Malignant Syndrome	Designated/Withdrawn	1987-12-14
PAJMKGZZBBTTOY-ZFORQUDYSA-N	PUBCHEM.COMPOUND:6918140	UMLS:C1800706	Treprostinil	Idiopathic Pulmonary Fibrosis	Designated	2020-12-08
PAJMKGZZBBTTOY-ZFORQUDYSA-N	PUBCHEM.COMPOUND:6918140	UMLS:C3203102	treprostinil	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	1997-06-04
PAJMKGZZBBTTOY-ZFORQUDYSA-N	PUBCHEM.COMPOUND:6918140	UMLS:C0036421	treprostinil	Systemic sclerosis	Designated	2020-06-08
PAJMKGZZBBTTOY-ZFORQUDYSA-N	PUBCHEM.COMPOUND:6918140	UMLS:C3203102	treprostinil	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	1997-06-04
PAJMKGZZBBTTOY-ZFORQUDYSA-N	PUBCHEM.COMPOUND:6918140	UMLS:C3203102	treprostinil	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	1997-06-04
PBUUPFTVAPUWDE-HSLMEMBISA-N	PUBCHEM.COMPOUND:5362269	UMLS:C0220654	Mafosfamide	neoplastic meningitis	Designated	2003-01-21
PBUUPFTVAPUWDE-UGZDLDLSSA-N	PUBCHEM.COMPOUND:76968809	UMLS:C0220654	Mafosfamide	neoplastic meningitis	Designated	2003-01-21
PBUUPFTVAPUWDE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:104746	UMLS:C0220654	Mafosfamide	neoplastic meningitis	Designated	2003-01-21
PBZBXDCHQQCLGL-UHFFFAOYSA-M	PUBCHEM.COMPOUND:138402875	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
PBZBXDCHQQCLGL-UHFFFAOYSA-M	PUBCHEM.COMPOUND:138402875	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
PCHKPVIQAHNQLW-CQSZACIVSA-N	PUBCHEM.COMPOUND:24958200	UMLS:C4721610	niraparib	Ovarian Cancer	Designated/Approved	2010-04-30
PCHKPVIQAHNQLW-CQSZACIVSA-N	PUBCHEM.COMPOUND:24958200	UMLS:C4721610	niraparib	Ovarian Cancer	Designated/Approved	2010-04-30
PCHKPVIQAHNQLW-CQSZACIVSA-N	PUBCHEM.COMPOUND:24958200	UMLS:C4721610	niraparib	Ovarian Cancer	Designated/Approved	2010-04-30
PCOBBVZJEWWZFR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:121892	UMLS:C0543888	ezogabine	Epileptic encephalopathy	Designated	2018-06-21
PDWGVXJIDIRQME-DCNFBYMVSA-N	PUBCHEM.COMPOUND:71812122	UMLS:C0017636	(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate	Glioblastoma multiforme	Designated	2017-11-08
PDWUPXJEEYOOTR-IUAIQHPESA-N	PUBCHEM.COMPOUND:135326	UMLS:C0031511	Iobenguane I 123	Pheochromocytomas	Designated/Approved	2006-12-01
PDWUPXJEEYOOTR-IUAIQHPESA-N	PUBCHEM.COMPOUND:135326	UMLS:C0027819	Iobenguane I 123	Neuroblastomas	Designated/Approved	2006-12-01
PDWUPXJEEYOOTR-JRGAVVOBSA-N	PUBCHEM.COMPOUND:71184	UMLS:C0206754	iobenguane I 131	Neuroendocrine Tumors	Designated	2007-07-05
PDWUPXJEEYOOTR-JRGAVVOBSA-N	PUBCHEM.COMPOUND:71184	UMLS:C0206754	Iobenguane I 131	Neuroendocrine Tumors	Designated/Approved	2006-01-18
PEDCQBHIVMGVHV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:753	UMLS:C0151740	Glyceol	Intracranial Hypertension	Designated/Withdrawn	1990-02-22
PEDCQBHIVMGVHV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:753	UMLS:C0006114	Glyceol	Cerebral Edema	Designated/Withdrawn	1990-02-22
PENDGIOBPJLVBT-AMXFZXBBSA-N	PUBCHEM.COMPOUND:156417	UMLS:C0032064	cethromycin	Plague	Designated	2009-09-09
PENDGIOBPJLVBT-AMXFZXBBSA-N	PUBCHEM.COMPOUND:156417	UMLS:C0155866	cethromycin	Inhalation anthrax	Designated	2007-02-28
PENDGIOBPJLVBT-AMXFZXBBSA-N	PUBCHEM.COMPOUND:156417	UMLS:C0041351	cethromycin	Tularemia	Designated	2009-09-09
PENDGIOBPJLVBT-COVUKVLKSA-N	PUBCHEM.COMPOUND:11354711	UMLS:C0041351	cethromycin	Tularemia	Designated	2009-09-09
PENDGIOBPJLVBT-COVUKVLKSA-N	PUBCHEM.COMPOUND:11354711	UMLS:C0032064	cethromycin	Plague	Designated	2009-09-09
PENDGIOBPJLVBT-COVUKVLKSA-N	PUBCHEM.COMPOUND:11354711	UMLS:C0155866	cethromycin	Inhalation anthrax	Designated	2007-02-28
PENDGIOBPJLVBT-HMMOOPTJSA-N	PUBCHEM.COMPOUND:5282045	UMLS:C0155866	cethromycin	Inhalation anthrax	Designated	2007-02-28
PENDGIOBPJLVBT-HMMOOPTJSA-N	PUBCHEM.COMPOUND:5282045	UMLS:C0041351	cethromycin	Tularemia	Designated	2009-09-09
PENDGIOBPJLVBT-HMMOOPTJSA-N	PUBCHEM.COMPOUND:5282045	UMLS:C0032064	cethromycin	Plague	Designated	2009-09-09
PENDGIOBPJLVBT-ONLVEXIXSA-N	PUBCHEM.COMPOUND:447451	UMLS:C0041351	cethromycin	Tularemia	Designated	2009-09-09
PENDGIOBPJLVBT-ONLVEXIXSA-N	PUBCHEM.COMPOUND:447451	UMLS:C0155866	cethromycin	Inhalation anthrax	Designated	2007-02-28
PENDGIOBPJLVBT-ONLVEXIXSA-N	PUBCHEM.COMPOUND:447451	UMLS:C0032064	cethromycin	Plague	Designated	2009-09-09
PENDGIOBPJLVBT-WNGDBVLYSA-N	PUBCHEM.COMPOUND:146157949	UMLS:C0032064	cethromycin	Plague	Designated	2009-09-09
PENDGIOBPJLVBT-WNGDBVLYSA-N	PUBCHEM.COMPOUND:146157949	UMLS:C0041351	cethromycin	Tularemia	Designated	2009-09-09
PENDGIOBPJLVBT-WNGDBVLYSA-N	PUBCHEM.COMPOUND:146157949	UMLS:C0155866	cethromycin	Inhalation anthrax	Designated	2007-02-28
PFTAWBLQPZVEMU-ZFWWWQNUSA-N	PUBCHEM.COMPOUND:182232	UMLS:C3542021	(+)-Epicatechin	Duchenne and Becker Muscular Dystrophy	Designated	2020-04-06
PGAVKCOVUIYSFO-XVFCMESISA-N	PUBCHEM.COMPOUND:6133	UMLS:C4551720	Uridine 5'-triphosphate	Primary Ciliary Dyskinesia	Designated/Withdrawn	1996-06-26
PGAVKCOVUIYSFO-XVFCMESISA-N	PUBCHEM.COMPOUND:6133	UMLS:C0010674	Uridine 5'-triphosphate	Cystic Fibrosis	Designated/Withdrawn	1995-12-04
PGTVWKLGGCQMBR-FLBATMFCSA-N	PUBCHEM.COMPOUND:6918305	UMLS:C0014544	ganaxolone	Epilepsy	Designated	2015-03-24
PGTVWKLGGCQMBR-FLBATMFCSA-N	PUBCHEM.COMPOUND:6918305	UMLS:C3887898	Ganaxolone	Infantile spasms	Designated	1994-05-25
PGTVWKLGGCQMBR-FLBATMFCSA-N	PUBCHEM.COMPOUND:6918305	UMLS:C0543888	ganaxolone	Epileptic encephalopathy	Designated	2017-06-28
PGTVWKLGGCQMBR-FLBATMFCSA-N	PUBCHEM.COMPOUND:6918305	UMLS:C0038220	ganaxolone	Status Epilepticus	Designated	2016-04-14
PGTVWKLGGCQMBR-FLBATMFCSA-N	PUBCHEM.COMPOUND:6918305	UMLS:C0016667	ganaxolone	Fragile X Syndrome	Designated	2016-12-28
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0342788	Levocarnitine	Carnitine Deficiency	Designated/Approved	1988-09-06
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0600688	levocarnitine	Toxicity	Designated	1989-11-15
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0022661	Levocarnitine	End stage renal disease	Designated/Approved	1988-09-06
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C2025219	Levocarnitine	Secondary carnitine deficiency	Designated/Approved	1984-07-26
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0342788	Levocarnitine	Carnitine Deficiency	Designated/Approved	1984-02-28
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C2025219	levocarnitine	Secondary carnitine deficiency	Designated	1989-11-15
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0022661	Levocarnitine	End stage renal disease	Designated/Withdrawn	1986-11-24
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0342788	Levocarnitine	Carnitine Deficiency	Designated/Withdrawn	1986-11-24
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0162670	Levocarnitine	MITOCHONDRIAL MYOPATHY	Designated	1997-04-07
PHIQHXFUZVPYII-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:10917	UMLS:C0878544	Levocarnitine	Cardiomyopathy	Designated	1993-11-22
PHLBKPHSAVXXEF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5533	UMLS:C0751122	trazodone	Dravet Syndrome	Designated	2017-08-18
PHXJVRSECIGDHY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24826799	UMLS:C0023473	ponatinib	Chronic myeloid leukemia	Designated/Approved	2009-11-20
PHXJVRSECIGDHY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24826799	UMLS:C0238198	ponatinib	Gastrointestinal Stromal Tumors	Designated/Withdrawn	2015-03-12
PHXJVRSECIGDHY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24826799	UMLS:C1709527	ponatinib	Philadelphia chromosome-positive acute lymphoblastic leukemia	Designated/Approved	2009-11-20
PIBARDGJJAGJAJ-NQIIRXRSSA-N	PUBCHEM.COMPOUND:118323590	UMLS:C0024790	(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	Paroxysmal nocturnal hemoglobinuria	Designated	2017-11-02
PIBARDGJJAGJAJ-NQIIRXRSSA-N	PUBCHEM.COMPOUND:118323590	UMLS:C4521256	(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	Glomerulopathy	Designated	2017-12-14
PIMQWRZWLQKKBJ-SFHVURJKSA-N	PUBCHEM.COMPOUND:46926350	UMLS:C0023434	dinaciclib	Chronic Lymphocytic Leukemia	Designated	2011-08-25
PIQCTGMSNWUMAF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398510	UMLS:C0010606	dovitinib	Adenoid Cystic Carcinoma	Designated	2013-09-26
PIQCTGMSNWUMAF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135398510	UMLS:C0026764	Dovitinib	Multiple Myeloma	Designated/Withdrawn	2006-10-03
PIWHBPJCPCXFEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:127893	UMLS:C0022661	Epoetin alfa	End stage renal disease	Designated/Approved	1986-04-10
PIWHBPJCPCXFEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:127893	UMLS:C0019693	Epoetin alfa	HIV infection	Designated/Approved	1991-07-01
PIWHBPJCPCXFEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:127893	UMLS:C3463824	Epoetin alfa	MYELODYSPLASTIC SYNDROME	Designated	1993-12-20
PIWHBPJCPCXFEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:127893	UMLS:C0002871	Epoetin alfa	Anemia	Designated/Approved	1991-07-01
PIWHBPJCPCXFEU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:127893	UMLS:C0002871	Epoetin alfa	Anemia	Designated/Approved	1986-04-10
PJDFLNIOAUIZSL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5665	UMLS:C3887898	vigabatrin	Infantile spasms	Designated/Approved	2000-06-12
PJHKBYALYHRYSK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69286	UMLS:C1456270	triheptanoin	fatty acid oxidation disorder	Designated/Approved	2015-04-15
PJHKBYALYHRYSK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69286	UMLS:C0017921	Triheptanoin	Pompe Disease	Designated	2008-02-01
PJHKBYALYHRYSK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69286	UMLS:C0017919	Triheptanoin	glycogen storage disorder	Designated	2008-02-01
PKCDDUHJAFVJJB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11640390	UMLS:C0206686	linsitinib	Adrenocortical carcinoma	Designated/Withdrawn	2012-03-09
PKVRCIRHQMSYJX-AIFWHQITSA-N	PUBCHEM.COMPOUND:108150	UMLS:C1261473	trabectedin	Soft tissue sarcoma	Designated/Approved	2004-09-30
PKVRCIRHQMSYJX-AIFWHQITSA-N	PUBCHEM.COMPOUND:108150	UMLS:C4721610	trabectedin	Ovarian Cancer	Designated	2005-03-29
PLHJCIYEEKOWNM-HHHXNRCGSA-N	PUBCHEM.COMPOUND:159324	UMLS:C0026764	tipifarnib	Multiple Myeloma	Designated	2017-06-22
PLHJCIYEEKOWNM-HHHXNRCGSA-N	PUBCHEM.COMPOUND:159324	UMLS:C0079772	tipifarnib	T-Cell Lymphoma	Designated	2020-04-06
PLHJCIYEEKOWNM-HHHXNRCGSA-N	PUBCHEM.COMPOUND:159324	UMLS:C0023467	Tipifarnib	Acute myeloid leukemia	Designated	2004-07-06
PMATZTZNYRCHOR-AVZWOAAISA-N	PUBCHEM.COMPOUND:122172945	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-AVZWOAAISA-N	PUBCHEM.COMPOUND:122172945	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-AVZWOAAISA-N	PUBCHEM.COMPOUND:122172945	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-AVZWOAAISA-N	PUBCHEM.COMPOUND:122172945	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-BMGRVWOJSA-N	PUBCHEM.COMPOUND:71306795	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-CGLBZJNRSA-N	PUBCHEM.COMPOUND:5284373	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-GNSAQUIPSA-N	PUBCHEM.COMPOUND:62280	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-GNSAQUIPSA-N	PUBCHEM.COMPOUND:62280	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-GNSAQUIPSA-N	PUBCHEM.COMPOUND:62280	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-GNSAQUIPSA-N	PUBCHEM.COMPOUND:62280	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-IMVLJIQESA-N	PUBCHEM.COMPOUND:5280754	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-KMSBSJHKSA-N	PUBCHEM.COMPOUND:6435893	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-KMSBSJHKSA-N	PUBCHEM.COMPOUND:6435893	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-KMSBSJHKSA-N	PUBCHEM.COMPOUND:6435893	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-KMSBSJHKSA-N	PUBCHEM.COMPOUND:6435893	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-LQJDIJJQSA-N	PUBCHEM.COMPOUND:73896891	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-NFOUMSERSA-N	PUBCHEM.COMPOUND:16404350	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-NFOUMSERSA-N	PUBCHEM.COMPOUND:16404350	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-NFOUMSERSA-N	PUBCHEM.COMPOUND:16404350	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-NFOUMSERSA-N	PUBCHEM.COMPOUND:16404350	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-NFOUMSERSA-N	PUBCHEM.COMPOUND:16404350	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-NSJDOISKSA-N	PUBCHEM.COMPOUND:71463825	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-NSJDOISKSA-N	PUBCHEM.COMPOUND:71463825	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-NSJDOISKSA-N	PUBCHEM.COMPOUND:71463825	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-NSJDOISKSA-N	PUBCHEM.COMPOUND:71463825	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-ONJQHLSTSA-N	PUBCHEM.COMPOUND:129009974	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-QVSDIVLPSA-N	PUBCHEM.COMPOUND:5497195	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-RNWFWJGASA-N	PUBCHEM.COMPOUND:138107778	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-RNWFWJGASA-N	PUBCHEM.COMPOUND:138107778	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-RNWFWJGASA-N	PUBCHEM.COMPOUND:138107778	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-RNWFWJGASA-N	PUBCHEM.COMPOUND:138107778	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-RYZPDLMBSA-N	PUBCHEM.COMPOUND:123134270	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-RYZPDLMBSA-N	PUBCHEM.COMPOUND:123134270	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-RYZPDLMBSA-N	PUBCHEM.COMPOUND:123134270	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-RYZPDLMBSA-N	PUBCHEM.COMPOUND:123134270	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-SCYOXIPCSA-N	PUBCHEM.COMPOUND:123134263	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-SCYOXIPCSA-N	PUBCHEM.COMPOUND:123134263	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-SCYOXIPCSA-N	PUBCHEM.COMPOUND:123134263	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-SCYOXIPCSA-N	PUBCHEM.COMPOUND:123134263	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-SRFWORPQSA-N	PUBCHEM.COMPOUND:25246316	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-SRFWORPQSA-N	PUBCHEM.COMPOUND:25246316	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-SRFWORPQSA-N	PUBCHEM.COMPOUND:25246316	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-SRFWORPQSA-N	PUBCHEM.COMPOUND:25246316	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2909	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2909	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2909	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2909	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2909	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-VJRYSDSKSA-N	PUBCHEM.COMPOUND:24883466	UMLS:C3273245	Cyclosporine	Acute Rejection	Designated	2003-11-25
PMATZTZNYRCHOR-VJRYSDSKSA-N	PUBCHEM.COMPOUND:24883466	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-VJRYSDSKSA-N	PUBCHEM.COMPOUND:24883466	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-VJRYSDSKSA-N	PUBCHEM.COMPOUND:24883466	UMLS:C0018133	cyclosporine	Graft-Versus-Host Disease	Designated/Withdrawn	2009-02-17
PMATZTZNYRCHOR-VJRYSDSKSA-N	PUBCHEM.COMPOUND:24883466	UMLS:C0815080	Cyclosporine	organ rejection	Designated	2003-11-25
PMATZTZNYRCHOR-VPYFBNRVSA-N	PUBCHEM.COMPOUND:49867938	UMLS:C0319157	cyclosporine A	virus	Designated	2008-04-09
PMATZTZNYRCHOR-VPYFBNRVSA-N	PUBCHEM.COMPOUND:49867938	UMLS:C0339303	cyclosporine A	Corneal graft rejection	Designated	2008-09-30
PMATZTZNYRCHOR-VPYFBNRVSA-N	PUBCHEM.COMPOUND:49867938	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-VPYFBNRVSA-N	PUBCHEM.COMPOUND:49867938	UMLS:C0022577	Cyclosporine A	Vernal keratoconjunctivitis	Designated	2007-05-04
PMATZTZNYRCHOR-VPYFBNRVSA-N	PUBCHEM.COMPOUND:49867938	UMLS:C1318020	cyclosporine A	Stromal keratitis	Designated	2008-04-09
PMATZTZNYRCHOR-WCIOLWJGSA-N	PUBCHEM.COMPOUND:5458585	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMATZTZNYRCHOR-WIUPBDCUSA-N	PUBCHEM.COMPOUND:132274082	UMLS:C0002736	Cyclosporin A	Amyotrophic Lateral Sclerosis	Designated	2004-10-29
PMHDSACGRKBACK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4961254	UMLS:C0016719	D-amino acid oxidase inhibitor	Friedreich's Ataxia	Designated/Withdrawn	2017-12-06
PMJIHLSCWIDGMD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11313622	UMLS:C3250443	Tideglusib	DM1	Designated	2017-06-19
PMJIHLSCWIDGMD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11313622	UMLS:C0027126	Tideglusib	Myotonic Dystrophy	Designated	2017-06-19
POGQSBRIGCQNEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:129228	UMLS:C0238111	rufinamide	Lennox-Gastaut syndrome	Designated/Approved	2004-10-08
POHUROFYRXELIO-YUMQZZPRSA-N	PUBCHEM.COMPOUND:121488179	UMLS:C0036202	Alidornase alfa	Sarcoidosis	Designated	2020-07-21
POJWUDADGALRAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:204	UMLS:C0014527	allantoin	Epidermolysis Bullosa	Designated/Withdrawn	2002-11-21
POJWUDADGALRAB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:204	UMLS:C2220104	allantoin	Skin blistering	Designated/Withdrawn	2002-11-21
PPHTXRNHTVLQED-UHFFFAOYSA-N	PUBCHEM.COMPOUND:172997	UMLS:C0085413	lixivaptan	Autosomal dominant polycystic kidney disease	Designated	2017-09-18
PPJYSSNKSXAVDB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65552	UMLS:C0549473	Tetraiodothyroacetic acid	Cancer of the Thyroid	Designated	2000-05-01
PPKXEPBICJTCRU-XMZRARIVSA-N	PUBCHEM.COMPOUND:63013	UMLS:C0032768	Tramadol hydrochloride	Postherpetic neuralgia	Designated	2005-04-26
PPKXEPBICJTCRU-XMZRARIVSA-N	PUBCHEM.COMPOUND:63013	UMLS:C0442874	Tramadol hydrochloride	Neuropathy	Designated	2005-01-28
PPKXEPBICJTCRU-XMZRARIVSA-N	PUBCHEM.COMPOUND:63013	UMLS:C0019682	Tramadol hydrochloride	HIV	Designated	2005-01-28
PQAPVTKIEGUPRN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11455910	UMLS:C0035335	N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide	Retinoblastoma	Designated	2020-09-14
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C2931826	miltefosine	PAM	Designated	2016-12-06
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0036323	miltefosine	Schistosomiasis	Designated	2017-08-02
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0338427	miltefosine	Primary amebic encephalitis	Designated	2016-12-06
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0013370	miltefosine	amebiasis	Designated	2017-06-19
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0338428	miltefosine	Granulomatous amebic encephalitis	Designated	2017-06-19
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0079731	miltefosine	B-Cell Lymphoma	Designated	2009-03-18
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0079772	miltefosine	T-Cell Lymphoma	Designated	2009-03-18
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C1276146	miltefosine	Cutaneous lymphoma	Designated	2009-03-18
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0023281	miltefosine	Leishmaniasis	Designated/Approved	2006-10-10
PQLXHQMOHUQAKB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3599	UMLS:C0000880	miltefosine	Acanthamoeba Keratitis	Designated	2016-12-06
PRDJGNVQBVXXEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:437740	UMLS:C0035335	thioureidobutyronitrile	Retinoblastoma	Designated	2015-11-17
PRDJGNVQBVXXEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:437740	UMLS:C0235974	thioureidobutyronitrile	PANCREATIC CANCER	Designated	2016-01-20
PRDJGNVQBVXXEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:437740	UMLS:C4721610	thioureidobutyronitrile	Ovarian Cancer	Designated	2015-07-14
PRFBWBYKWZVQJF-RRABGKBLSA-M	PUBCHEM.COMPOUND:23668369	UMLS:C0520799	recilisib sodium	Acute Radiation Syndrome	Designated/Withdrawn	2012-06-01
PRFBWBYKWZVQJF-RRABGKBLSA-M	PUBCHEM.COMPOUND:23668369	UMLS:C0520799	recilisib sodium	Acute Radiation Syndrome	Designated/Withdrawn	2012-09-04
PRMWGUBFXWROHD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9924495	UMLS:C0238111	perampanel	Lennox-Gastaut syndrome	Designated	2012-12-07
PRRZDZJYSJLDBS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6994776	UMLS:C0279000	3-bromopyruvate	Liver and Intrahepatic Bile Duct Cancer	Designated	2013-03-05
PRRZDZJYSJLDBS-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6994776	UMLS:C0235974	3-bromopyruvate	PANCREATIC CANCER	Designated	2014-04-29
PRRZDZJYSJLDBS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:70684	UMLS:C0025202	3-bromo-2-oxopropanoic acid	melanoma	Designated	2020-05-01
PSGAAPLEWMOORI-PEINSRQWSA-N	PUBCHEM.COMPOUND:6279	UMLS:C0398650	Medroxyprogesterone acetate	Immune thrombocytopenic purpura	Designated	2001-02-22
PSIFNNKUMBGKDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3961	UMLS:C0024796	losartan	Marfan Syndrome	Designated	2011-12-12
PSIFNNKUMBGKDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3961	UMLS:C0014527	Losartan	Epidermolysis Bullosa	Designated	2019-01-29
PSVUJBVBCOISSP-SPFKKGSWSA-N	PUBCHEM.COMPOUND:123628	UMLS:C0235974	glufosfamide	PANCREATIC CANCER	Designated	2006-09-18
PSWFFKRAVBDQEG-YGQNSOCVSA-N	PUBCHEM.COMPOUND:451417	UMLS:C0036202	thymopentin	Sarcoidosis	Designated	2011-02-04
PSXPIRGEVYHPKP-GXKRWWSZSA-N	PUBCHEM.COMPOUND:135544142	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
PTFCDOFLOPIGGS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:32051	UMLS:C0024748	Recombinant human alpha-mannosidase	alpha-Mannosidosis	Designated	2006-02-02
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0024299	Allopurinol sodium	Lymphoma	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0280099	Allopurinol sodium	Solid Tumor	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0006826	Allopurinol sodium	MALIGNANCIES	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0006826	Allopurinol sodium	MALIGNANCIES	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0024299	Allopurinol sodium	Lymphoma	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0023418	Allopurinol sodium	leukemia	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0023418	Allopurinol sodium	leukemia	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-M	PUBCHEM.COMPOUND:70691471	UMLS:C0280099	Allopurinol sodium	Solid Tumor	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135534565	UMLS:C0280099	Allopurinol sodium	Solid Tumor	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135534565	UMLS:C0023418	Allopurinol sodium	leukemia	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135534565	UMLS:C0024299	Allopurinol sodium	Lymphoma	Designated/Approved	1992-10-16
PTJRZVJXXNYNLN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135534565	UMLS:C0006826	Allopurinol sodium	MALIGNANCIES	Designated/Approved	1992-10-16
PTKRPOIHIOAMPP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:73334909	UMLS:C0017638	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	gliomas	Designated	2013-11-26
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0023443	Cladribine	Hairy Cell Leukemia	Designated/Approved	1990-11-15
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0026769	Cladribine	Multiple Sclerosis	Designated	1994-04-19
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0023434	cladribine	Chronic Lymphocytic Leukemia	Designated/Withdrawn	1990-12-31
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0023467	Cladribine	Acute myeloid leukemia	Designated/Withdrawn	1990-07-20
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0024305	Cladribine	Non-Hodgkin's Lymphoma	Designated/Withdrawn	1993-04-19
PTOAARAWEBMLNO-KVQBGUIXSA-N	PUBCHEM.COMPOUND:20279	UMLS:C0027873	cladribine	Neuromyelitis Optica	Designated	2015-03-19
PTOIAAWZLUQTIO-GXFFZTMASA-N	PUBCHEM.COMPOUND:10220503	UMLS:C0851578	tasimelteon	Sleep disorder	Designated/Approved	2010-04-30
PTOIAAWZLUQTIO-GXFFZTMASA-N	PUBCHEM.COMPOUND:10220503	UMLS:C0795864	tasimelteon	Smith-Magenis syndrome	Designated/Approved	2010-04-30
PTOIAAWZLUQTIO-GXFFZTMASA-N	PUBCHEM.COMPOUND:10220503	UMLS:C0851578	tasimelteon	Sleep disorder	Designated/Approved	2010-04-30
PTOIAAWZLUQTIO-GXFFZTMASA-N	PUBCHEM.COMPOUND:10220503	UMLS:C0795864	tasimelteon	Smith-Magenis syndrome	Designated/Approved	2010-04-30
PUDHBTGHUJUUFI-SCTWWAJVSA-N	PUBCHEM.COMPOUND:6918011	UMLS:C0206754	lanreotide acetate	Neuroendocrine Tumors	Designated/Approved	2011-08-25
PUDHBTGHUJUUFI-SCTWWAJVSA-N	PUBCHEM.COMPOUND:6918011	UMLS:C0024586	lanreotide acetate	Carcinoid syndrome	Designated/Approved	2011-09-08
PUDHBTGHUJUUFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71349	UMLS:C0206754	lanreotide acetate	Neuroendocrine Tumors	Designated/Approved	2011-08-25
PUDHBTGHUJUUFI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71349	UMLS:C0024586	lanreotide acetate	Carcinoid syndrome	Designated/Approved	2011-09-08
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C2931788	avacopan	Atypical Hemolytic Uremic Syndrome	Designated	2014-11-17
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C4050407	avacopan	Wegener Granulomatosis	Designated	2014-06-02
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C3495801	avacopan	Granulomatosis with polyangiitis	Designated	2014-06-02
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C2347126	avacopan	Microscopic Polyangiitis	Designated	2014-06-02
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C0042384	avacopan	Vasculitides	Designated	2014-06-02
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C0008728	avacopan	Churg-Strauss Syndrome	Designated	2014-06-02
PUKBOVABABRILL-YZNIXAGQSA-N	PUBCHEM.COMPOUND:49841217	UMLS:C4521256	avacopan	Glomerulopathy	Designated	2017-03-20
PURKAOJPTOLRMP-ASMGOKTBSA-N	PUBCHEM.COMPOUND:71470491	UMLS:C0010674	D9-ivacaftor	Cystic Fibrosis	Designated	2017-01-18
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PURKAOJPTOLRMP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16220172	UMLS:C0010674	ivacaftor	Cystic Fibrosis	Designated/Approved	2006-12-20
PUUSSSIBPPTKTP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71237	UMLS:C0458219	neridronate	Complex regional pain syndrome	Designated	2013-03-25
PVCULFYROUOVGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081349	UMLS:C0023467	Laromustine	Acute myelogenous leukemia	Designated	2014-03-27
PVCULFYROUOVGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081349	UMLS:C0023467	laromustine	Acute myelogenous leukemia	Designated	2004-10-21
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0027947	angiotensin 1-7	Neutropenia	Designated	2010-06-17
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0520799	TXA127	Acute Radiation Syndrome	Designated	2013-10-25
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C3203102	Angiotensin-(1-7)	PULMONARY ARTERIAL HYPERTENSION	Designated	2011-09-13
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C1261473	angiotensin 1-7	Sarcoma	Designated	2010-01-29
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0027947	Angiotensin 1-7	Neutropenia	Designated	2000-02-16
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C3463824	Angiotensin 1-7	MYELODYSPLASTIC SYNDROME	Designated	2001-08-03
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0040034	angiotensin 1-7	Thrombocytopenia	Designated	2010-06-17
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0024299	angiotensin 1-7	Lymphoma	Designated	2010-06-17
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0686353	Angiotensin (1-7)	Limb-girdle muscular dystrophy	Designated	2013-11-26
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0079474	Angiotensin (1-7)	Recessive dystrophic epidermolysis bullosa	Designated	2016-09-01
PVHLMTREZMEJCG-GDTLVBQBSA-N	PUBCHEM.COMPOUND:123805	UMLS:C0026850	Angiotensin (1-7)	Muscular Dystrophy	Designated	2016-02-08
PWILYDZRJORZDR-MISYRCLQSA-N	PUBCHEM.COMPOUND:213054	UMLS:C1412063	soraprazan	Stargardt disease	Designated	2017-12-22
PWILYDZRJORZDR-MISYRCLQSA-N	PUBCHEM.COMPOUND:213054	UMLS:C0036916	soraprazan	STD	Designated	2017-12-22
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0572025	Acetylcysteine	Acetaminophen overdose	Designated	1987-08-13
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0235280	N-acetylcysteine	Ototoxicity	Designated	2012-07-19
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0006826	N-acetylcysteine	Cancers	Designated	2012-07-19
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0162557	N-acetylcysteine	Acute liver failure	Designated	2002-09-09
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0572025	acetylcysteine	Acetaminophen overdose	Designated/Approved	2001-10-19
PWKSKIMOESPYIA-BYPYZUCNSA-N	PUBCHEM.COMPOUND:12035	UMLS:C0475715	N-acetylcysteine	Apnea of prematurity	Designated/Withdrawn	2010-10-21
PWOQRKCAHTVFLB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:22420	UMLS:C0002880	Revimmune	Autoimmune hemolytic anemia	Designated	2011-02-18
PYZRQGJRPPTADH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3878	UMLS:C0238111	Lamotrigine	Lennox-Gastaut syndrome	Designated/Approved	1995-08-23
PZBPHYLKIMOZPR-FIYGWYQWSA-K	PUBCHEM.COMPOUND:71661158	UMLS:C0206754	Gallium (68Ga) edotreotide	Neuroendocrine Tumors	Designated/Withdrawn	2015-07-01
PZBPHYLKIMOZPR-ZWIFOJARSA-K	PUBCHEM.COMPOUND:145994621	UMLS:C0206754	Gallium (68Ga) edotreotide	Neuroendocrine Tumors	Designated/Withdrawn	2015-07-01
PZRHRDRVRGEVNW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4197	UMLS:C0235527	milrinone	Right heart failure	Designated	2018-01-08
QADPYRIHXKWUSV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53235510	UMLS:C0206698	Infigratinib	Cholangiocarcinoma	Designated	2019-09-11
QAGYKUNXZHXKMR-HKWSIXNMSA-N	PUBCHEM.COMPOUND:64143	UMLS:C0026764	nelfinavir	Multiple Myeloma	Designated/Withdrawn	2017-02-14
QAMYWGZHLCQOOJ-IJJXRQIPSA-N	PUBCHEM.COMPOUND:74891361	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QAMYWGZHLCQOOJ-ONAKUIRGSA-N	PUBCHEM.COMPOUND:117590636	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QAMYWGZHLCQOOJ-SLSRVFANSA-N	PUBCHEM.COMPOUND:146158903	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QAMYWGZHLCQOOJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:22525136	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QAMYWGZHLCQOOJ-WRNBYXCMSA-N	PUBCHEM.COMPOUND:17755248	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QAMYWGZHLCQOOJ-XXLUYSOPSA-N	PUBCHEM.COMPOUND:122362420	UMLS:C1261473	eribulin mesylate	Soft tissue sarcoma	Designated/Approved	2012-05-14
QBKSWRVVCFFDOT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3503	UMLS:C0206686	Gossypol	cancer of the adrenal cortex	Designated	1990-10-22
QCHFTSOMWOSFHM-WPRPVWTQSA-N	PUBCHEM.COMPOUND:5910	UMLS:C0043352	Pilocarpine	Xerostomia	Designated/Approved	1990-09-24
QCHFTSOMWOSFHM-WPRPVWTQSA-N	PUBCHEM.COMPOUND:5910	UMLS:C3887461	Pilocarpine	Head and Neck Cancer	Designated/Approved	1990-09-24
QCZAWDGAVJMPTA-RNFRBKRXSA-N	PUBCHEM.COMPOUND:117817422	UMLS:C0017638	vorasidenib	Glioma	Designated	2018-09-10
QEEAPRPFLLJWCF-UHFFFAOYSA-K	PUBCHEM.COMPOUND:13344	UMLS:C2673444	Potassium citrate	Hypocitraturia	Designated/Approved	1984-11-01
QEEAPRPFLLJWCF-UHFFFAOYSA-K	PUBCHEM.COMPOUND:13344	UMLS:C0009566	Potassium citrate	Complication	Designated/Approved	1984-11-01
QEEAPRPFLLJWCF-UHFFFAOYSA-K	PUBCHEM.COMPOUND:13344	UMLS:C0558595	Potassium citrate	Uric acid nephrolithiasis	Designated/Approved	1984-11-01
QEEAPRPFLLJWCF-UHFFFAOYSA-K	PUBCHEM.COMPOUND:13344	UMLS:C0023869	Potassium citrate	Lithiasis	Designated/Approved	1984-11-01
QEEAPRPFLLJWCF-UHFFFAOYSA-K	PUBCHEM.COMPOUND:13344	UMLS:C0022650	Potassium citrate	renal stones	Designated/Approved	1984-11-01
QEEJLLNYQOBRRM-KSHGRFHLSA-N	PUBCHEM.COMPOUND:16132344	UMLS:C0010481	Corticorelin ovine triflutate	CUSHINGS SYNDROME	Designated/Approved	1989-11-24
QELUYTUMUWHWMC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4021	UMLS:C0002736	edaravone	Amyotrophic Lateral Sclerosis	Designated/Approved	2015-05-12
QELUYTUMUWHWMC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4021	UMLS:C0002736	edaravone	Amyotrophic Lateral Sclerosis	Designated	2015-03-12
QFCXANHHBCGMAS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9808844	UMLS:C0024623	telatinib	Gastric Cancer	Designated	2010-05-17
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0042166	sirolimus	Intermediate uveitis	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0042164	sirolimus	Uveitis	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0751437	sirolimus	Anterior	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0009450	sirolimus	Infectious	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0041341	rapamycin	Tuberous Sclerosis Complex	Designated	2007-03-20
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0751438	sirolimus	Posterior	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C4518725	sirolimus	Noninfectious panuveitis	Designated	2011-11-04
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0002895	sirolimus	Sickle Cell Disease	Designated	2018-03-13
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0206731	sirolimus	Angiofibroma	Designated	2017-05-17
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0041341	sirolimus	Tuberous Sclerosis	Designated	2017-05-17
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0751674	sirolimus	Lymphangioleiomyomatosis	Designated/Approved	2012-10-31
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0005283	sirolimus	BETA-THALASSEMIA	Designated	2016-06-21
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0265334	sirolimus	Pachyonychia Congenita	Designated	2013-03-18
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0265319	rapamycin	Facial angiofibromas	Designated	2016-02-24
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C1300127	rapamycin	Perivascular Epithelioid Cell Tumors	Designated	2017-12-21
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0265319	sirolimus	Facial angiofibromas	Designated	2017-02-13
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0041341	sirolimus	Tuberous Sclerosis Complex	Designated	2017-02-13
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0751674	sirolimus	Lymphangioleiomyomatosis	Designated	2014-11-17
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0751674	sirolimus	Lymphangioleiomyomatosis	Designated	2014-06-25
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0041341	rapamycin	Tuberous Sclerosis Complex	Designated	2016-02-24
QFJCIRLUMZQUOT-HPLJOQBZSA-N	PUBCHEM.COMPOUND:5284616	UMLS:C0041341	sirolimus	Tuberous Sclerosis Complex	Designated	2019-08-26
QFLNTQDOVCLQKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54718618	UMLS:C0040038	tecarfarin	Thromboembolism	Designated	2019-03-07
QFLNTQDOVCLQKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54718618	UMLS:C0022661	tecarfarin	End stage renal disease	Designated	2019-03-07
QFLNTQDOVCLQKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54718618	UMLS:C0004238	tecarfarin	Atrial Fibrillation	Designated	2019-03-07
QGFORSXNKQLDNO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65632	UMLS:C0006267	erdosteine	Bronchiectasis	Designated	2013-12-20
QGJZLNKBHJESQX-FZFNOLFKSA-N	PUBCHEM.COMPOUND:64971	UMLS:C0278883	Betulinic acid	Metastatic melanoma	Designated	2007-08-09
QGNJRVVDBSJHIZ-AQDFTDIISA-N	PUBCHEM.COMPOUND:10245972	UMLS:C0035334	zuretinol acetate	Retinitis Pigmentosa	Designated/Withdrawn	2010-12-02
QGNJRVVDBSJHIZ-AQDFTDIISA-N	PUBCHEM.COMPOUND:10245972	UMLS:C0854723	zuretinol acetate	Retinal Dystrophies	Designated	2010-12-02
QHADVLVFMKEIIP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44603533	UMLS:C0750952	merestinib	Biliary Tract Cancer	Designated	2017-04-10
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0018133	cannabidiol	GRAFT VERSUS HOST DISEASE	Designated	2016-11-29
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0238111	cannabidiol	Lennox-Gastaut syndrome	Designated/Approved	2014-02-27
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0241910	cannabidiol	Autoimmune hepatitis	Designated	2018-06-25
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C3887898	cannabidiol	Infantile spasms	Designated	2016-06-13
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0751122	cannabidiol	Dravet Syndrome	Designated/Withdrawn	2014-07-01
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0017636	cannabidiol	Glioblastoma multiforme	Designated	2014-08-20
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0032897	cannabidiol	Prader Willi syndrome	Designated	2020-08-21
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0751122	cannabidiol	Dravet Syndrome	Designated/Approved	2013-11-14
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C3887898	cannabidiol	Infantile spasms	Designated	2015-07-23
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0041341	cannabidiol	Tuberous Sclerosis Complex	Designated/Approved	2016-04-19
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0751122	cannabidiol	Dravet Syndrome	Designated/Approved	2013-11-14
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0238111	cannabidiol	Lennox-Gastaut syndrome	Designated/Approved	2014-02-27
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0238111	cannabidiol	Lennox-Gastaut syndrome	Designated/Withdrawn	2014-06-23
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0016667	cannabidiol	Fragile X Syndrome	Designated	2016-02-23
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0018133	cannabidiol	GRAFT VERSUS HOST DISEASE	Designated	2015-07-14
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0036341	cannabidiol	Schizophrenia	Designated	2014-11-17
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0751122	cannabidiol	Dravet Syndrome	Designated	2017-12-21
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0017638	cannabidiol	Glioma	Designated	2014-09-24
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0162635	Cannabidiol	Angelman Syndrome	Designated	2021-03-22
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0017636	cannabidiol	Glioblastoma	Designated	2020-04-28
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0014527	cannabidiol	Epidermolysis Bullosa	Designated	2020-04-20
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C3898147	cannabidiol	Neonatal Hypoxic Ischemic Encephalopathy	Designated	2015-04-22
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0014553	cannabidiol	childhood absence epilepsy	Designated	2019-08-15
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0022116	cannabidiol	Ischemia	Designated	2018-11-05
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	PUBCHEM.COMPOUND:644019	UMLS:C0035126	cannabidiol	Reperfusion Injury	Designated	2018-11-05
QIOCQCYXBYUYLH-YACUFSJGSA-N	PUBCHEM.COMPOUND:76900653	UMLS:C3540630	Pelcitoclax	Small Cell Lung Cancer	Designated	2020-09-23
QJAGBAPUFWBVSD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86278354	UMLS:C0017636	olaptesed pegol	Glioblastoma	Designated	2014-08-19
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0018133	Tacrolimus	Graft-Versus-Host-Disease	Designated	1998-04-06
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0815080	tacrolimus	organ rejection	Designated/Approved	2013-12-20
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0022577	Tacrolimus	Vernal keratoconjunctivitis	Designated	2020-06-03
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0815080	tacrolimus	organ rejection	Designated/Approved	2013-12-20
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C3203102	tacrolimus	PULMONARY ARTERIAL HYPERTENSION	Designated	2015-05-04
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0085692	tacrolimus	Hemorrhagic cystitis	Designated	2012-07-06
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C0815080	Tacrolimus	organ rejection	Designated/Approved	2005-06-06
QJJXYPPXXYFBGM-LFZNUXCKSA-N	PUBCHEM.COMPOUND:445643	UMLS:C3203102	tacrolimus	PULMONARY ARTERIAL HYPERTENSION	Designated	2015-03-16
QJVSMHJWAOSBMD-MYXYZBIASA-L	PUBCHEM.COMPOUND:135564751	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
QJYMZHMIZZYHBI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56841946	UMLS:C0026896	monarsen	Myasthenia Gravis	Designated/Withdrawn	2003-11-14
QLMBAIRFQQLJJX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54909	UMLS:C3203102	cicletanine hydrochloride	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	2008-06-24
QLMMOGWZCFQAPU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6419718	UMLS:C0699743	omigapil	Congenital muscular dystrophy	Designated	2008-06-24
QMHSXPLYMTVAMK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5281035	UMLS:C0032580	pyrvinium	Familial Adenomatous Polyposis	Designated	2015-01-05
QNAZTOHXCZPOSA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9862248	UMLS:C0162309	sobetirome	X-Linked Adrenoleukodystrophy	Designated	2011-04-29
QNTASHOAVRSLMD-FCARAQADSA-N	PUBCHEM.COMPOUND:21763506	UMLS:C0026847	cholest-4-en-3-one, oxime	Spinal Muscular Atrophy	Designated/Withdrawn	2009-02-17
QNTASHOAVRSLMD-GYKMGIIDSA-N	PUBCHEM.COMPOUND:76971721	UMLS:C0026847	cholest-4-en-3-one, oxime	Spinal Muscular Atrophy	Designated/Withdrawn	2009-02-17
QNTASHOAVRSLMD-SIWSWZRQSA-N	PUBCHEM.COMPOUND:9930827	UMLS:C0026847	cholest-4-en-3-one, oxime	Spinal Muscular Atrophy	Designated/Withdrawn	2009-02-17
QNTNKSLOFHEFPK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25201759	UMLS:C0020179	ubiquinol	Huntington's Disease	Designated	2004-04-12
QNTNKSLOFHEFPK-UPTCCGCDSA-N	PUBCHEM.COMPOUND:9962735	UMLS:C0020179	ubiquinol	Huntington's Disease	Designated	2004-04-12
QPAKKWCQMHUHNI-GQIQPHNSSA-N	PUBCHEM.COMPOUND:86278273	UMLS:C0555198	Chlorotoxin	Malignant Glioma	Designated	2007-12-18
QPAKKWCQMHUHNI-GQIQPHNSSA-N	PUBCHEM.COMPOUND:86278273	UMLS:C0025202	chlorotoxin	melanoma	Designated	2008-12-02
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0001306	Oxandrolone	Acute alcoholic hepatitis	Designated/Withdrawn	1994-03-18
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0019682	Oxandrolone	HIV	Designated	1991-09-06
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0342538	Oxandrolone	Constitutional delay of growth and puberty	Designated/Withdrawn	1990-10-05
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0013336	Oxandrolone	Short stature	Designated/Withdrawn	1990-07-05
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0041408	Oxandrolone	Turner's Syndrome	Designated/Withdrawn	1990-07-05
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0033677	Oxandrolone	protein calorie malnutrition	Designated/Withdrawn	1994-03-18
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0917713	Oxandrolone	Becker's Muscular Dystrophy	Designated	1997-04-22
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0006625	Oxandrolone	Wasting syndrome	Designated	1991-09-06
QSLJIVKCVHQPLV-PEMPUTJUSA-N	PUBCHEM.COMPOUND:5878	UMLS:C0013264	Oxandrolone	Duchenne's Muscular Dystrophy	Designated	1997-04-22
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0023487	Arsenic trioxide	Acute Promyelocytic Leukemia	Designated/Approved	1998-03-03
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0220630	arsenic trioxide	Liver Cancer	Designated	2003-06-13
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0023434	Arsenic trioxide	Chronic Lymphocytic Leukemia	Designated	2003-05-13
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C3463824	arsenic trioxide	MYELODYSPLASTIC SYNDROME	Designated	2000-07-17
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0026764	Arsenic trioxide	Multiple Myeloma	Designated	2000-04-28
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0023487	Arsenic trioxide	Acute Promyelocytic Leukemia	Designated/Approved	1998-03-03
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0023473	arsenic trioxide	Chronic myeloid leukemia	Designated	2001-10-18
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0555198	Arsenic trioxide	Malignant Glioma	Designated	2005-03-04
QTLQKAJBUDWPIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14888	UMLS:C0018133	arsenic trioxide	Graft-Versus-Host Disease	Designated	2018-07-30
QUIJNHUBAXPXFS-XLJNKUFUSA-N	PUBCHEM.COMPOUND:5388906	UMLS:C0041296	bedaquiline	Active Tuberculosis	Designated/Approved	2005-01-10
QUIJNHUBAXPXFS-XLJNKUFUSA-N	PUBCHEM.COMPOUND:5388906	UMLS:C0041296	bedaquiline	Active Tuberculosis	Designated/Approved	2005-01-10
QUIJNHUBAXPXFS-XLJNKUFUSA-N	PUBCHEM.COMPOUND:5388906	UMLS:C0009450	Bedaquiline	Infection	Designated	2017-07-27
QUIJNHUBAXPXFS-XLJNKUFUSA-N	PUBCHEM.COMPOUND:5388906	UMLS:C0041296	bedaquiline	Active Tuberculosis	Designated/Approved	2005-01-10
QUIJNHUBAXPXFS-XLJNKUFUSA-N	PUBCHEM.COMPOUND:5388906	UMLS:C0026912	Bedaquiline	Mycobacteria	Designated	2017-07-27
QUMMZNCRRKUJLQ-ZMGJSDJYSA-M	PUBCHEM.COMPOUND:71680544	UMLS:C0035344	Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate	Retinopathy of Prematurity	Designated	2020-03-30
QUMWKKVIZAIAHU-LBPRGKRZSA-N	PUBCHEM.COMPOUND:70675172	UMLS:C0030809	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	Pemphigus Vulgaris	Designated/Withdrawn	2015-01-26
QURWXBZNHXJZBE-JNFYKTHFSA-N	PUBCHEM.COMPOUND:90488794	UMLS:C0013604	icatibant	Edema	Designated/Withdrawn	2004-05-05
QURWXBZNHXJZBE-JNFYKTHFSA-N	PUBCHEM.COMPOUND:90488794	UMLS:C0002994	icatibant	Angioedema	Designated/Approved	2003-11-25
QURWXBZNHXJZBE-MCDGZUPGSA-N	PUBCHEM.COMPOUND:71364	UMLS:C0002994	icatibant	Angioedema	Designated/Approved	2003-11-25
QURWXBZNHXJZBE-MCDGZUPGSA-N	PUBCHEM.COMPOUND:71364	UMLS:C0013604	icatibant	Edema	Designated/Withdrawn	2004-05-05
QURWXBZNHXJZBE-SKXRKSCCSA-N	PUBCHEM.COMPOUND:6918173	UMLS:C0002994	icatibant	Angioedema	Designated/Approved	2003-11-25
QURWXBZNHXJZBE-SKXRKSCCSA-N	PUBCHEM.COMPOUND:6918173	UMLS:C0013604	icatibant	Edema	Designated/Withdrawn	2004-05-05
QURWXBZNHXJZBE-UAULPJDASA-N	PUBCHEM.COMPOUND:137705994	UMLS:C0013604	icatibant	Edema	Designated/Withdrawn	2004-05-05
QURWXBZNHXJZBE-UAULPJDASA-N	PUBCHEM.COMPOUND:137705994	UMLS:C0002994	icatibant	Angioedema	Designated/Approved	2003-11-25
QURWXBZNHXJZBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14724482	UMLS:C0013604	icatibant	Edema	Designated/Withdrawn	2004-05-05
QURWXBZNHXJZBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14724482	UMLS:C0002994	icatibant	Angioedema	Designated/Approved	2003-11-25
QXKHYNVANLEOEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4114	UMLS:C3273245	methoxsalen	Acute Rejection	Designated	1994-05-12
QXKHYNVANLEOEG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4114	UMLS:C0018133	Methoxsalen	GRAFT VERSUS HOST DISEASE	Designated	1998-10-14
QXLQZLBNPTZMRK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:436058	UMLS:C0023449	Pegaspargase	Acute lymphocytic leukemia	Designated/Approved	1989-10-20
QXLQZLBNPTZMRK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:436058	UMLS:C0023449	Pegaspargase	Acute lymphocytic leukemia	Designated/Approved	1989-10-20
QXRSDHAAWVKZLJ-PVYNADRNSA-N	PUBCHEM.COMPOUND:448013	UMLS:C4721610	Patupilone	Ovarian Cancer	Designated/Withdrawn	2005-10-04
QXRSDHAAWVKZLJ-PVYNADRNSA-N	PUBCHEM.COMPOUND:448013	UMLS:C0238122	patupilone	Fallopian Tube Cancer	Designated/Withdrawn	2010-02-02
QXWYKJLNLSIPIN-JGVFFNPUSA-N	PUBCHEM.COMPOUND:92974	UMLS:C0259749	droxidopa	Autonomic neuropathy	Designated/Approved	2007-01-17
QXWYKJLNLSIPIN-JGVFFNPUSA-N	PUBCHEM.COMPOUND:92974	UMLS:C0020651	droxidopa	ORTHOSTATIC HYPOTENSION	Designated/Approved	2007-01-17
QXWYKJLNLSIPIN-JGVFFNPUSA-N	PUBCHEM.COMPOUND:92974	UMLS:C1291314	droxidopa	hydroxylase deficiency	Designated/Approved	2007-01-17
QXWYKJLNLSIPIN-JGVFFNPUSA-N	PUBCHEM.COMPOUND:92974	UMLS:C0393911	droxidopa	Autonomic failure	Designated/Approved	2007-01-17
QXWZQTURMXZVHJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9913767	UMLS:C3203102	selexipag	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2010-04-30
QXWZQTURMXZVHJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9913767	UMLS:C2363973	selexipag	Chronic thromboembolic pulmonary hypertension	Designated	2018-10-02
RAGOYPUPXAKGKH-XAKZXMRKSA-N	PUBCHEM.COMPOUND:468595	UMLS:C0238013	posaconazole	Invasive aspergillosis	Designated	2016-10-04
RAGOYPUPXAKGKH-XAKZXMRKSA-N	PUBCHEM.COMPOUND:468595	UMLS:C0043541	posaconazole	Zygomycosis	Designated	2004-07-16
RAJWOBJTTGJROA-QJISAEMRSA-N	PUBCHEM.COMPOUND:440114	UMLS:C0032897	Etiocholanedione	Prader-Willi Syndrome	Designated	1996-05-07
RAJWOBJTTGJROA-QJISAEMRSA-N	PUBCHEM.COMPOUND:440114	UMLS:C0002874	Etiocholanedione	Aplastic Anemia	Designated	1995-11-03
RCBJUJRVBGYTEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71587716	UMLS:C0220613	CT-2584 Mesylate	Adult Soft Tissue Sarcoma	Designated/Withdrawn	1999-04-16
RCBJUJRVBGYTEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71587716	UMLS:C0345967	CT-2584 mesylate	Malignant mesothelioma	Designated/Withdrawn	1999-04-16
RCINICONZNJXQF-MZXODVADSA-N	PUBCHEM.COMPOUND:36314	UMLS:C0276535	Paclitaxel	AIDS-related Kaposi's sarcoma	Designated/Approved	1997-03-25
RCINICONZNJXQF-MZXODVADSA-N	PUBCHEM.COMPOUND:36314	UMLS:C0276535	Paclitaxel	AIDS-related Kaposi's sarcoma	Designated	1997-04-15
RCINICONZNJXQF-MZXODVADSA-N	PUBCHEM.COMPOUND:36314	UMLS:C0235974	paclitaxel	PANCREATIC CANCER	Designated	2009-05-01
RDALZZCKQFLGJP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:73051434	UMLS:C0026764	1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide	Multiple Myeloma	Designated/Withdrawn	2015-07-08
RDHQFKQIGNGIED-MRVPVSSYSA-N	PUBCHEM.COMPOUND:7045767	UMLS:C0016667	acetyl-l-carnitine	Fragile X Syndrome	Designated/Withdrawn	2012-07-24
REOZWEGFPHTFEI-JKSUJKDBSA-N	PUBCHEM.COMPOUND:11601669	UMLS:C0016667	Cannabidivarin	Fragile X Syndrome	Designated	2017-06-06
REOZWEGFPHTFEI-JKSUJKDBSA-N	PUBCHEM.COMPOUND:11601669	UMLS:C0035372	cannabidivarin	Rett Syndrome	Designated	2016-11-30
REQQVBGILUTQNN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:90420193	UMLS:C0036421	Ziritaxestat	Systemic sclerosis	Designated/Withdrawn	2020-01-27
RGLRXNKKBLIBQS-XNHQSDQCSA-N	PUBCHEM.COMPOUND:657180	UMLS:C0342543	Leuprolide acetate	Central Precocious Puberty	Designated/Approved	1988-07-25
RGYQPQARIQKJKH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:58496428	UMLS:C0008312	Setanaxib	Primary Biliary Cholangitis	Designated	2020-10-16
RHGKLRLOHDJJDR-BYPYZUCNSA-N	PUBCHEM.COMPOUND:9750	UMLS:C0242488	L-citrulline	Acute Lung Injury	Designated	2017-01-09
RHGKLRLOHDJJDR-BYPYZUCNSA-N	PUBCHEM.COMPOUND:9750	UMLS:C0002895	L-citrulline	Sickle Cell Disease	Designated	2020-10-07
RHGKLRLOHDJJDR-BYPYZUCNSA-N	PUBCHEM.COMPOUND:9750	UMLS:C0268542	L-Citrulline	Ornithine Transcarbamylase Deficiency	Designated	2020-11-03
RHYVGCKRBKDRDX-UHFFFAOYSA-L	PUBCHEM.COMPOUND:126480146	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
RHYVGCKRBKDRDX-UHFFFAOYSA-L	PUBCHEM.COMPOUND:126480146	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
RIIKDGPBTPECSW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:124147085	UMLS:C3203102	N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide	PULMONARY ARTERIAL HYPERTENSION	Designated	2018-03-01
RIKMMFOAQPJVMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3406	UMLS:C0572025	Fomepizole	Acetaminophen overdose	Designated	2021-03-02
RIKMMFOAQPJVMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3406	UMLS:C0413194	fomepizole	Ethylene glycol poisoning	Designated/Approved	1988-12-22
RIKMMFOAQPJVMX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3406	UMLS:C0413194	fomepizole	Ethylene glycol poisoning	Designated/Approved	1988-12-22
RITAVMQDGBJQJZ-FMIVXFBMSA-N	PUBCHEM.COMPOUND:6450551	UMLS:C0235974	axitinib	PANCREATIC CANCER	Designated/Withdrawn	2007-05-31
RJCWBNBKOKFWNY-IDPLTSGASA-N	PUBCHEM.COMPOUND:71811910	UMLS:C0016719	omaveloxolone	Friedreich's Ataxia	Designated	2017-06-19
RJCWBNBKOKFWNY-IDPLTSGASA-N	PUBCHEM.COMPOUND:71811910	UMLS:C0025202	omaveloxolone	Malignant Melanoma	Designated	2017-09-05
RJKFOVLPORLFTN-LEKSSAKUSA-N	PUBCHEM.COMPOUND:5994	UMLS:C0876926	progesterone	Traumatic Brain Injury	Designated/Withdrawn	2009-09-03
RJKFOVLPORLFTN-LEKSSAKUSA-N	PUBCHEM.COMPOUND:5994	UMLS:C5203917	progesterone	Ocular Graft Versus Host Disease	Designated	2020-06-03
RMDMBHQVNHQDDD-VFWKRBOSSA-L	PUBCHEM.COMPOUND:10287099	UMLS:C0017636	trans sodium crocetinate	Glioblastoma	Designated	2011-07-21
RMDMBHQVNHQDDD-VFWKRBOSSA-L	PUBCHEM.COMPOUND:10287099	UMLS:C0220650	trans sodium crocetinate	brain metastasis	Designated	2012-12-03
RMGPNQKZEPTAOC-QMMMGPOBSA-N	PUBCHEM.COMPOUND:54274194	UMLS:C0027404	4-((L-valyl)oxy)butanoic acid	Narcolepsy	Designated	2019-06-12
RNAICSBVACLLGM-GNAZCLTHSA-N	PUBCHEM.COMPOUND:5909	UMLS:C0022575	Pilocarpine HCl	Keratoconjunctivitis Sicca	Designated/Approved	1992-02-28
RNAICSBVACLLGM-GNAZCLTHSA-N	PUBCHEM.COMPOUND:5909	UMLS:C1527336	Pilocarpine HCl	Sjogren Syndrome	Designated/Approved	1992-02-28
RNAICSBVACLLGM-GNAZCLTHSA-N	PUBCHEM.COMPOUND:5909	UMLS:C0043352	Pilocarpine HCl	Xerostomia	Designated/Approved	1992-02-28
RNBGYGVWRKECFJ-ARQDHWQXSA-N	PUBCHEM.COMPOUND:10267	UMLS:C0002895	Fructose-1,6-diphosphate	Sickle Cell Disease	Designated/Withdrawn	1998-05-29
RNBGYGVWRKECFJ-JGWLITMVSA-N	PUBCHEM.COMPOUND:46937007	UMLS:C0002895	Fructose-1,6-diphosphate	Sickle Cell Disease	Designated/Withdrawn	1998-05-29
RNBGYGVWRKECFJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:718	UMLS:C0002895	Fructose-1,6-diphosphate	Sickle Cell Disease	Designated/Withdrawn	1998-05-29
RNBGYGVWRKECFJ-VRPWFDPXSA-N	PUBCHEM.COMPOUND:172313	UMLS:C0002895	Fructose-1,6-diphosphate	Sickle Cell Disease	Designated/Withdrawn	1998-05-29
RNBGYGVWRKECFJ-ZXXMMSQZSA-N	PUBCHEM.COMPOUND:445557	UMLS:C0002895	Fructose-1,6-diphosphate	Sickle Cell Disease	Designated/Withdrawn	1998-05-29
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C0242647	zanubrutinib	Nodal marginal zone lymphoma	Designated	2020-08-24
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C0024419	Zanubrutinib	Waldenstrom's Macroglobulinemia	Designated	2016-06-29
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C0023434	Zanubrutinib	Chronic Lymphocytic Leukemia	Designated	2016-07-20
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C4721414	zanubrutinib	Mantle cell lymphoma	Designated/Approved	2016-06-23
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C2200312	zanubrutinib	marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated	2020-08-24
RNOAOAWBMHREKO-QFIPXVFZSA-N	PUBCHEM.COMPOUND:135565884	UMLS:C0349632	zanubrutinib	Splenic marginal zone lymphoma	Designated	2020-08-24
RONWGALEIBILOG-VMJVVOMYSA-N	PUBCHEM.COMPOUND:56927704	UMLS:C0024530	quinine Sulfate	Malaria	Designated/Approved	2004-06-03
RONWGALEIBILOG-VMJVVOMYSA-N	PUBCHEM.COMPOUND:56927704	UMLS:C0024530	quinine Sulfate	Malaria	Designated/Approved	2004-06-03
RONWGALEIBILOG-VMJVVOMYSA-N	PUBCHEM.COMPOUND:56927704	UMLS:C0024530	quinine sulfate	Malaria	Designated	2008-12-02
RONWGALEIBILOG-VMJVVOMYSA-N	PUBCHEM.COMPOUND:56927704	UMLS:C0024530	quinine sulfate	Malaria	Designated	2008-12-02
RPPDZANZFFUGHG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46738098	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
RPPDZANZFFUGHG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46738098	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
RPTUSVTUFVMDQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3637	UMLS:C1963138	Hydralazine	Hypertension	Designated	2004-04-09
RPTUSVTUFVMDQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3637	UMLS:C0341950	Hydralazine	Severe Preeclampsia	Designated	2004-04-09
RPTUSVTUFVMDQK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3637	UMLS:C0013537	Hydralazine	Eclampsia	Designated	2004-04-09
RQNWIZPPADIBDY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5359596	UMLS:C0023467	arsenic	Acute myelocytic leukemia	Designated	2001-11-02
RQZAXGRLVPAYTJ-GQFGMJRRSA-N	PUBCHEM.COMPOUND:11683	UMLS:C4084774	Megestrol acetate	Weight loss	Designated/Approved	1988-04-13
RQZAXGRLVPAYTJ-GQFGMJRRSA-N	PUBCHEM.COMPOUND:11683	UMLS:C0001175	Megestrol acetate	AIDS	Designated/Approved	1988-04-13
RQZAXGRLVPAYTJ-GQFGMJRRSA-N	PUBCHEM.COMPOUND:11683	UMLS:C0006625	Megestrol acetate	Cachexia	Designated/Approved	1988-04-13
RSGPTDNHQUJVBP-MDTVQASCSA-N	PUBCHEM.COMPOUND:129629077	UMLS:C0022716	copper histidinate	Menkes disease	Designated	2012-05-14
RSIWALKZYXPAGW-NSHDSACASA-N	PUBCHEM.COMPOUND:58111426	UMLS:C0019829	(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	Hodgkin Lymphoma	Designated	2015-04-29
RSQDGTJKZWTAGL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137321858	UMLS:C0334267	Porfimer sodium	Transitional cell carcinoma in situ	Designated	1989-11-15
RSQDGTJKZWTAGL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137321858	UMLS:C4551642	Porfimer sodium	Carcinoma in situ of the Urinary Bladder	Designated	1989-11-15
RSQDGTJKZWTAGL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137321858	UMLS:C0345967	porfimer sodium	Malignant mesothelioma	Designated	2011-12-02
RSQDGTJKZWTAGL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137321858	UMLS:C0152018	Porfimer sodium	Esophageal carcinoma	Designated/Approved	1989-06-06
RSQDGTJKZWTAGL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137321858	UMLS:C0206698	Porfimer sodium	Cholangiocarcinoma	Designated	2004-11-18
RSQGZEAXODVTOL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23729157	UMLS:C0002736	tirasemtiv	Amyotrophic Lateral Sclerosis	Designated	2010-03-02
RTGDFNSFWBGLEC-SYZQJQIISA-N	PUBCHEM.COMPOUND:5281078	UMLS:C0026896	Mycophenolate mofetil	Myasthenia Gravis	Designated/Withdrawn	2005-12-19
RTGDFNSFWBGLEC-SYZQJQIISA-N	PUBCHEM.COMPOUND:5281078	UMLS:C0030809	Mycophenolate mofetil	Pemphigus Vulgaris	Designated/Withdrawn	2006-05-26
RTHCYVBBDHJXIQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3386	UMLS:C0004352	Fluoxetine	Autism	Designated	1999-04-30
RTHCYVBBDHJXIQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3386	UMLS:C0005887	Fluoxetine	Body dysmorphic disorder	Designated	2004-04-14
RTRQQBHATOEIAF-UUOKFMHZSA-N	PUBCHEM.COMPOUND:17513	UMLS:C0023434	acadesine	Chronic Lymphocytic Leukemia	Designated	2011-03-03
RTRQQBHATOEIAF-UUOKFMHZSA-N	PUBCHEM.COMPOUND:17513	UMLS:C0026764	acadesine	Multiple Myeloma	Designated	2011-05-04
RUDATBOHQWOJDD-BSWAIDMHSA-N	PUBCHEM.COMPOUND:10133	UMLS:C0442893	chenodiol	Systemic disease	Designated/Approved	1984-09-21
RUDATBOHQWOJDD-BSWAIDMHSA-N	PUBCHEM.COMPOUND:10133	UMLS:C0238052	chenodiol	CEREBROTENDINOUS XANTHOMATOSIS	Designated	2010-03-22
RUDATBOHQWOJDD-BSWAIDMHSA-N	PUBCHEM.COMPOUND:10133	UMLS:C0238052	chenodeoxycholic acid	CEREBROTENDINOUS XANTHOMATOSIS	Designated	2007-02-12
RUDATBOHQWOJDD-BSWAIDMHSA-N	PUBCHEM.COMPOUND:10133	UMLS:C0238052	Chenodeoxycholic acid	CEREBROTENDINOUS XANTHOMATOSIS	Designated	2004-01-29
RUDATBOHQWOJDD-UZVSRGJWSA-N	PUBCHEM.COMPOUND:31401	UMLS:C0008312	Ursodiol	Primary Biliary Cirrhosis	Designated/Approved	1991-06-20
RUDATBOHQWOJDD-UZVSRGJWSA-N	PUBCHEM.COMPOUND:31401	UMLS:C2827436	ursodiol	Cystic Fibrosis Liver Disease	Designated	2007-10-23
RUDATBOHQWOJDD-UZVSRGJWSA-N	PUBCHEM.COMPOUND:31401	UMLS:C0008312	Ursodiol	Primary Biliary Cirrhosis	Designated/Withdrawn	1991-02-19
RUPXJRIDSUCQAN-PQNNUJSWSA-N	PUBCHEM.COMPOUND:119058042	UMLS:C0268328	givosiran	Acute hepatic porphyria	Designated/Approved	2016-08-29
RVGRUAULSDPKGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24751	UMLS:C0006434	Poloxamer 188	Burns	Designated	1990-02-22
RVGRUAULSDPKGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24751	UMLS:C2945695	poloxamer 188	Limb ischemia	Designated	2013-11-08
RVGRUAULSDPKGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24751	UMLS:C0038525	Poloxamer 188	Subarachnoid Hemorrhage	Designated	1997-08-05
RVGRUAULSDPKGF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24751	UMLS:C0242084	Poloxamer 188	Ruptured cerebral aneurysm	Designated	1997-08-05
RWHUEXWOYVBUCI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25077649	UMLS:C0342543	Nafarelin acetate	Central Precocious Puberty	Designated/Approved	1988-07-20
RWWYLEGWBNMMLJ-YSOARWBDSA-N	PUBCHEM.COMPOUND:121304016	UMLS:C5203670	remdesivir	COVID-19	Designated/Withdrawn	2020-03-23
RWWYLEGWBNMMLJ-YSOARWBDSA-N	PUBCHEM.COMPOUND:121304016	UMLS:C0282687	Remdesivir	Ebola Virus Disease	Designated	2015-09-18
RXRGZNYSEHTMHC-BQBZGAKWSA-N	PUBCHEM.COMPOUND:454194	UMLS:C0023467	Troxacitabine	Acute myeloid leukemia	Designated/Withdrawn	2005-04-04
RYAYYVTWKAOAJF-QISPRATLSA-N	PUBCHEM.COMPOUND:73297272	UMLS:C0023827	milademetan	liposarcoma	Designated	2017-02-13
RYKKQQUKJJGFMN-HVDRVSQOSA-N	PUBCHEM.COMPOUND:115198	UMLS:C0016667	metadoxine	Fragile X Syndrome	Designated	2013-12-16
RYYVLZVUVIJVGH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2519	UMLS:C0475715	Caffeine	Apnea of prematurity	Designated/Approved	1988-09-20
RZEKVGVHFLEQIL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2662	UMLS:C0263725	Celecoxib	Hemophilic arthropathy	Designated	2020-07-30
RZFNKJVCPDLQQA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2725002	UMLS:C0032326	Quinacrine hydrochloride	Pneumothorax	Designated/Withdrawn	1984-10-17
RZHKDBRREKOZEW-AAXZNHDCSA-N	PUBCHEM.COMPOUND:158782	UMLS:C0027651	Edotreotide	Tumors	Designated	2005-07-28
RZJQGNCSTQAWON-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5090	UMLS:C0263725	rofecoxib	Hemophilic arthropathy	Designated	2017-09-26
RZJQGNCSTQAWON-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5090	UMLS:C3495559	rofecoxib	Juvenile rheumatoid arthritis	Designated	2004-03-16
RZPNFYXFSHGGBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2916	UMLS:C4316899	Phosphocysteamine	Cystinosis	Designated/Withdrawn	1988-09-12
RZRMFQMNPDPAIX-AJTOSFMRSA-N	PUBCHEM.COMPOUND:126961379	UMLS:C0020615	dasiglucagon	Hypoglycemia	Designated	2017-08-10
RZRMFQMNPDPAIX-AJTOSFMRSA-N	PUBCHEM.COMPOUND:126961379	UMLS:C3888018	dasiglucagon	Congenital Hyperinsulinism	Designated	2017-08-10
SCKYRAXSEDYPSA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2749	UMLS:C0162530	Ciclopirox	congenital erythropoietic porphyria	Designated	2018-04-17
SCTJKHUUZLXJIP-RUZDIDTESA-N	PUBCHEM.COMPOUND:23628250	UMLS:C0524909	tenofovir exalidex	chronic hepatitis b	Designated	2018-02-20
SCTJKHUUZLXJIP-RUZDIDTESA-N	PUBCHEM.COMPOUND:23628250	UMLS:C0019163	tenofovir exalidex	Hepatitis B infection	Designated	2018-02-20
SCTZUZTYRMOMKT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:216327	UMLS:C0002895	Bis(4-fluorophenyl)phenylacetamide	Sickle Cell Disease	Designated	2000-03-02
SCVHJVCATBPIHN-SJCJKPOMSA-N	PUBCHEM.COMPOUND:12000240	UMLS:C0745744	emricasan	End Stage Liver Disease	Designated	2013-11-20
SCVHJVCATBPIHN-SJCJKPOMSA-N	PUBCHEM.COMPOUND:12000240	UMLS:C0016059	emricasan	Fibrosis	Designated	2013-11-20
SCVHJVCATBPIHN-SJCJKPOMSA-N	PUBCHEM.COMPOUND:12000240	UMLS:C0023890	emricasan	Cirrhosis	Designated	2013-11-20
SCZVLDHREVKTSH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5280666	UMLS:C0023467	chrysoeriol	Acute myeloid leukemia	Designated	2017-06-22
SDDSJMXGJNWMJY-BRHAQHMBSA-N	PUBCHEM.COMPOUND:16757521	UMLS:C0010674	cobiprostone	Cystic Fibrosis	Designated/Withdrawn	2002-11-14
SDEAXTCZPQIFQM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51039094	UMLS:C0220650	tucatinib	brain metastases	Designated/Approved	2017-06-05
SDEAXTCZPQIFQM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51039094	UMLS:C0678222	tucatinib	Breast cancer	Designated/Approved	2017-06-05
SDEAXTCZPQIFQM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51039094	UMLS:C0009404	tucatinib	Colorectal Cancer	Designated	2017-09-18
SDMBRCRVFFHJKR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:157692	UMLS:C0020445	gemcabene	FAMILIAL HYPERCHOLESTEROLEMIA	Designated	2014-02-06
SDUQYLNIPVEERB-QPPQHZFASA-N	PUBCHEM.COMPOUND:60750	UMLS:C0206698	gemcitabine	Cholangiocarcinoma	Designated	2016-01-11
SDUQYLNIPVEERB-QPPQHZFASA-N	PUBCHEM.COMPOUND:60750	UMLS:C0206698	Gemcitabine	Cholangiocarcinoma	Designated	2020-05-18
SDUQYLNIPVEERB-QPPQHZFASA-N	PUBCHEM.COMPOUND:60750	UMLS:C0007138	gemcitabine	Urothelial carcinoma	Designated	2015-12-30
SECKRCOLJRRGGV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135400189	UMLS:C3203102	vardenafil	PULMONARY ARTERIAL HYPERTENSION	Designated	2019-04-22
SEEPANYCNGTZFQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5215	UMLS:C0085315	Sulfadiazine	toxoplasma gondii encephalitis	Designated/Approved	1994-03-14
SEEPANYCNGTZFQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5215	UMLS:C0001175	Sulfadiazine	AIDS	Designated/Approved	1994-03-14
SELCJVNOEBVTAC-HLDPIHRNSA-N	PUBCHEM.COMPOUND:56935717	UMLS:C4721610	etirinotecan pegol	Ovarian Cancer	Designated	2011-04-18
SELCJVNOEBVTAC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71300725	UMLS:C4721610	etirinotecan pegol	Ovarian Cancer	Designated	2011-04-18
SFNSLLSYNZWZQG-VQIMIIECSA-N	PUBCHEM.COMPOUND:25166913	UMLS:C3463824	glasdegib	MYELODYSPLASTIC SYNDROME	Designated	2017-10-20
SFNSLLSYNZWZQG-VQIMIIECSA-N	PUBCHEM.COMPOUND:25166913	UMLS:C0023467	Glasdegib	Acute myeloid leukemia	Designated/Approved	2017-06-28
SFVLTCAESLKEHH-WKAQUBQDSA-N	PUBCHEM.COMPOUND:11764719	UMLS:C0162670	elamipretide	MITOCHONDRIAL MYOPATHY	Designated	2017-09-05
SFVLTCAESLKEHH-WKAQUBQDSA-N	PUBCHEM.COMPOUND:11764719	UMLS:C3887709	elamipretide	Optic Neuropathy	Designated	2018-04-02
SFVLTCAESLKEHH-WKAQUBQDSA-N	PUBCHEM.COMPOUND:11764719	UMLS:C0574083	elamipretide	Barth Syndrome	Designated	2018-03-22
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0015967	Melphalan	hyperthermic	Designated/Withdrawn	1992-03-03
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0035335	melphalan	Retinoblastoma	Designated	2012-11-19
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0206698	melphalan	Cholangiocarcinoma	Designated	2015-07-14
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0026764	Melphalan	Multiple Myeloma	Designated/Approved	1992-02-24
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0025202	melphalan	melanoma	Designated	2012-11-19
SGDBTWWWUNNDEQ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:460612	UMLS:C0278883	Melphalan	Metastatic melanoma	Designated/Withdrawn	1992-03-03
SGEIEGAXKLMUIZ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:208924	UMLS:C0238190	arimoclomol	INCLUSION BODY MYOSITIS	Designated	2017-11-02
SGEIEGAXKLMUIZ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:208924	UMLS:C0002736	arimoclomol	Amyotrophic Lateral Sclerosis	Designated	2005-03-29
SGEIEGAXKLMUIZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53427024	UMLS:C0002736	arimoclomol	Amyotrophic Lateral Sclerosis	Designated	2005-03-29
SGEIEGAXKLMUIZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53427024	UMLS:C0238190	arimoclomol	INCLUSION BODY MYOSITIS	Designated	2017-11-02
SGEIEGAXKLMUIZ-XUVDNFPMSA-N	PUBCHEM.COMPOUND:9568077	UMLS:C0238190	arimoclomol	INCLUSION BODY MYOSITIS	Designated	2017-11-02
SGEIEGAXKLMUIZ-XUVDNFPMSA-N	PUBCHEM.COMPOUND:9568077	UMLS:C0002736	arimoclomol	Amyotrophic Lateral Sclerosis	Designated	2005-03-29
SGEIEGAXKLMUIZ-YZGLPLCXSA-N	PUBCHEM.COMPOUND:92461203	UMLS:C0238190	arimoclomol	INCLUSION BODY MYOSITIS	Designated	2017-11-02
SGEIEGAXKLMUIZ-YZGLPLCXSA-N	PUBCHEM.COMPOUND:92461203	UMLS:C0002736	arimoclomol	Amyotrophic Lateral Sclerosis	Designated	2005-03-29
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N	PUBCHEM.COMPOUND:6507255	UMLS:C0238190	arimoclomol	INCLUSION BODY MYOSITIS	Designated	2017-11-02
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N	PUBCHEM.COMPOUND:6507255	UMLS:C0002736	arimoclomol	Amyotrophic Lateral Sclerosis	Designated	2005-03-29
SGMZJAMFUVOLNK-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6209	UMLS:C0008370	Choline chloride	Cholestasis	Designated	1994-02-10
SGMZJAMFUVOLNK-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6209	UMLS:C0008412	Choline chloride	Choline Deficiency	Designated	2006-07-20
SGMZJAMFUVOLNK-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6209	UMLS:C2711227	Choline chloride	Hepatic steatosis	Designated	1994-02-10
SGMZJAMFUVOLNK-UHFFFAOYSA-M	PUBCHEM.COMPOUND:6209	UMLS:C0008412	Choline chloride	Choline Deficiency	Designated	1994-02-10
SGOIRFVFHAKUTI-ZCFIWIBFSA-N	PUBCHEM.COMPOUND:464205	UMLS:C0019693	tenofovir	HIV infection	Designated/Approved	2009-03-17
SGOOQMRIPALTEL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54676478	UMLS:C0023418	Roquinimex	leukemia	Designated/Withdrawn	1993-07-01
SHGAZHPCJJPHSC-XFYACQKRSA-N	PUBCHEM.COMPOUND:5282379	UMLS:C0079154	isotretinoin	congenital ichthyosis	Designated	2014-04-10
SHGAZHPCJJPHSC-YCNIQYBTSA-N	PUBCHEM.COMPOUND:444795	UMLS:C0023487	Tretinoin	Acute Promyelocytic Leukemia	Designated/Approved	1990-10-24
SHGAZHPCJJPHSC-YCNIQYBTSA-N	PUBCHEM.COMPOUND:444795	UMLS:C1279296	Tretinoin	Chronic leukemia	Designated	1993-01-14
SHGAZHPCJJPHSC-YCNIQYBTSA-N	PUBCHEM.COMPOUND:444795	UMLS:C0079772	Tretinoin	T-cell non-Hodgkin's lymphoma	Designated	2003-04-11
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	PUBCHEM.COMPOUND:449171	UMLS:C0344290	9-cis-retinoic acid	Vitreoretinopathy	Designated/Withdrawn	1997-01-02
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	PUBCHEM.COMPOUND:449171	UMLS:C0023487	Alitretinoin	Acute Promyelocytic Leukemia	Designated	1992-04-10
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	PUBCHEM.COMPOUND:449171	UMLS:C0036220	alitretinoin	Kaposi Sarcoma	Designated	2021-01-12
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	PUBCHEM.COMPOUND:449171	UMLS:C0276535	Alitretinoin	AIDS-related Kaposi's sarcoma	Designated/Approved	1998-03-24
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	PUBCHEM.COMPOUND:449171	UMLS:C0035305	9-cis-retinoic acid	Retinal Detachment	Designated/Withdrawn	1997-01-02
SHZGCJCMOBCMKK-DHVFOXMCSA-N	PUBCHEM.COMPOUND:17106	UMLS:C0282577	L-fucose	Congenital disorder of glycosylation	Designated	2019-01-14
SHZGCJCMOBCMKK-DHVFOXMCSA-N	PUBCHEM.COMPOUND:17106	UMLS:C0272187	L-fucose	Leukocyte adhesion deficiency	Designated	2020-06-08
SIEYLFHKZGLBNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64737	UMLS:C0032768	bupivacaine hydrochloride	Postherpetic neuralgia	Designated	2016-05-31
SIEYLFHKZGLBNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64737	UMLS:C0030193	bupivacaine hydrochloride	Pain	Designated	2016-05-31
SJHNWSAWWOAWJH-MRXNPFEDSA-N	PUBCHEM.COMPOUND:118224491	UMLS:C0023467	(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide	Acute myeloid leukemia	Designated	2021-04-05
SJUWEPZBTXEUMU-CTHHTMFSSA-N	PUBCHEM.COMPOUND:132470909	UMLS:C0013264	halofuginone hydrobromide	DUCHENNE MUSCULAR DYSTROPHY	Designated	2011-10-13
SJUWEPZBTXEUMU-LDXVYITESA-N	PUBCHEM.COMPOUND:400771	UMLS:C0013264	halofuginone hydrobromide	DUCHENNE MUSCULAR DYSTROPHY	Designated	2011-10-13
SJUWEPZBTXEUMU-LIOBNPLQSA-N	PUBCHEM.COMPOUND:11591339	UMLS:C0013264	halofuginone hydrobromide	DUCHENNE MUSCULAR DYSTROPHY	Designated	2011-10-13
SJUWEPZBTXEUMU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62893	UMLS:C0013264	halofuginone hydrobromide	DUCHENNE MUSCULAR DYSTROPHY	Designated	2011-10-13
SJVQHLPISAIATJ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:50905713	UMLS:C0023434	duvelisib	Chronic Lymphocytic Leukemia	Designated/Approved	2013-04-15
SJVQHLPISAIATJ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:50905713	UMLS:C0855095	duvelisib	Small Lymphocytic Lymphoma	Designated/Approved	2013-04-15
SJVQHLPISAIATJ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:50905713	UMLS:C0024301	duvelisib	follicular lymphoma	Designated/Approved	2013-08-01
SJVQHLPISAIATJ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:50905713	UMLS:C0079772	duvelisib	T-Cell Lymphoma	Designated	2019-10-02
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0751757	Gamma-hydroxybutyric acid	Idiopathic Hypersomnia	Designated	2019-07-31
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C1457887	Gamma-hydroxybutyric acid	Symptoms	Designated/Withdrawn	1985-01-22
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0233773	Gamma-hydroxybutyric acid	Hypnagogic hallucinations	Designated/Withdrawn	1985-01-22
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0027404	Gamma-hydroxybutyric acid	Narcolepsy	Designated/Withdrawn	1985-01-22
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0456511	Gamma-hydroxybutyric acid	Sleep Paralysis	Designated/Withdrawn	1985-01-22
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0456511	Gamma hydroxybutyrate	Sleep Paralysis	Designated	1987-12-03
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0233773	Gamma hydroxybutyrate	Hypnagogic hallucinations	Designated	1987-12-03
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0027404	Gamma hydroxybutyrate	Narcolepsy	Designated	1987-12-03
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0007384	Gamma hydroxybutyrate	Cataplexy	Designated	1987-12-03
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C1457887	Gamma hydroxybutyrate	Symptoms	Designated	1987-12-03
SJZRECIVHVDYJC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10413	UMLS:C0007384	Gamma-hydroxybutyric acid	Cataplexy	Designated/Withdrawn	1985-01-22
SKDNPCDRIUQGAL-XTJCVSPVSA-N	PUBCHEM.COMPOUND:89584363	UMLS:C0282529	1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	Rhizomelic chondrodysplasia punctata	Designated	2019-08-08
SKYZYDSNJIOXRL-BTQNPOSSSA-M	PUBCHEM.COMPOUND:44358405	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
SKYZYDSNJIOXRL-BTQNPOSSSA-M	PUBCHEM.COMPOUND:44358405	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
SKYZYDSNJIOXRL-BTQNPOSSSA-M	PUBCHEM.COMPOUND:44358405	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
SKYZYDSNJIOXRL-BTQNPOSSSA-N	PUBCHEM.COMPOUND:9410	UMLS:C0030567	Apomorphine HCl	Parkinson's Disease	Designated/Approved	1993-04-22
SKYZYDSNJIOXRL-BTQNPOSSSA-N	PUBCHEM.COMPOUND:9410	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
SKYZYDSNJIOXRL-BTQNPOSSSA-N	PUBCHEM.COMPOUND:9410	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
SKYZYDSNJIOXRL-BTQNPOSSSA-N	PUBCHEM.COMPOUND:9410	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
SLVOKEOPLJCHCQ-SEYXRHQNSA-N	PUBCHEM.COMPOUND:9932595	UMLS:C0023281	oleylphosphocholine	Leishmaniasis	Designated	2013-10-25
SLVOKEOPLJCHCQ-UHFFFAOYSA-O	PUBCHEM.COMPOUND:6710777	UMLS:C0023281	oleylphosphocholine	Leishmaniasis	Designated	2013-10-25
SLXKOJJOQWFEFD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:564	UMLS:C0339335	Aminocaproic acid	Traumatic hyphema	Designated	1995-01-06
SMANXXCATUTDDT-QPJJXVBHSA-N	PUBCHEM.COMPOUND:941361	UMLS:C0018991	flunarizine	Hemiplegia	Designated/Withdrawn	2013-06-24
SMANXXCATUTDDT-QPJJXVBHSA-N	PUBCHEM.COMPOUND:941361	UMLS:C0018991	flunarizine	Hemiplegia	Designated	1986-01-06
SMANXXCATUTDDT-QPJJXVBHSA-N	PUBCHEM.COMPOUND:941361	UMLS:C0338488	flunarizine	Alternating hemiplegia	Designated	2018-11-20
SMANXXCATUTDDT-QPJJXVBHSA-N	PUBCHEM.COMPOUND:941361	UMLS:C0270862	flunarizine	Hemiplegic migraine	Designated	2016-07-20
SONNWYBIRXJNDC-VIFPVBQESA-N	PUBCHEM.COMPOUND:6041	UMLS:C0015732	phenylephrine	Fecal Incontinence	Designated	2002-02-14
SONNWYBIRXJNDC-VIFPVBQESA-N	PUBCHEM.COMPOUND:6041	UMLS:C0039685	phenylephrine	Tetralogy of Fallot	Designated	2012-01-31
SOVUOXKZCCAWOJ-HJYUBDRYSA-N	PUBCHEM.COMPOUND:54686904	UMLS:C0023467	tigecycline	Acute myeloid leukemia	Designated	2013-10-23
SPCMQFLNOVTUBM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60150609	UMLS:C0338451	hydromethylthionine mesylate	Frontotemporal dementia	Designated	2018-11-20
SQXUKOJKIWCALK-PKLMIRHRSA-N	PUBCHEM.COMPOUND:78425810	UMLS:C0268274	venglustat malate	GM2 Gangliosidosis	Designated	2020-08-13
SSJGXNSABQPEKM-SBUIBGKBSA-N	PUBCHEM.COMPOUND:56841989	UMLS:C2239176	peptide YY	HEPATOCELLULAR CARCINOMA	Designated	2011-04-18
SSNHGLKFJISNTR-FWUPRJFYSA-N	PUBCHEM.COMPOUND:44148067	UMLS:C0458219	delta-9-tetrahydrocannabinol and cannabidiol	Complex regional pain syndrome	Designated	2018-03-07
SSNHGLKFJISNTR-FWUPRJFYSA-N	PUBCHEM.COMPOUND:44148067	UMLS:C0014527	delta-9-tetrahydrocannabinol and cannabidiol	Epidermolysis Bullosa	Designated	2020-04-14
SSNHGLKFJISNTR-FWUPRJFYSA-N	PUBCHEM.COMPOUND:44148067	UMLS:C0020179	delta-9-tetrahydrocannabinol and cannabidiol	Huntington's Disease	Designated	2019-01-29
SSQJFGMEZBFMNV-PMACEKPBSA-N	PUBCHEM.COMPOUND:107778	UMLS:C0876926	dexanabinol	Traumatic Brain Injury	Designated	2004-08-11
SSQJFGMEZBFMNV-PMACEKPBSA-N	PUBCHEM.COMPOUND:107778	UMLS:C0543419	dexanabinol	Sequelae	Designated	2004-08-11
SSQPWTVBQMWLSZ-AAQCHOMXSA-N	PUBCHEM.COMPOUND:9831415	UMLS:C0020179	Ethyl eicosapentaenoate	Huntington's Disease	Designated	2000-04-06
STJMRWALKKWQGH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2783	UMLS:C0342751	Clenbuterol	Pompe disease	Designated	2017-01-09
STJMRWALKKWQGH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2783	UMLS:C0017921	Clenbuterol	Pompe Disease	Designated	2017-01-09
STJMRWALKKWQGH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2783	UMLS:C0002736	clenbuterol	Amyotrophic Lateral Sclerosis	Designated	2018-10-02
STJMRWALKKWQGH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2783	UMLS:C0017921	clenbuterol	Pompe Disease	Designated	2014-10-27
STPKWKPURVSAJF-LJEWAXOPSA-N	PUBCHEM.COMPOUND:9831643	UMLS:C0005411	maralixibat	Biliary Atresia	Designated	2020-10-21
STPKWKPURVSAJF-LJEWAXOPSA-N	PUBCHEM.COMPOUND:9831643	UMLS:C0085280	maralixibat	Alagille Syndrome	Designated	2013-09-04
STPKWKPURVSAJF-LJEWAXOPSA-N	PUBCHEM.COMPOUND:9831643	UMLS:C4551898	maralixibat	Progressive familial intrahepatic cholestasis	Designated	2013-09-04
STUWGJZDJHPWGZ-LBPRGKRZSA-N	PUBCHEM.COMPOUND:56649450	UMLS:C1849265	alpelisib	Overgrowth	Designated	2019-11-18
STWTUEAWRAIWJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565042	UMLS:C0026847	branaplam	Spinal Muscular Atrophy	Designated	2018-01-23
STWTUEAWRAIWJG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135565042	UMLS:C0020179	Branaplam	huntingtons disease	Designated	2020-10-19
STWVLEKJQQRGMO-GUYCJALGSA-N	PUBCHEM.COMPOUND:126642132	UMLS:C0036202	5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine	Sarcoidosis	Designated	2020-01-14
STWVLEKJQQRGMO-GUYCJALGSA-N	PUBCHEM.COMPOUND:126642132	UMLS:C1800706	5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine	Idiopathic Pulmonary Fibrosis	Designated	2019-02-25
SUBDBMMJDZJVOS-DEOSSOPVSA-N	PUBCHEM.COMPOUND:9568614	UMLS:C0341106	esomeprazole	Eosinophilic esophagitis	Designated	2019-05-15
SUBDBMMJDZJVOS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4594	UMLS:C0341106	esomeprazole	Eosinophilic esophagitis	Designated	2019-05-15
SUBDBMMJDZJVOS-XMMPIXPASA-N	PUBCHEM.COMPOUND:9579578	UMLS:C0341106	esomeprazole	Eosinophilic esophagitis	Designated	2019-05-15
SUFPWYYDCOKDLL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91885568	UMLS:C0238013	olorofim	Invasive aspergillosis	Designated	2020-01-16
SUFPWYYDCOKDLL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91885568	UMLS:C0009186	olorofim	Coccidioidomycosis	Designated	2020-03-11
SVOQIEJWJCQGDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135449332	UMLS:C0002874	eltrombopag	Aplastic Anemia	Designated/Approved	2013-11-08
SVOQIEJWJCQGDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135449332	UMLS:C0002874	eltrombopag	Aplastic Anemia	Designated/Approved	2013-11-08
SVOQIEJWJCQGDQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135449332	UMLS:C0398650	eltrombopag	Idiopathic thrombocytopenia purpura	Designated/Approved	2008-05-05
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0041228	Pafuramidine maleate	African Trypanosomiasis	Designated	2007-08-31
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C1535939	pafuramidine maleate	Pneumocystis jiroveci pneumonia	Designated	2006-11-17
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C1535939	pafuramidine maleate	Pneumocystis jiroveci pneumonia	Designated	2006-11-17
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C1535939	pafuramidine maleate	Pneumocystis jiroveci pneumonia	Designated	2006-11-17
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0041228	Pafuramidine maleate	African Trypanosomiasis	Designated	2007-08-31
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0024530	Pafuramidine maleate	Malaria	Designated	2007-05-14
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0024530	Pafuramidine maleate	Malaria	Designated	2007-05-14
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0024530	Pafuramidine maleate	Malaria	Designated	2007-05-14
SWMNGXODFOCPKQ-BTJKTKAUSA-N	PUBCHEM.COMPOUND:154731101	UMLS:C0041228	Pafuramidine maleate	African Trypanosomiasis	Designated	2007-08-31
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-CISAEKETSA-N	PUBCHEM.COMPOUND:133566183	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-DLRASJFKSA-N	PUBCHEM.COMPOUND:45588099	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-DOUNNPEJSA-N	PUBCHEM.COMPOUND:6918026	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-HFQRKYADSA-N	PUBCHEM.COMPOUND:5311370	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWXOGPJRIDTIRL-KTJGOPLGSA-N	PUBCHEM.COMPOUND:70689318	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0001206	vapreotide	Acromegaly	Designated	2003-11-04
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0020541	vapreotide	Portal Hypertension	Designated	2000-01-10
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0030290	vapreotide	Pancreatic Fistulas	Designated	2000-01-10
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0007095	Vapreotide	Carcinoid Tumors	Designated	2004-04-06
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0333106	vapreotide	variceal hemorrhage	Designated	2000-01-10
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0014852	vapreotide	ESOPHAGEAL	Designated	2000-01-10
SWXOGPJRIDTIRL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71306	UMLS:C0032787	vapreotide	Postoperative Complications	Designated	2000-03-06
SWZXEVABPLUDIO-WSZYKNRRSA-N	PUBCHEM.COMPOUND:25067547	UMLS:C0026764	oprozomib	Multiple Myeloma	Designated	2014-10-28
SWZXEVABPLUDIO-WSZYKNRRSA-N	PUBCHEM.COMPOUND:25067547	UMLS:C0024419	oprozomib	Waldenstrom's Macroglobulinemia	Designated	2014-08-25
SXNJFOWDRLKDSF-XKHVUIRMSA-N	PUBCHEM.COMPOUND:10461508	UMLS:C0023467	volasertib	Acute myeloid leukemia	Designated/Withdrawn	2014-04-14
SXNJFOWDRLKDSF-XKHVUIRMSA-N	PUBCHEM.COMPOUND:10461508	UMLS:C1261473	Volasertib	Soft tissue sarcoma	Designated	2020-10-08
SZFPYBIJACMNJV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:148177	UMLS:C0027819	perifosine	Neuroblastoma	Designated/Withdrawn	2010-07-09
SZFPYBIJACMNJV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:148177	UMLS:C0026764	perifosine	Multiple Myeloma	Designated/Withdrawn	2009-09-03
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IAAJYNJHSA-N	PUBCHEM.COMPOUND:45375806	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IECBXEDQSA-N	PUBCHEM.COMPOUND:129010435	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-IQWMDFIBSA-N	PUBCHEM.COMPOUND:45375808	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-KVOQBTHKSA-N	PUBCHEM.COMPOUND:72699160	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-LVPOHEQUSA-N	PUBCHEM.COMPOUND:73425384	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0019196	sofosbuvir	Hepatitis C Virus Infection	Designated/Approved	2016-10-25
TTZHDVOVKQGIBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:91302628	UMLS:C0524910	sofosbuvir	chronic hepatitis c	Designated/Approved	2016-10-25
TTZSNFLLYPYKIL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:52920501	UMLS:C0206754	surufatinib	Neuroendocrine Tumors	Designated	2019-11-21
TUMIEHFYGNUNBB-JJUQEKPGSA-L	PUBCHEM.COMPOUND:71774773	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
TUMIEHFYGNUNBB-JJUQEKPGSA-L	PUBCHEM.COMPOUND:71774773	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
TVTXCJFHQKSQQM-LJQIRTBHSA-N	PUBCHEM.COMPOUND:53358942	UMLS:C0032463	idasanutlin	Polycythemia Vera	Designated/Withdrawn	2017-11-29
TXCWBWKVIZGWEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25024769	UMLS:C0024623	masitinib mesylate	Gastric Cancer	Designated	2015-09-14
TXCWBWKVIZGWEQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25024769	UMLS:C0002736	masitinib mesylate	Amyotrophic Lateral Sclerosis	Designated	2015-03-18
TXEIIPDJKFWEEC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11001318	UMLS:C0206245	tafamidis	Familial Amyloid Polyneuropathy	Designated	2006-05-23
TXGZJQLMVSIZEI-UQMAOPSPSA-N	PUBCHEM.COMPOUND:400010	UMLS:C3203102	bardoxolone	PULMONARY ARTERIAL HYPERTENSION	Designated	2015-03-30
TXGZJQLMVSIZEI-UQMAOPSPSA-N	PUBCHEM.COMPOUND:400010	UMLS:C0235974	Bardoxolone	PANCREATIC CANCER	Designated	2008-08-06
TYNLGDBUJLVSMA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:26248	UMLS:C0014527	Diacerein	Epidermolysis Bullosa	Designated	2018-11-02
TYNLGDBUJLVSMA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:26248	UMLS:C0014527	diacerein	Epidermolysis Bullosa	Designated	2014-10-15
TZDUHAJSIBHXDL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9883933	UMLS:C0032768	gabapentin enacarbil	Postherpetic neuralgia	Designated/Approved	2011-06-07
TZKBVRDEOITLRB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51038269	UMLS:C0023473	olverembatinib	Chronic myeloid leukemia	Designated	2020-04-22
TZOWVYPYWJLZTK-IMTBSYHQSA-N	PUBCHEM.COMPOUND:57524523	UMLS:C3887898	1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	Infantile spasms	Designated	2017-03-20
TZOWVYPYWJLZTK-IMTBSYHQSA-N	PUBCHEM.COMPOUND:57524523	UMLS:C0038220	1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane	Status Epilepticus	Designated	2016-07-07
TZRFSLHOCZEXCC-HIVFKXHNSA-A	PUBCHEM.COMPOUND:71301230	UMLS:C0020445	mipomersen	FAMILIAL HYPERCHOLESTEROLEMIA	Designated/Approved	2006-05-23
TZSZZENYCISATO-WIOPSUGQSA-N	PUBCHEM.COMPOUND:92045025	UMLS:C3203102	rodatristat ethyl	PULMONARY ARTERIAL HYPERTENSION	Designated	2015-10-06
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0282193	deferiprone	Iron Overload	Designated/Approved	2001-12-12
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0016719	deferiprone	Friedreich's Ataxia	Designated	2008-07-31
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0018939	deferiprone	Hematologic Disorders	Designated/Approved	2001-12-12
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0282193	deferiprone	Iron Overload	Designated/Approved	2001-12-12
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0037061	deferiprone	Siderosis	Designated	2011-09-01
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C0018939	deferiprone	Hematologic Disorders	Designated/Approved	2001-12-12
TZXKOCQBRNJULO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2972	UMLS:C5194180	deferiprone	Iron accumulation	Designated	2017-06-15
UAHFGYDRQSXQEB-LEBBXHLNSA-N	PUBCHEM.COMPOUND:16197727	UMLS:C0085106	afamelanotide	Familial Benign Chronic Pemphigus	Designated	2014-05-14
UAHFGYDRQSXQEB-LEBBXHLNSA-N	PUBCHEM.COMPOUND:16197727	UMLS:C0263610	afamelanotide	Solar urticaria	Designated	2009-12-11
UAHFGYDRQSXQEB-LEBBXHLNSA-N	PUBCHEM.COMPOUND:16197727	UMLS:C0032708	afamelanotide	Porphyria	Designated	2016-02-04
UAHFGYDRQSXQEB-LEBBXHLNSA-N	PUBCHEM.COMPOUND:16197727	UMLS:C0162530	afamelanotide	Erythropoietic Porphyrias	Designated/Approved	2008-07-17
UAIXRPCCYXNJMQ-RZIPZOSSSA-N	PUBCHEM.COMPOUND:45265653	UMLS:C0524662	Buprenorphine hydrochloride	Opiate Addiction	Designated/Withdrawn	1994-06-15
UAIXRPCCYXNJMQ-RZIPZOSSSA-N	PUBCHEM.COMPOUND:45265653	UMLS:C0524662	Buprenorphine hydrochloride	Opiate Addiction	Designated/Withdrawn	1994-06-15
UAIXRPCCYXNJMQ-RZIPZOSSSA-N	PUBCHEM.COMPOUND:45265653	UMLS:C0524662	Buprenorphine hydrochloride	Opiate Addiction	Designated/Withdrawn	1994-06-15
UAIXRPCCYXNJMQ-RZIPZOSSSA-N	PUBCHEM.COMPOUND:45265653	UMLS:C0524662	Buprenorphine hydrochloride	Opiate Addiction	Designated/Withdrawn	1994-06-15
UANPKWBWEAQNQY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:136040192	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
UBPYILGKFZZVDX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5328940	UMLS:C0023473	bosutinib	Chronic myelogenous leukemia	Designated/Approved	2009-02-24
UBPYILGKFZZVDX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5328940	UMLS:C0023473	bosutinib	Chronic myelogenous leukemia	Designated/Approved	2009-02-24
UBQYURCVBFRUQT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2973	UMLS:C0023223	deferoxamine	Leg Ulcers	Designated	2019-03-15
UCEQXRCJXIVODC-PMACEKPBSA-N	PUBCHEM.COMPOUND:11494412	UMLS:C2239176	tivantinib	HEPATOCELLULAR CARCINOMA	Designated/Withdrawn	2013-10-16
UCTRAOBQFUDCSR-SECBINFHSA-N	PUBCHEM.COMPOUND:10130337	UMLS:C0027404	Solriamfetol	Narcolepsy	Designated/Approved	2012-08-20
UDKVBVICMUEIKS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6239	UMLS:C0032326	Quinacrine hydrochloride	Pneumothorax	Designated/Withdrawn	1984-10-17
UEAYTGFTNACKMX-VMXHOPILSA-N	PUBCHEM.COMPOUND:9872764	UMLS:C0036220	H-Leu-Pro-Pro-Ser-Arg-OH	Kaposi Sarcoma	Designated	2012-09-20
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0006826	Thalidomide	MALIGNANCIES	Designated	1998-02-27
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0036220	Thalidomide	Kaposi's Sarcoma	Designated	1998-07-29
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0010346	Thalidomide	Crohn's Disease	Designated	1999-04-06
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0019682	Thalidomide	HIV	Designated	1996-03-11
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0026764	Thalidomide	Multiple Myeloma	Designated/Approved	1998-10-14
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0041296	Thalidomide	Infection caused by Mycobacterium tuberculosis	Designated	1993-01-12
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0026918	Thalidomide	Mycobacterial infection	Designated	1993-01-12
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0343467	Thalidomide	Erythema nodosum leprosum	Designated/Approved	1995-07-26
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0018133	Thalidomide	GRAFT VERSUS HOST DISEASE	Designated	1990-03-05
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C3463824	thalidomide	MYELODYSPLASTIC SYNDROME	Designated	2004-09-27
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0018133	Thalidomide	GRAFT VERSUS HOST DISEASE	Designated	1990-03-05
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0018133	thalidomide	GRAFT VERSUS HOST DISEASE	Designated	1988-09-19
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C2937365	Thalidomide	Recurrent aphthous ulcers	Designated	1995-05-15
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0039445	thalidomide	hereditary hemorrhagic telangiectasia	Designated	2017-07-19
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C0023348	Thalidomide	Lepromatous leprosy	Designated	1988-11-15
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C2937365	Thalidomide	Recurrent aphthous stomatitis	Designated	1995-05-01
UEJJHQNACJXSKW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5426	UMLS:C1265234	Thalidomide	Non-Tuberculous Mycobacteria	Designated	1993-01-12
UFBJCMHMOXMLKC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1493	UMLS:C0002736	2,4 dinitrophenol	Amyotrophic Lateral Sclerosis	Designated	2020-09-08
UFBJCMHMOXMLKC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1493	UMLS:C0020179	2,4-dinitrophenol	Huntington Disease	Designated	2019-02-11
UFPFGVNKHCLJJO-SSKFGXFMSA-N	PUBCHEM.COMPOUND:24737642	UMLS:C0026764	(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide	Multiple Myeloma	Designated	2017-06-28
UFSKUSARDNFIRC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16678941	UMLS:C0038525	Lumacaftor	Subarachnoid Hemorrhage	Designated	2020-09-09
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0020179	cysteamine	Huntington's Disease	Designated	2008-05-09
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0751383	cysteamine	Batten Disease	Designated	2008-08-06
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0015624	Cysteamine	Nephropathic cystinosis	Designated	1986-05-01
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0027877	cysteamine	neuronal ceroid lipofuscinoses	Designated	2008-08-06
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0010674	Cysteamine	Cystic Fibrosis	Designated	2014-09-11
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0015624	Cysteamine	Nephropathic cystinosis	Designated/Approved	1991-01-25
UFULAYFCSOUIOV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:6058	UMLS:C0235974	cysteamine	PANCREATIC CANCER	Designated	2013-09-11
UGFAIRIUMAVXCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:281	UMLS:C1800706	carbon monoxide	Idiopathic Pulmonary Fibrosis	Designated	2016-08-16
UGFAIRIUMAVXCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:281	UMLS:C0034069	carbon monoxide	IPF	Designated	2016-08-16
UGFAIRIUMAVXCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:281	UMLS:C0002895	carbon monoxide	Sickle Cell Disease	Designated	2012-09-28
UGFAIRIUMAVXCW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:281	UMLS:C0948031	carbon monoxide	Primary Graft Dysfunction	Designated	2020-04-14
UGFHIPBXIWJXNA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60652	UMLS:C0079154	liarozole	congenital ichthyosis	Designated/Withdrawn	2004-06-18
UGJMXCAKCUNAIE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3446	UMLS:C0032768	gabapentin	Postherpetic neuralgia	Designated/Approved	2010-11-08
UGJMXCAKCUNAIE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3446	UMLS:C0002736	gabapentin	Amyotrophic Lateral Sclerosis	Designated	1995-07-05
UGPMCIBIHRSCBV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:45382195	UMLS:C0339296	thymosin beta 4	Neurotrophic keratopathy	Designated	2013-12-31
UGPMCIBIHRSCBV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:45382195	UMLS:C0014527	Thymosin beta 4	Epidermolysis Bullosa	Designated	2004-05-28
UHTHHESEBZOYNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081361	UMLS:C0206682	vandetanib	Follicular thyroid carcinoma	Designated/Approved	2005-10-21
UHTHHESEBZOYNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081361	UMLS:C0238461	vandetanib	Carcinoma	Designated/Approved	2005-10-21
UHTHHESEBZOYNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081361	UMLS:C0238462	vandetanib	Anaplastic Thyroid	Designated/Approved	2005-10-21
UHTHHESEBZOYNR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3081361	UMLS:C0278851	vandetanib	Thyroid carcinoma	Designated/Approved	2005-10-21
UHWVSEOVJBQKBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21109	UMLS:C3203102	trimetazidine	PULMONARY ARTERIAL HYPERTENSION	Designated	2018-08-07
UHWVSEOVJBQKBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21109	UMLS:C3850141	Trimetazidine	Acute-On-Chronic Liver Failure	Designated	2018-03-15
UHWVSEOVJBQKBE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21109	UMLS:C0007193	trimetazidine	Dilated cardiomyopathy	Designated	2018-10-30
UIAGMCDKSXEBJQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4497	UMLS:C0038525	nimodipine	Subarachnoid Hemorrhage	Designated/Approved	2011-09-16
UIARLYUEJFELEN-LROUJFHJSA-N	PUBCHEM.COMPOUND:126565	UMLS:C0027022	lestaurtinib	Myeloproliferative Disorders	Designated	2009-09-03
UIARLYUEJFELEN-LROUJFHJSA-N	PUBCHEM.COMPOUND:126565	UMLS:C0023467	lestaurtinib	Acute myeloid leukemia	Designated	2006-03-24
UIBPZXXSPHGPDS-UXLZJAPBSA-N	PUBCHEM.COMPOUND:71587612	UMLS:C0010674	D-peptide of the sequence AKRHHGYKRKFH - NH2	Cystic Fibrosis	Designated	2002-10-23
UJCHIZDEQZMODR-BYPYZUCNSA-N	PUBCHEM.COMPOUND:10176265	UMLS:C0035334	N-acetyl cysteine amide	Retinitis Pigmentosa	Designated	2013-12-31
UJYFZCVPOSZDMK-YPPDDXJESA-L	PUBCHEM.COMPOUND:121000421	UMLS:C0008312	saroglitazar magnesium	Primary Biliary Cholangitis	Designated	2021-01-26
UKLNMMHNWFDKNT-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23668197	UMLS:C0002736	sodium chlorite	Amyotrophic Lateral Sclerosis	Designated	2011-08-22
UKUYYHVRVSDDQG-UBXFZUKZSA-N	PUBCHEM.COMPOUND:86566352	UMLS:C0043346	Pro-Pro-Thr-Val-Pro-Thr-Arg	Xeroderma Pigmentosum	Designated	2017-07-27
UKZANTJXIMWQCH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5351141	UMLS:C0032326	Quinacrine hydrochloride	Pneumothorax	Designated/Withdrawn	1984-10-17
ULBPPCHRAVUQMC-AWUBODBRSA-N	PUBCHEM.COMPOUND:56841032	UMLS:C0017205	isofagomine tartrate	Gaucher Disease	Designated/Withdrawn	2006-01-10
ULBPPCHRAVUQMC-MUMXBIPUSA-N	PUBCHEM.COMPOUND:23581846	UMLS:C0017205	isofagomine tartrate	Gaucher Disease	Designated/Withdrawn	2006-01-10
ULBPPCHRAVUQMC-RWOHWRPJSA-N	PUBCHEM.COMPOUND:70697642	UMLS:C0017205	isofagomine tartrate	Gaucher Disease	Designated/Withdrawn	2006-01-10
ULRUOUDIQPERIJ-PQURJYPBSA-N	PUBCHEM.COMPOUND:91668186	UMLS:C0555198	sacituzumab govitecan	Malignant Glioma	Designated	2020-10-08
ULRUOUDIQPERIJ-PQURJYPBSA-N	PUBCHEM.COMPOUND:91668186	UMLS:C0235974	sacituzumab govitecan	PANCREATIC CANCER	Designated	2014-05-29
ULRUOUDIQPERIJ-PQURJYPBSA-N	PUBCHEM.COMPOUND:91668186	UMLS:C3540630	sacituzumab govitecan	Small Cell Lung Cancer	Designated	2013-11-27
ULXXDDBFHOBEHA-CWDCEQMOSA-N	PUBCHEM.COMPOUND:10184653	UMLS:C0235974	afatinib	PANCREATIC CANCER	Designated	2019-07-09
ULXXDDBFHOBEHA-CWDCEQMOSA-N	PUBCHEM.COMPOUND:10184653	UMLS:C0085136	afatinib	central nervous system tumors	Designated	2014-06-04
ULXXDDBFHOBEHA-CWDCEQMOSA-N	PUBCHEM.COMPOUND:10184653	UMLS:C0007131	afatinib	Non-Small Cell Lung Cancer	Designated/Approved	2012-12-03
ULXXDDBFHOBEHA-CWDCEQMOSA-N	PUBCHEM.COMPOUND:10184653	UMLS:C0007131	afatinib	Non-Small Cell Lung Cancer	Designated/Approved	2012-12-03
ULXXDDBFHOBEHA-CWDCEQMOSA-N	PUBCHEM.COMPOUND:10184653	UMLS:C0007131	afatinib	non-small cell lung cancer	Designated/Approved	2015-08-03
UOKSXAOZBSWROR-DOELHFPHSA-N	PUBCHEM.COMPOUND:146048056	UMLS:C0235974	(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate	PANCREATIC CANCER	Designated	2019-08-26
UOMKBIIXHQIERR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:38072	UMLS:C0476089	cridanimod	Endometrial Cancer	Designated	2011-01-12
UOWZUVNAGUAEQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5803	UMLS:C1337013	Tiratricol	Well-Differentiated Thyroid Cancer	Designated	1991-08-13
UOWZUVNAGUAEQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5803	UMLS:C0039082	tiratricol	Syndrome	Designated	2019-01-16
UOWZUVNAGUAEQC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5803	UMLS:C1420103	tiratricol	MCT8	Designated	2019-01-16
UOZODPSAJZTQNH-LSWIJEOBSA-N	PUBCHEM.COMPOUND:165580	UMLS:C0041296	Aminosidine	Tuberculosis	Designated	1993-05-14
UOZODPSAJZTQNH-LSWIJEOBSA-N	PUBCHEM.COMPOUND:165580	UMLS:C0026914	Aminosidine	Mycobacterium avium Complex	Designated	1993-11-15
UOZODPSAJZTQNH-LSWIJEOBSA-N	PUBCHEM.COMPOUND:165580	UMLS:C0023283	paromomycin	Cutaneous leishmaniasis	Designated	2015-02-11
UOZODPSAJZTQNH-LSWIJEOBSA-N	PUBCHEM.COMPOUND:165580	UMLS:C0023290	aminosidine	Visceral leishmaniasis	Designated	2005-03-29
UOZODPSAJZTQNH-LSWIJEOBSA-N	PUBCHEM.COMPOUND:165580	UMLS:C0023290	Aminosidine	Visceral leishmaniasis	Designated	1994-09-09
UPUIQOIQVMNQAP-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23665770	UMLS:C0014867	Sodium tetradecyl sulfate	Esophageal Varices	Designated	1986-06-10
UPZWINBEAHDTLA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11438771	UMLS:C0016667	basimglurant	Fragile X Syndrome	Designated	2012-03-09
UQCNKQCJZOAFTQ-ISWURRPUSA-N	PUBCHEM.COMPOUND:5284604	UMLS:C0030200	Oxymorphone	intractable pain	Designated	1985-03-19
UQRORFVVSGFNRO-UTINFBMNSA-N	PUBCHEM.COMPOUND:51634	UMLS:C0027854	miglustat	Neurological Manifestations	Designated/Withdrawn	2008-11-12
UQRORFVVSGFNRO-UTINFBMNSA-N	PUBCHEM.COMPOUND:51634	UMLS:C0028064	miglustat	Niemann-Pick Disease	Designated/Withdrawn	2008-11-12
UQRORFVVSGFNRO-UTINFBMNSA-N	PUBCHEM.COMPOUND:51634	UMLS:C0751383	miglustat	Batten Disease	Designated	2021-01-19
UQRORFVVSGFNRO-UTINFBMNSA-N	PUBCHEM.COMPOUND:51634	UMLS:C0017205	miglustat	Gaucher Disease	Designated/Approved	1998-05-29
UQRORFVVSGFNRO-UTINFBMNSA-N	PUBCHEM.COMPOUND:51634	UMLS:C0220756	Miglustat	niemann-pick disease type c	Designated	2021-02-02
UQRORFVVSGFNRO-XFWSIPNHSA-N	PUBCHEM.COMPOUND:501391	UMLS:C0002986	lucerastat	Fabry Disease	Designated	2015-10-29
URCVCIZFVQDVPM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3035714	UMLS:C0027819	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	Neuroblastoma	Designated/Withdrawn	2004-09-30
UREBDLICKHMUKA-CXSFZGCWSA-N	PUBCHEM.COMPOUND:5743	UMLS:C3538749	dexamethasone	Myeloma	Designated/Approved	2018-03-26
UREBDLICKHMUKA-CXSFZGCWSA-N	PUBCHEM.COMPOUND:5743	UMLS:C0242852	dexamethasone	Proliferative vitreoretinopathy	Designated	2021-01-26
UREBDLICKHMUKA-CXSFZGCWSA-N	PUBCHEM.COMPOUND:5743	UMLS:C0026764	dexamethasone	Multiple Myeloma	Designated	2019-02-26
UREBDLICKHMUKA-CXSFZGCWSA-N	PUBCHEM.COMPOUND:5743	UMLS:C0026764	dexamethasone	Multiple Myeloma	Designated/Approved	2018-03-26
UREBDLICKHMUKA-DVTGEIKXSA-N	PUBCHEM.COMPOUND:9782	UMLS:C0004135	betamethasone	Ataxia Telangiectasia	Designated	2015-10-07
URGAHOPLAPQHLN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:19758701	UMLS:C4024937	Sodium aluminosilicate	Chronic hepatic encephalopathy	Designated	2005-03-04
URLYINUFLXOMHP-HTVVRFAVSA-N	PUBCHEM.COMPOUND:43860	UMLS:C0023467	Triciribine phosphate	Acute myeloid leukemia	Designated	2017-04-24
USSIQXCVUWKGNF-KRWDZBQOSA-N	PUBCHEM.COMPOUND:643985	UMLS:C0032768	d-methadone	Postherpetic neuralgia	Designated	2016-06-02
USUZGMWDZDXMDG-CYBMUJFWSA-N	PUBCHEM.COMPOUND:44139752	UMLS:C0010481	osilodrostat	Cushing's disease	Designated/Approved	2013-09-13
UTQHLYJFMFKSGI-UBINZTMLSA-N	PUBCHEM.COMPOUND:56928166	UMLS:C0027796	Contulakin-G	Neuropathic Pain	Designated	2005-07-07
UTQHLYJFMFKSGI-UBINZTMLSA-N	PUBCHEM.COMPOUND:56928166	UMLS:C0037929	Contulakin-G	Spinal Cord Injury	Designated	2005-07-07
UTQHLYJFMFKSGI-ZUMWLQPESA-N	PUBCHEM.COMPOUND:101205708	UMLS:C0027796	Contulakin-G	Neuropathic Pain	Designated	2005-07-07
UTQHLYJFMFKSGI-ZUMWLQPESA-N	PUBCHEM.COMPOUND:101205708	UMLS:C0037929	Contulakin-G	Spinal Cord Injury	Designated	2005-07-07
UUAKQNIPIXQZFN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57380530	UMLS:C4721610	anlotinib hydrochloride	Ovarian Cancer	Designated	2015-12-31
UUBHZHZSIKRVIV-KCXSXWJSSA-N	PUBCHEM.COMPOUND:6437836	UMLS:C2239176	peretinoin	HEPATOCELLULAR CARCINOMA	Designated	2011-09-23
UUOUOERPONYGOS-CLCRDYEYSA-N	PUBCHEM.COMPOUND:91488	UMLS:C0042164	Fluocinolone	Uveitis	Designated/Approved	2000-07-31
UUSZLLQJYRSZIS-LXNNNBEUSA-N	PUBCHEM.COMPOUND:9812534	UMLS:C0023449	Plitidepsin	Acute lymphoblastic leukemia	Designated/Withdrawn	2004-06-18
UUSZLLQJYRSZIS-LXNNNBEUSA-N	PUBCHEM.COMPOUND:9812534	UMLS:C0026764	plitidepsin	Multiple Myeloma	Designated	2004-09-30
UUVWYPNAQBNQJQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2123	UMLS:C5204526	Altretamine	Advanced Adenocarcinoma	Designated/Approved	1984-02-09
UUVWYPNAQBNQJQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2123	UMLS:C0948216	Altretamine	Adenocarcinoma of the Ovary	Designated/Approved	1984-02-09
UUYDYUZBCIHUFZ-MDTVQASCSA-L	PUBCHEM.COMPOUND:151722	UMLS:C0022716	copper histidinate	Menkes disease	Designated	2012-05-14
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C0036421	pomalidomide	Systemic sclerosis	Designated/Withdrawn	2013-08-22
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C0002871	pomalidomide	Anemia	Designated/Withdrawn	2010-09-21
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C0036220	pomalidomide	Kaposi Sarcoma	Designated/Approved	2018-04-04
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C0026764	pomalidomide	Multiple Myeloma	Designated/Approved	2003-01-15
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C0026987	pomalidomide	Myelofibrosis	Designated/Withdrawn	2010-09-21
UVSMNLNDYGZFPF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134780	UMLS:C1292778	pomalidomide	Myeloproliferative neoplasm	Designated/Withdrawn	2010-09-21
UWFYSQMTEOIJJG-FDTZYFLXSA-N	PUBCHEM.COMPOUND:9880	UMLS:C0019572	Cyproterone acetate	Hirsutism	Designated/Withdrawn	1984-10-26
UWXSAYUXVSFDBQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:42642648	UMLS:C0750952	varlitinib	Biliary Tract Cancer	Designated	2015-08-05
UWXSAYUXVSFDBQ-CYBMUJFWSA-N	PUBCHEM.COMPOUND:42642648	UMLS:C0024623	varlitinib	Gastric Cancer	Designated	2016-06-20
UXNXMBYCBRBRFD-MUUNZHRXSA-N	PUBCHEM.COMPOUND:137528262	UMLS:C0002994	berotralstat	Angioedema	Designated/Approved	2017-11-01
UZHSEJADLWPNLE-GRGSLBFTSA-N	PUBCHEM.COMPOUND:5284596	UMLS:C0033774	naloxone	Pruritus	Designated	2010-11-23
UZHSEJADLWPNLE-GRGSLBFTSA-N	PUBCHEM.COMPOUND:5284596	UMLS:C0026948	naloxone	Mycosis Fungoides	Designated	2010-11-23
VAAUVRVFOQPIGI-DAMLXXHOSA-L	PUBCHEM.COMPOUND:24867842	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
VAAUVRVFOQPIGI-ONNSZKPLSA-L	PUBCHEM.COMPOUND:98042587	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
VAAUVRVFOQPIGI-SPQHTLEESA-N	PUBCHEM.COMPOUND:5479530	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
VAOCPAMSLUNLGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4173	UMLS:C0343386	metronidazole	Clostridium difficile infection	Designated	2016-04-05
VAOCPAMSLUNLGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4173	UMLS:C0376620	metronidazole	Pouchitis	Designated	2011-04-26
VAOCPAMSLUNLGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4173	UMLS:C0376620	metronidazole	Pouchitis	Designated	2008-09-17
VAOCPAMSLUNLGC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4173	UMLS:C0263449	Metronidazole	Perioral Dermatitis	Designated	1991-10-24
VAZJLPXFVQHDFB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:20977	UMLS:C0000880	polyhexanide	Acanthamoeba Keratitis	Designated	2017-11-06
VAZLWPAHMORDGR-UHFFFAOYSA-L	PUBCHEM.COMPOUND:393405	UMLS:C0220650	motexafin gadolinium	brain metastases	Designated	2003-01-27
VAZLWPAHMORDGR-UHFFFAOYSA-L	PUBCHEM.COMPOUND:393405	UMLS:C0280100	motexafin gadolinium	solid tumors	Designated	2003-01-27
VAZLWPAHMORDGR-UHFFFAOYSA-L	PUBCHEM.COMPOUND:393405	UMLS:C0220650	motexafin gadolinium	brain metastases	Designated	2003-01-27
VAZLWPAHMORDGR-UHFFFAOYSA-L	PUBCHEM.COMPOUND:393405	UMLS:C0280100	motexafin gadolinium	solid tumors	Designated	2003-01-27
VBGWSQKGUZHFPS-FHVLXVBRSA-N	PUBCHEM.COMPOUND:118984459	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBGWSQKGUZHFPS-FHVLXVBRSA-N	PUBCHEM.COMPOUND:118984459	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBGWSQKGUZHFPS-VGMMZINCSA-N	PUBCHEM.COMPOUND:44152182	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBGWSQKGUZHFPS-VGMMZINCSA-N	PUBCHEM.COMPOUND:44152182	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBGWSQKGUZHFPS-ZVYAWBDLSA-N	PUBCHEM.COMPOUND:129628207	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBGWSQKGUZHFPS-ZVYAWBDLSA-N	PUBCHEM.COMPOUND:129628207	UMLS:C0002994	ecallantide	Angioedema	Designated/Approved	2003-02-04
VBUWHHLIZKOSMS-RIWXPGAOSA-N	PUBCHEM.COMPOUND:53314964	UMLS:C0036202	Aviptadil	Sarcoidosis	Designated	2020-07-23
VBUWHHLIZKOSMS-RIWXPGAOSA-N	PUBCHEM.COMPOUND:53314964	UMLS:C3203102	aviptadil	PULMONARY ARTERIAL HYPERTENSION	Designated	2005-02-22
VBUWHHLIZKOSMS-RIWXPGAOSA-N	PUBCHEM.COMPOUND:53314964	UMLS:C0035222	Vasoactive intestinal peptide	Acute respiratory distress syndrome	Designated	2001-03-09
VBUWHHLIZKOSMS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16129679	UMLS:C1695984	Vasoactive intestinal polypeptide	Esophageal food impaction	Designated	1993-06-23
VCMJCVGFSROFHV-PFEQFJNWSA-N	PUBCHEM.COMPOUND:5486830	UMLS:C0282474	tenofovir disoproxil fumarate	Mother to Child Transmission	Designated/Withdrawn	2016-09-27
VCMJCVGFSROFHV-PFEQFJNWSA-N	PUBCHEM.COMPOUND:5486830	UMLS:C0019169	tenofovir disoproxil fumarate	hepatitis B virus	Designated/Withdrawn	2016-09-27
VCMJCVGFSROFHV-VIEYUMQNSA-N	PUBCHEM.COMPOUND:86280652	UMLS:C0282474	tenofovir disoproxil fumarate	Mother to Child Transmission	Designated/Withdrawn	2016-09-27
VCMJCVGFSROFHV-VIEYUMQNSA-N	PUBCHEM.COMPOUND:86280652	UMLS:C0019169	tenofovir disoproxil fumarate	hepatitis B virus	Designated/Withdrawn	2016-09-27
VCMJCVGFSROFHV-WZGZYPNHSA-N	PUBCHEM.COMPOUND:6398764	UMLS:C0282474	tenofovir disoproxil fumarate	Mother to Child Transmission	Designated/Withdrawn	2016-09-27
VCMJCVGFSROFHV-WZGZYPNHSA-N	PUBCHEM.COMPOUND:6398764	UMLS:C0019169	tenofovir disoproxil fumarate	hepatitis B virus	Designated/Withdrawn	2016-09-27
VCPMZDWBEWTGNW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4988454	UMLS:C0032768	1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one	Postherpetic neuralgia	Designated/Withdrawn	2013-09-26
VDCRFBBZFHHYGT-IOSLPCCCSA-N	PUBCHEM.COMPOUND:135410906	UMLS:C2936664	Loxoribine	Common Variable Immunodeficiency	Designated/Withdrawn	1992-02-24
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C0221002	cinacalcet	Primary hyperparathyroidism	Designated/Approved	2010-04-30
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C0687150	cinacalcet	Parathyroid Carcinoma	Designated/Approved	2003-05-12
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C1384672	cinacalcet	HPT	Designated	2016-09-07
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C0221002	cinacalcet	Primary hyperparathyroidism	Designated/Approved	2010-04-30
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C1561643	cinacalcet	Chronic Kidney Disease	Designated	2016-09-07
VDHAWDNDOKGFTD-MRXNPFEDSA-N	PUBCHEM.COMPOUND:156419	UMLS:C0020503	cinacalcet	Secondary hyperparathyroidism	Designated	2016-09-07
VDNLFJGJEQUWRB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:3856851	UMLS:C0558356	rose bengal disodium	Ocular Melanoma	Designated	2019-02-11
VDNLFJGJEQUWRB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:3856851	UMLS:C0278883	Rose Bengal Disodium	Metastatic melanoma	Designated	2006-12-21
VDNLFJGJEQUWRB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:3856851	UMLS:C2239176	rose bengal disodium	HEPATOCELLULAR CARCINOMA	Designated	2011-04-18
VDNLFJGJEQUWRB-UHFFFAOYSA-L	PUBCHEM.COMPOUND:3856851	UMLS:C0027819	Rose bengal disodium	Neuroblastoma	Designated	2018-11-02
VERWOWGGCGHDQE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57379345	UMLS:C3539721	ceritinib	Non-Small Cell Lung Cancer	Designated/Approved	2013-09-27
VERWOWGGCGHDQE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57379345	UMLS:C3539721	ceritinib	Non-Small Cell Lung Cancer	Designated/Approved	2013-09-27
VFCRKLWBYMDAED-REWPJTCUSA-N	PUBCHEM.COMPOUND:46224413	UMLS:C0079218	nirogacestat	Desmoid tumor	Designated	2018-06-07
VFKZTMPDYBFSTM-GUCUJZIJSA-N	PUBCHEM.COMPOUND:5284380	UMLS:C1334274	Mitolactol	Invasive Carcinoma	Designated	1989-01-23
VFKZTMPDYBFSTM-GUCUJZIJSA-N	PUBCHEM.COMPOUND:5284380	UMLS:C0302592	Mitolactol	Carcinoma of the Uterine Cervix	Designated	1989-01-23
VFKZTMPDYBFSTM-GUCUJZIJSA-N	PUBCHEM.COMPOUND:5284380	UMLS:C0750974	Mitolactol	primary brain tumors	Designated	1995-07-12
VFLDPWHFBUODDF-FCXRPNKRSA-N	PUBCHEM.COMPOUND:969516	UMLS:C0010674	diferuloylmethane	Cystic Fibrosis	Designated/Withdrawn	2003-06-13
VGGGPCQERPFHOB-RDBSUJKOSA-N	PUBCHEM.COMPOUND:72172	UMLS:C0023467	Ubenimex	Acute myeloid leukemia	Designated	2020-08-07
VGGGPCQERPFHOB-RDBSUJKOSA-N	PUBCHEM.COMPOUND:72172	UMLS:C3203102	ubenimex	PULMONARY ARTERIAL HYPERTENSION	Designated	2015-11-19
VGGGPCQERPFHOB-RDBSUJKOSA-N	PUBCHEM.COMPOUND:72172	UMLS:C0023473	Ubenimex	Chronic myeloid leukemia	Designated	2021-03-08
VGGGPCQERPFHOB-RDBSUJKOSA-N	PUBCHEM.COMPOUND:72172	UMLS:C2239176	Ubenimex	HEPATOCELLULAR CARCINOMA	Designated	2020-06-12
VHBABGAFHUKREU-ICKLFXEKSA-N	PUBCHEM.COMPOUND:11977455	UMLS:C0024530	dihydroartemisinin and piperaquine	Malaria	Designated	2007-01-08
VHVPQPYKVGDNFY-AVQIMAJZSA-N	PUBCHEM.COMPOUND:6917738	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-AVQIMAJZSA-N	PUBCHEM.COMPOUND:6917738	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-AVQIMAJZSA-N	PUBCHEM.COMPOUND:6917738	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHVPQPYKVGDNFY-DFMJLFEVSA-N	PUBCHEM.COMPOUND:14179008	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-DFMJLFEVSA-N	PUBCHEM.COMPOUND:14179008	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-DFMJLFEVSA-N	PUBCHEM.COMPOUND:14179008	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHVPQPYKVGDNFY-TUJWMRSMSA-N	PUBCHEM.COMPOUND:14179013	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-TUJWMRSMSA-N	PUBCHEM.COMPOUND:14179013	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-TUJWMRSMSA-N	PUBCHEM.COMPOUND:14179013	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHVPQPYKVGDNFY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3793	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3793	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHVPQPYKVGDNFY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3793	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-VXTATNQMSA-N	PUBCHEM.COMPOUND:45039617	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-VXTATNQMSA-N	PUBCHEM.COMPOUND:45039617	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-VXTATNQMSA-N	PUBCHEM.COMPOUND:45039617	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHVPQPYKVGDNFY-ZPGVKDDISA-N	PUBCHEM.COMPOUND:55283	UMLS:C0009186	itraconazole	Coccidioidomycosis	Designated	2020-11-17
VHVPQPYKVGDNFY-ZPGVKDDISA-N	PUBCHEM.COMPOUND:55283	UMLS:C0027962	Itraconazole	Nevus	Designated	2016-05-19
VHVPQPYKVGDNFY-ZPGVKDDISA-N	PUBCHEM.COMPOUND:55283	UMLS:C0007117	Itraconazole	Basal cell carcinoma	Designated	2016-05-19
VHXNKPBCCMUMSW-FQEVSTJZSA-N	PUBCHEM.COMPOUND:472335	UMLS:C0019682	rubitecan	Human Immunodeficiency Virus	Designated	2002-07-17
VHXNKPBCCMUMSW-FQEVSTJZSA-N	PUBCHEM.COMPOUND:472335	UMLS:C0021051	rubitecan	Immunodeficiency Syndrome	Designated	2002-07-17
VHZXNQKVFDBFIK-DTCRIMCDSA-N	PUBCHEM.COMPOUND:69944058	UMLS:C0010481	fluasterone	Cushing Syndrome	Designated	2018-03-28
VHZXNQKVFDBFIK-DTCRIMCDSA-N	PUBCHEM.COMPOUND:69944058	UMLS:C2711227	fluasterone	Steatosis	Designated	2018-03-28
VHZXNQKVFDBFIK-DTCRIMCDSA-N	PUBCHEM.COMPOUND:69944058	UMLS:C0400966	fluasterone	Nonalcoholic Fatty Liver Disease	Designated	2018-03-28
VHZXNQKVFDBFIK-DTCRIMCDSA-N	PUBCHEM.COMPOUND:69944058	UMLS:C0020456	fluasterone	Hyperglycemia	Designated	2018-03-28
VHZXNQKVFDBFIK-NBBHSKLNSA-N	PUBCHEM.COMPOUND:133967	UMLS:C2711227	fluasterone	Steatosis	Designated	2018-03-28
VHZXNQKVFDBFIK-NBBHSKLNSA-N	PUBCHEM.COMPOUND:133967	UMLS:C0400966	fluasterone	Nonalcoholic Fatty Liver Disease	Designated	2018-03-28
VHZXNQKVFDBFIK-NBBHSKLNSA-N	PUBCHEM.COMPOUND:133967	UMLS:C0020456	fluasterone	Hyperglycemia	Designated	2018-03-28
VHZXNQKVFDBFIK-NBBHSKLNSA-N	PUBCHEM.COMPOUND:133967	UMLS:C0010481	fluasterone	Cushing Syndrome	Designated	2018-03-28
VHZXNQKVFDBFIK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21906940	UMLS:C2711227	fluasterone	Steatosis	Designated	2018-03-28
VHZXNQKVFDBFIK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21906940	UMLS:C0400966	fluasterone	Nonalcoholic Fatty Liver Disease	Designated	2018-03-28
VHZXNQKVFDBFIK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21906940	UMLS:C0010481	fluasterone	Cushing Syndrome	Designated	2018-03-28
VHZXNQKVFDBFIK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21906940	UMLS:C0020456	fluasterone	Hyperglycemia	Designated	2018-03-28
VHZXNQKVFDBFIK-WYTRLKPUSA-N	PUBCHEM.COMPOUND:145705956	UMLS:C0020456	fluasterone	Hyperglycemia	Designated	2018-03-28
VHZXNQKVFDBFIK-WYTRLKPUSA-N	PUBCHEM.COMPOUND:145705956	UMLS:C0010481	fluasterone	Cushing Syndrome	Designated	2018-03-28
VHZXNQKVFDBFIK-WYTRLKPUSA-N	PUBCHEM.COMPOUND:145705956	UMLS:C0400966	fluasterone	Nonalcoholic Fatty Liver Disease	Designated	2018-03-28
VHZXNQKVFDBFIK-WYTRLKPUSA-N	PUBCHEM.COMPOUND:145705956	UMLS:C2711227	fluasterone	Steatosis	Designated	2018-03-28
VIDRYROWYFWGSY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66245	UMLS:C3827656	Sotalol HCl	Ventricular Tachyarrhythmias	Designated/Approved	1988-09-23
VIDRYROWYFWGSY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:66245	UMLS:C3812282	sotalol hydrochloride	Ventricular Arrhythmias	Designated	2014-02-10
VIUAUNHCRHHYNE-JTQLQIEISA-N	PUBCHEM.COMPOUND:44187362	UMLS:C0235974	pimasertib	PANCREATIC CANCER	Designated/Withdrawn	2010-01-29
VJZITPJGSQKZMX-XDPRQOKASA-N	PUBCHEM.COMPOUND:3035016	UMLS:C3540630	amrubicin	Small Cell Lung Cancer	Designated/Withdrawn	2008-03-10
VKDGNNYJFSHYKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57004	UMLS:C1535939	Eflornithine HCl	Pneumocystis carinii Pneumonia	Designated/Withdrawn	1986-04-18
VKDGNNYJFSHYKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57004	UMLS:C0041218	Eflornithine HCl	Trypanosoma brucei gambiense	Designated/Approved	1986-04-23
VKDGNNYJFSHYKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57004	UMLS:C0041228	Eflornithine HCl	Sleeping sickness	Designated/Approved	1986-04-23
VKDGNNYJFSHYKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57004	UMLS:C0009450	Eflornithine HCl	Infection	Designated/Approved	1986-04-23
VKDGNNYJFSHYKD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:57004	UMLS:C0024623	eflornithine HCL	Gastric Cancer	Designated	2015-04-07
VKHAHZOOUSRJNA-GCNJZUOMSA-N	PUBCHEM.COMPOUND:55245	UMLS:C0010481	mifepristone	Cushing Syndrome	Designated/Approved	2007-07-05
VKHAHZOOUSRJNA-GCNJZUOMSA-N	PUBCHEM.COMPOUND:55245	UMLS:C0039082	Mifepristone	Syndrome	Designated/Withdrawn	2005-02-07
VKHAHZOOUSRJNA-GCNJZUOMSA-N	PUBCHEM.COMPOUND:55245	UMLS:C0001231	Mifepristone	Ectopic ACTH secretion	Designated/Withdrawn	2005-02-07
VKHAHZOOUSRJNA-GCNJZUOMSA-N	PUBCHEM.COMPOUND:55245	UMLS:C4721610	mifepristone	Ovarian Cancer	Designated	2016-01-14
VLARUOGDXDTHEH-UHFFFAOYSA-L	PUBCHEM.COMPOUND:27503	UMLS:C0024899	Cromolyn sodium	Mastocytosis	Designated/Approved	1984-03-08
VLCYCQAOQCDTCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3009	UMLS:C4287997	Eflornithine	Anaplastic Glioma	Designated	2006-09-29
VLCYCQAOQCDTCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3009	UMLS:C0032580	eflornithine	Familial Adenomatous Polyposis	Designated	2011-02-04
VLCYCQAOQCDTCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3009	UMLS:C0027819	eflornithine	Neuroblastoma	Designated	2017-11-22
VLCYCQAOQCDTCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3009	UMLS:C0235974	eflornithine	PANCREATIC CANCER	Designated	2016-12-14
VLCYCQAOQCDTCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3009	UMLS:C0027819	eflornithine	Neuroblastoma	Designated	2010-11-23
VLPFTAMPNXLGLX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10850	UMLS:C3887898	tricaprilin	Infantile spasms	Designated	2020-10-27
VLPIATFUUWWMKC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4178	UMLS:C2931139	mexiletine	Nondystrophic myotonia	Designated	2010-09-02
VLPIATFUUWWMKC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4178	UMLS:C0553604	mexiletine	Myotonic Disorders	Designated	2020-03-16
VLULRUCCHYVXOH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:73777259	UMLS:C0555198	7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one	Malignant Glioma	Designated	2018-06-04
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0917808	Apomorphine hydrochloride	Vegetative State	Designated	2006-05-23
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0876926	Apomorphine hydrochloride	Traumatic Brain Injury	Designated	2006-05-23
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0751699	Apomorphine hydrochloride	Minimally Conscious State	Designated	2006-05-23
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0521654	Apomorphine	Motor dysfunction	Designated/Withdrawn	1997-10-20
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0030567	Apomorphine	Parkinson's Disease	Designated/Withdrawn	1997-10-20
VMWNQDUVQKEIOC-CYBMUJFWSA-N	PUBCHEM.COMPOUND:6005	UMLS:C0030567	Apomorphine	Parkinson's Disease	Designated	1995-07-17
VMZMNAABQBOLAK-DBILLSOUSA-N	PUBCHEM.COMPOUND:9941444	UMLS:C0010481	pasireotide	Cushing's disease	Designated/Approved	2009-07-24
VMZMNAABQBOLAK-DBILLSOUSA-N	PUBCHEM.COMPOUND:9941444	UMLS:C0001206	pasireotide	Acromegaly	Designated/Approved	2009-08-25
VMZMNAABQBOLAK-DBILLSOUSA-N	PUBCHEM.COMPOUND:9941444	UMLS:C0010481	pasireotide	Cushing's disease	Designated/Approved	2009-07-24
VNFPBHJOKIVQEB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2812	UMLS:C0376620	Clotrimazole	Pouchitis	Designated	2005-06-14
VNFPBHJOKIVQEB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2812	UMLS:C0002895	Clotrimazole	Sickle Cell Disease	Designated	1995-04-24
VNFPBHJOKIVQEB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2812	UMLS:C0020179	Clotrimazole	Huntington's Disease	Designated	2006-03-13
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0008312	budesonide	Primary Biliary Cholangitis	Designated	2019-02-11
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0241910	budesonide	Autoimmune hepatitis	Designated	2019-02-01
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0017661	budesonide	Immunoglobulin A Nephropathy	Designated	2010-05-17
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0035078	budesonide	Kidney Failure	Designated	2010-05-17
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0341106	budesonide	Eosinophilic esophagitis	Designated	2018-05-08
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0009324	budesonide	Ulcerative Colitis	Designated	2013-05-06
VOVIALXJUBGFJZ-KWVAZRHASA-N	PUBCHEM.COMPOUND:5281004	UMLS:C0341106	budesonide	Eosinophilic esophagitis	Designated	2006-12-20
VOVZXURTCKPRDQ-CQSZACIVSA-N	PUBCHEM.COMPOUND:72165228	UMLS:C0023473	asciminib	Chronic myelogenous leukemia	Designated	2017-02-27
VPAWVRUHMJVRHU-GYKQLYQFSA-N	PUBCHEM.COMPOUND:9690122	UMLS:C0023467	Perfosfamide	Acute myelogenous leukemia	Designated/Withdrawn	1989-12-04
VPAWVRUHMJVRHU-HYORBCNSSA-N	PUBCHEM.COMPOUND:70697640	UMLS:C0023467	Perfosfamide	Acute myelogenous leukemia	Designated/Withdrawn	1989-12-04
VPAWVRUHMJVRHU-RWNHWRGESA-N	PUBCHEM.COMPOUND:6918238	UMLS:C0023467	Perfosfamide	Acute myelogenous leukemia	Designated/Withdrawn	1989-12-04
VPAWVRUHMJVRHU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:38347	UMLS:C0023467	Perfosfamide	Acute myelogenous leukemia	Designated/Withdrawn	1989-12-04
VPAWVRUHMJVRHU-VGDKGRGNSA-N	PUBCHEM.COMPOUND:9554809	UMLS:C0023467	Perfosfamide	Acute myelogenous leukemia	Designated/Withdrawn	1989-12-04
VPVOXUSPXFPWBN-VKHMYHEASA-N	PUBCHEM.COMPOUND:135398579	UMLS:C0751435	sepiapterin	Hyperphenylalaninemia	Designated	2021-03-04
VPVOXUSPXFPWBN-VKHMYHEASA-N	PUBCHEM.COMPOUND:135398579	UMLS:C0751436	sepiapterin	Tetrahydrobiopterin Deficiency	Designated	2020-02-19
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0024776	sodium phenylbutyrate	Maple Syrup Urine Disease	Designated	2014-08-19
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0154246	sodium phenylbutyrate	Urea Cycle Disorders	Designated	2013-06-06
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0039730	sodium phenylbutyrate	Thalassemia	Designated	1992-07-02
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C1291575	sodium phenylbutyrate	Ornithine Transcarbamylase	Designated/Approved	1993-11-22
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0026847	Sodium phenylbutyrate	Spinal Muscular Atrophy	Designated	2007-01-25
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0023487	Phenylbutyrate	Acute Promyelocytic Leukemia	Designated	2000-01-19
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0268542	sodium phenylbutyrate	Deficiency	Designated/Approved	1993-11-22
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0154246	sodium phenylbutyrate	Urea Cycle Disorders	Designated/Approved	1993-11-22
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0026847	sodium 4-phenylbutyrate	Spinal Muscular Atrophy	Designated	2011-10-18
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0154246	sodium phenylbutyrate	urea cycle disorder	Designated	2010-01-19
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C4684861	Sodium phenylbutyrate	Recurrent Malignant Glioma	Designated	1998-04-24
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0026847	Sodium phenylbutyrate	Spinal Muscular Atrophy	Designated	2007-03-20
VPZRWNZGLKXFOE-UHFFFAOYSA-M	PUBCHEM.COMPOUND:5258	UMLS:C0019045	sodium phenylbutyrate	Hemoglobinopathy	Designated	1992-07-02
VQJFFWJUYDGTQZ-MGUDINDMSA-N	PUBCHEM.COMPOUND:54612642	UMLS:C0023467	Zosuquidar trihydrochloride	Acute myeloid leukemia	Designated	2005-12-15
VQODGRNSFPNSQE-CXSFZGCWSA-N	PUBCHEM.COMPOUND:9400	UMLS:C0339303	dexamethasone phosphate	Corneal graft rejection	Designated	2008-12-02
VRNHFZYMPDKTBS-WYUJEMNCSA-N	PUBCHEM.COMPOUND:71652162	UMLS:C0149778	reltecimod	Soft Tissue Infections	Designated	2011-10-12
VSGNNIFQASZAOI-UHFFFAOYSA-L	PUBCHEM.COMPOUND:6116	UMLS:C0085681	Calcium acetate	Hyperphosphatemia	Designated/Approved	1988-12-22
VSGNNIFQASZAOI-UHFFFAOYSA-L	PUBCHEM.COMPOUND:6116	UMLS:C0022661	Calcium acetate	End stage renal disease	Designated	1989-06-27
VSGNNIFQASZAOI-UHFFFAOYSA-L	PUBCHEM.COMPOUND:6116	UMLS:C0022661	Calcium acetate	End stage renal failure	Designated/Approved	1988-12-22
VSGNNIFQASZAOI-UHFFFAOYSA-L	PUBCHEM.COMPOUND:6116	UMLS:C0085681	Calcium acetate	Hyperphosphatemia	Designated	1989-06-27
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0037054	Hydroxyurea	Hemoglobin S	Designated/Approved	1990-10-01
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0002895	Hydroxyurea	SICKLE CELL ANEMIA	Designated	2017-03-02
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0002895	hydroxyurea	SICKLE CELL ANEMIA	Designated	2005-04-15
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0002895	hydroxycarbamide (hydroxyurea)	Sickle Cell Disease	Designated/Approved	2013-07-24
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0002895	hydroxyurea	Sickle Cell Disease	Designated	2015-03-16
VSNHCAURESNICA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3657	UMLS:C0002895	Hydroxyurea	SICKLE CELL ANEMIA	Designated/Approved	1990-10-01
VTYYLEPIZMXCLO-UHFFFAOYSA-L	PUBCHEM.COMPOUND:10112	UMLS:C0022661	Calcium carbonate	End stage renal disease	Designated	1990-06-06
VTYYLEPIZMXCLO-UHFFFAOYSA-L	PUBCHEM.COMPOUND:10112	UMLS:C0085681	Calcium carbonate	Hyperphosphatemia	Designated	1990-06-06
VUAFHZCUKUDDBC-BYPYZUCNSA-N	PUBCHEM.COMPOUND:656604	UMLS:C0010691	bucillamine	Cystinuria	Designated	2015-10-22
VUAXHMVRKOTJKP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11684	UMLS:C0268583	2,2-dimethylbutanoic acid	Methylmalonic acidemia	Designated	2020-12-10
VUAXHMVRKOTJKP-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11684	UMLS:C0268579	2,2-dimethylbutanoic acid	Propionic acidemia	Designated	2020-12-10
VUGBLGCUPUUDOI-GNXCPKRQSA-N	PUBCHEM.COMPOUND:87900910	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
VVIAGPKUTFNRDU-ABLWVSNPSA-L	PUBCHEM.COMPOUND:135823198	UMLS:C4721579	Leucovorin calcium	Metastatic colorectal cancer	Designated/Withdrawn	1988-06-23
VVIAGPKUTFNRDU-ABLWVSNPSA-N	PUBCHEM.COMPOUND:135403648	UMLS:C4721579	Leucovorin	Metastatic colorectal cancer	Designated/Approved	1986-12-08
VVIAGPKUTFNRDU-STQMWFEESA-N	PUBCHEM.COMPOUND:135398559	UMLS:C0029463	Levoleucovorin	Osteosarcoma	Designated/Approved	1991-08-01
VVIAGPKUTFNRDU-STQMWFEESA-N	PUBCHEM.COMPOUND:135398559	UMLS:C0338106	levoleucovorin	adenocarcinoma of the colon	Designated/Approved	1990-12-18
VVIAGPKUTFNRDU-STQMWFEESA-N	PUBCHEM.COMPOUND:135398559	UMLS:C0334277	levoleucovorin	Metastatic adenocarcinoma	Designated/Approved	1990-12-18
VWBBRFHSPXRJQD-QNTKWALQSA-L	PUBCHEM.COMPOUND:135564391	UMLS:C0002888	levomefolate calcium	Megaloblastic anemia	Designated	2015-02-10
VWBBRFHSPXRJQD-QNTKWALQSA-L	PUBCHEM.COMPOUND:135564391	UMLS:C0016412	levomefolate calcium	Folate deficiency	Designated	2015-02-10
VXBAJLGYBMTJCY-NSCUHMNNSA-N	PUBCHEM.COMPOUND:16739650	UMLS:C0017638	zotiraciclib	Glioma	Designated	2019-11-21
VYGQUTWHTHXGQB-FFHKNEKCSA-N	PUBCHEM.COMPOUND:5280531	UMLS:C0006287	vitamin A palmitate	Bronchopulmonary Dysplasia	Designated	2015-07-14
VYGQUTWHTHXGQB-FFHKNEKCSA-N	PUBCHEM.COMPOUND:5280531	UMLS:C0006287	Retinol palmitate	Bronchopulmonary Dysplasia	Designated	2016-08-08
VYUWDIKZJLOZJL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11638255	UMLS:C0017636	Varbulin	Glioblastoma multiforme	Designated	2009-11-05
VZZJRYRQSPEMTK-CALCHBBNSA-N	PUBCHEM.COMPOUND:24775005	UMLS:C0025149	sonidegib	Medulloblastoma	Designated	2015-03-23
WAEXFXRVDQXREF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5311	UMLS:C4727838	vorinostat	Advanced Melanoma	Designated	2016-10-13
WAEXFXRVDQXREF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5311	UMLS:C0026764	vorinostat	Multiple Myeloma	Designated/Withdrawn	2003-06-12
WAEXFXRVDQXREF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5311	UMLS:C0025500	vorinostat	Mesothelioma	Designated/Withdrawn	2004-03-17
WAEXFXRVDQXREF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5311	UMLS:C0079772	vorinostat	T-cell non-Hodgkin's lymphoma	Designated/Approved	2004-03-16
WANIDIGFXJFFEL-SANMLTNESA-N	PUBCHEM.COMPOUND:73051463	UMLS:C0010481	relacorilant	Cushing Syndrome	Designated	2018-10-15
WANIDIGFXJFFEL-SANMLTNESA-N	PUBCHEM.COMPOUND:73051463	UMLS:C0235974	relacorilant	PANCREATIC CANCER	Designated	2018-09-27
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	PUBCHEM.COMPOUND:135410875	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
WBYWAXJHAXSJNI-VOTSOKGWSA-N	PUBCHEM.COMPOUND:444539	UMLS:C0023521	Trans-Cinnamic Acid	Krabbe Disease	Designated	2021-02-03
WBYWAXJHAXSJNI-VOTSOKGWSA-N	PUBCHEM.COMPOUND:444539	UMLS:C0268274	Trans-Cinnamic Acid	GM2 Gangliosidosis	Designated	2020-11-24
WBYWAXJHAXSJNI-VOTSOKGWSA-N	PUBCHEM.COMPOUND:444539	UMLS:C0268242	Trans-Cinnamic Acid	niemann-pick disease type a	Designated	2020-11-24
WCXAUCDLLSWGQS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:126485502	UMLS:C0026764	4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide	Multiple Myeloma	Designated	2019-02-28
WDDPHFBMKLOVOX-AYQXTPAHSA-N	PUBCHEM.COMPOUND:119182	UMLS:C0023467	clofarabine	Acute myelogenous leukemia	Designated	2002-03-14
WDDPHFBMKLOVOX-AYQXTPAHSA-N	PUBCHEM.COMPOUND:119182	UMLS:C0023467	clofarabine	Acute myeloid leukemia	Designated	2019-01-24
WDDPHFBMKLOVOX-AYQXTPAHSA-N	PUBCHEM.COMPOUND:119182	UMLS:C0023449	clofarabine	Acute lymphoblastic leukemia	Designated/Approved	2002-02-07
WDENQIQQYWYTPO-IBGZPJMESA-N	PUBCHEM.COMPOUND:71226662	UMLS:C4721414	acalabrutinib	Mantle cell lymphoma	Designated/Approved	2015-09-21
WDENQIQQYWYTPO-IBGZPJMESA-N	PUBCHEM.COMPOUND:71226662	UMLS:C0023434	acalabrutinib	Chronic Lymphocytic Leukemia	Designated/Approved	2015-05-13
WDENQIQQYWYTPO-IBGZPJMESA-N	PUBCHEM.COMPOUND:71226662	UMLS:C0024419	acalabrutinib	Waldenstrom Macroglobulinemia	Designated	2015-10-22
WDJUZGPOPHTGOT-XUDUSOBPSA-N	PUBCHEM.COMPOUND:441207	UMLS:C0010674	digitoxin	Cystic Fibrosis	Designated	2005-05-27
WDJUZGPOPHTGOT-XUDUSOBPSA-N	PUBCHEM.COMPOUND:441207	UMLS:C4721610	digitoxin	Ovarian Cancer	Designated	2001-11-02
WDJUZGPOPHTGOT-XUDUSOBPSA-N	PUBCHEM.COMPOUND:441207	UMLS:C1261473	digitoxin	Soft Tissue Sarcomas	Designated	2001-10-18
WDLCALUKNKNIDF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23615599	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1989-11-24
WDLCALUKNKNIDF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:23615599	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1988-09-20
WDOGQTQEKVLZIJ-WAYWQWQTSA-L	PUBCHEM.COMPOUND:21159388	UMLS:C0206682	Combretastatin A4 Phosphate	follicular thyroid cancer	Designated	2003-07-23
WDOGQTQEKVLZIJ-WAYWQWQTSA-L	PUBCHEM.COMPOUND:21159388	UMLS:C4721610	Combretastatin A4 phosphate	Ovarian Cancer	Designated	2006-05-08
WDOGQTQEKVLZIJ-WAYWQWQTSA-L	PUBCHEM.COMPOUND:21159388	UMLS:C0238462	Combretastatin A4 Phosphate	Thyroid cancer	Designated	2003-07-23
WDOGQTQEKVLZIJ-WAYWQWQTSA-L	PUBCHEM.COMPOUND:21159388	UMLS:C0238461	Combretastatin A4 Phosphate	anaplastic thyroid cancer	Designated	2003-07-23
WDOGQTQEKVLZIJ-WAYWQWQTSA-N	PUBCHEM.COMPOUND:5351387	UMLS:C4721610	Combretastatin A4 phosphate	Ovarian Cancer	Designated	2006-05-08
WDOGQTQEKVLZIJ-WAYWQWQTSA-N	PUBCHEM.COMPOUND:5351387	UMLS:C0238461	Combretastatin A4 Phosphate	anaplastic thyroid cancer	Designated	2003-07-23
WDOGQTQEKVLZIJ-WAYWQWQTSA-N	PUBCHEM.COMPOUND:5351387	UMLS:C0206682	Combretastatin A4 Phosphate	follicular thyroid cancer	Designated	2003-07-23
WDOGQTQEKVLZIJ-WAYWQWQTSA-N	PUBCHEM.COMPOUND:5351387	UMLS:C0238462	Combretastatin A4 Phosphate	Thyroid cancer	Designated	2003-07-23
WDQPAMHFFCXSNU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2794	UMLS:C0026918	clofazimine	Mycobacterial infections	Designated	2018-08-17
WDQPAMHFFCXSNU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2794	UMLS:C0343467	Clofazimine	Erythema nodosum leprosum	Designated/Approved	1984-06-11
WDQPAMHFFCXSNU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2794	UMLS:C0023348	Clofazimine	Lepromatous leprosy	Designated/Approved	1984-06-11
WDQPAMHFFCXSNU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2794	UMLS:C0041296	clofazimine	Active Tuberculosis	Designated	2014-06-25
WDZCUPBHRAEYDL-BGZYVKEHSA-N	PUBCHEM.COMPOUND:136246610	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-BGZYVKEHSA-N	PUBCHEM.COMPOUND:136246610	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-BGZYVKEHSA-N	PUBCHEM.COMPOUND:136246610	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-BGZYVKEHSA-N	PUBCHEM.COMPOUND:136246610	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-BGZYVKEHSA-N	PUBCHEM.COMPOUND:136246610	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-FHDUCCPFSA-N	PUBCHEM.COMPOUND:136122663	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-FHDUCCPFSA-N	PUBCHEM.COMPOUND:136122663	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-FHDUCCPFSA-N	PUBCHEM.COMPOUND:136122663	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-FHDUCCPFSA-N	PUBCHEM.COMPOUND:136122663	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-FHDUCCPFSA-N	PUBCHEM.COMPOUND:136122663	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-GZAUEHORSA-N	PUBCHEM.COMPOUND:135403821	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-GZAUEHORSA-N	PUBCHEM.COMPOUND:135403821	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-GZAUEHORSA-N	PUBCHEM.COMPOUND:135403821	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-GZAUEHORSA-N	PUBCHEM.COMPOUND:135403821	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-GZAUEHORSA-N	PUBCHEM.COMPOUND:135403821	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-HJTBMZGUSA-N	PUBCHEM.COMPOUND:135749824	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-HJTBMZGUSA-N	PUBCHEM.COMPOUND:135749824	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-HJTBMZGUSA-N	PUBCHEM.COMPOUND:135749824	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-HJTBMZGUSA-N	PUBCHEM.COMPOUND:135749824	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-HJTBMZGUSA-N	PUBCHEM.COMPOUND:135749824	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-LBJWSYCFSA-N	PUBCHEM.COMPOUND:137091916	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-LBJWSYCFSA-N	PUBCHEM.COMPOUND:137091916	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-LBJWSYCFSA-N	PUBCHEM.COMPOUND:137091916	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-LBJWSYCFSA-N	PUBCHEM.COMPOUND:137091916	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-LBJWSYCFSA-N	PUBCHEM.COMPOUND:137091916	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-LYDPARFQSA-N	PUBCHEM.COMPOUND:135968625	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-LYDPARFQSA-N	PUBCHEM.COMPOUND:135968625	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-LYDPARFQSA-N	PUBCHEM.COMPOUND:135968625	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-LYDPARFQSA-N	PUBCHEM.COMPOUND:135968625	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-LYDPARFQSA-N	PUBCHEM.COMPOUND:135968625	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-METIDKAPSA-N	PUBCHEM.COMPOUND:135932821	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-METIDKAPSA-N	PUBCHEM.COMPOUND:135932821	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-METIDKAPSA-N	PUBCHEM.COMPOUND:135932821	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-METIDKAPSA-N	PUBCHEM.COMPOUND:135932821	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-METIDKAPSA-N	PUBCHEM.COMPOUND:135932821	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-NAFQJNKLSA-N	PUBCHEM.COMPOUND:136238508	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-NAFQJNKLSA-N	PUBCHEM.COMPOUND:136238508	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-NAFQJNKLSA-N	PUBCHEM.COMPOUND:136238508	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-NAFQJNKLSA-N	PUBCHEM.COMPOUND:136238508	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-NAFQJNKLSA-N	PUBCHEM.COMPOUND:136238508	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-PRHSTWAZSA-N	PUBCHEM.COMPOUND:135659016	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-PRHSTWAZSA-N	PUBCHEM.COMPOUND:135659016	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-PRHSTWAZSA-N	PUBCHEM.COMPOUND:135659016	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-PRHSTWAZSA-N	PUBCHEM.COMPOUND:135659016	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-PRHSTWAZSA-N	PUBCHEM.COMPOUND:135659016	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-PWXWUWFUSA-N	PUBCHEM.COMPOUND:135925739	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-PWXWUWFUSA-N	PUBCHEM.COMPOUND:135925739	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-PWXWUWFUSA-N	PUBCHEM.COMPOUND:135925739	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-PWXWUWFUSA-N	PUBCHEM.COMPOUND:135925739	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-PWXWUWFUSA-N	PUBCHEM.COMPOUND:135925739	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-QEDJKGLXSA-N	PUBCHEM.COMPOUND:136073066	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-QEDJKGLXSA-N	PUBCHEM.COMPOUND:136073066	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-QEDJKGLXSA-N	PUBCHEM.COMPOUND:136073066	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-QEDJKGLXSA-N	PUBCHEM.COMPOUND:136073066	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-QEDJKGLXSA-N	PUBCHEM.COMPOUND:136073066	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-QFWJEWEWSA-N	PUBCHEM.COMPOUND:135887820	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-QFWJEWEWSA-N	PUBCHEM.COMPOUND:135887820	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-QFWJEWEWSA-N	PUBCHEM.COMPOUND:135887820	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-QFWJEWEWSA-N	PUBCHEM.COMPOUND:135887820	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-QFWJEWEWSA-N	PUBCHEM.COMPOUND:135887820	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-RDKOBYJASA-N	PUBCHEM.COMPOUND:137235501	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-RDKOBYJASA-N	PUBCHEM.COMPOUND:137235501	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-RDKOBYJASA-N	PUBCHEM.COMPOUND:137235501	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-RDKOBYJASA-N	PUBCHEM.COMPOUND:137235501	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-RDKOBYJASA-N	PUBCHEM.COMPOUND:137235501	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-USLNORDZSA-N	PUBCHEM.COMPOUND:137030254	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WDZCUPBHRAEYDL-USLNORDZSA-N	PUBCHEM.COMPOUND:137030254	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-USLNORDZSA-N	PUBCHEM.COMPOUND:137030254	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-USLNORDZSA-N	PUBCHEM.COMPOUND:137030254	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-USLNORDZSA-N	PUBCHEM.COMPOUND:137030254	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-YUUOHQKVSA-N	PUBCHEM.COMPOUND:138404395	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1996-03-12
WDZCUPBHRAEYDL-YUUOHQKVSA-N	PUBCHEM.COMPOUND:138404395	UMLS:C0001175	Rifapentine	AIDS	Designated	1996-03-12
WDZCUPBHRAEYDL-YUUOHQKVSA-N	PUBCHEM.COMPOUND:138404395	UMLS:C0001175	Rifapentine	AIDS	Designated	1995-06-09
WDZCUPBHRAEYDL-YUUOHQKVSA-N	PUBCHEM.COMPOUND:138404395	UMLS:C0026914	Rifapentine	Mycobacterium avium Complex	Designated	1995-06-09
WDZCUPBHRAEYDL-YUUOHQKVSA-N	PUBCHEM.COMPOUND:138404395	UMLS:C0041327	Rifapentine	Pulmonary tuberculosis	Designated/Approved	1995-06-09
WELIVEBWRWAGOM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69532	UMLS:C0026764	Beta alethine	Multiple Myeloma	Designated	1997-03-24
WELIVEBWRWAGOM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69532	UMLS:C0278883	Beta alethine	Metastatic melanoma	Designated	1997-03-24
WEQLWGNDNRARGE-DJIMGWMZSA-N	PUBCHEM.COMPOUND:14580381	UMLS:C0020179	(+)-alpha-dihydrotetrabenazine	Huntington's Disease	Designated	2018-12-05
WESWYMRNZNDGBX-YLCXCWDSSA-N	PUBCHEM.COMPOUND:65329	UMLS:C2930826	mefloquine HCL	Acute malaria	Designated/Approved	1988-04-13
WESWYMRNZNDGBX-YLCXCWDSSA-N	PUBCHEM.COMPOUND:65329	UMLS:C0024535	mefloquine HCL	Plasmodium falciparum Malaria	Designated/Approved	1988-04-13
WESWYMRNZNDGBX-YLCXCWDSSA-N	PUBCHEM.COMPOUND:65329	UMLS:C2930826	mefloquine HCL	Acute malaria	Designated/Approved	1988-04-13
WESWYMRNZNDGBX-YLCXCWDSSA-N	PUBCHEM.COMPOUND:65329	UMLS:C0024535	mefloquine HCL	Plasmodium falciparum Malaria	Designated/Approved	1988-04-13
WEUITFNOCGSIHW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:154732136	UMLS:C0555198	carboxyamidotriazole orotate	Malignant Glioma	Designated	2018-05-10
WFKAJVHLWXSISD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68424	UMLS:C0019045	Isobutyramide	Hemoglobinopathies	Designated	1992-12-18
WFKAJVHLWXSISD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68424	UMLS:C0002895	Isobutyramide	Sickle Cell Disease	Designated	1994-05-25
WFKAJVHLWXSISD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68424	UMLS:C0005283	Isobutyramide	beta Thalassemia	Designated	1994-05-25
WFKAJVHLWXSISD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68424	UMLS:C0005283	Isobutyramide	BETA-THALASSEMIA	Designated	1992-12-18
WHNFPRLDDSXQCL-UAZQEYIDSA-N	PUBCHEM.COMPOUND:44273719	UMLS:C1828256	Alpha-melanocyte stimulating hormone	Acute renal failure due to ischemia	Designated	1997-08-19
WHTVZRBIWZFKQO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2719	UMLS:C0017636	chloroquine	Glioblastoma multiforme	Designated	2015-05-20
WHVPOEPABJZBBY-XQYLJSSYSA-N	PUBCHEM.COMPOUND:67548346	UMLS:C0016736	epoprostenol	Frostbite	Designated	2020-04-20
WHVPOEPABJZBBY-XQYLJSSYSA-N	PUBCHEM.COMPOUND:67548346	UMLS:C3203102	Epoprostenol	Primary Pulmonary Hypertension	Designated/Approved	1985-09-25
WHVPOEPABJZBBY-XQYLJSSYSA-N	PUBCHEM.COMPOUND:67548346	UMLS:C0042373	epoprostenol	Vascular Disease	Designated/Approved	1999-03-22
WHVPOEPABJZBBY-XQYLJSSYSA-N	PUBCHEM.COMPOUND:67548346	UMLS:C0264936	epoprostenol	Secondary pulmonary hypertension	Designated/Approved	1999-03-22
WHXMKTBCFHIYNQ-SECBINFHSA-N	PUBCHEM.COMPOUND:3033825	UMLS:C0002736	levosimendan	Amyotrophic Lateral Sclerosis	Designated/Withdrawn	2017-04-10
WIJZXSAJMHAVGX-DHLKQENFSA-N	PUBCHEM.COMPOUND:71657455	UMLS:C0023467	ivosidenib	Acute myeloid leukemia	Designated/Approved	2015-06-09
WIJZXSAJMHAVGX-DHLKQENFSA-N	PUBCHEM.COMPOUND:71657455	UMLS:C3463824	ivosidenib	Myelodysplastic Syndromes	Designated	2020-05-20
WIJZXSAJMHAVGX-DHLKQENFSA-N	PUBCHEM.COMPOUND:71657455	UMLS:C0017638	ivosidenib	Glioma	Designated	2018-05-01
WIJZXSAJMHAVGX-DHLKQENFSA-N	PUBCHEM.COMPOUND:71657455	UMLS:C0023467	ivosidenib	Acute myeloid leukemia	Designated/Approved	2015-06-09
WIJZXSAJMHAVGX-DHLKQENFSA-N	PUBCHEM.COMPOUND:71657455	UMLS:C0206698	ivosidenib	Cholangiocarcinoma	Designated	2017-04-26
WJEOLQLKVOPQFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10074640	UMLS:C0024899	masitinib	Mastocytosis	Designated	2005-09-14
WJEOLQLKVOPQFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10074640	UMLS:C0238198	masitinib	Gastrointestinal Stromal Tumors	Designated	2005-04-20
WJEOLQLKVOPQFV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10074640	UMLS:C0235974	masitinib	PANCREATIC CANCER	Designated	2009-07-21
WJIGGYYSZBWCGC-MRXNPFEDSA-N	PUBCHEM.COMPOUND:25221720	UMLS:C1855465	emixustat	STGD	Designated	2017-01-04
WJIGGYYSZBWCGC-MRXNPFEDSA-N	PUBCHEM.COMPOUND:25221720	UMLS:C1412063	emixustat	Stargardt disease	Designated	2017-01-04
WKGXYQFOCVYPAC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3331	UMLS:C0238111	Felbamate	Lennox-Gastaut syndrome	Designated/Approved	1989-01-24
WKSAUQYGYAYLPV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4993	UMLS:C0039373	pyrimethamine	Tay-Sachs Disease	Designated	2011-08-16
WKSAUQYGYAYLPV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4993	UMLS:C0036161	pyrimethamine	Sandhoff Disease	Designated	2011-08-16
WKSAUQYGYAYLPV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4993	UMLS:C0017083	pyrimethamine	Gangliosidoses	Designated	2011-08-16
WLJVXDMOQOGPHL-UHFFFAOYSA-M	PUBCHEM.COMPOUND:4409936	UMLS:C1578499	Phenylacetate	Radiation Therapy	Designated	1998-03-06
WLJVXDMOQOGPHL-UHFFFAOYSA-M	PUBCHEM.COMPOUND:4409936	UMLS:C4684861	Phenylacetate	Recurrent Malignant Glioma	Designated	1998-03-06
WLJVXDMOQOGPHL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:999	UMLS:C1578499	Phenylacetate	Radiation Therapy	Designated	1998-03-06
WLJVXDMOQOGPHL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:999	UMLS:C4684861	Phenylacetate	Recurrent Malignant Glioma	Designated	1998-03-06
WLYZKTXOAMAVEO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135515521	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
WMBOCUXXNSOQHM-DHZHZOJOSA-N	PUBCHEM.COMPOUND:5352899	UMLS:C0555198	butylidenephthalide	Malignant Glioma	Designated	2015-08-05
WMBOCUXXNSOQHM-FLIBITNWSA-N	PUBCHEM.COMPOUND:642376	UMLS:C0555198	butylidenephthalide	Malignant Glioma	Designated	2015-08-05
WMBOCUXXNSOQHM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62368	UMLS:C0555198	butylidenephthalide	Malignant Glioma	Designated	2015-08-05
WMGFVAGNIYUEEP-WUYNJSITSA-N	PUBCHEM.COMPOUND:439207	UMLS:C0017919	amylopectin	Glycogen Storage Disease	Designated	2015-03-24
WMWTYOKRWGGJOA-CENSZEJFSA-N	PUBCHEM.COMPOUND:444036	UMLS:C0341106	fluticasone propionate	Eosinophilic esophagitis	Designated	2015-12-29
WMWTYOKRWGGJOA-CENSZEJFSA-N	PUBCHEM.COMPOUND:444036	UMLS:C0341106	fluticasone propionate	Eosinophilic esophagitis	Designated	2011-01-19
WOFMFGQZHJDGCX-ZULDAHANSA-N	PUBCHEM.COMPOUND:441336	UMLS:C0341106	mometasone furoate	Eosinophilic esophagitis	Designated	2019-06-26
WOLHOYHSEKDWQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64150	UMLS:C0013384	Amantadine HCl	Dyskinesia	Designated/Withdrawn	2015-07-20
WOLHOYHSEKDWQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:64150	UMLS:C0013384	Amantadine hydrochloride	Dyskinesia	Designated/Approved	2015-04-09
WONYMNWUJVKVII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:160565	UMLS:C0795889	3,5-diiodothyropropionic acid	Allan-Herndon-Dudley syndrome	Designated	2013-05-14
WONYMNWUJVKVII-UHFFFAOYSA-N	PUBCHEM.COMPOUND:160565	UMLS:C0795889	3,5-diiodothyropropionic acid	Allan-Herndon-Dudley syndrome	Designated	2020-07-28
WOSKHXYHFSIKNG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9823820	UMLS:C0025202	lenvatinib	melanoma	Designated	2014-03-26
WOSKHXYHFSIKNG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9823820	UMLS:C2239176	lenvatinib	HEPATOCELLULAR CARCINOMA	Designated/Approved	2014-03-27
WOSKHXYHFSIKNG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9823820	UMLS:C0238463	lenvatinib	papillary thyroid cancer	Designated/Approved	2012-12-27
WOVKYSAHUYNSMH-RRKCRQDMSA-N	PUBCHEM.COMPOUND:6035	UMLS:C0750974	Broxuridine	primary brain tumors	Designated	1995-09-18
WOXKDUGGOYFFRN-IIBYNOLFSA-N	PUBCHEM.COMPOUND:110635	UMLS:C3203102	tadalafil	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2006-12-18
WOXKDUGGOYFFRN-IIBYNOLFSA-N	PUBCHEM.COMPOUND:110635	UMLS:C0013264	tadalafil	DUCHENNE MUSCULAR DYSTROPHY	Designated	2015-05-04
WPEWQEMJFLWMLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11315474	UMLS:C0010606	Rivoceranib	Adenoid Cystic Carcinoma	Designated	2021-02-02
WPHKIQPVPYJNAX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:46207586	UMLS:C4721610	ilorasertib	Ovarian Cancer	Designated/Withdrawn	2012-03-16
WPTTVJLTNAWYAO-FUARBKCBSA-N	PUBCHEM.COMPOUND:70700216	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-FUARBKCBSA-N	PUBCHEM.COMPOUND:70700216	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-KPOXMGGZSA-N	PUBCHEM.COMPOUND:400769	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-KPOXMGGZSA-N	PUBCHEM.COMPOUND:400769	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-OROHISIGSA-N	PUBCHEM.COMPOUND:24896135	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-OROHISIGSA-N	PUBCHEM.COMPOUND:24896135	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-OYWPANLISA-N	PUBCHEM.COMPOUND:133109022	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-OYWPANLISA-N	PUBCHEM.COMPOUND:133109022	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-UFHYVYMVSA-N	PUBCHEM.COMPOUND:49827815	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-UFHYVYMVSA-N	PUBCHEM.COMPOUND:49827815	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53315588	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:53315588	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPTTVJLTNAWYAO-ZREYCQBLSA-N	PUBCHEM.COMPOUND:131632414	UMLS:C0085413	bardoxolone methyl	Autosomal dominant polycystic kidney disease	Designated	2019-06-03
WPTTVJLTNAWYAO-ZREYCQBLSA-N	PUBCHEM.COMPOUND:131632414	UMLS:C1567741	bardoxolone methyl	Alport Syndrome	Designated	2017-07-03
WPYMKLBDIGXBTP-UHFFFAOYSA-M	PUBCHEM.COMPOUND:242	UMLS:C0036341	benzoate	Schizophrenia	Designated	2012-07-06
WQZGKKKJIJFFOK-QTVWNMPRSA-N	PUBCHEM.COMPOUND:18950	UMLS:C1291601	D-mannose	isomerase deficiency	Designated	2019-01-14
WQZGKKKJIJFFOK-QTVWNMPRSA-N	PUBCHEM.COMPOUND:18950	UMLS:C1417244	D-mannose	mannose phosphate isomerase	Designated	2019-01-14
WQZGKKKJIJFFOK-SVZMEOIVSA-N	PUBCHEM.COMPOUND:6036	UMLS:C2752015	D-Galactose	PHOSPHOGLUCOMUTASE 1 DEFICIENCY	Designated	2019-01-14
WREGKURFCTUGRC-POYBYMJQSA-N	PUBCHEM.COMPOUND:24066	UMLS:C0001175	Zalcitabine	AIDS	Designated	1986-12-09
WREGKURFCTUGRC-POYBYMJQSA-N	PUBCHEM.COMPOUND:24066	UMLS:C0001175	Zalcitabine	AIDS	Designated/Approved	1988-06-28
WRFHGDPIDHPWIQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10257882	UMLS:C0022658	sparsentan	Nephropathy	Designated	2021-01-11
WRFHGDPIDHPWIQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10257882	UMLS:C0017668	sparsentan	Focal segmental glomerulosclerosis	Designated	2015-01-05
WRLGYAWRGXKSKG-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674889	UMLS:C0038220	phenobarbital sodium	Status Epilepticus	Designated	2020-02-26
WRLGYAWRGXKSKG-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674889	UMLS:C0159020	phenobarbital sodium	Neonatal seizures	Designated	2020-02-27
WRLGYAWRGXKSKG-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674889	UMLS:C0159020	Phenobarbital Sodium	Neonatal seizures	Designated	2020-09-30
WRLGYAWRGXKSKG-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674889	UMLS:C0159020	Phenobarbital sodium	Neonatal seizures	Designated	2018-03-28
WSEVKKHALHSUMB-RYVRVIGHSA-N	PUBCHEM.COMPOUND:129012199	UMLS:C0020615	exendin-(9-39)	Hypoglycemia	Designated	2011-06-01
WSEVKKHALHSUMB-RYVRVIGHSA-N	PUBCHEM.COMPOUND:129012199	UMLS:C3888018	exendin-(9-39)	Hyperinsulinemic Hypoglycemia	Designated	2011-06-01
WSNVXWWLBYSQIM-DMHHVDOYSA-N	PUBCHEM.COMPOUND:49855308	UMLS:C4048195	Encaleret sulfate	Autosomal dominant hypocalcemia	Designated	2020-11-24
WTCJDYDZHHFTEW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24182261	UMLS:C0010674	gallium citrate	Cystic Fibrosis	Designated	2019-06-24
WTJXVDPDEQKTCV-VQAITOIOSA-N	PUBCHEM.COMPOUND:54685925	UMLS:C0080032	Minocycline HCl	malignant pleural effusion	Designated/Withdrawn	1992-06-19
WTJXVDPDEQKTCV-VQAITOIOSA-N	PUBCHEM.COMPOUND:54685925	UMLS:C0036202	Minocycline hydrochloride	Sarcoidosis	Designated	2006-03-28
WTPZYIZNHQOCOQ-VQIWEWKSSA-N	PUBCHEM.COMPOUND:78324948	UMLS:C3203102	2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate	PULMONARY ARTERIAL HYPERTENSION	Designated	2018-01-23
WTWWXOGTJWMJHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9873	UMLS:C0012634	Perflubron	Disease	Designated	2001-04-26
WTWWXOGTJWMJHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9873	UMLS:C0035222	Perflubron	ARDS	Designated	2001-04-26
WTWWXOGTJWMJHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9873	UMLS:C0748355	Perflubron	Acute respiratory distress	Designated	2001-04-26
WUBBRNOQWQTFEX-UHFFFAOYSA-M	PUBCHEM.COMPOUND:54690315	UMLS:C0010346	Aminosalicylate sodium	Crohn's Disease	Designated/Withdrawn	1993-04-06
WUBBRNOQWQTFEX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4649	UMLS:C0010346	Aminosalicylate sodium	Crohn's Disease	Designated/Withdrawn	1993-04-06
WUBBRNOQWQTFEX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4649	UMLS:C0010346	4-aminosalicylic acid	Crohn's Disease	Designated	2006-04-26
WUBBRNOQWQTFEX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4649	UMLS:C0009324	4-aminosalicylic acid	Ulcerative Colitis	Designated	1989-12-13
WUBBRNOQWQTFEX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4649	UMLS:C0041296	Aminosalicylic acid	Tuberculosis	Designated/Approved	1992-02-19
WUIABRMSWOKTOF-FOBMNYSPSA-N	PUBCHEM.COMPOUND:57336513	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUIABRMSWOKTOF-NUAMMRKQSA-N	PUBCHEM.COMPOUND:54608728	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUIABRMSWOKTOF-OCBSMOPSSA-N	PUBCHEM.COMPOUND:72466	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUIABRMSWOKTOF-OYALTWQYSA-O	PUBCHEM.COMPOUND:71587153	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUIABRMSWOKTOF-PATWWPTKSA-N	PUBCHEM.COMPOUND:46930981	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUIABRMSWOKTOF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:21864427	UMLS:C0080032	Bleomycin sulfate	malignant pleural effusion	Designated/Approved	1993-09-17
WUILNKCFCLNXOK-CFBAGHHKSA-N	PUBCHEM.COMPOUND:5469318	UMLS:C0235974	salirasib	PANCREATIC CANCER	Designated/Withdrawn	2006-12-18
WVDSKQXKCDZXLH-OHIDFYLOSA-N	PUBCHEM.COMPOUND:71526737	UMLS:C3714796	macimorelin acetate	Growth hormone deficiency	Designated/Approved	2007-05-14
WVTKBKWTSCPRNU-KYJUHHDHSA-N	PUBCHEM.COMPOUND:73078	UMLS:C0023467	tetrandrine	Acute myeloid leukemia	Designated	2016-12-13
WVTKBKWTSCPRNU-KYJUHHDHSA-N	PUBCHEM.COMPOUND:73078	UMLS:C0023473	tetrandrine	Chronic myeloid leukemia	Designated	2016-05-19
WVXNSAVVKYZVOE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25066467	UMLS:C0279543	Rebastinib	Philadelphia Chromosome Positive Chronic Myeloid Leukemia	Designated	2009-09-03
WVXNSAVVKYZVOE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25066467	UMLS:C0238288	rebastinib	Facioscapulohumeral muscular dystrophy	Designated	2018-05-23
WVYXNIXAMZOZFK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42616	UMLS:C0006826	Diaziquone	MALIGNANCIES	Designated/Withdrawn	1983-11-10
WVYXNIXAMZOZFK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:42616	UMLS:C0004114	Diaziquone	Astrocytomas	Designated/Withdrawn	1983-11-10
WWFDJIVIDXJAQR-FFWSQMGZSA-N	PUBCHEM.COMPOUND:131801471	UMLS:C0026847	nusinersen	Spinal Muscular Atrophy	Designated/Approved	2011-04-18
WWJFFVUVFNBJTN-VHDFTHOZSA-N	PUBCHEM.COMPOUND:102515122	UMLS:C0009186	Nikkomycin Z	Coccidioidomycosis	Designated	2006-02-14
WWJFFVUVFNBJTN-VHDFTHOZSA-N	PUBCHEM.COMPOUND:102515122	UMLS:C0009186	Nikkomycin Z	Coccidioidomycosis	Designated	2006-02-14
WWVANQJRLPIHNS-ZKWXMUAHSA-N	PUBCHEM.COMPOUND:128878	UMLS:C0559477	2-iminobiotin	Perinatal asphyxia	Designated	2009-02-24
WXJFKKQWPMNTIM-VWLOTQADSA-N	PUBCHEM.COMPOUND:483477	UMLS:C0037356	brincidofovir	smallpox	Designated	2018-06-05
WXNXCEHXYPACJF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1995	UMLS:C0087012	N-acetyl-DL-leucine	Spinocerebellar ataxia	Designated	2018-06-06
WXNXCEHXYPACJF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1995	UMLS:C0268274	N-acetyl-DL-leucine	GM2 Gangliosidosis	Designated	2018-03-26
WXNXCEHXYPACJF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1995	UMLS:C0018790	N-acetyl-DL-leucine	SCA	Designated	2018-06-06
WXNXCEHXYPACJF-ZETCQYMHSA-N	PUBCHEM.COMPOUND:70912	UMLS:C0004135	N-Acetyl-Leucine	Ataxia Telangiectasia	Designated	2018-10-02
WXXSNCNJFUAIDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11304743	UMLS:C3203102	riociguat	PULMONARY ARTERIAL HYPERTENSION	Designated/Approved	2013-09-19
WXXSNCNJFUAIDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11304743	UMLS:C2363973	riociguat	Chronic thromboembolic pulmonary hypertension	Designated/Approved	2013-09-19
WXXSNCNJFUAIDG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:11304743	UMLS:C0036421	riociguat	Systemic sclerosis	Designated/Withdrawn	2014-07-24
WYHIICXRPHEJKI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:71433	UMLS:C0677050	trientine hydrochloride	Manganism	Designated	2010-11-02
WYQFJHHDOKWSHR-MNOVXSKESA-N	PUBCHEM.COMPOUND:58557659	UMLS:C1384600	upadacitinib	Systemic juvenile idiopathic arthritis	Designated	2017-08-16
WYQFJHHDOKWSHR-MNOVXSKESA-N	PUBCHEM.COMPOUND:58557659	UMLS:C2931173	upadacitinib	Pediatric ulcerative colitis	Designated	2019-12-30
WYQFJHHDOKWSHR-MNOVXSKESA-N	PUBCHEM.COMPOUND:58557659	UMLS:C3495559	upadacitinib	juvenile idiopathic arthritis	Designated	2015-09-18
WYQFJHHDOKWSHR-MNOVXSKESA-N	PUBCHEM.COMPOUND:58557659	UMLS:C3714757	upadacitinib	Juvenile idiopathic arthritis	Designated	2015-09-18
WYQPLTPSGFELIB-JTQPXKBDSA-N	PUBCHEM.COMPOUND:443936	UMLS:C0030343	difluprednate	Panuveitis	Designated/Approved	2008-09-30
WYQPLTPSGFELIB-JTQPXKBDSA-N	PUBCHEM.COMPOUND:443936	UMLS:C4325554	difluprednate	Traumatic anterior uveitis	Designated/Approved	2008-09-30
WZHKXNSOCOQYQX-XFUHGIIQSA-N	PUBCHEM.COMPOUND:44368295	UMLS:C0015544	His-D-Trp-Ala-Trp-D-Phe-Lys NH2	growth failure	Designated/Withdrawn	1990-05-23
WZPBZJONDBGPKJ-CAOOACKPSA-N	PUBCHEM.COMPOUND:5466987	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-CAOOACKPSA-N	PUBCHEM.COMPOUND:5466987	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-CAOOACKPSA-N	PUBCHEM.COMPOUND:5466987	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-FSPLSTOPSA-N	PUBCHEM.COMPOUND:54117	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-FSPLSTOPSA-N	PUBCHEM.COMPOUND:54117	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-FSPLSTOPSA-N	PUBCHEM.COMPOUND:54117	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-HMTIBFNOSA-N	PUBCHEM.COMPOUND:86741379	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-HMTIBFNOSA-N	PUBCHEM.COMPOUND:86741379	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-HMTIBFNOSA-N	PUBCHEM.COMPOUND:86741379	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-IYZXUIDESA-N	PUBCHEM.COMPOUND:5459211	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-IYZXUIDESA-N	PUBCHEM.COMPOUND:5459211	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-IYZXUIDESA-N	PUBCHEM.COMPOUND:5459211	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-NACOFCMISA-N	PUBCHEM.COMPOUND:22842006	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-NACOFCMISA-N	PUBCHEM.COMPOUND:22842006	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-NACOFCMISA-N	PUBCHEM.COMPOUND:22842006	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-PSGLRMFWSA-N	PUBCHEM.COMPOUND:56842327	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-PSGLRMFWSA-N	PUBCHEM.COMPOUND:56842327	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-PSGLRMFWSA-N	PUBCHEM.COMPOUND:56842327	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2274	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
WZPBZJONDBGPKJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2274	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2274	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-VEHQQRBSSA-N	PUBCHEM.COMPOUND:5742832	UMLS:C0006267	aztreonam	Bronchiectasis	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-VEHQQRBSSA-N	PUBCHEM.COMPOUND:5742832	UMLS:C0037090	aztreonam	Respiratory symptoms	Designated/Withdrawn	2009-05-15
WZPBZJONDBGPKJ-VEHQQRBSSA-N	PUBCHEM.COMPOUND:5742832	UMLS:C0010674	aztreonam	Cystic Fibrosis	Designated/Approved	2002-03-12
XAKLYHGHEFMDAP-UNMCSNQZSA-N	PUBCHEM.COMPOUND:57887037	UMLS:C0279530	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	Bone Cancer	Designated	2007-06-15
XASIMHXSUQUHLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2536	UMLS:C0149521	camostat	Chronic pancreatitis	Designated	2011-05-18
XAUDJQYHKZQPEU-KVQBGUIXSA-N	PUBCHEM.COMPOUND:451668	UMLS:C3463824	decitabine	Myelodysplastic Syndromes	Designated/Approved	1999-03-08
XAUDJQYHKZQPEU-KVQBGUIXSA-N	PUBCHEM.COMPOUND:451668	UMLS:C0002895	decitabine	SICKLE CELL ANEMIA	Designated/Withdrawn	2002-09-09
XAUDJQYHKZQPEU-KVQBGUIXSA-N	PUBCHEM.COMPOUND:451668	UMLS:C0023467	decitabine	Acute myeloid leukemia	Designated/Withdrawn	2006-08-04
XAUDJQYHKZQPEU-KVQBGUIXSA-N	PUBCHEM.COMPOUND:451668	UMLS:C0085669	5-aza-2'-deoxycytidine	Acute leukemia	Designated	1987-08-03
XAUDJQYHKZQPEU-KVQBGUIXSA-N	PUBCHEM.COMPOUND:451668	UMLS:C0023473	decitabine	Chronic myelogenous leukemia	Designated/Withdrawn	1999-03-08
XAYGBKHKBBXDAK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:59634741	UMLS:C0039730	Mitapivat	Thalassemia	Designated	2020-06-08
XAYGBKHKBBXDAK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:59634741	UMLS:C0002895	mitapivat	Sickle Cell Disease	Designated	2020-11-12
XCPGHVQEEXUHNC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2179	UMLS:C1547229	Amsacrine	Acute	Designated/Withdrawn	1984-12-07
XCPGHVQEEXUHNC-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2179	UMLS:C0023418	Amsacrine	leukemia	Designated/Withdrawn	1984-12-07
XDAOLTSRNUSPPH-XMMPIXPASA-N	PUBCHEM.COMPOUND:6480466	UMLS:C0041327	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole	Pulmonary tuberculosis	Designated	2007-07-12
XDCNKOBSQURQOZ-UHFFFAOYSA-L	PUBCHEM.COMPOUND:135414247	UMLS:C0009324	Balsalazide disodium	Ulcerative Colitis	Designated/Approved	2005-08-12
XDPFHGWVCTXHDX-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23665888	UMLS:C0158683	menadione sodium bisulfite	Polycystic liver disease	Designated	2014-05-14
XDPFHGWVCTXHDX-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23665888	UMLS:C0085413	Menadione Sodium Bisulfite	Autosomal dominant polycystic kidney disease	Designated	2014-05-14
XDRYMKDFEDOLFX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4735	UMLS:C0279000	pentamidine	Liver and Intrahepatic Bile Duct Cancer	Designated/Withdrawn	2013-08-12
XDRYMKDFEDOLFX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4735	UMLS:C4721610	pentamidine	Ovarian Cancer	Designated/Withdrawn	2013-08-12
XDRYMKDFEDOLFX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4735	UMLS:C0235974	pentamidine	PANCREATIC CANCER	Designated/Withdrawn	2010-09-13
XDXDZDZNSLXDNA-TZNDIEGXSA-N	PUBCHEM.COMPOUND:42890	UMLS:C3463824	Idarubicin	Myelodysplastic Syndromes	Designated/Withdrawn	1992-12-01
XDXDZDZNSLXDNA-TZNDIEGXSA-N	PUBCHEM.COMPOUND:42890	UMLS:C0023473	Idarubicin	Chronic myelogenous leukemia	Designated/Withdrawn	1992-12-02
XDZAHHULFQIBFE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24875489	UMLS:C0079773	methylparaben suberohydroxamic acid phenyl ester	cutaneous T-cell lymphoma	Designated	2013-04-15
XFCLJVABOIYOMF-QPLCGJKRSA-N	PUBCHEM.COMPOUND:3005573	UMLS:C1384494	Toremifene	Metastatic Carcinoma	Designated/Approved	1991-09-19
XFCLJVABOIYOMF-QPLCGJKRSA-N	PUBCHEM.COMPOUND:3005573	UMLS:C0678222	Toremifene	Carcinoma of the Breast	Designated/Approved	1991-09-19
XFCLJVABOIYOMF-QPLCGJKRSA-N	PUBCHEM.COMPOUND:3005573	UMLS:C0079218	Toremifene	desmoid tumors	Designated	1993-08-17
XGALLCVXEZPNRQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123631	UMLS:C3539721	gefitinib	Non-Small Cell Lung Cancer	Designated/Approved	2014-08-26
XGZVUEUWXADBQD-UHFFFAOYSA-L	PUBCHEM.COMPOUND:11125	UMLS:C1800706	lithium carbonate	Idiopathic Pulmonary Fibrosis	Designated	2021-03-29
XHWRWCSCBDLOLM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135400184	UMLS:C2239176	nolatrexed	HEPATOCELLULAR CARCINOMA	Designated/Withdrawn	2001-10-18
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C1337013	selpercatinib	Thyroid Cancers	Designated/Approved	2019-11-21
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C0238461	selpercatinib	anaplastic thyroid cancer	Designated/Approved	2019-11-21
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C3539721	selpercatinib	Non-Small Cell Lung Cancer	Designated/Approved	2019-10-30
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C0235974	6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile	PANCREATIC CANCER	Designated	2018-10-10
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C0549473	selpercatinib	medullary	Designated/Approved	2019-11-21
XIIOFHFUYBLOLW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:134436906	UMLS:C0238462	selpercatinib	Thyroid cancer	Designated/Approved	2019-11-21
XIJXHOVKJAXCGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:14326905	UMLS:C0017638	5-iodo-2-pyrimidinone-2'-deoxyribose	Glioma	Designated	2006-05-26
XIJXHOVKJAXCGJ-XLPZGREQSA-N	PUBCHEM.COMPOUND:9840777	UMLS:C0017638	ropidoxuridine	Glioma	Designated	2016-05-19
XIJXHOVKJAXCGJ-XLPZGREQSA-N	PUBCHEM.COMPOUND:9840777	UMLS:C0017638	5-iodo-2-pyrimidinone-2'-deoxyribose	Glioma	Designated	2006-05-26
XIKSEDLKDYKPTO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10038269	UMLS:C0268381	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	AL Amyloidosis	Designated	2014-10-15
XJDYQYNYISTAMO-GFDYFVENSA-N	PUBCHEM.COMPOUND:25063260	UMLS:C3463824	ezatiostat hydrochloride	MYELODYSPLASTIC SYNDROME	Designated	2013-01-09
XKYJAZULGNDPLX-IXIFSOOLSA-N	PUBCHEM.COMPOUND:87060529	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
XKYJAZULGNDPLX-VKZZUTNHSA-N	PUBCHEM.COMPOUND:9894479	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
XLXXBYJYWULGGD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:69619483	UMLS:C0235280	2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide	Ototoxicity	Designated/Withdrawn	2017-12-14
XLZOVRYBVCMCGL-BPNVQINPSA-L	PUBCHEM.COMPOUND:49867944	UMLS:C0017636	disufenton sodium	Glioblastoma multiforme	Designated/Withdrawn	2016-08-22
XLZOVRYBVCMCGL-BPNVQINPSA-L	PUBCHEM.COMPOUND:49867944	UMLS:C0555198	Disufenton sodium	Malignant Glioma	Designated	2020-08-14
XLZOVRYBVCMCGL-BPNVQINPSA-L	PUBCHEM.COMPOUND:49867944	UMLS:C0555198	Disufenton sodium	Malignant Glioma	Designated	2020-08-14
XLZOVRYBVCMCGL-BPNVQINPSA-L	PUBCHEM.COMPOUND:49867944	UMLS:C0017636	disufenton sodium	Glioblastoma multiforme	Designated/Withdrawn	2016-08-22
XMAYWYJOQHXEEK-ANWICMFUSA-N	PUBCHEM.COMPOUND:16757695	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMAYWYJOQHXEEK-NASUQTAISA-N	PUBCHEM.COMPOUND:5702077	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMAYWYJOQHXEEK-OZXSUGGESA-N	PUBCHEM.COMPOUND:456201	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMAYWYJOQHXEEK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3823	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMAYWYJOQHXEEK-ZEQKJWHPSA-N	PUBCHEM.COMPOUND:47576	UMLS:C0010481	2S,4R ketoconazole	Cushing's Syndrome	Designated	2012-03-09
XMAYWYJOQHXEEK-ZEQKJWHPSA-N	PUBCHEM.COMPOUND:47576	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMAYWYJOQHXEEK-ZZHFZYNASA-N	PUBCHEM.COMPOUND:73951506	UMLS:C0595916	Ketoconazole	nephrotoxicity	Designated/Withdrawn	1991-03-27
XMCDZRXQAGFWAK-PMCOHIMVSA-L	PUBCHEM.COMPOUND:60196280	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
XMYKNCNAZKMVQN-NYYWCZLTSA-N	PUBCHEM.COMPOUND:9571836	UMLS:C4048328	3-aminopyridine-2-carboxaldehyde thiosemicarbazone	cervical cancer	Designated	2017-11-08
XMYKNCNAZKMVQN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3006315	UMLS:C4048328	3-aminopyridine-2-carboxaldehyde thiosemicarbazone	cervical cancer	Designated	2017-11-08
XMYKNCNAZKMVQN-WCIBSUBMSA-N	PUBCHEM.COMPOUND:5468049	UMLS:C4048328	3-aminopyridine-2-carboxaldehyde thiosemicarbazone	cervical cancer	Designated	2017-11-08
XNACDNPGABUBFR-FKNPGSCZSA-N	PUBCHEM.COMPOUND:56840904	UMLS:C0027819	Iobenguane Sulfate I-123	Neuroblastoma	Designated	2005-10-17
XNACDNPGABUBFR-FKNPGSCZSA-N	PUBCHEM.COMPOUND:56840904	UMLS:C0031511	iobenguane sulfate I-123	Pheochromocytomas	Designated	2005-10-21
XNACDNPGABUBFR-GNPGNDBSSA-N	PUBCHEM.COMPOUND:76971242	UMLS:C0031511	Iobenguane Sulfate I 131	Pheochromocytoma	Designated/Approved/Withdrawn	1984-11-14
XNOPRXBHLZRZKH-DSZYJQQASA-N	PUBCHEM.COMPOUND:439302	UMLS:C0032897	oxytocin	Prader-Willi Syndrome	Designated	2014-11-24
XNOPRXBHLZRZKH-DSZYJQQASA-N	PUBCHEM.COMPOUND:439302	UMLS:C0032897	oxytocin	Prader-Willi Syndrome	Designated	2017-06-15
XNSAINXGIQZQOO-SRVKXCTJSA-N	PUBCHEM.COMPOUND:638678	UMLS:C0035220	Protirelin	infant respiratory distress syndrome	Designated/Withdrawn	1993-08-24
XNSAINXGIQZQOO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:32281	UMLS:C0007097	Thyrotropin alfa	Carcinomas	Designated/Approved	2001-08-03
XNXVOSBNFZWHBV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:521874	UMLS:C0555198	Methoxyamine hydrochloride	Malignant Glioma	Designated	2020-10-22
XOAAWQZATWQOTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1123	UMLS:C0019880	taurine	Homocystinuria	Designated	2010-03-22
XOGTZOOQQBDUSI-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23662354	UMLS:C0085692	Mesna	Hemorrhagic cystitis	Designated/Approved	1985-11-14
XPEHHUISIBFLHX-QFWMXSHPSA-N	PUBCHEM.COMPOUND:121439966	UMLS:C0010674	N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide	Cystic Fibrosis	Designated	2018-03-07
XPVOJYDIBHYVFL-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5458180	UMLS:C0019202	Trientine HCl	Wilson's Disease	Designated/Approved	1984-12-24
XQFRJNBWHJMXHO-RRKCRQDMSA-N	PUBCHEM.COMPOUND:5905	UMLS:C1261473	Idoxuridine	Sarcomas	Designated	1996-04-08
XQYZDYMELSJDRZ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4680	UMLS:C1412000	papaverine	Mesenteric Ischemia	Designated	2017-08-03
XRASPMIURGNCCH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68740	UMLS:C0458219	zoledronic acid	Complex regional pain syndrome	Designated	2013-05-06
XRASPMIURGNCCH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68740	UMLS:C0020437	Zoledronate	Hypercalcemia	Designated/Approved	2000-08-18
XRASPMIURGNCCH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68740	UMLS:C0027651	Zoledronate	Tumor	Designated/Approved	2000-08-18
XRPSUWYWZUQALB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:86298861	UMLS:C0010674	2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide	Cystic Fibrosis	Designated	2015-05-13
XRVDGNKRPOAQTN-FQEVSTJZSA-N	PUBCHEM.COMPOUND:52938427	UMLS:C0009324	ozanimod	Ulcerative Colitis	Designated	2015-12-29
XRVDGNKRPOAQTN-FQEVSTJZSA-N	PUBCHEM.COMPOUND:52938427	UMLS:C0010346	ozanimod	Crohns Disease	Designated	2017-11-01
XSENLDLUMVYRET-BTQNPOSSSA-N	PUBCHEM.COMPOUND:72710735	UMLS:C0028064	arimoclomol citrate	neimann-pick disease	Designated	2015-01-13
XSFPZBUIBYMVEA-CELUQASASA-N	PUBCHEM.COMPOUND:25253377	UMLS:C0206754	telotristat etiprate	Neuroendocrine Tumors	Designated/Approved	2012-03-09
XSFPZBUIBYMVEA-CELUQASASA-N	PUBCHEM.COMPOUND:25253377	UMLS:C0024586	telotristat etiprate	Carcinoid syndrome	Designated/Approved	2012-03-09
XSMSNFMDVXXHGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:59473233	UMLS:C0023434	entospletinib	Chronic Lymphocytic Leukemia	Designated	2014-04-14
XSMSNFMDVXXHGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:59473233	UMLS:C0023467	entospletinib	Acute myeloid leukemia	Designated	2017-06-15
XSMSNFMDVXXHGJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:59473233	UMLS:C0867389	entospletinib	Chronic graft-versus-host disease	Designated	2017-08-10
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0079154	urea	Lamellar ichthyosis	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0265267	urea	Child syndrome	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0239849	urea	Harlequin Ichthyosis	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0265962	urea	Netherton Syndrome	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0268238	urea	Neutral lipid storage disease	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0079588	urea	X-linked ichthyosis	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C1955934	urea	Trichothiodystrophy	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0011606	urea	Erythroderma	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C0079153	urea	Epidermolytic hyperkeratosis	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C3543867	urea	Collodion Baby	Designated	2011-11-07
XSQUKJJJFZCRTK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1176	UMLS:C3665333	urea	Kid syndrome	Designated	2011-11-07
XSSYCIGJYCVRRK-NKWVEPMBSA-N	PUBCHEM.COMPOUND:135538685	UMLS:C0019693	Carbovir	HIV infection	Designated/Withdrawn	1989-12-13
XSSYCIGJYCVRRK-NKWVEPMBSA-N	PUBCHEM.COMPOUND:135538685	UMLS:C0001175	Carbovir	AIDS	Designated/Withdrawn	1989-12-13
XSSYCIGJYCVRRK-RQJHMYQMSA-N	PUBCHEM.COMPOUND:135433604	UMLS:C0001175	Carbovir	AIDS	Designated/Withdrawn	1989-12-13
XSSYCIGJYCVRRK-RQJHMYQMSA-N	PUBCHEM.COMPOUND:135433604	UMLS:C0019693	Carbovir	HIV infection	Designated/Withdrawn	1989-12-13
XSSYCIGJYCVRRK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135403630	UMLS:C0019693	Carbovir	HIV infection	Designated/Withdrawn	1989-12-13
XSSYCIGJYCVRRK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:135403630	UMLS:C0001175	Carbovir	AIDS	Designated/Withdrawn	1989-12-13
XTTZERNUQAFMOF-QMMMGPOBSA-N	PUBCHEM.COMPOUND:11658860	UMLS:C0751122	Lorcaserin	Dravet Syndrome	Designated	2020-08-31
XTTZERNUQAFMOF-QMMMGPOBSA-N	PUBCHEM.COMPOUND:11658860	UMLS:C0751122	lorcaserin	Dravet Syndrome	Designated	2017-04-17
XUHBBTKJWIBQMY-MHZLTWQESA-N	PUBCHEM.COMPOUND:9831652	UMLS:C0876926	Anatibant	Traumatic Brain Injury	Designated	2005-04-15
XUJNEKJLAYXESH-REOHCLBHSA-N	PUBCHEM.COMPOUND:5862	UMLS:C0349506	L-cysteine	Photosensitivity	Designated	1994-05-16
XUJNEKJLAYXESH-REOHCLBHSA-N	PUBCHEM.COMPOUND:5862	UMLS:C0162568	L-cysteine	Erythropoietic Protoporphyria	Designated	1994-05-16
XULSCZPZVQIMFM-IPZQJPLYSA-N	PUBCHEM.COMPOUND:10153627	UMLS:C0005411	odevixibat	Biliary Atresia	Designated	2019-01-16
XUZMWHLSFXCVMG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:44205240	UMLS:C0024141	baricitinib	SYSTEMIC LUPUS ERYTHEMATOSUS	Designated	2017-11-02
XVDFMHARQUBJRE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68643	UMLS:C0028754	Betahistine dihydrochloride	Obesity	Designated	2007-11-08
XVDFMHARQUBJRE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:68643	UMLS:C0032897	Betahistine dihydrochloride	Prader Willi syndrome	Designated	2007-11-08
XWFCFMXQTBGXQW-GOSISDBHSA-N	PUBCHEM.COMPOUND:44242317	UMLS:C0343386	cadazolid	Clostridium difficile infection	Designated	2017-08-08
XWHPUCFOTRBMGS-UHFFFAOYSA-L	PUBCHEM.COMPOUND:23724874	UMLS:C0006826	Disodium clodronate tetrahydrate	Malignancy	Designated	1990-03-05
XWLUWCNOOVRFPX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56339	UMLS:C0038220	Fosphenytoin	Status Epilepticus	Designated/Approved	1991-06-04
XWLUWCNOOVRFPX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56339	UMLS:C0014549	Fosphenytoin	Grand mal	Designated/Approved	1991-06-04
XXJWYDDUDKYVKI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9933475	UMLS:C0017636	cediranib	Glioblastoma	Designated	2010-12-13
XXUPXHKCPIKWLR-JHUOEJJVSA-N	PUBCHEM.COMPOUND:5282175	UMLS:C0035334	unoprostone isopropyl	Retinitis Pigmentosa	Designated/Withdrawn	2010-09-16
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0242647	ibrutinib	marginal zone lymphoma	Designated/Approved	2016-02-02
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0023434	ibrutinib	Chronic Lymphocytic Leukemia	Designated/Approved	2012-04-06
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0349632	ibrutinib	Splenic marginal zone lymphoma	Designated/Approved	2015-02-05
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0023434	ibrutinib	Small Lymphocytic Lymphoma	Designated/Approved	2013-05-30
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0024301	ibrutinib	follicular lymphoma	Designated	2014-09-08
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0023434	ibrutinib	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2012-03-27
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0024299	ibrutinib	Lymphoma	Designated/Approved	2016-02-02
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0024419	ibrutinib	Waldenstrom's Macroglobulinemia	Designated/Approved	2013-10-15
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C1367654	ibrutinib	Marginal zone lymphoma	Designated/Approved	2016-02-02
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0024623	ibrutinib	Gastric Cancer	Designated	2018-02-01
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0867389	ibrutinib	Chronic Graft Versus Host Disease	Designated/Approved	2016-06-23
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0026764	ibrutinib	Multiple Myeloma	Designated	2013-05-16
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0235974	ibrutinib	PANCREATIC CANCER	Designated	2017-06-12
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C4721414	ibrutinib	Mantle cell lymphoma	Designated/Approved	2012-12-03
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0023434	ibrutinib	Chronic Lymphocytic Leukemia	Designated/Approved	2012-04-06
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C1332166	ibrutinib	Gastroesophageal Junction Adenocarcinoma	Designated	2018-02-01
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C1332201	ibrutinib	Diffuse Large B-Cell Lymphoma	Designated	2013-10-23
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0242647	ibrutinib	Nodal marginal zone lymphoma	Designated/Approved	2015-02-05
XYFPWWZEPKGCCK-GOSISDBHSA-N	PUBCHEM.COMPOUND:24821094	UMLS:C0023434	ibrutinib	Chronic Lymphocytic Leukemia	Designated/Approved	2012-04-06
XYGBKMMCQDZQOZ-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23663870	UMLS:C0027404	sodium oxybate	Narcolepsy	Designated/Approved	1994-11-07
XYGBKMMCQDZQOZ-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23663870	UMLS:C0027404	sodium oxybate	Narcolepsy	Designated/Approved	1994-11-07
XYGBKMMCQDZQOZ-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23663870	UMLS:C0027404	sodium oxybate	Narcolepsy	Designated/Approved	1994-11-07
XYLJNLCSTIOKRM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2435	UMLS:C5203917	brimonidine	Ocular Graft Versus Host Disease	Designated	2017-08-03
XYLJNLCSTIOKRM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:2435	UMLS:C0751711	Brimonidine	Anterior Ischemic Optic Neuropathy	Designated	2000-02-07
XZAFZXJXZHRNAQ-STQMWFEESA-N	PUBCHEM.COMPOUND:9952884	UMLS:C0023467	vosaroxin	Acute myeloid leukemia	Designated	2009-10-28
XZWYZXLIPXDOLR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4091	UMLS:C0751783	metformin	Lafora Disease	Designated	2017-12-14
XZWYZXLIPXDOLR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4091	UMLS:C0032460	metformin	Polycystic Ovary Syndrome	Designated/Withdrawn	2014-05-29
XZWYZXLIPXDOLR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4091	UMLS:C0751778	metformin	progressive myoclonus epilepsy	Designated	2017-12-14
XZZUHXILQXLTGV-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674730	UMLS:C0002895	varespladib sodium	Sickle Cell Disease	Designated/Withdrawn	2007-11-19
XZZUHXILQXLTGV-UHFFFAOYSA-M	PUBCHEM.COMPOUND:23674730	UMLS:C0742343	varespladib sodium	Acute Chest Syndrome	Designated/Withdrawn	2007-11-19
YALNUENQHAQXEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9804992	UMLS:C0032463	Givinostat	Polycythemia Vera	Designated	2017-09-28
YALNUENQHAQXEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9804992	UMLS:C0013264	givinostat	DUCHENNE MUSCULAR DYSTROPHY	Designated	2013-04-12
YALNUENQHAQXEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9804992	UMLS:C0917713	givinostat	Becker Muscular Dystrophy	Designated	2013-04-12
YASYEJJMZJALEJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:22230	UMLS:C3850141	citric acid monohydrate	Acute-On-Chronic Liver Failure	Designated	2017-06-21
YBJHBAHKTGYVGT-ZKWXMUAHSA-N	PUBCHEM.COMPOUND:171548	UMLS:C0007959	Biotin	Charcot-Marie-Tooth Disease	Designated	2020-09-08
YBVNFKZSMZGRAD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:8813	UMLS:C1535939	Pentamidine isethionate	Pneumocystis carinii Pneumonia	Designated/Approved	1984-02-28
YBVNFKZSMZGRAD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:8813	UMLS:C1535939	Pentamidine isethionate	Pneumocystis carinii Pneumonia	Designated	1984-10-29
YBVNFKZSMZGRAD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:8813	UMLS:C1535939	Pentamidine isethionate	Pneumocystis carinii Pneumonia	Designated/Approved	1988-01-12
YCHYFHOSGQABSW-RTBURBONSA-N	PUBCHEM.COMPOUND:3083542	UMLS:C0011633	lenabasum	Dermatomyositis	Designated	2018-07-18
YCPOZVAOBBQLRI-PHDIDXHHSA-N	PUBCHEM.COMPOUND:95839	UMLS:C4721610	Treosulfan	Ovarian Cancer	Designated	1994-05-16
YCPOZVAOBBQLRI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:9296	UMLS:C4721610	Treosulfan	Ovarian Cancer	Designated	1994-05-16
YCPOZVAOBBQLRI-WDSKDSINSA-N	PUBCHEM.COMPOUND:9882105	UMLS:C4721610	Treosulfan	Ovarian Cancer	Designated	1994-05-16
YDDMIZRDDREKEP-HWTBNCOESA-N	PUBCHEM.COMPOUND:57327016	UMLS:C3540630	lurbinectedin	Small Cell Lung Cancer	Designated/Approved	2018-08-01
YDDMIZRDDREKEP-HWTBNCOESA-N	PUBCHEM.COMPOUND:57327016	UMLS:C4721610	lurbinectedin	Ovarian Cancer	Designated	2012-08-20
YDDMIZRDDREKEP-HWTBNCOESA-N	PUBCHEM.COMPOUND:57327016	UMLS:C0262584	lurbinectedin	SCLC	Designated/Approved	2018-08-01
YDOIFHVUBCIUHF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3663	UMLS:C0079773	hypericin	cutaneous T-cell lymphoma	Designated	2000-02-07
YDOIFHVUBCIUHF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3663	UMLS:C0017636	Hypericin	Glioblastoma multiforme	Designated	2000-08-03
YDZYKNJZCVIKPP-VWLOTQADSA-N	PUBCHEM.COMPOUND:9870520	UMLS:C0007095	netazepide	Carcinoids	Designated	2009-09-10
YEEGWNXDUZONAA-RYDPDVNUSA-K	PUBCHEM.COMPOUND:65430	UMLS:C0010674	gallium citrate	Cystic Fibrosis	Designated	2019-06-24
YEEGWNXDUZONAA-UHFFFAOYSA-K	PUBCHEM.COMPOUND:34058	UMLS:C0010674	gallium citrate	Cystic Fibrosis	Designated	2019-06-24
YEHCICAEULNIGD-MZMPZRCHSA-N	PUBCHEM.COMPOUND:47811	UMLS:C0040517	Pergolide	Tourette's Syndrome	Designated/Withdrawn	1997-11-20
YEZNLOUZAIOMLT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:610479	UMLS:C0038868	tolfenamic acid	Progressive supranuclear palsy	Designated	2016-07-13
YEZNLOUZAIOMLT-UHFFFAOYSA-N	PUBCHEM.COMPOUND:610479	UMLS:C0338451	tolfenamic acid	Frontotemporal dementia	Designated	2016-07-13
YFGBQHOOROIVKG-FKBYEOEOSA-N	PUBCHEM.COMPOUND:443363	UMLS:C0279000	opioid growth factor	Liver and Intrahepatic Bile Duct Cancer	Designated	2013-04-16
YFGBQHOOROIVKG-FKBYEOEOSA-N	PUBCHEM.COMPOUND:443363	UMLS:C0235974	[met5]-enkephalin	PANCREATIC CANCER	Designated	2013-01-24
YFGHCGITMMYXAQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4236	UMLS:C4551761	Modafinil	Excessive daytime sleepiness	Designated/Approved	1993-03-15
YFGHCGITMMYXAQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4236	UMLS:C0027404	Modafinil	Narcolepsy	Designated/Approved	1993-03-15
YFHRCLAKZBDRHN-MRXNPFEDSA-N	PUBCHEM.COMPOUND:60199242	UMLS:C0017205	venglustat	Gaucher Disease	Designated	2014-09-11
YFHRCLAKZBDRHN-MRXNPFEDSA-N	PUBCHEM.COMPOUND:60199242	UMLS:C0085413	venglustat	Autosomal dominant polycystic kidney disease	Designated	2018-05-01
YFHRCLAKZBDRHN-MRXNPFEDSA-N	PUBCHEM.COMPOUND:60199242	UMLS:C0002986	Venglustat	Fabry's Disease	Designated	2014-08-26
YGCADXGQGUPFOA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:154925881	UMLS:C0235974	5-methyl cromolyn	PANCREATIC CANCER	Designated	2020-09-23
YHTTWXCDIRTOQX-FQJIPJFPSA-N	PUBCHEM.COMPOUND:134611625	UMLS:C0235974	internalized-arginylglycylaspartic acid cyclic peptide	PANCREATIC CANCER	Designated	2019-01-29
YIQPUIGJQJDJOS-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65015	UMLS:C0023467	plerixafor	Acute myeloid leukemia	Designated/Withdrawn	2011-07-28
YJGVMLPVUAXIQN-HAEOHBJNSA-N	PUBCHEM.COMPOUND:72435	UMLS:C0017638	Picropodophyllin	Glioma	Designated	2017-07-27
YKGYIDJEEQRWQH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3447	UMLS:C0042384	Gabexate	Vasculitis	Designated	2020-09-18
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0442874	capsaicin	Neuropathy	Designated	2003-05-02
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0032768	capsaicin	Postherpetic neuralgia	Designated/Approved	2009-05-22
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0027796	capsaicin	Neuropathic Pain	Designated/Approved	2009-05-22
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0019682	capsaicin	HIV	Designated	2003-05-02
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0311337	capsaicin	Intermetatarsal Neuroma	Designated	2006-09-29
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0014804	capsaicin	Erythromelalgia	Designated	2002-10-23
YKPUWZUDDOIDPM-SOFGYWHQSA-N	PUBCHEM.COMPOUND:1548943	UMLS:C0032768	Capsaicin	Postherpetic neuralgia	Designated	2005-08-03
YKPUWZUDDOIDPM-VURMDHGXSA-N	PUBCHEM.COMPOUND:1548942	UMLS:C0032768	civamide	Postherpetic neuralgia	Designated	2009-02-17
YKPUWZUDDOIDPM-VURMDHGXSA-N	PUBCHEM.COMPOUND:1548942	UMLS:C0032768	civamide	Postherpetic neuralgia	Designated	2002-12-09
YKUQEKXHQFYULM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:156867	UMLS:C0024530	Pyronaridine tetraphosphate	Malaria	Designated	2020-02-11
YKUQEKXHQFYULM-UHFFFAOYSA-N	PUBCHEM.COMPOUND:156867	UMLS:C0282687	pyronaridine tetraphosphate	Ebola Infection	Designated	2019-02-28
YLDCUKJMEKGGFI-QCSRICIXSA-N	PUBCHEM.COMPOUND:135449284	UMLS:C0038522	Inosine pranobex	Subacute Sclerosing Panencephalitis	Designated	1988-09-20
YLLWQNAEYILHLV-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25014811	UMLS:C0032897	diazoxide choline	Prader-Willi Syndrome	Designated	2014-05-13
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C3463824	Imatinib mesylate	Myelodysplastic Syndromes	Designated/Approved	2005-10-05
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0206141	Imatinib mesylate	Idiopathic Hypereosinophilic Syndrome	Designated/Approved	2005-08-25
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0812325	Imatinib mesylate	Growth Factor Gene	Designated/Approved	2005-10-05
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C3203102	imatinib mesylate	PULMONARY ARTERIAL HYPERTENSION	Designated	2020-06-15
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0206647	imatinib mesylate	Dermatofibrosarcoma Protuberans	Designated/Approved	2005-12-19
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0238198	imatinib mesylate	Gastrointestinal Stromal Tumors	Designated/Approved	2001-11-01
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0238198	imatinib mesylate	Gastrointestinal Stromal Tumors	Designated/Approved	2001-11-01
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0221013	Imatinib mesylate	Systemic mastocytosis	Designated/Approved	2005-09-09
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0027022	Imatinib mesylate	Myeloproliferative Disorders	Designated/Approved	2005-10-05
YLMAHDNUQAMNNX-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123596	UMLS:C0346421	Imatinib mesylate	Chronic eosinophilic leukemia	Designated/Approved	2005-08-25
YLXBBCDOUAHKIB-LJKCMNKDSA-N	PUBCHEM.COMPOUND:121488160	UMLS:C1332201	Rosomidnar	Diffuse Large B-Cell Lymphoma	Designated/Withdrawn	2016-03-10
YLXBBCDOUAHKIB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:119058033	UMLS:C1332201	Rosomidnar	Diffuse Large B-Cell Lymphoma	Designated/Withdrawn	2016-03-10
YOBPSXOHCHDCMU-FDDQUTDISA-M	PUBCHEM.COMPOUND:137705394	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOBPSXOHCHDCMU-IXIFSOOLSA-L	PUBCHEM.COMPOUND:86287429	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOBPSXOHCHDCMU-IXIFSOOLSA-M	PUBCHEM.COMPOUND:23709629	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOBPSXOHCHDCMU-OOUOULNMSA-M	PUBCHEM.COMPOUND:77906400	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOBPSXOHCHDCMU-UHFFFAOYSA-M	PUBCHEM.COMPOUND:53394792	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOBPSXOHCHDCMU-VKZZUTNHSA-M	PUBCHEM.COMPOUND:23679441	UMLS:C0002736	Ceftriaxone sodium	Amyotrophic Lateral Sclerosis	Designated	2006-03-28
YOZNUFWCRFCGIH-UHFFFAOYSA-K	PUBCHEM.COMPOUND:146014417	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
YOZNUFWCRFCGIH-UHFFFAOYSA-K	PUBCHEM.COMPOUND:146014417	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
YOZNUFWCRFCGIH-WZHZPDAFSA-K	PUBCHEM.COMPOUND:44475014	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated	2000-09-22
YOZNUFWCRFCGIH-WZHZPDAFSA-K	PUBCHEM.COMPOUND:44475014	UMLS:C0238080	Hydroxocobalamin	Cyanide poisoning	Designated/Approved	2003-11-25
YQEZLKZALYSWHR-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3821	UMLS:C0458219	ketamine	Complex regional pain syndrome	Designated	2019-02-01
YQNQNVDNTFHQSW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:41684	UMLS:C0010418	Nitazoxanide	Cryptosporidiosis	Designated/Approved	1996-12-12
YQNQNVDNTFHQSW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:41684	UMLS:C0017536	nitazoxanide	INTESTINAL GIARDIASIS	Designated/Approved	2002-02-14
YQNQNVDNTFHQSW-UHFFFAOYSA-N	PUBCHEM.COMPOUND:41684	UMLS:C0013370	nitazoxanide	Intestinal Amebiasis	Designated	2001-10-23
YQZNKYXGZSVEHI-VXKWHMMOSA-N	PUBCHEM.COMPOUND:9935639	UMLS:C0026764	melphalan flufenamide	Plasma cell myeloma	Designated/Approved	2015-03-16
YSGASDXSLKIKOD-UHFFFAOYSA-N	PUBCHEM.COMPOUND:60511	UMLS:C0020179	Remacemide	Huntington's Disease	Designated/Withdrawn	2000-03-06
YTCZZXIRLARSET-ZTWNIFTGSA-M	PUBCHEM.COMPOUND:71587534	UMLS:C3203102	beraprost sodium 314d	PULMONARY ARTERIAL HYPERTENSION	Designated/Withdrawn	2011-12-22
YTFHCXIPDIHOIA-DHZHZOJOSA-N	PUBCHEM.COMPOUND:10295295	UMLS:C0015306	palovarotene	MULTIPLE OSTEOCHONDROMAS	Designated	2017-11-06
YTFHCXIPDIHOIA-DHZHZOJOSA-N	PUBCHEM.COMPOUND:10295295	UMLS:C0016037	palovarotene	fibrodysplasia ossificans progressiva	Designated	2014-07-21
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0022650	Tiopronin	Nephrolithiasis	Designated/Approved	1986-01-17
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0010691	Tiopronin	Cystinuria	Designated/Approved	1986-01-17
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0022650	Tiopronin	Nephrolithiasis	Designated/Approved	1986-01-17
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0022650	Tiopronin	Nephrolithiasis	Designated/Approved	1986-01-17
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0010691	Tiopronin	Cystinuria	Designated/Approved	1986-01-17
YTGJWQPHMWSCST-UHFFFAOYSA-N	PUBCHEM.COMPOUND:5483	UMLS:C0010691	Tiopronin	Cystinuria	Designated/Approved	1986-01-17
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1989-11-24
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1988-09-20
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1988-09-20
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1988-09-20
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1989-11-24
YTIJUXVIZLYQTB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:16048622	UMLS:C0042510	Bethanidine sulfate	Ventricular Fibrillation	Designated/Withdrawn	1989-11-24
YTKUWDBFDASYHO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:65628	UMLS:C0026764	bendamustine	Multiple Myeloma	Designated	2017-06-22
YUFWAVFNITUSHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56927696	UMLS:C0007462	Guanethidine monosulfate	Causalgia	Designated/Withdrawn	1986-01-06
YUFWAVFNITUSHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56927696	UMLS:C0034931	Guanethidine monosulfate	Reflex Sympathetic Dystrophy	Designated/Withdrawn	1986-01-06
YUFWAVFNITUSHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56927696	UMLS:C0007462	Guanethidine monosulfate	Causalgia	Designated/Withdrawn	1986-01-06
YUFWAVFNITUSHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:56927696	UMLS:C0034931	Guanethidine monosulfate	Reflex Sympathetic Dystrophy	Designated/Withdrawn	1986-01-06
YUQCJZVVMQZBFE-JPUFUMQZSA-N	PUBCHEM.COMPOUND:145982170	UMLS:C0026764	roneparstat	Multiple Myeloma	Designated	2015-03-19
YUUGYIUSCYNSQR-LBPRGKRZSA-N	PUBCHEM.COMPOUND:24946690	UMLS:C0039730	bitopertin	thalassemia	Designated/Withdrawn	2017-08-16
YVPXVXANRNDGTA-WDYNHAJCSA-N	PUBCHEM.COMPOUND:10206	UMLS:C0242584	Cepharanthine	Immune thrombocytopenia	Designated	2020-09-22
YVPXVXANRNDGTA-WDYNHAJCSA-N	PUBCHEM.COMPOUND:10206	UMLS:C0398650	Cepharanthine	Immune Thrombocytopenia	Designated	2020-09-22
YVPXVXANRNDGTA-WDYNHAJCSA-N	PUBCHEM.COMPOUND:10206	UMLS:C0014859	Cepharanthine	esophageal cancer	Designated	2021-01-14
YWQFJNWMWZMXRW-HXUWFJFHSA-N	PUBCHEM.COMPOUND:90445883	UMLS:C0002895	olinciguat	Sickle Cell Disease	Designated	2018-06-04
YZBLFMPOMVTDJY-AMFIFCOJSA-N	PUBCHEM.COMPOUND:86287400	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-AMFIFCOJSA-N	PUBCHEM.COMPOUND:86287400	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-BFPKLJSTSA-N	PUBCHEM.COMPOUND:9571036	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-BFPKLJSTSA-N	PUBCHEM.COMPOUND:9571036	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-CBYMMZEQSA-N	PUBCHEM.COMPOUND:16760141	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-CBYMMZEQSA-N	PUBCHEM.COMPOUND:16760141	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-DSNUORPKSA-N	PUBCHEM.COMPOUND:6436009	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-DSNUORPKSA-N	PUBCHEM.COMPOUND:6436009	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-HFVHDGGLSA-N	PUBCHEM.COMPOUND:153640463	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-HFVHDGGLSA-N	PUBCHEM.COMPOUND:153640463	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-IRFODQMOSA-N	PUBCHEM.COMPOUND:131954608	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-IRFODQMOSA-N	PUBCHEM.COMPOUND:131954608	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-JLOCULIASA-N	PUBCHEM.COMPOUND:154825546	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-JLOCULIASA-N	PUBCHEM.COMPOUND:154825546	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-KAAHEXRMSA-N	PUBCHEM.COMPOUND:137701808	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-KAAHEXRMSA-N	PUBCHEM.COMPOUND:137701808	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-LRWNSQJFSA-N	PUBCHEM.COMPOUND:139031013	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-LRWNSQJFSA-N	PUBCHEM.COMPOUND:139031013	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-LSGXYNIPSA-N	PUBCHEM.COMPOUND:9832912	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-LSGXYNIPSA-N	PUBCHEM.COMPOUND:9832912	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-RWJZGKSFSA-N	PUBCHEM.COMPOUND:71312368	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-RWJZGKSFSA-N	PUBCHEM.COMPOUND:71312368	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-UBOCAARVSA-N	PUBCHEM.COMPOUND:9604461	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-UBOCAARVSA-N	PUBCHEM.COMPOUND:9604461	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:72728820	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:72728820	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-XHQXRQCGSA-N	PUBCHEM.COMPOUND:91885488	UMLS:C0042961	moxidectin	Volvulus	Designated/Approved	2010-09-29
YZBLFMPOMVTDJY-XHQXRQCGSA-N	PUBCHEM.COMPOUND:91885488	UMLS:C0029001	moxidectin	Onchocerciasis	Designated/Approved	2010-09-29
YZOQZEXYFLXNKA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:10309114	UMLS:C0025202	N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide	melanoma	Designated/Withdrawn	2004-08-13
YZPQNHUVIVIUCT-JTJNLBSYSA-F	PUBCHEM.COMPOUND:121494085	UMLS:C0038362	Sucralfate	Oral mucositis	Designated/Withdrawn	1993-07-15
YZPQNHUVIVIUCT-JTJNLBSYSA-F	PUBCHEM.COMPOUND:121494085	UMLS:C1568868	Sucralfate	Oral Mucositis	Designated/Withdrawn	1993-07-15
YZPQNHUVIVIUCT-JTJNLBSYSA-F	PUBCHEM.COMPOUND:121494085	UMLS:C1578499	Sucralfate	Radiation Therapy	Designated/Withdrawn	1993-07-15
YZPQNHUVIVIUCT-JTJNLBSYSA-F	PUBCHEM.COMPOUND:121494085	UMLS:C3887461	Sucralfate	Head and Neck Cancer	Designated/Withdrawn	1993-07-15
YZSIZVRFVQKMJU-RDGPPVDQSA-N	PUBCHEM.COMPOUND:135565889	UMLS:C1140680	etarfolatide	ovarian carcinomas	Designated	2000-02-16
ZADWXFSZEAPBJS-SNVBAGLBSA-N	PUBCHEM.COMPOUND:405012	UMLS:C0025202	indoximod	melanoma	Designated	2017-10-26
ZAHQPTJLOCWVPG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:51082	UMLS:C0023467	Mitoxantrone HCl	Acute myelogenous leukemia	Designated/Approved	1987-07-13
ZAXCMPAWRCMABN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25199925	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
ZAXCMPAWRCMABN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25199925	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
ZAXCMPAWRCMABN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25199925	UMLS:C3540630	Nedaplatin	Small Cell Lung Cancer	Designated	2020-08-05
ZAXCMPAWRCMABN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25199925	UMLS:C0014859	nedaplatin	esophageal cancer	Designated	2020-08-31
ZBBHBTPTTSWHBA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4474	UMLS:C1970431	nicardipine	PITT-HOPKINS SYNDROME	Designated	2019-11-26
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C1709527	Dasatinib	Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	2005-11-18
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C0007194	Dasatinib	Hypertrophic Cardiomyopathy	Designated	2020-10-26
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C0023473	dasatinib	Chronic myelogenous leukemia	Designated/Approved	2005-11-28
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C0023473	dasatinib	Chronic myelogenous leukemia	Designated/Approved	2005-11-28
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C0028326	Dasatinib	Noonan Syndrome	Designated	2020-10-26
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3062316	UMLS:C1709527	Dasatinib	Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	2005-11-18
ZBVJFYPGLGEMIN-IKNXIQPFSA-N	PUBCHEM.COMPOUND:60196291	UMLS:C0342543	triptorelin pamoate	Central Precocious Puberty	Designated/Approved	2012-08-20
ZBVJFYPGLGEMIN-IKNXIQPFSA-N	PUBCHEM.COMPOUND:60196291	UMLS:C4721610	Triptorelin pamoate	Ovarian carcinoma	Designated/Withdrawn	1990-08-10
ZBVJFYPGLGEMIN-OYLNGHKZSA-N	PUBCHEM.COMPOUND:25074469	UMLS:C4721610	Triptorelin pamoate	Ovarian carcinoma	Designated/Withdrawn	1990-08-10
ZBVJFYPGLGEMIN-OYLNGHKZSA-N	PUBCHEM.COMPOUND:25074469	UMLS:C0342543	triptorelin pamoate	Central Precocious Puberty	Designated/Approved	2012-08-20
ZBVJFYPGLGEMIN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25091037	UMLS:C0342543	triptorelin pamoate	Central Precocious Puberty	Designated/Approved	2012-08-20
ZBVJFYPGLGEMIN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25091037	UMLS:C4721610	Triptorelin pamoate	Ovarian carcinoma	Designated/Withdrawn	1990-08-10
ZCIGNRJZKPOIKD-CQXVEOKZSA-N	PUBCHEM.COMPOUND:25151504	UMLS:C0019704	cobicistat	Human immunodeficiency virus type 1	Designated/Approved	2017-06-15
ZCIGNRJZKPOIKD-CQXVEOKZSA-N	PUBCHEM.COMPOUND:25151504	UMLS:C0019704	cobicistat	Human immunodeficiency virus type 1	Designated/Approved	2017-06-15
ZCIGNRJZKPOIKD-CQXVEOKZSA-N	PUBCHEM.COMPOUND:25151504	UMLS:C0009450	cobicistat	Infection	Designated/Approved	2017-06-15
ZCIGNRJZKPOIKD-CQXVEOKZSA-N	PUBCHEM.COMPOUND:25151504	UMLS:C0009450	cobicistat	Infection	Designated/Approved	2017-06-15
ZCJXQWYMBJYJNB-LRDBBFHQSA-N	PUBCHEM.COMPOUND:54949	UMLS:C1535939	Trimetrexate glucuronate	Pneumocystis carinii Pneumonia	Designated/Approved	1986-05-15
ZCJXQWYMBJYJNB-LRDBBFHQSA-N	PUBCHEM.COMPOUND:54949	UMLS:C0281361	Trimetrexate glucuronate	Pancreatic adenocarcinoma	Designated/Withdrawn	1985-07-25
ZCJXQWYMBJYJNB-LRDBBFHQSA-N	PUBCHEM.COMPOUND:54949	UMLS:C0007131	Trimetrexate glucuronate	Non-Small Cell Carcinoma of the Lung	Designated/Withdrawn	1988-01-13
ZCJXQWYMBJYJNB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:336805	UMLS:C0281361	Trimetrexate glucuronate	Pancreatic adenocarcinoma	Designated/Withdrawn	1985-07-25
ZCJXQWYMBJYJNB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:336805	UMLS:C1535939	Trimetrexate glucuronate	Pneumocystis carinii Pneumonia	Designated/Approved	1986-05-15
ZCJXQWYMBJYJNB-UHFFFAOYSA-N	PUBCHEM.COMPOUND:336805	UMLS:C0007131	Trimetrexate glucuronate	Non-Small Cell Carcinoma of the Lung	Designated/Withdrawn	1988-01-13
ZCTCZKWJFTYNMZ-WKUCUCPSSA-J	PUBCHEM.COMPOUND:135564527	UMLS:C0812413	pemetrexed disodium	Malignant Pleural Mesothelioma	Designated/Approved	2001-08-28
ZCVMWBYGMWKGHF-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3827	UMLS:C0024899	ketotifen	Mastocytosis	Designated	2015-02-25
ZDRRIRUAESZNIH-BZGUUIOASA-N	PUBCHEM.COMPOUND:75409771	UMLS:C0281947	Urofollitropin	pituitary dysfunction	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-BZGUUIOASA-N	PUBCHEM.COMPOUND:75409771	UMLS:C3671958	Urofollitropin	Reproductive failure	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-BZGUUIOASA-N	PUBCHEM.COMPOUND:75409771	UMLS:C0022735	Urofollitropin	Hypogonadotropic Hypogonadism	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-BZGUUIOASA-N	PUBCHEM.COMPOUND:75409771	UMLS:C0032460	Urofollitropin	Polycystic Ovarian Disease	Designated/Approved	1987-11-25
ZDRRIRUAESZNIH-JLSAMJFVSA-N	PUBCHEM.COMPOUND:73759969	UMLS:C0032460	Urofollitropin	Polycystic Ovarian Disease	Designated/Approved	1987-11-25
ZDRRIRUAESZNIH-JLSAMJFVSA-N	PUBCHEM.COMPOUND:73759969	UMLS:C0281947	Urofollitropin	pituitary dysfunction	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-JLSAMJFVSA-N	PUBCHEM.COMPOUND:73759969	UMLS:C0022735	Urofollitropin	Hypogonadotropic Hypogonadism	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-JLSAMJFVSA-N	PUBCHEM.COMPOUND:73759969	UMLS:C3671958	Urofollitropin	Reproductive failure	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62819	UMLS:C0022735	Urofollitropin	Hypogonadotropic Hypogonadism	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62819	UMLS:C0281947	Urofollitropin	pituitary dysfunction	Designated/Withdrawn	1997-12-05
ZDRRIRUAESZNIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62819	UMLS:C0032460	Urofollitropin	Polycystic Ovarian Disease	Designated/Approved	1987-11-25
ZDRRIRUAESZNIH-UHFFFAOYSA-N	PUBCHEM.COMPOUND:62819	UMLS:C3671958	Urofollitropin	Reproductive failure	Designated/Withdrawn	1997-12-05
ZDXPYRJPNDTMRX-VKHMYHEASA-N	PUBCHEM.COMPOUND:5961	UMLS:C0002895	L-glutamine	Sickle Cell Disease	Designated/Approved	2001-08-01
ZDXPYRJPNDTMRX-VKHMYHEASA-N	PUBCHEM.COMPOUND:5961	UMLS:C0024523	Glutamine	Malabsorption	Designated/Approved	1995-03-06
ZDXPYRJPNDTMRX-VKHMYHEASA-N	PUBCHEM.COMPOUND:5961	UMLS:C0036992	Glutamine	Short Bowel Syndrome	Designated/Approved	1995-03-06
ZEZFKUBILQRZCK-MJSCXXSSSA-N	PUBCHEM.COMPOUND:6918502	UMLS:C0032897	beloranib	Prader-Willi Syndrome	Designated/Withdrawn	2013-01-15
ZFPZEYHRWGMJCV-ZHALLVOQSA-N	PUBCHEM.COMPOUND:9926832	UMLS:C0016667	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	Fragile X Syndrome	Designated	2011-10-12
ZGXJTSGNIOSYLO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137	UMLS:C0555198	5-aminolevulinic acid	Malignant Glioma	Designated/Approved	2013-01-15
ZGXJTSGNIOSYLO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137	UMLS:C0025286	5-aminolevulinic acid	Meningioma	Designated	2020-11-12
ZGXJTSGNIOSYLO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:137	UMLS:C0555198	5-Aminolevulinic Acid	Malignant Glioma	Designated	2021-03-29
ZHBJMVNZRZUQEP-KIKMAQITSA-L	PUBCHEM.COMPOUND:46203139	UMLS:C0235974	Minnelide	PANCREATIC CANCER	Designated	2013-02-18
ZHNFLHYOFXQIOW-LPYZJUEESA-N	PUBCHEM.COMPOUND:16211610	UMLS:C0024530	quinine Sulfate	Malaria	Designated/Approved	2004-06-03
ZHNFLHYOFXQIOW-LPYZJUEESA-N	PUBCHEM.COMPOUND:16211610	UMLS:C0024530	quinine sulfate	Malaria	Designated	2008-12-02
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0349632	bendamustine hydrochloride	Splenic marginal zone lymphoma	Designated/Approved	2013-11-26
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C1955690	bendamustine hydrochloride	Extranodal marginal zone B-cell lymphoma	Designated/Approved	2013-11-26
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0023434	Bendamustine hydrochloride	Chronic Lymphocytic Leukemia	Designated/Approved	2007-08-17
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0024301	bendamustine hydrochloride	follicular lymphoma	Designated/Approved	2013-11-26
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0024419	bendamustine hydrochloride	lymphoplasmacytic lymphoma	Designated/Approved	2013-11-26
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0242647	bendamustine hydrochloride	Mucosa-associated lymphoma	Designated/Approved	2013-11-26
ZHSKUOZOLHMKEA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:77082	UMLS:C0855139	bendamustine hydrochloride	Nodal Marginal Zone Lymphoma	Designated/Approved	2013-11-26
ZJIHMALTJRDNQI-OLALXQGDSA-N	PUBCHEM.COMPOUND:11644097	UMLS:C0002986	migalastat hydrochloride	Fabry Disease	Designated/Approved	2004-02-25
ZJIHMALTJRDNQI-VFQQELCFSA-N	PUBCHEM.COMPOUND:13018787	UMLS:C0017921	duvoglustat hydrochloride	Pompe Disease	Designated/Withdrawn	2007-06-18
ZJUUIXYKTPSIOH-LEZJFEBPSA-N	PUBCHEM.COMPOUND:16126905	UMLS:C3539721	4-demethyl-4-cholesteryloxycarbonylpenclomedine	Non-Small Cell Lung Cancer	Designated	2017-09-19
ZJUUIXYKTPSIOH-LEZJFEBPSA-N	PUBCHEM.COMPOUND:16126905	UMLS:C0686377	4-demethyl-4-cholesteryloxycarbonylpenclomedine	CNS metastases	Designated	2017-09-19
ZJVFLBOZORBYFE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3671	UMLS:C0023521	ibudilast	Krabbe Disease	Designated	2015-06-01
ZJVFLBOZORBYFE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3671	UMLS:C0002736	ibudilast	Amyotrophic Lateral Sclerosis	Designated	2016-10-06
ZJVFLBOZORBYFE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3671	UMLS:C0017636	Ibudilast	Glioblastoma	Designated	2018-10-02
ZJZDXGQUNVNYQP-MXEXKMKYSA-N	PUBCHEM.COMPOUND:24894654	UMLS:C0206754	satoreotide tetraxetan	Neuroendocrine Tumors	Designated	2014-09-24
ZKKLPDLKUGTPME-UHFFFAOYSA-N	PUBCHEM.COMPOUND:15251598	UMLS:C1800706	ammonium tetrathiomolybdate	Idiopathic Pulmonary Fibrosis	Designated	2008-05-05
ZKKLPDLKUGTPME-UHFFFAOYSA-N	PUBCHEM.COMPOUND:15251598	UMLS:C0019202	Ammonium tetrathiomolybdate	Wilson's Disease	Designated	1994-01-31
ZLHFILGSQDJULK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24771867	UMLS:C0079774	alisertib	Peripheral T-Cell Lymphoma	Designated/Withdrawn	2012-05-14
ZLHFILGSQDJULK-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24771867	UMLS:C3540630	alisertib	Small Cell Lung Cancer	Designated/Withdrawn	2013-07-12
ZLHFONARZHCSET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123608	UMLS:C0586354	aminolevulinic acid hydrochloride	Esophageal dysplasia	Designated	2007-03-20
ZLHFONARZHCSET-UHFFFAOYSA-N	PUBCHEM.COMPOUND:123608	UMLS:C0555198	Aminolevulinic acid hydrochloride	Malignant Glioma	Designated	2020-09-09
ZLHZLMOSPGACSZ-NSHDSACASA-N	PUBCHEM.COMPOUND:456199	UMLS:C0041296	Pretomanid	Tuberculosis	Designated/Approved	2007-07-05
ZLVMAMIPILWYHQ-INIZCTEOSA-N	PUBCHEM.COMPOUND:71137	UMLS:C0006826	docarpamine	Cancer	Designated	2020-04-14
ZLVMAMIPILWYHQ-INIZCTEOSA-N	PUBCHEM.COMPOUND:71137	UMLS:C0003962	docarpamine	Ascites	Designated	2020-04-14
ZMJWRJKGPUDEOX-LMXUULCNSA-A	PUBCHEM.COMPOUND:16197725	UMLS:C0376620	alicaforsen	Pouchitis	Designated	2008-06-24
ZMQMTKVVAMWKNY-YSXLEBCMSA-N	PUBCHEM.COMPOUND:6918632	UMLS:C0029002	emodepside	River Blindness	Designated	2016-09-13
ZNNLBTZKUZBEKO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3488	UMLS:C0038525	glyburide	Subarachnoid Hemorrhage	Designated	2016-02-08
ZNNLBTZKUZBEKO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3488	UMLS:C0878589	glyburide	acute spinal cord injury	Designated	2015-09-29
ZNNLBTZKUZBEKO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3488	UMLS:C0948008	Glyburide	Ischemic stroke	Designated	2017-01-12
ZNNLBTZKUZBEKO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3488	UMLS:C0006114	Glyburide	Cerebral Edema	Designated	2017-01-12
ZOAIEFWMQLYMTF-PEHXSSJGSA-N	PUBCHEM.COMPOUND:11570943	UMLS:C0017638	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	Glioma	Designated/Withdrawn	2014-04-30
ZOCKGBMQLCSHFP-KQRAQHLDSA-N	PUBCHEM.COMPOUND:454216	UMLS:C4551642	Valrubicin	Carcinoma in situ of the Urinary Bladder	Designated/Approved	1994-05-23
ZOEFCCMDUURGSE-CQVUSSRSSA-N	PUBCHEM.COMPOUND:16129617	UMLS:C0013264	cosyntropin	DUCHENNE MUSCULAR DYSTROPHY	Designated/Withdrawn	2017-07-06
ZOEFCCMDUURGSE-CQVUSSRSSA-N	PUBCHEM.COMPOUND:16129617	UMLS:C3887898	cosyntropin	Infantile spasms	Designated	2017-08-02
ZPFVQKPWGDRLHL-ZLYBXYBFSA-N	PUBCHEM.COMPOUND:153997	UMLS:C0023467	Zosuquidar trihydrochloride	Acute myeloid leukemia	Designated	2005-12-15
ZPNFWUPYTFPOJU-IAUBLLHJSA-N	PUBCHEM.COMPOUND:129627711	UMLS:C0019080	Aprotinin	Blood loss	Designated/Approved	1993-11-17
ZPNFWUPYTFPOJU-LPYSRVMUSA-N	PUBCHEM.COMPOUND:16130295	UMLS:C0019080	Aprotinin	Blood loss	Designated/Approved	1993-11-17
ZPNFWUPYTFPOJU-UHFFFAOYSA-N	PUBCHEM.COMPOUND:22833874	UMLS:C0019080	Aprotinin	Blood loss	Designated/Approved	1993-11-17
ZPNFWUPYTFPOJU-VKTQZXOTSA-N	PUBCHEM.COMPOUND:146027575	UMLS:C0019080	Aprotinin	Blood loss	Designated/Approved	1993-11-17
ZPNFWUPYTFPOJU-YSFZTAPISA-N	PUBCHEM.COMPOUND:53487898	UMLS:C0019080	Aprotinin	Blood loss	Designated/Approved	1993-11-17
ZPUHVPYXSITYDI-ZYOSQDPASA-N	PUBCHEM.COMPOUND:134715513	UMLS:C0017636	paclitaxel poliglumex	Glioblastoma multiforme	Designated	2012-09-20
ZPXSCAKFGYXMGA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4020	UMLS:C0027404	mazindol	Narcolepsy	Designated	2016-07-06
ZPXSCAKFGYXMGA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:4020	UMLS:C0013264	Mazindol	DUCHENNE MUSCULAR DYSTROPHY	Designated	1986-12-08
ZPYIELFRIYUVQP-BHBJEIPNSA-N	PUBCHEM.COMPOUND:72734342	UMLS:C4721610	squalamine lactate	Ovarian Cancer	Designated	2001-05-11
ZPYIELFRIYUVQP-BHBJEIPNSA-N	PUBCHEM.COMPOUND:72734342	UMLS:C0677936	squalamine lactate	cancer refractory	Designated	2001-05-11
ZQGJCHHKJNSPMS-UHFFFAOYSA-L	PUBCHEM.COMPOUND:24828759	UMLS:C0398650	fostamatinib disodium hexahydrate	Immune thrombocytopenic purpura	Designated/Approved	2015-08-25
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C0349632	parsaclisib	Splenic marginal zone lymphoma	Designated	2019-09-10
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C0024301	Parsaclisib	follicular lymphoma	Designated	2019-09-25
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C1367654	parsaclisib	Marginal zone lymphoma	Designated	2019-10-09
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C4721414	parsaclisib	Mantle cell lymphoma	Designated	2019-06-12
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C0242647	parsaclisib	Nodal marginal zone lymphoma	Designated	2019-10-07
ZQPDJCIXJHUERQ-QWRGUYRKSA-N	PUBCHEM.COMPOUND:86677874	UMLS:C0002880	parsaclisib	Autoimmune hemolytic anemia	Designated	2020-07-28
ZRJBHWIHUMBLCN-BMIGLBTASA-N	PUBCHEM.COMPOUND:1633595	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-HNWKQCISSA-N	PUBCHEM.COMPOUND:71308731	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-HNWKQCISSA-N	PUBCHEM.COMPOUND:71308731	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-HZRLMBICSA-N	PUBCHEM.COMPOUND:9794806	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-JRYCNTDSSA-N	PUBCHEM.COMPOUND:4369233	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-JYXJEATCSA-N	PUBCHEM.COMPOUND:44461111	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-JYXJEATCSA-N	PUBCHEM.COMPOUND:44461111	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-MEBBXXQBSA-N	PUBCHEM.COMPOUND:6565233	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-MEBBXXQBSA-N	PUBCHEM.COMPOUND:6565233	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-QDEBKDIKSA-N	PUBCHEM.COMPOUND:5912039	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-QDEBKDIKSA-N	PUBCHEM.COMPOUND:5912039	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-SEQYCRGISA-N	PUBCHEM.COMPOUND:907504	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-SEQYCRGISA-N	PUBCHEM.COMPOUND:907504	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1253	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:1253	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-YQEJDHNASA-N	PUBCHEM.COMPOUND:854026	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRJBHWIHUMBLCN-YQEJDHNASA-N	PUBCHEM.COMPOUND:854026	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-ZUZCIYMTSA-N	PUBCHEM.COMPOUND:449069	UMLS:C0751122	Huperzine A	Dravet Syndrome	Designated	2017-04-12
ZRJBHWIHUMBLCN-ZUZCIYMTSA-N	PUBCHEM.COMPOUND:449069	UMLS:C0238111	(-)-huperzine A	Lennox-Gastaut syndrome	Designated	2020-06-15
ZRVUJXDFFKFLMG-UHFFFAOYSA-N	PUBCHEM.COMPOUND:54677470	UMLS:C3495559	meloxicam	Juvenile rheumatoid arthritis	Designated/Approved	2002-11-22
ZSSLCFLHEFXANG-GOSISDBHSA-N	PUBCHEM.COMPOUND:25052630	UMLS:C3203102	Zamicastat	PULMONARY ARTERIAL HYPERTENSION	Designated	2019-07-15
ZSSLCFLHEFXANG-GOSISDBHSA-N	PUBCHEM.COMPOUND:25052630	UMLS:C0020542	Zamicastat	Pulmonary Hypertension	Designated	2019-07-15
ZUJBBVJXXYRPFS-DYKIIFRCSA-N	PUBCHEM.COMPOUND:71722017	UMLS:C1096155	dusquetide	Macrophage Activation Syndrome	Designated	2016-08-10
ZVAGBRFUYHSUHA-CFWFSBERSA-N	PUBCHEM.COMPOUND:16727411	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-CFWFSBERSA-N	PUBCHEM.COMPOUND:16727411	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-CFWFSBERSA-N	PUBCHEM.COMPOUND:16727411	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-LZOXOEDVSA-N	PUBCHEM.COMPOUND:16681698	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-LZOXOEDVSA-N	PUBCHEM.COMPOUND:16681698	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-LZOXOEDVSA-N	PUBCHEM.COMPOUND:16681698	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-QUIKYCSHSA-N	PUBCHEM.COMPOUND:56843157	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-QUIKYCSHSA-N	PUBCHEM.COMPOUND:56843157	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-QUIKYCSHSA-N	PUBCHEM.COMPOUND:56843157	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-RKMKAUCSSA-N	PUBCHEM.COMPOUND:71816154	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-RKMKAUCSSA-N	PUBCHEM.COMPOUND:71816154	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-RKMKAUCSSA-N	PUBCHEM.COMPOUND:71816154	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:70700268	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:70700268	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-UHFFFAOYSA-N	PUBCHEM.COMPOUND:70700268	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-VLJPQPJMSA-N	PUBCHEM.COMPOUND:46930996	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-VLJPQPJMSA-N	PUBCHEM.COMPOUND:46930996	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-VLJPQPJMSA-N	PUBCHEM.COMPOUND:46930996	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVAGBRFUYHSUHA-XEKNBVSESA-N	PUBCHEM.COMPOUND:122362431	UMLS:C0023434	obatoclax mesylate	Chronic Lymphocytic Leukemia	Designated/Withdrawn	2004-10-08
ZVAGBRFUYHSUHA-XEKNBVSESA-N	PUBCHEM.COMPOUND:122362431	UMLS:C0026987	Obatoclax mesylate	myelofibrosis	Designated/Withdrawn	2006-12-01
ZVAGBRFUYHSUHA-XEKNBVSESA-N	PUBCHEM.COMPOUND:122362431	UMLS:C3463824	Obatoclax mesylate	MYELODYSPLASTIC SYNDROME	Designated/Withdrawn	2006-11-06
ZVEMACCDKBQNGX-KALODSIISA-N	PUBCHEM.COMPOUND:23622962	UMLS:C0019045	Arginine butyrate	Hemoglobinopathies	Designated	1992-04-07
ZVEMACCDKBQNGX-KALODSIISA-N	PUBCHEM.COMPOUND:23622962	UMLS:C0002895	Arginine butyrate	Sickle Cell Disease	Designated/Withdrawn	1994-05-25
ZVEMACCDKBQNGX-KALODSIISA-N	PUBCHEM.COMPOUND:23622962	UMLS:C0005283	Arginine butyrate	beta Thalassemia	Designated/Withdrawn	1994-05-25
ZVEMACCDKBQNGX-KALODSIISA-N	PUBCHEM.COMPOUND:23622962	UMLS:C0005283	Arginine butyrate	BETA-THALASSEMIA	Designated	1992-04-07
ZVGNESXIJDCBKN-DBGJUELJSA-N	PUBCHEM.COMPOUND:117590639	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-DEIWUYIYSA-N	PUBCHEM.COMPOUND:135391138	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-JMEUZRPYSA-N	PUBCHEM.COMPOUND:132472265	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-KFGPIHIUSA-N	PUBCHEM.COMPOUND:70678896	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-LGPUCNCQSA-N	PUBCHEM.COMPOUND:46174142	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-SZYXOGSFSA-N	PUBCHEM.COMPOUND:102580518	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-UHFFFAOYSA-N	PUBCHEM.COMPOUND:151383	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-UUEYKCAUSA-N	PUBCHEM.COMPOUND:10034073	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-VUCVDCOISA-N	PUBCHEM.COMPOUND:91885501	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVGNESXIJDCBKN-ZJHJTZDTSA-N	PUBCHEM.COMPOUND:131668620	UMLS:C0343386	fidaxomicin	Clostridium difficile infection	Designated/Approved	2010-12-13
ZVHNDZWQTBEVRY-UHFFFAOYSA-N	PUBCHEM.COMPOUND:25062766	UMLS:C0026987	momelotinib	myelofibrosis	Designated	2010-08-05
ZVVAINSYJGRDTR-TYLGTTGKSA-N	PUBCHEM.COMPOUND:60767	UMLS:C0018674	Enadoline hydrochloride	HEAD INJURY	Designated	1997-01-28
ZVVGTYQPRVEJOH-GGZXVAPBSA-N	PUBCHEM.COMPOUND:85471918	UMLS:C0524910	glecaprevir and pibrentasvir	chronic hepatitis c	Designated/Approved	2017-01-09
ZVVGTYQPRVEJOH-GGZXVAPBSA-N	PUBCHEM.COMPOUND:85471918	UMLS:C0019196	glecaprevir and pibrentasvir	Hepatitis C Virus Infection	Designated/Approved	2017-01-09
ZVXLKCOOOKREJD-OERAVCCFSA-N	PUBCHEM.COMPOUND:154562176	UMLS:C0013264	viltolarsen	DUCHENNE MUSCULAR DYSTROPHY	Designated/Approved	2017-01-12
ZWBTYMGEBZUQTK-AMWSOCTHSA-N	PUBCHEM.COMPOUND:136117120	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-AMWSOCTHSA-N	PUBCHEM.COMPOUND:136117120	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-AMWSOCTHSA-N	PUBCHEM.COMPOUND:136117120	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-ASBZJICESA-N	PUBCHEM.COMPOUND:135950975	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-ASBZJICESA-N	PUBCHEM.COMPOUND:135950975	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-ASBZJICESA-N	PUBCHEM.COMPOUND:135950975	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-DNEPJJHDSA-N	PUBCHEM.COMPOUND:135925740	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-DNEPJJHDSA-N	PUBCHEM.COMPOUND:135925740	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-DNEPJJHDSA-N	PUBCHEM.COMPOUND:135925740	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-HBZSWILLSA-N	PUBCHEM.COMPOUND:137295261	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-HBZSWILLSA-N	PUBCHEM.COMPOUND:137295261	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-HBZSWILLSA-N	PUBCHEM.COMPOUND:137295261	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-OZFKZPMASA-N	PUBCHEM.COMPOUND:135458645	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-OZFKZPMASA-N	PUBCHEM.COMPOUND:135458645	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-OZFKZPMASA-N	PUBCHEM.COMPOUND:135458645	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-OZKAIBRQSA-N	PUBCHEM.COMPOUND:136257950	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-OZKAIBRQSA-N	PUBCHEM.COMPOUND:136257950	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-OZKAIBRQSA-N	PUBCHEM.COMPOUND:136257950	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-PVLSIAFMSA-N	PUBCHEM.COMPOUND:135398743	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-PVLSIAFMSA-N	PUBCHEM.COMPOUND:135398743	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-PVLSIAFMSA-N	PUBCHEM.COMPOUND:135398743	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-SHULBWHJSA-N	PUBCHEM.COMPOUND:137313637	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-SHULBWHJSA-N	PUBCHEM.COMPOUND:137313637	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWBTYMGEBZUQTK-SHULBWHJSA-N	PUBCHEM.COMPOUND:137313637	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-WOYMMMRKSA-N	PUBCHEM.COMPOUND:136053407	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-WOYMMMRKSA-N	PUBCHEM.COMPOUND:136053407	UMLS:C0019693	Rifabutin	HIV infection	Designated/Approved	1989-12-18
ZWBTYMGEBZUQTK-WOYMMMRKSA-N	PUBCHEM.COMPOUND:136053407	UMLS:C0026914	Rifabutin	Mycobacterium avium Complex	Designated	1989-12-18
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:114869	UMLS:C0026769	Tizanidine HCl	Multiple Sclerosis	Designated	1994-01-31
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:114869	UMLS:C0026838	Tizanidine HCl	Spasticity	Designated	1994-01-31
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:114869	UMLS:C0037929	Tizanidine HCl	Spinal Cord Injury	Designated	1994-01-31
ZXERDUOLZKYMJM-ZWECCWDJSA-N	PUBCHEM.COMPOUND:447715	UMLS:C0008312	obeticholic acid	Primary Biliary Cirrhosis	Designated/Approved	2008-04-09
ZXFWJPKXEMFBOG-LWVMDMHWSA-N	PUBCHEM.COMPOUND:118984442	UMLS:C0022660	Anaritide acetate	Acute renal failure	Designated/Withdrawn	1992-08-27
ZXRVKCBLGJOCEE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3448	UMLS:C0162635	4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol	Angelman Syndrome	Designated	2016-09-06
ZXRVKCBLGJOCEE-UHFFFAOYSA-N	PUBCHEM.COMPOUND:3448	UMLS:C0016667	Gaboxadol	Fragile X Syndrome	Designated	2017-10-03
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	PUBCHEM.COMPOUND:323	UMLS:C0007134	Coumarin	Renal Cell Carcinoma	Designated	1994-12-22
ZYRLHJIMTROTBO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24770514	UMLS:C1261473	Devimistat	Sarcoma	Designated	2020-10-26
ZYRLHJIMTROTBO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24770514	UMLS:C0079774	6,8-bis(benzylthio)octanoic acid	Peripheral T-Cell Lymphoma	Designated	2018-02-28
ZYRLHJIMTROTBO-UHFFFAOYSA-N	PUBCHEM.COMPOUND:24770514	UMLS:C0006413	6,8-bis(benzylthio)octanoic acid	Burkitts Lymphoma	Designated	2018-01-25
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N	PUBCHEM.COMPOUND:3035000	UMLS:C0013264	vamorolone	DUCHENNE MUSCULAR DYSTROPHY	Designated	2011-12-02
ZYULQCDNUYJBRI-HSGWXFLFSA-N	PUBCHEM.COMPOUND:24989762	UMLS:C0206754	flubrobenguane (18F)	Neuroendocrine Tumors	Designated	2019-06-04
